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Foreword 
 
“Research can be defined as the attempt to derive generalisable new 
knowledge by addressing clearly defined questions with systematic and 
rigorous methods.” Research Governance Framework for Health and 
Social Care (2005) 
 
The aim of this thesis is to clearly communicate an area of clinical research that 
is highly relevant to my profession and other health care providers, service 
users and health service commissioners. I explored the ‘black box’ of 
uncertainty in a defined complex clinical area. This was achieved by identifying 
key questions, developing and designing a methodologically appropriate and 
relevant clinical research study. The findings were evaluated and reported by 
critical commentary from the perspective of a novice in clinical research.  
 
This thesis intends to build on previous learning in research knowledge and 
skills gained and accredited in the modular taught programme as part fulfilment 
for a Doctorate of Clinical Research. Therefore this thesis is presented on the 
basis of implementing critical skills for clinical research and is underpinned by 
an understanding of the Complex Interventions Framework (Medical Research 
Council, 2000, Craig et al., 2008). In addition it is relevant to highlight the 
context of this research given the limited resources of professional part-time 
capacity available for this study. Consequently this thesis is explicitly for the 
fulfilment of the clinical research component of the Doctorate.  
 
The purpose of this thesis is to contribute to a strategic body of evidence in 
support of a specific clinical area that deserves further research. This piece of 
work plans to build on an existing body of knowledge in the clinical area of 
spasticity and neurological rehabilitation to contribute in the discovery of new 
knowledge that can inform clinical practice. I do however acknowledge there are 
likely to be limitations in scope and impact of this small scale study. 
 
The overall structure of the thesis intends to present a logical framework and 
contributes to the existing body of evidence. This follows the principles of Good 
Clinical ‘research’ Practice (Research Governance Framework for Health and 
Social Care, 2005). The thesis structure follows a logical template with an 
introduction to the key issues of spasticity, its current management and 
highlights the specific areas of uncertainty from critical appraisal of the 
literature. A research design is proposed with justification for a mixed 
methodology. The research process delivery is offered with subsequent findings 
and evaluation. The thesis then details the key findings, critical analysis and 
conclusions providing a unique contribution to new knowledge. The rationale for 
this structure is that it provides a coherent link from one chapter to another with 
a logical progression from concept, to delivery, to evaluation. 
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Abstract 
 
Title: Dynamic Elastomeric Fabric Orthoses (DEFO) And Physiotherapy 
After Botulinum toxin (BT) In Adults With Spasticity: A Feasibility Study 
Using Mixed Methods. 
Aim: A study to investigate the potential feasibility (including estimated effect-
size), acceptability and health benefits of DEFO and physiotherapy in treatment 
of spasticity following intramuscular injection of BT.                                                                                  
Participants: Adults living in the community with focal spasticity of the upper or 
lower limb (Modified Ashworth Scale 2-3) recruited at a regional Spasticity 
Clinic.                                                                                                
Intervention: provision of an individually fitted DEFO (worn daily up to 8 hours) 
usual care and physiotherapy (as required) for 6 weeks.                                 
Methods: Mixed methods embedded design feasibility study: Quantitative: 
Feasibility single-blind RCT: Intervention Group: DEFO intervention protocol, 
usual care and physiotherapy, Control Group: usual care and physiotherapy. 
Qualitative: Topic guided interviews of the intervention group and clinicians.                                                   
Measures: Goal Attainment Scale (GAS) primary measure and secondary 
measures for function and care benefit; Arm Activity measure (ArmA), Leeds 
Arm Impact Score (LASIS), VAS for pain, European Quality of Life-5 
Dimensions (EQ-5D), gait velocity (10MTT). Variance and fidelity was captured 
with: DEFO wearing record, Activity Log, clinical records and Physiotherapy 
modalities.                                                                                               
Analysis: ANCOVA adjusted means and statistical comparison for significance 
of measures (at baseline, after six weeks and twelve weeks) between groups 
and to inform power calculations. Thematic Analysis of clinician and participant 
transcribed interviews. Quantitative and qualitative findings were integrated and 
triangulated to inform a larger study.                                                        
Results: Participants (n=25) recruited over twelve months, (n=22) completed 
study. Statistical analysis showed improvements in both groups with greater 
health benefit in the intervention group with mean difference in the GAS of 
12.17 (95%CI: 3.16 to 21.18; p = 0.014) but no statistical significance in the 
secondary measures. Effect-size was estimated from the GAS findings for 200 
per group for a larger study. Physiotherapy modalities for spasticity were linked 
to ‘passive’ and ‘active’ function. Feasibility and acceptability was established 
with Thematic Analysis providing valuable insight into patient and clinician 
perspectives on disability.                                                                    
Conclusions: Findings indicated potential added health benefits including carer 
benefit. Feasibility, acceptability and clinical application of DEFO as a potential 
new intervention were established. This has implications for future spasticity 
management with patient benefit for passive and active function. Further 
research is indicated with a fully powered study (based on the GAS sample 
results) to evaluate DEFO efficacy in people with spasticity following BT. 
Key words: Spasticity, Botulinum toxin, physiotherapy, dynamic orthoses.  
Acknowledgements: DM Orthotics Ltd© 
Ethical registration and approval: Ref: 12/SC/0518 (NRES) Committee South 
Central-Berkshire B-ethical approval registered with local NHS R&D and Exeter 
University.  
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Definitions 
 
Aphasia  ‘is an acquired language impairment following brain damage that affects 
some or all language modalities: expression and understanding of speech, reading and 
writing’. Brady, M, C et al., (2012) Speech and language therapy for aphasia following 
stroke. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD000425. DOI: 
10.1002/14651858.CD000425.pub3. 
Botulinum toxin ‘The most potent neurotoxin known and is produced by the gram 
negative bacterium Clostridium botulinum. The paralytic effect of the toxin is due to 
blockade of neuromuscular transmission. Injection into a muscle causes chemical 
denervation and local paralysis and this effect has led to the development of the toxin 
as a therapeutic tool’. Barnes and Davis, (2000, p143) 
 
Contracture results ‘when a joint cannot be moved regularly through its full range of 
motion causing physiological changes in the surrounding muscles and other tissues 
causing them to shorten, which restricts mobility around the joint’. Farmer et al., (2001, 
cited in NHS, QIS©, 2005) 
 
Mixed methods ‘A research design with philosophical assumptions as well as methods 
of inquiry. As a methodology, it involves philosophical assumptions that guide the 
direction of the collection and analysis of data and the mixture of qualitative and 
quantitative approaches in many phases in the research process. As a method, it 
focuses on collecting, analysing and mixing both quantitative and qualitative data in a 
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single or series of studies. Its central premise is that the use of quantitative and 
qualitative approaches in combination provides a better understanding of research 
problems than either approach alone’. Creswell and Plano Clark, (2007, p.5)                               
                                                  
Orthosis or splint A removable external device which provides a means of 
maintaining the specific position of a limb by providing static or dynamic support. They 
are which are designed to ‘apply, distribute or remove forces to or from the body in a 
controlled manner to perform one or both basic functions of control of body motion and 
alteration or prevention in the shape of body tissue.’ Rose, G. (1986). 
 
Physiotherapy ‘Physiotherapy helps restore movement and function when someone is 
affected by injury, illness or disability. Physiotherapists help people affected by injury, 
illness or disability through movement and exercise, manual therapy, education and 
advice. At the core is the patient’s involvement in their own care, through education, 
awareness, empowerment and participation in their treatment’ Accessed: 15 May 2014, 
Chartered Society of Physiotherapy (2013) http://www.csp.org.uk/your-health/what-
physiotherapy 
  
Spasticity: ‘a motor disorder characterized by a velocity-dependent increase of tonic 
stretch-reflexes with exaggerated tendon jerks, resulting from hyperexcitability of the 
stretch reflex’ Lance (1980, pp485-494). More recently: ‘disordered sensori-motor 
control resulting from an Upper Motor Neuron (UMN) lesion, presenting as intermittent 
or sustained involuntary activation of muscles’ EU-SPASM, Pandyan et al., (2005, p.2). 
 
Transcription is explained as ‘a process of rigorous orthographic transcript verbatim of 
verbal (and non-verbal where relevant) utterances’ Reissman, C, K. (1993). 
 
Abbreviations  
ABI            Acquired Brain Injury 
ANCOVA  Analysis of covariance 
ARAT        Action Research Arm Test  
ArmA        Arm Activity measure 
BSRM       British Society of Rehabilitation Medicine 
BT             Botulinum toxin 
CASP        Critical Appraisal Skills Programme  
CCG          Clinical Commissioning Group 
CI              Confidence Interval 
CNS          Central Nervous System 
CP             Cerebral Palsy  
DEFO        Dynamic Elastomeric Fabric Orthosis 
DMO         Dynamic Movement Orthosis 
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EQ-5D       European Quality of Life-5 Dimensions  
FES           Functional Electrical Stimulation 
GAS          Goal Attainment Scale 
ICF            International Classification of Functioning 
LASIS       Leeds Arm Spasticity Impact Score  
MAS          Modified Ashworth Scale 
MMAS       Modified, Modified Ashworth Scale 
MRC         Medical Research Council 
MS            Multiple Sclerosis 
MTU          Muscle Tendon Unit 
N               Number 
NHS          National Health Service 
PEDro       Physiotherapy Evidence Database and Resource 
PCI            Physiological Cost Index 
PCT          Primary Care Trust  
PICOS      Population, Intervention, Comparators, Outcomes, Study Design 
PIS            Participant Information Sheet  
PPI            Patient and Public Involvement 
RRG          Research Reference Group 
SCI            Spinal Cord Injury 
SIGN         Scottish Intercollegiate Guidelines Network 
SMART     Specific Measurable Achievable Realistic Timed 
SPSS        Statistical Package for Social Sciences 
TBI            Traumatic Brain Injury 
UMNL       Upper Motor Neuron Lesion 
UK            United Kingdom 
VAS          Visual Analogue Scale 
WHO         World Health Organisation 
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Chapter 1 
Introduction: Opening the ‘black box’ 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Clinical practice in the field of neurological rehabilitation highlights important 
areas of uncertainty that deserve scrutiny. Spasticity management following 
Botulinum toxin (BT) is identified as a specific clinical field that warrants further 
research. On opening the ‘black box’ of spasticity rehabilitation, this clinical 
practice is strewn with uncertainty. It is acknowledged by Khan et al., (2013, 
p.15) ‘investigating complex interventions such as MD (multidisciplinary) 
spasticity management is challenging in the real world’. This study found limited 
evidence for practice specific guidance following BT and highlights research 
uncertainties; what are the optimum treatment strategy, intensity, location and 
specificity? Direction for research is recommended including; the evaluation of 
the contribution of individual components of rehabilitation, consensus of 
appropriate patient-centred outcomes and wider patient and caregiver 
perspectives (Khan et al., 2013). 
 
The significance of this clinical practice area is now discussed in light of a 
preliminary review of the literature which identified key topics that justified 
further study. This evidence provided background for the current study and was 
critically evaluated to find what was known and to identify the knowledge gaps. 
This was in order to inform relevant research questions.  
 
Key points: 
 
 Opening and unpacking the ‘black box’ of rehabilitation 
 Introduction of key topics: spasticity, rehabilitation, 
physiotherapy, health technology 
 A ‘window of opportunity’ following Botulinum toxin (BT) 
 Collaboration with health technology industry 
 Defining DEFO, application and function 
 Identified research problem and uncertainties  
 
14 
 
This chapter provides context and rationale to explain the research approach. It 
includes an introduction to the area of clinical practice studied and introduces 
constituent themes within the thesis, including the underlying philosophical 
bases and methodology that are later expanded upon. An overview of the 
knowledge base of spasticity is presented, including its impact and 
management. Next neurological rehabilitation is appraised with perspectives on 
research and physiotherapy. Developments in health technology are 
acknowledged for their recent contribution to health care with the potential for 
translational research in the field of neurological rehabilitation. Finally the 
research approach for this study is introduced providing the purpose and 
structure of the thesis. 
 
 
1.1 Spasticity: Impact and management 
 
Spasticity commonly follows damage or disease to the central nervous system 
(CNS). Spasticity is a phenomenon that is acknowledged to be complex in 
presentation and management (Sheean, 1998; Barnes, 2001; RCP et al., 2009). 
Spasticity can present as harmful over-activity of muscles with the impact of 
abnormal postures and movement. Common aims for treatment are to provide 
symptom relief, improve function and prevent deterioration.  
 
From an epidemiological perspective, there are no accurate figures available for 
the prevalence of spasticity. However it is prevalent in many neurological 
conditions and those with acquired brain injury. Both Sommerfeld et al., (2012) 
and van Kuijk and colleagues, (2007) corroborated the findings of Watkins et 
al., (2002); who identified spasticity in approximately one third of people with 
stroke, 75% people with severe traumatic brain injury, 60% of people with 
Multiple Sclerosis (MS). In addition it is prevalent in other neurological 
conditions such as people with Cerebral Palsy and Spinal Cord Injury. 
 
The impact of spasticity, if left untreated, can lead to increased muscle tension 
and shortening of muscles and soft tissues resulting in contractures, pain and 
increased disability. Secondary complications such as the potential 
development of pressure ulcers due to reduced functional activity can be both 
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distressing and costly to manage. Targeted successful treatment can 
demonstrate measureable impact on both caregiver burden (Bhakta et al., 
2000) and secondary complications (Boyd et al., 2000). Personal health and 
wellbeing are paramount in treatment planning and should be considered within 
a rehabilitation framework such as that in the International Classification of 
Functioning (ICF) Disability and Health model proposed by the World Health 
Organisation (WHO, 2001). This model is presented and explained in Figure 
3.2, Chapter 3.5.  
 
Spasticity is acknowledged to be a complex, highly variable and dynamic 
phenomenon (Barnes, 2001). It can lead to both reduced movement excursion 
and altered muscle pattern generation. Sheean (1998) observed prolonged 
absence of volitional movement results in biomechanical changes in the 
structure of the muscle and soft tissues such as reduced elasticity and 
compliance. Commonly spasticity produces altered timing, force generation and 
resistance to movement. This increases the potential for deformity of limbs with 
resultant disability and functional dependence (O’Dwyer et al., 1996). In focal 
spasticity and multi-focal spasticity the impact of increased tension and 
shortening in the agonist muscles produces an inhibiting effect on the activation 
of the antagonist muscles. Consequently the antagonist muscles are impaired 
from prolonged overstretching and this contributes to altered length, strength 
ratios (Gracies, 2005) and ultimately reduced movement. 
 
Pandyan et al., (2005) suggests it is unlikely abnormal muscle activity in 
spasticity results exclusively from stretch reflex hyper-excitability. Other 
‘positive’ characteristics include: increased muscle tone, exaggerated tendon 
reflexes, repetitive and released flexor reflexes. Both neurogenic and 
biomechanical components of muscle over activity contribute to changes in the 
muscle architecture (O’Dwyer et al., 1996). 
 
Both Sheean (2001) and Barnes (2001) agree it is important to recognise both 
the neural and biomechanical components of muscle stiffness as treatment 
options differ. The biomechanical component is unresponsive to medication but 
amenable to stretching and optimal positioning to maintain muscle length 
(Pope, 2007; Katalinic et al., 2010; 2011; Sheean et al., 2010; Tyson et al., 
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2011). However, the neural component is velocity-dependent as described by 
Lance (1980) and responds to medical intervention; directed to the nervous 
system both centrally and locally. When spasticity presents globally affecting 
more than one limb or area of the body; it can be effectively managed by oral 
anti-spasmodic medication (Stevenson and Jarrett, 2006; Thompson et al., 
2005). It is not the purpose of this study to investigate this area of clinical 
practice.  
 
On the other hand it is clear management of focal spasticity warrants further 
investigation. A European consensus (Wissel et al., 2009) has drawn up 
recommendations for management of adult spasticity using Botulinum toxin 
(BT) as part of an integrated treatment strategy. BT is used as a therapeutic 
component in the management of localised spasticity by intra-muscular injection 
to targeted neuromuscular nerve blockade and thus temporary partial paralysis 
of selected muscle(s). This enables selective weakening of targeted hyperactive 
muscles (RCP et al., 2009). BT has anti-nociceptive and muscle relaxant 
properties and is thus clinically indicated in the treatment of focal limb spasticity. 
It has become a preferred treatment option for focal spasticity due to its 
selectivity, reversibility and rarity of adverse reactions (Bakheit et al., 2001; 
Moore, 2002; Pittock et al., 2003; Naumann and Jankovic, 2004; Jankovic et al., 
2005; Simpson et al., 2008). 
 
 According to Gracies et al., (2007, p.1796) BT provides a ‘window of 
opportunity’ for optimising rehabilitation for ‘active’ or ‘passive’ functional gains’ 
(Sheean, 2001; Simpson et al., 2008). This is worthy of further consideration as 
there is no clear guidance on what treatments are most effective during this 
time limited opportunity. It is however widely acknowledged BT has the potential 
to reduce the overall costs of long term care of people with focal and multi-focal 
spasticity when used in a combination of directed functional rehabilitation and 
‘passive’ care (RCP et al., 2009). Interestingly it is not yet clear what explicit 
components of functional rehabilitation are most effective.  
 
Whilst the evidence is overwhelming in support of the efficacy of BT (RCP et al., 
2009) the impact on economic benefit is in doubt (Wallesch et al., 1997; Ward 
et al., 2005). More recently the multi-centred BoTULS trial (Shaw et al., 2010) 
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raised further doubt regarding cost-effectiveness. The current cost of BT per 
average treatment is £288-£333 (for 2 vials Botox-Dysport, PCH Pharmacy, 
2014) and it would appear clinically expedient to direct these costs effectively to 
produce cost-efficient outcomes.  
 
Wissel and colleagues (2009) outlined the research challenges that still exist, 
namely muscle identification and injection guidance, cost-effectiveness, 
recommendations pre and post injection and trial design. In particular the 
European consensus (Wissel et al., 2009, p.22) highlighted that more studies 
are required ‘to ascertain the optimal, timing, duration and intensity of post 
botulinum toxin physical therapy’. Furthermore the consensus recommends the 
use of valid and sensitive clinical scales and follows the International 
Classification of Functioning (ICF) model (WHO, 2001) to assess and evaluate 
the impact of the intervention and outcome (Figure 3.2, Chapter 3.5).  
 
To date according to Thompson et al., (2005) the management of spasticity is 
based on a ‘logical and pragmatic approach’ with no formally agreed evidence 
based model. Thompson and colleagues propose a spasticity management 
model according to level; mild, moderate and severe. This model simplifies a 
management approach linking the presentation of severity with a stepped 
approach. What is agreed is that education, promotion of self-management and 
access to supporting services with knowledge and skills in this field can help to 
prevent secondary complications. Furthermore methods of promoting active 
movement and modification in unhelpful patterns of movement when 
accompanied by pharmacological treatment are important factors in optimal 
management. This is one of the primary functions of neurological rehabilitation. 
Neurological rehabilitation, outcome and efficacy of treatment are considered as 
the underlying basis for this study. 
 
 
1.2 Neurological rehabilitation: Outcome and efficacy of treatment  
 
Fundamental issues about rehabilitation can provide greater insight into its 
complexity. Firstly rehabilitation can be seen as a construct which is based on a 
model of service delivery and on the composite team members who deliver the 
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defined service approach by effective team-working (Wade, 1992; Khan et al., 
2013). Secondly the nature of rehabilitation is multi-faceted and thus requires a 
team approach.  Each member of the multi-disciplinary team (MDT) contributes 
a valuable role to deliver patient centred care. Individual roles are well-defined 
but can often overlap and merge to produce more efficient practice and 
outcomes (Booth and Hewison, 2002). Accurate comprehensive assessment is 
required to identify the individual’s clinical status, functional problems and 
confounding conditions or other important issues. Treatment plans involving the 
patient and caregivers can be formulated with the MDT to ensure realistic goal 
setting and expectation of outcomes (Seigert and Taylor, 2004). It is particularly 
important to choose measures in rehabilitation which have construct validity and 
that are chosen to measure what is relevant and of importance to the patient 
and not just the clinician (Rushton and Miller, 2002; Broetz and Birbaumer, 
2013). A framework for evidence-based choice of measures is recommended 
for neurological physiotherapy by Tyson et al., (2008). Communication between 
members of the MDT and the patient and family is essential to ensure efficacy 
of treatment (Khan et al., 2013) and are fully engaged (MacDonald et al., 2013). 
 
It is claimed by Wade (1992) and yet again by Wissel et al., (2009) neurological 
rehabilitation has made little progress to date to evidence efficacy due to the 
lack of consensus on what methods are used to measure progress. However, it 
is widely agreed that clinical assessment provides a starting point for 
measurement. The ‘Medical’ model for rehabilitation, with a diagnostic and 
prescriptive bias, is one that has been commonly used such as when following 
protocols in orthopaedic rehabilitation and in medical research. The ‘Medical’ 
model assumes a simplistic mechanical view of illness from a structural 
impairment or functioning basis. This model has a bias of bio-medical 
perception of normalcy (Seelman, 2004). Criticisms of this model include limited 
assumptions of quality of life, adaptation and social access. It has a limited view 
when considering aspects of mind, family relationships and environmental 
factors. In this model the authority lies with the professional with a clinician 
directing care from a position of knowledge and power following a biological 
approach in diagnostic formulations and associated treatments. In contrast an 
integrative ‘Bio-psychosocial’ model such as the ICF model of rehabilitation 
(WHO, 2001) is less prescriptive and more person-centred which allows for 
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individual variances and acknowledges the interactions between physical, 
psychosocial and environmental factors for optimal recovery.  
It is important to evaluate the outcome of a healthcare episode holistically, 
taking into consideration all of the components including personal perspective, 
role, relationships and beliefs (WHO, 2001; Stucki et al., 2007). This is the 
reason why the UK has adopted the ICF model of rehabilitation (Chapter 3.5). 
However the success of its implementation in clinical practice was found to be 
dependent on two factors according to Tempest et al., (2012), firstly to adopt 
the ICF in ways that meet the local service needs and secondly to adapt the ICF 
language and format. Implications drawn from this action research suggest that 
the ICF, as a conceptual framework, can be used in clinical practice as a 
vehicle to implement local service priorities. In order for the global ICF 
classification to be successfully adopted into clinical practice in this study the 
language terminology and format was adapted to the local needs of the team.    
 
Another consideration includes the use of predicted outcomes. The British 
Society of Rehabilitation Medicine (Skinner and Turner-Stokes, 2006) suggest 
rehabilitation warrants a ‘basket’ of approved measures using well-validated 
measures to provide defined evidence to guide efficacy of practice. Outcomes 
from a co-ordinated approach should be based on the identified and defined 
needs of the individual which can be translated into specific goals. The current 
study considered this finding and used accepted methodology and clinical 
measures. The outcomes selected in this study included measures of improved 
ease of handling and care provision. 
 
In addition it is useful to establish common predictive variables in rehabilitation.  
The different variables were considered that could affect the outcome. These 
included: age, localisation of disease or damage and extent, time since onset, 
co-morbidity, premorbid circumstances such as personality and intelligence and 
social circumstances. It was also considered important to have an 
understanding of what standard care consists. This was used as an ethical 
measure to ensure the patient had the usual care they would normally receive. 
It was also used as a control for variability in the delivery of care, providing a 
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constant for comparison. Usual care was consequently and explicitly used in 
this study protocol. 
 
Whilst it is widely accepted there is a translational gap between researchers 
and clinicians in the health care professions, there is commonality in both 
striving to develop a sound evidence base for practice. This is apparent in 
rehabilitation medicine where the complexity of research is reported to be 
problematic. Medical evidence is often presented using the randomized 
controlled trial (RCT) as the gold standard of hierarchy. However, a number of 
authors in the field have challenged this with the claim that RCTs often 
unrepresentative of the population studied and thus it is hard to interpret results 
and apply them to individual patients (Goodman, 1999; Partridge, 2002; Skinner 
and Turner-Stokes, 2006).  
 
Confounding factors in neurological research are commonly reported. 
Significantly this includes the problem of small numbers with each diagnostic 
group representative of a wide range of diverse conditions. Further problems 
that consistently confound rehabilitation research are the issues of moving 
baseline with spontaneous recovery or disease progression and difficulty in 
adherence to a uniform treatment approach.  Even the goal for outcome is 
widely variable and dependent on the individual’s personal perspective and 
circumstance. Whilst the RCT helps to counter these issues of systematic bias, 
(Shadish et al., 2002) the fact remains that this approach is universally 
accepted as the preferred design for clinical research. The alternative is to use 
case reports which have their merits, but do not provide the robust statistical 
evidence for clinical confidence. A pragmatic approach is needed in the aim for 
best evidence in clinical practice with an understanding of complexity. The MRC 
(Craig et al., 2008) recommends clinical research should use a mixed method of 
RCT and qualitative design. This approach is considered (in Chapter 3.1). 
 
The Spasticity Guidelines (RCP et al., 2009) recommend evaluation at three 
levels: goal attainment; impairment as in the reduction of spasticity; and 
functional impact. Objective markers and outcome measures should be 
selected as both valid and reliable (Wade, 1992).  
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Measures of impairment can be used to direct future management. However, 
Richardson and colleagues, (2000a) argue that it is often more important for the 
patient and caregiver to demonstrate outcome in terms of functional 
performance or goal attainment. The Goal Attainment Scale (GAS) can be used 
to measure real-life functional gains (Turner-Stokes, 2003; 2009; Ashford and 
Turner-Stokes, 2006: Turner-Stokes and Ashford, 2007) and was used as the 
primary outcome measure. Both the GAS and secondary measures selected for 
the study are detailed (in Chapter 4.5).  
 
Next professional perspectives are presented from within a philosophical basis 
of neuroscience. This is underpinned by a rehabilitation philosophy and eclectic 
model of practice that has influenced the research approach.  
 
 
1.3 Physiotherapy: professional perspectives 
 
Clinical experience in neurological physiotherapy has provided an advanced 
understanding of neuroscience and neuroplasticity based on the potential of the 
CNS to adapt, (Merzenich et al., 1991; Kidd, Lawes and Musa, 1992; Taub, 
1993; Nudo, 1999; 2006). It can be argued there is much untapped potential for 
people with spasticity to change. Human movement is complex. It involves the 
interaction between the individual, the task and the environment (Shumway-
Cook and Woollacott, 2001).  
 
Posture and movement are intrinsically linked. For motor recovery people 
require opportunities for directed patterns of movement and postures that are 
behaviourally acceptable; leading to more movement. Optimal postural 
alignment provides a starting point for comfort and confidence to progress 
movement. This suggests a psychosocial element by creating motivation and 
reward (Maclean et al., 2000; Laviola, 2001; Danzl et al., 2012). By providing an 
environment that enhances and rewards movement further functional gains can 
be made (Broetz and Birbaumer, 2013).  
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Knowledge and practice skills are established in two fundamental approaches 
to neurological rehabilitation. A ‘hands on’ approach, such as in the 
Neurodevelopmental ‘Bobath’ Approach (Bobath, 1990; Davies, 2002; Raine et 
al., 2009) is often reported beneficial. Yet there are often limited resources to 
direct movement patterns with sufficient input to establish learning. Alternatively 
the ‘Movement Science’ (Carr and Shepherd, 1987; 2010) approach has been 
demonstrated to produce effective learning through guided, massed practice. 
Both of these practices have elements that can separately and collectively 
deliver active functional rehabilitation. However, the needs of people with 
spasticity commonly require care with ‘passive’ function. These needs are often 
more difficult to be met as it requires a prolonged delivery approach with 
sustained input. This is problematic as resources for this level of input are often 
limited and a compromise in postural management is made on a pragmatic 
rather than optimal basis.   
 
There is no current evidence (Kwakkel et al., 1999; van Vliet et al., 2001; 2005) 
to support one approach over another. There has been a shift in emphasis of 
rehabilitation from management at impairment level to one of enablement in 
real-life situations. Indeed the two approaches are no longer poles apart and 
quote literature from the same evidence base to support their distinct 
philosophical stance. Practice in the clinical setting is more pragmatic with 
hybridisation of different approaches. In fact it is not uncommon for 
physiotherapists to be eclectic in their clinical practice as they develop 
experience and knowledge from different learning opportunities along their 
career path. This approach is supported by Stroke Guidelines ‘physiotherapists 
should not limit their practice to one ‘approach’, but should select interventions 
according to the individual needs of the patient’ (Scottish Intercollegiate 
Guidelines Network (SIGN) 118, 2010, p.17). Indeed the recent evidence in the 
Cochrane review (Khan et al., 2013) recommends therapy as most beneficial 
based on a mixture of different treatments tailored for the individual from a wide 
range of available treatment options. 
 
Current practice demands a treatment approach that is based on the best 
available evidence, through critical analysis and evaluation of the evidence 
base (Straus and Sackett, 1998; Sackett, 2002; Akobeng, 2005). Evidence 
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based practice (EBP) “means integrating individual clinical expertise with the 
best available external clinical evidence from systematic research” (Sackett, 
1996). It is the integration of clinical expertise, patient values, and the best 
research evidence into the decision making process for patient care. Clinical 
expertise refers to the clinician’s cumulated experience, education and clinical 
skills. In addition the patient contributes personal expectations and values. 
Accordingly clinically relevant research that has been conducted using sound 
methodology provides evidence for best practice (Sackett, 2002). Clinical 
practice in neurological rehabilitation is influenced by knowledge of theories 
presented from a historical perspective and how they have evolved contributing 
to current Motor Control Theory and its clinical applications (Shumway-Cook 
and Woollacott, 2001, pp. 11-25). These are tempered by discoveries in 
neuroscience which report that the CNS is not hierarchical, but soft wired, 
capable of adaptation (neuroplasticity) and has the potential for recovery 
through re-organization (Merzenich et al., 1991; Kidd, Lawes and Musa, 1992; 
Taub, 1993; Nudo, 1999; 2006; Pitts and O’Brien, 2008).  
 
These findings have provided physiotherapists with opportunities to deliver 
therapy and neuro-rehabilitation in new ways. By implication neuroplasticity 
offers the opportunity to direct recovery. This is by adapting to, or compensating 
for impairments through environmental and therapeutic stimulation towards 
purposeful activity.  
 
As previously reported, BT is a medical component used to direct temporary 
partial paralysis of targeted muscle(s) in the overarching strategy for the 
treatment of spasticity in adults. It is recommended in the Spasticity Guidelines 
(RCP et al., 2009) as a successful treatment option for multi-focal and focal 
spasticity when used in combination with physical therapy. Whilst this is the 
accepted case it remains unclear what physical treatments should follow and 
exactly when they should be applied for optimal dose-efficacy (Khan et al., 
2013). It is however agreed that the overarching aim of the treatment for 
overactive muscles is to maintain muscle length and prevent secondary 
shortening of soft tissues. The suggested treatments include methods of 
maintaining muscle length and optimal positioning by passive and active 
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stretching such as splints/orthotics and physiotherapy and movement (Edwards, 
2001; Pope, 2007; Sheean et al., 2010; Kilbride et al., 2015). 
 
Having highlighted the recommended mainstay of treatment for focal spasticity 
as passive and active (dynamic) muscle stretch and movement this study aimed 
to explore the role of a potential new treatment that could deliver both. The 
emphasis being on the potential for re-educating movement patterns by 
directing muscle to adapt both biomechanically and neuroplasticity for optimal 
change during a specific time-frame. 
 
 The neuroscience behind dynamic motion orthoses (DMO) is based on 
neuroplasticity for learning adaptive patterns of optimal posture and movement 
by proprioceptive sensory stimulation (Gracies et al., 2000; Matthews, 2008). 
This is due to the cylindrical use of elasticized and non-elasticized materials 
introducing a force along a weakened muscle line of activation, providing an 
exoskeleton. The inherent elastic properties of the material provide a localised 
corrective force by long term low level stretch on the neural components of tone 
with resultant improved levels of spasticity (Gracies et al., 2000). It is proposed 
this effect modulates the stretch reflex. The customised fit offers slight 
compression with specific tension and resistive forces that offer support as 
required, yet afford freedom of movement. The freedom of movement benefits 
the non-neural biomechanical components such as viscoelastic properties, 
muscle fibre stiffness phenomenon of thixotropy (Goldspink and Williams 1990), 
muscle length–tension relationship and muscle fibre type. It is proposed the 
combination effect of directed, interactive movement and proprioceptive 
feedback provides the opportunity for muscle plasticity which in turn can 
influence neuroplasticity (Pitts and O’Brien, 2008). 
Professional knowledge and experience in BT injection therapy for management 
of spasticity raised awareness of the limitations in spasticity service delivery and 
variance in patient experience. Some of the preliminary work informing this 
thesis was based on key aspects of professional learning in a small scale 
service project. This was in the development and testing of a new audit tool for 
the use of splints in adults with neurological conditions. This work was based on 
the findings of a national survey (Adrienne and Manigandan, 2011), which 
highlighted local clinical inconsistencies in theoretical underpinning for splinting 
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provision and practice. It was discovered that there was a significant gap in 
local, national and international clinical practice. The knowledge base was 
explored and used to develop a splinting audit tool which was then tested. The 
new audit tool was validated in practice and findings published (Stone, 2012) 
and presented by poster at Association of Chartered Physiotherapists in 
Neurology (ACPIN) National Conference (2012). The audit tool has since been 
used locally to inform splinting service development, local guidelines and 
monitor standards of practice. 
 
Within the current framework of clinical guidelines for management of spasticity 
splinting is recommended (ACPIN, 1998; Intercollegiate Stroke Working Party, 
2012; RCP et al., 2009; Kilbride et al., 2015). The roles of the Occupational 
Therapist and Physiotherapist overlap in this area of clinical practice (Booth and 
Hewison, 2002) based on knowledge skills experience and competency. From a 
practice perspective splinting remains contentious and the evidence base is 
conflicting with limited guidance (Lannin and Herbert, 2003; Adrienne and 
Manigandan, 2011). The 1998 splinting Guidelines are outdated. Consequently 
the new splinting Guidelines (Kilbride et al., 2015) developed by collaboration 
between both professions were keenly received. These new splinting guidelines 
are informed by findings from a national cross-sectional survey of clinicians 
(Kilbride et al., 2013).  
 
Evidence for splinting in relation to spasticity management is reported in the 
systematic review (Chapter 2.4). A preliminary evaluation of the literature 
introduced the idea of research of dynamic splinting and direction to explore 
research possibilities in health technology products. 
  
1.4 Health technology: A role in rehabilitation  
The last twenty years has witnessed a health industry revolution with an 
international arena for improving health and wellbeing. More recently the 
Olympics and Paralympics were held in the UK in 2012, followed by the 
Commonwealth Games 2014 raised the researcher’s awareness in the growth 
of health-related technology. This phenomenal development in health 
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technology has created a learning platform (for thinking outside the box) and 
provided the opportunity to investigate how new technology developed in one 
field can be translated in application to another.  
 
Increasing demand for health technology in both sports and neurosciences has 
evolved with overlaps in design and application. Subsequently market forces 
have driven the development of health related technological products such as 
Kinesio-tape and dynamic Lycra® garments. Technological design features 
include the targeted use of the inherent tensile properties to enhance movement 
patterns. These are commonly seen on the sports field with various colours and 
applications including: protection against injury; or optimising movement. The 
tensile property is an important factor and has obvious applications in situations 
where in human movement there are imbalances between muscle forces 
around one, or more joints and resulting in altered stability, functional 
movement or potential injury.  
 
Change in the political landscape has led to a new and exciting time for the 
health technology industry. The boundaries between statutory Health Service 
providers and non-statutory providers have recently become blurred with new 
NHS Commissioning structures in place and competitive tendering 
transparency. In 2013 Primary Care Trusts (PCTs) devolved their remit from 
combined commissioner and provider arms into new Clinical Commissioning 
Groups (CCGs). This has opened up the opportunity for further market 
competition with contract tenders from alternative providers of health care 
services and health technology.  
Existing statutory NHS providers need to be astute to recognise how 
competition and working collaboratively can benefit the health of target 
populations.  As the ageing population in the UK is set to rise, new challenges 
will compete for optimal efficiency and effectiveness in resource management. 
For example new technologies are adopted in everyday life and are moving 
rapidly, crossing boundaries of sports and fitness industry into the health 
industry. It can be proposed that patients (the public) are now driving the market 
forces as they become more informed. 
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It is worth considering why splinting is so controversial and yet dynamic support 
is so popular. Controversy is based on conflicting evidence of efficacy (Lannin 
and Herbert, 2003; Adrienne and Manigandan, 2011) and compliance (O’Brien 
and Bailey, 2008; Kuipers et al., 2009). In addition acceptability from physical 
functionality and social perspective is believed to influence practical application 
and design popularity. Thus it can be argued that people are likely to make a 
pragmatic decision on splint wearing based on ‘what works’ and ‘how it looks’.  
Clinical experience of poor compliance of splint wearing in the community is 
supported by the survey findings of Adrienne and Manigandan, (2011). Often 
splints are rigid and cumbersome which impact on compliance (O’Brien and 
Bailey, 2008). In contrast dynamic splints allow movement and are lightweight. 
It is evident from the popularity of Kinesio-tape and brightly coloured splints 
worn in public that cosmetic and social acceptability are considerations. In other 
words splint efficacy may not be the most important factor in wearing 
compliance. For this reason it was worth exploring removable dynamic splints 
and their application in clinical practice. The preliminary findings are outlined 
below together with an introduction to collaboration with the health technology 
industry. 
 
 
1.5 Dynamic Elastomeric Fabric Orthoses (DEFO): Health technology 
industry collaboration  
 
Splints and orthoses are removable devices which provide a means of 
maintaining the specific position of a limb either providing static or dynamic 
support (Rose, 1983). Literature for splint efficacy is shown to be conflicting and 
inconclusive (Lannin and Herbert, 2003). Evidence from animal studies has 
informed clinical practice. Tardieu et al., (1988) and O’Dwyer et al., (1996) 
advocate optimal times for maintaining muscle length. They recommend splints 
should be worn for at least six hours to be effective. Compliance for rigid splints 
is uncertain (O’Brien and Bailey, 2008; Kuipers et al., 2009); however there is 
descriptive evidence (Coghill and Simkiss, 2010; Elliott et al., 2011a) which 
corroborates indicative levels of compliance and acceptability (in children) in the 
wearing of dynamic orthoses. 
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Dynamic Elastomeric Fabric Orthoses (DEFO) consist of garments with stitched 
sections of layered Lycra® of varying thickness to achieve specific tensions and 
an overall pattern of direction of force. The garments are designed to cover the 
body or limb of the wearer; measured to fit and customised to the individual’s 
needs. The inherent property of the design of the garment is to enable the 
wearer to move rather than to restrict movement and thus it is referred to as a 
‘dynamic’ orthosis. Most commonly the orthosis is provided for children with 
cerebral palsy and is used as an adjunct to other therapies for optimal benefit 
such as physiotherapy. It has also been used in few studies in the treatment of 
adults with neurological conditions (Gracies et al., 2000; Bridges, 2004; Betts, 
2006; Watson et al., 2007).  
 
There are a number of companies which produce DEFOs, or dynamic Lycra® 
garments. There are technical differences in the garments provided. The Health 
Technology Companies in the UK include: DM Orthotics Ltd©; Tru-Life©; Second 
Skin© and Jobskin©. DM Orthotics Ltd© is a manufacturer that produces a range 
of soft surgical goods including Lycra® based products such as Dynamic 
Movement Orthosis® (DMO®) and DEFO’s. The DMO® product technical 
characteristics include a fabric made from a mix of Polyamide and Dorlastan 
(Lycra®) 83% and double faced with cotton 17%. In the DEFO layers of 
customised elastomeric material are customised to improve muscle balance, by 
directing muscle control during active movement and exerting postural 
alignment (on an individual basis).  
 
Each DEFO is measured and customised to the individual. There are numerous 
measurements taken due to the need for the orthosis to be a snug fit but 
comfortable. This is to ensure it fits to provide stability with directive forces for 
optimising postural control. It also provides flexibility and allows movement. The 
upper limb DEFO in this study is termed a ‘glove’ if worn below the elbow or a 
‘long sleeve glove’ (Figure 1.1) if above the elbow. The lower limb DEFO in this 
study is termed a ‘sock’ (Figure 1.2) Over the last few years the design of the 
DM Orthotics Ltd© products have developed from DMO® body suits for children 
with cerebral palsy and neuromuscular conditions to a range of customised 
orthoses to meet the wider needs of paediatric conditions (Matthews et al., 
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2009) and more recently the adult sports (Sawle et al., 2012) and neurology 
population.                            
 
Figure 1.1 DEFO long sleeve glove             Figure 1.2 DEFO Sock 
 
                     
 
DM Orthotics Ltd©                                           DM Orthotics Ltd©    
 
From a preliminary review of the literature there was an identified gap in the 
existing body of evidence. Whilst there was evidence to support the use of 
dynamic splints and Lycra® garments in children with movement disorders 
(Coghill and Simkiss, 2010) there was limited evidence for use in limb spasticity 
(Matthews et al., 2007; Elliott et al., 2011a). The research gap identified limited 
available evidence for the use of dynamic Lycra® (DMO) worn as a splint in the 
treatment of adults with neurological conditions (Gracies et al., 1997; 2000; 
Bridges, 2004; Betts, 2006; Watson et al., 2007) and no evidence for specific 
interventions with the potential to effectively direct muscle activity following BT. 
In addition there was limited qualitative evidence reported on use of dynamic 
Lycra® in adults (Oglieve et al., 2006). This provided a justification for further 
research.  
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Firstly two key studies propose further research is needed to explore the 
efficacy of dynamic splinting (Lannin and Herbert, 2003; Gracies et al., 2000). 
Secondly it is acknowledged that dynamic Lycra® splints are evidenced 
(descriptively) as effective and acceptable in the management of children with 
spasticity and movement disorders (Corn et al., 2003; Matthews et al., 2007; 
Coghill and Simkiss, 2010; Elliott et al., 2011a). However, the majority of studies 
reported focussed on whole body suits rather than specific limb orthoses. 
Discomfort and toileting issues were also reported on suits in the Technologies 
Scoping report (Calvert and Kelly, 2013). Whilst there are gains to be made on 
improving dynamic core stability there is less understood in terms of the effects 
of dynamic support in limbs. Spasticity is known to have an increased impact 
distally on limbs. Importantly Lycra® splint intervention has been scarcely 
evaluated in an adult population with few published case studies and reports 
(Gracies et al., 1997; 2000; Bridges, 2004; Betts, 2006). These studies are 
indicative of acceptability and compliance in a clinical setting with predominantly 
descriptive findings of efficacy. 
 
The inherent characteristics of the DEFO provide flexibility and allow movement 
yet affords a level of stability. This fits with the theoretical construct in support of 
the use of splints in the potential for prolonged stretch by addressing the non-
neural components (connective tissue and muscle fibre length and number of 
sarcomeres) which in turn modify the neural mechanisms as in spasticity. This 
is seen as increased sensitivity to stretch of reflexes (Hoffman (H) and tendon 
reflexes). The reduction in sensitivity to stretch has been demonstrated in 
healthy adults by Guissard and Duchateau, (2004) however the evidence for 
studies with different healthy and patient populations show inconsistencies with 
variance in position, frequency, magnitude and duration (Mirbagheri et al., 
2008). Although there is potential for prolonged stretch to address changes in 
muscle length the exact mechanisms are not fully understood in the presence of 
spasticity. A further complication arises in the variance of response to different 
length of stretch and temporary rebound increases in spasticity (Ofori et al., 
2012) in different conditions such as Multiple Sclerosis. These changes and 
their effects on function require further investigation.   
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Treatment with the DEFO intervention was proposed as a potential new clinical 
treatment option following BT with the possibility to bridge the gap in the 
existing body of knowledge in the field. The opportunity to collaborate with 
health technology industry (Appendix 2), thus to bridge the technology 
research gap and how this was achieved is discussed in Chapter 8.2. 
 
 
1.6 Identified research problem and uncertainties 
 
Adults with focal spasticity experience long-term management by attending 
clinics for cyclical treatments with Botulinum toxin (BT). Whilst providing an 
effective treatment option (Jankovic et al., 2005; RCP et al., 2009) it is of time-
limited effect with the potential to create dependency on repeated cycles 
(Barnes and Davis, 2000). The European consensus report (Wissel et al., 2009) 
recommends a need to research which treatments following BT offer improved 
health benefit. 
 
The theoretical construct for splinting to be effective for neural and non-neural 
plasticity is complex and based on inconsistent and incomplete evidence. The 
rationale underpinning current splinting is based on early studies by Williams 
and Goldspink (1990) in that prolonged stretch of muscle has the potential to 
prevent the negative impact of remodelling muscle and connective tissue 
architecture (loss of sarcomeres in series, muscle fibre shortening and 
compliance or stiffness). The non-neural plastic changes of the muscle-tendon 
unit (MTU) with optimal length-tension ratios are reported by Williams and 
Goldspink (1978) to be affected by preservation of muscle length (by 
positioning). In the presence of spasticity, a positive feature of the UMNL, the 
neural effect is exaggeration of kinetic stretch reflexes with possible increased 
resistance to passive stretching of the MTU (Li et al., 2006). Thus increase in 
sensitivity and stretch reflex gain, or reduced threshold of the stretch reflex 
results in maladaptive velocity dependent muscle activity. There is further 
potential for prolonged stretch of the MTU to modify pre and post-synaptic 
mechanisms. Hence it can be argued prolonged and dynamic stretch can have 
a beneficial effect on both neural and non-neural components. 
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Significantly the pathophysiology of spasticity is complex and poses a challenge 
to researchers when measuring intervention outcomes. Whilst Gracies et al., 
(2007) argue there is a link between stretch and spasticity, the evidence for this 
remains incomplete. O’Dwyer and colleagues (1996) investigated the link 
between spasticity and activity post stroke and found they were not correlated 
with the implication that routine splinting for spasticity is incorrect. Furthermore 
routine splinting is not recommended by the RCP national Guidelines for stroke 
(Intercollegiate Stroke Working Party, 2012). Lannin and Ada (2011) 
recommend there is strong evidence that prolonged wearing of splints of the 
wrist in neutral or maximum extension does not prevent contracture after stroke. 
Lannin and Ada (2011, p.21) report the need; ‘to re-focus on improving muscle 
performance in order to enable activity rather than prepare the patient for 
function by affecting abnormal reflex activity.’ Furthermore the authors 
recommend researchers should evaluate the potential benefits of dynamic and 
newer technology splints.  
 
The DEFO with properties of compression providing proprioception and 
interactive stretch presents potential to facilitate muscle plasticity at a neural 
and non-neural level. The uncertainty of this intervention (DEFO) for the 
combined application with physiotherapy following BT was the basis for this 
study. 
 
 
1.7 Summary 
 
On opening and unpacking the ‘black box’ of clinical practice for spasticity 
treatment following BT an opportunity was identified that required further 
investigation. Spasticity is known to be a significant symptom following damage 
to the CNS. This can lead to disability, functional disturbance and carer burden. 
How this is clinically managed is variable, depending on presentation and 
severity and whether the spasticity is global or focal. To complicate matters 
rehabilitation includes elements of ‘active’ and ‘passive’ care. Furthermore 
standard rehabilitation is multi-faceted and requires a team approach which is 
often anything but standardised. Neurological physiotherapy consists of varied 
approaches with none evidenced as most effective. Splinting guidelines (1998) 
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are outdated and practice remains varied and contentious (Lannin and Herbert, 
2003; Lannin et al, 2003; Lannin and Ada, 2011; Adrienne and Manigandan, 
2011). Following focal spasticity management with BT, the individual 
contributions of splinting and physiotherapy components are often unclear with 
little understood about optimal timings, duration, intensity, treatment methods 
and outcomes.  
 
Recent developments in new technologies for sports, health and disability have 
raised their profile with associated industry actively pursuing gaps in the market. 
This has fuelled opportunities for translational research; by collaboration 
between Health Technology Industry and clinicians. The opportunity to 
collaborate with DM Orthotics Ltd© was used in this research study.  
 
A preliminary review of the literature highlighted gaps in knowledge for the 
optimal clinical management of people with spasticity following BT. Scientific 
and theoretical rationale was found for spasticity management with BT. Indeed 
there was a substantial body of evidence for the safe and effective use of BT as 
a preferred treatment option for focal spasticity. Good quality research is still 
required to investigate the efficacy of treatment options following BT (Wissel et 
al., 2009).  A future direction of investigation proposed by Lannin and Ada 
(2011) is in the re-focus on improving muscle performance. It can be argued 
dynamic splinting should be considered for investigation on this basis.  The 
existing evidence was explored in more depth by systematic review, (in 
Chapter 2). 
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Chapter 2   
Systematic Review 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
This Chapter presents the findings from an in depth systematic review of the 
current evidence base for clinical practice in spasticity management following 
BT in adults. It was guided by the findings of the preliminary literature review, (in 
Chapter 1). The purpose of the systematic review was to provide context and 
critical appraisal of the existing evidence base. This identified a gap in the 
knowledge base, thus informing direction and scope for future study in an 
identified area of original clinical research.  
This systematic review builds on the existing evidence base for spasticity 
management with Botulinum toxin (BT). The review followed a specific search 
strategy. The data extraction results are presented in two tables and the 
findings are evaluated using a systematic approach.  
The evidence for spasticity management in general or with BT is widely 
published and not within the scope of this review. Indeed there is a substantial 
body of evidence for the safe and effective use of BT as a preferred treatment 
option for focal spasticity due to its selectivity, reversibility and rarity of adverse 
reactions (Bakheit et al., 2001; Moore, 2002; Naumann and Jankovic, 2004; 
Jankovic et al., 2005; Simpson et al., 2008; Gracies et al.; 2007; and RCP et al., 
2009). 
   
Key points: 
 
 Purpose and structure of the systematic review: scope, quality 
and results 
 Search strategy 
 Data extraction 
 Data synthesis 
 Critical analysis of evidence: physiotherapy interventions for 
spasticity, splinting and dynamic orthoses 
 Identified gaps in the evidence 
 Research- implications and future direction 
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In short, it is known that BT is effective and safe for management of focal 
spasticity (RCP et al., 2009; Jost et al., 2014), but it is not known which specific 
interventions can re-direct muscle recovery to maximise outcome. In clinical 
practice both physiotherapy and splinting are commonly recommended 
following treatment with BT. However, splinting in neurology is controversial in 
that it lacks clarity in the available evidence base and thus can be debated as 
clinically contentious. Physiotherapy is widely acknowledged to be clinically 
appropriate for management of spasticity following BT (Ramdharry, 2006; 
Giovannelli et al., 2007, RCP et al., 2009, Wissel et al., 2009) but specific 
interventions used have been less rigorously evaluated. Significantly, dynamic 
Lycra® splinting/orthoses have become an accepted treatment option for 
children with spasticity and movement disorders, however this relatively new 
and potentially beneficial intervention has not been translated to the adult 
population. Consequently, two areas of practice (splinting and physiotherapy) 
were identified worthy of further investigation for their evidenced contribution to 
spasticity management in adults. 
 
The primary research question: Following intramuscular injection with 
Botulinum toxin (BT) for focal spasticity in adults: What is the likelihood that 
there are health benefits of treatment with DEFO (dynamic splint) and 
physiotherapy and usual care compared to usual care alone?  
 
The aim of the systematic review was to be as comprehensive in the search as 
possible yet to ensure the indexed material was equally clinically relevant to the 
identified research question. Therefore the scope and strategy of the review 
was conducted through the method of search strategy, data extraction, 
synthesis and critical appraisal outlined below.  
 
 
2.1 Search strategy  
 
Before the search was embarked upon a clear research question was identified 
in the form of PICOS; Population, Intervention, Comparators, Outcomes, and 
Study Design. From this it was clear which search topic should be included and 
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more importantly which should be excluded. A preliminary review of the 
literature suggested a paucity of evidence of dynamic splinting in adults with 
limb spasticity which provided the rationale to widen the search to include 
studies of children with limb spasticity. The primary population of the study were 
adult therefore only the most relevant articles were reviewed on the use of 
dynamic Lycra® orthoses in children. This was to provide scientific and 
theoretical context for the research. 
 
Population, Intervention, Comparators, Outcomes, Study design 
(PICOS): 
 
Population: People with limb spasticity.  
Intervention: Spasticity management with Botulinum toxin (BT) and 
physiotherapy and/or splinting/dynamic orthosis/Lycra®. 
Comparators: Usual care for spasticity management following BT (RCP et al., 
2009). 
Outcomes: Spasticity related measures of outcome for ‘active’ and ‘passive’ 
function, carer burden, pain, goals and quality measures. 
Study design: All research designs. 
 
Inclusion criteria 
 
 Studies with populations of >40% people with spasticity.  
 Studies that were primarily physiotherapy based rather than 
multidisciplinary based.  
 Studies that included static and/or dynamic splints and orthotics of the 
upper and/or lower limbs in the presence of spasticity with or without 
preceding BT. 
 
Exclusion criteria 
 
 Studies with populations of <40% people with spasticity.  
 Studies of general management of spasticity. 
 Studies that were primarily multidisciplinary based rather than 
physiotherapy based.  
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 Studies that were primarily of electrical stimulation or robotic therapy.  
 Studies that were primarily of non-removable casts.  
 Studies of children that used Lycra® primarily for body stability (body 
suits).  
 
The index words for the search were identified:  
Spasticity, Botulinum toxin, splint, orthosis, dynamic splint, dynamic 
orthosis, Lycra® and physiotherapy. 
 
The search strategy of this topic was supported by the local health library to be 
sensitive and utilise a simple preliminary search. This was repeated a number 
of times to look in more depth for any missed search terms and identify 
limitations in the strategy used.  
 
To ensure relevant articles were reviewed, literature searches were performed 
using NHS Evidence Health electronic data bases: Medline and CINAHL, 
PsychINFO, Embase, AMED; Cochrane; Clinical Evidence in National 
guidelines, Map of Medicine, Database of Abstracts of Reviews of Effects 
(DARE); Dialog DataStar; and hand search. The search covered a period from 
1990-2013. A method of both free text and subject searching was used for 
maximum effect. This method was useful to include new references that had not 
yet had thesaurus terms assigned to them. Appropriate key words and subject 
headings were searched using single and combination terms. Each single word 
or concept was initially searched and then later combined in the Medline 
database and mapped to thesaurus. The subject headings were then listed in a 
hierarchy of broader to narrower terms. Further terms were exploded to include 
all the narrower terms. The final collection for each concept was combined 
using ‘AND’ resulting in the key papers for this review. The search strategy 
included ‘wildcards’ to explore any truncated words such as ‘splint’. This 
strategy is exampled in Appendix 3.  Each search was themed then saved, 
abstracts evaluated for relevance and papers requested that were identified as 
key to the research study.  
 
38 
 
The reference lists of these papers were also reviewed to identify other 
potentially relevant scientific articles or published research evidence. By 
definition it was important to be inclusive in the review strategy to cover both 
published and grey literature so as not to miss relevant papers and evidence of 
clinically important issues. 
 
This search identified the benefit of utilising synopses of synthesised evidence 
and summaries of high quality systematic reviews, such as Clinical Evidence in 
National Guidelines, Map of Medicine, DARE and Cochrane. Reviews were 
then scrutinised further for relevant primary studies. 
 
 
2.2 Data extraction  
This literature review used a combination of themed categorization and critical 
appraisal for contribution of evidence. The evidence was initially assessed for 
quality using the Critical Appraisal Skills Programme (CASP, 2006; 2010). This 
appraisal included: appropriateness of the study design; recruitment strategy; 
procedural rigour; appropriate method of analysis and transparency in reporting 
of results and interpretation of findings. The identified themes were categorised 
in the format of evidence hierarchy as recommended by the Cochrane 
Collaboration (GRADE Working Group, 2004) and presented in tables 
chronologically to provide historical context. 
 
Levels of evidence hierarchy 
 
A preliminary review included a brief overview of spasticity and focal spasticity 
with key papers and guidelines on outcome and efficacy of treatment with BT 
from the perspectives of clinician, patient, health care team or carer and from 
health care delivery. Then papers meeting the inclusion criteria were reviewed 
systematically on physiotherapy interventions for spasticity management and 
splinting in relation to spasticity management.  
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This review aimed to identify gaps in knowledge with the potential to direct 
research for new evidence to support clinical efficacy and patient benefit. The 
SIGN scale (Pandyan et al., 2005, pp. 2-6; RCP, 2008) was implemented due to 
its simplicity and clarity for adequate assessment of study outcomes in the 
classification of evidence (Table 2.1).  
 
Table 2.1 GRADE Levels of evidence (adapted from GRADE Working 
Group, 2004). 
Level of 
evidence 
GRADE 
Guidance 
1++       Level A 
 
1+ 
 
1-           
 
2++       Level B 
 
 
 
 
2+ 
 
 
2-           
 
 
3           Level C 
4           Level D 
-High quality meta-analysis, systematic review of RCTs or 
RCT’s with a very low risk bias for systematic errors. 
-Well conducted meta-analysis, systematic review of RCTs 
or RCT’s with a very low risk bias for systematic errors. 
-Meta-analysis, systematic review of RCTs or RCTs with a 
very low risk bias for systematic errors. 
-High quality systematic reviews of case control or cohort 
studies. High quality systematic reviews of case control or 
cohort studies with a low risk of systematic errors, e.g. 
confounding with a high probability that the relationship is 
causal. 
-Well conducted case control or cohort studies with a low 
risk of systematic errors, e.g. confounding with a high 
probability that the relationship is causal. 
-Case control or cohort studies with a high risk of 
systematic errors, e.g. confounding with a high probability 
that the relationship is causal. 
-Non analytical studies e.g. case report, case series. 
-Expert opinions. 
 
 
 
All titles and abstracts were screened from the searches of the electronic 
databases and obviously irrelevant studies were excluded. The full texts of the 
remaining articles were obtained and assessed for appropriateness based on 
the previously defined inclusion criteria for eligibility.  
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Each study was reviewed and data extracted according to the following data 
extraction criteria:  
 
 Publication details; 
 Study design, setting, inclusion and exclusion criteria, method of 
allocation, risk of bias; 
 Population/ participant details; 
 Intervention details; 
 Outcome measures; 
 Withdrawals, follow-up of participants. 
(Higgins and Green, 2011). 
 
Critical appraisal method 
 
After the data extraction the method used for synthesis of the studies selected 
was by PICOS. This provided a framework for critical analysis. Methodological 
quality was appraised on homogeneity of participant characteristics, 
interventions, outcome measures and study design. 
  
Bias was assessed on the following: random sequence generation and 
allocation concealment (selection bias); blinding of participants and personnel 
(performance bias); blinding of outcome assessors (detection bias); attrition 
bias; reporting bias; and other sources of bias. 
 
 
 
2.3 Results  
Electronic and manual searches yielded a total of n=532 studies (titles and 
abstracts) with n=103 studies after initial screen and after duplicates were 
excluded (Figure 2.1). The remaining studies were scrutinised further and this 
resulted in n=28 studies which fully met the eligibility search criteria. The 
remaining studies n=75 were excluded as they did not meet the eligibility 
criteria. The studies included were categorized numerically for analysis (1-28). 
The search did not identify any exclusively qualitative or mixed method studies. 
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Figure 2.1 Flow diagram of selection of studies 
 
PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The systematic review identified 28 studies in total which met the search criteria 
from 532 studies. These included two sub-groups: 11 studies on spasticity 
management with physiotherapy; 17 studies Splinting and Dynamic Orthoses. 
Records identified through 
database searching (n = 529) 
CINAHL n=116      EMBASE n=127 
AMED n=120        MEDLINE n=138 
PsychINFO n=23   Cochrane n=2 
DARE n=3 
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Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 486) 
Records after screened 
(n = 103) 
Records excluded 
(n = 383) 
Full-text articles assessed 
for eligibility 
(n = 103) 
Full-text articles 
excluded, with 
reasons (n =75) 
Of which: 
n= 68 based on 
exclusion criteria 
n=7 based on 
exclusion criteria but 
potentially relevant 
for scientific and 
theoretical context 
 
Studies included in 
qualitative synthesis 
(n = 0) 
Studies included in 
quantitative synthesis  
(n =28) 
Duplicates excluded 
(n = 46) 
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The search also identified seven studies on best evidence for splinting practice 
and physiotherapy intervention. Although these studies did not meet the 
inclusion criteria they were used as scientific and theoretical background papers 
to inform the design of the study. These studies consisted of: two reviews of 
expert opinion and historical context (Stephenson, 1993; Richardson, 2002); 
three studies defining therapy content and developing intervention tools (Teasell 
et al., 2003; De Wit et al., 2007; Donaldson et al., 2009); an Irish splinting 
survey for evidence on splinting practice consensus (Adrienne and 
Manigandan, 2011), and a health technologies scoping report (Calvert and 
Kelly, 2013). Reviews were included and assessed for further studies which met 
the inclusion criteria for synthesis, excluding any primary study duplicates. 
 
Results are presented chronologically in Table 2.2 Summary of evidence: 
Sub-group 1; Spasticity management with physiotherapy and Table 2.3 
Summary of evidence: Sub-group 2; Splinting and Dynamic Orthoses with 
the levels of evidence according to analysis.  
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Table 2.2 Summary of evidence: Sub-group 1; Spasticity management with physiotherapy (chronological)  
Author Title Study Design Participants 
N= 
Intervention & 
Control 
Outcome Hierarchy 
of 
evidence* 
Tolfts and 
Stiller
1
 
(1997) 
Do patients with 
Traumatic brain injury 
benefit from 
Physiotherapy? A review 
of the evidence 
Review 10 Studies 
investigating 
splinting and 
casting 
Adults with 
Traumatic brain 
injury 
N=123 
Discussion on the 
effect of 
physiotherapy on: 
1. Range of 
movement, 
abnormal 
muscle tone, 
quality of 
movement, 
balance and 
conscious level 
2. The ability to 
perform 
functional tasks 
3. Outcome in 
areas such as 
daily living, 
vocational and 
social domains 
Lack of consistency in the 
treatment techniques used 
by physiotherapists makes 
meta-analysis difficult. 
There are many 
approaches to treatment 
of neurological patients. 
Gaining consensus for 
how a patient should be 
treated for a specific 
presenting problem is 
needed. 
Moderate 
1- 
B 
Low risk to 
systematic 
errors 
Reiter et al
2
 
(1998) 
Low dose botulinum toxin 
with ankle taping for the 
treatment of spastic 
equinovarus foot after 
stroke 
Single-blind RCT N=18 
Adults with 
stroke 
Intervention:  
a. Botulinum toxin 
into the Tibialis 
posterior muscle 
and ankle-foot 
taping 
b. Botulinum toxin 
into several calf 
muscles (control?) 
Gait velocity 
Intervention group: 
p=0.333 
Control: p= 0.182 
 
There were no significant 
between groups 
differences 
Moderate to 
Low 
2+ 
C 
Hyman et al
3
 
(2000) 
Botulinum toxin 
(Dysport®) treatment of 
hip adductor spasticity in 
multiple sclerosis: a 
prospective randomised 
double blind, placebo 
controlled dose ranging 
RCT double-blinded N=74 
Adults with 
Multiple 
Sclerosis 
Four groups  
1. 500U Dysport  
2. 1000U Dysport 
3. 1500U Dysport 
4. Placebo 
Control (placebo) 
All had usual 
Hip abduction measures 
(Goniometry) 
Moderate 
2+ 
C 
Risk of 
external 
validity from 
concurrent 
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study physiotherapy treatment 
Richardson 
et al
4
 (2000b) 
Treatment of focal 
spasticity with botulinum 
toxin: effect on the 
‘positive support reaction’ 
Case report Adults with 
Acquired brain 
injury 
N=4 
Intervention: 
botulinum toxin plus 
specialist 
rehabilitation not 
described 
No control 
Gait velocity: 10 meter 
walk test 
Attention to task: VAS 
Ankle passive ROM 
All 4 cases improved 
functional ability to take 
weight through foot and 
walk. 
Low 
3 
C 
Stark
5
 (2001) Physiotherapy and 
botulinum toxin in 
spasticity management 
Article  
2 case studies 
N=2 
Adults with 
1.Brain 
Haemorrhage 
2. Brain tumour 
Intervention: 
Botulinum toxin 
Physiotherapy 
Descriptive: Bobath 
and Movement 
Science 
approaches 
combined. 
In addition: serial 
casting, seating, 
splinting, taping and 
electrical stimulation 
and home 
programmes to 
include stretching. 
No control 
Tone: MAS, Spasm scale 
Passive ROM 
Pain: VAS 
Upper limb: Frenchay arm 
test, action research arm 
test (ARAT) 
Gait:10m walk test 
General function: 
Functional Independence 
Measure (FIM), Fugl 
Meyer scale and Barthel 
 
Successful outcomes 
using goal setting in 
addition to the above 
Low 
3 
C 
Giovannelli 
et al
6
 (2007) 
Early physiotherapy after 
injection of botulinum 
toxin increases the 
beneficial effects on 
spasticity in patients with 
multiple sclerosis  
Single blind RCT N=38 
Adults with 
Multiple 
Sclerosis 
Intervention: 
Botulinum toxin and 
additional 
physiotherapy  
Control: BT 
Physiotherapy 
described as 40 
minutes daily for 15 
consecutive days of 
specific and regular 
activity through 
passive or active 
and stretching of 
the muscles in the 
injected area 
MAS P<0.01 
VAS P=0.41 (week 2) 
P<0.01 (weeks 4 & 12) 
 
The first RCT to attempt to 
evaluate the effect of 
physiotherapy after 
Botulinum toxin type-A 
injection 
 
Moderate to 
low  
2- 
C 
Risk to 
internal 
validity bias 
with 
concurrent 
treatment  
Risk to 
external 
validity bias 
as not usual 
treatment 
Hellweg and Physiotherapy after Systematic Review 14 studies Literature Results** Moderate to 
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Johannes
7
 
(2008) 
traumatic brain injury: a 
systematic review of the 
literature 
subgroups 
N=3,551 
(excluding 
Lannin et al 
2003b N=28) 
 
systematic search 
of databases 
January 2006 to 
May 2007 
Inclusion and 
exclusion criteria 
specified and 
hierarchy of 
evidence graded 
using SIGN scale 
(RCP, 2008)** 
 Sensory stimulation- A 
 Treatment intensity-A 
 Serial casting-B for 
ROM and C for tone, 
splinting-A (but a more 
recent study suggests 
otherwise) 
 Fitness or aerobic 
training-A 
 Functional training-A 
High 
1- 
B 
Risk of 
internal bias 
Raters not 
determined 
 
Platz et al
 8
 
(2009b) 
Best conventional therapy 
versus modular 
impairment-oriented 
training for arm paresis 
after stroke: A single–
blind multicentre 
randomized controlled 
trial 
RCT Single blind N=148 
Adults with 
stroke 
Intervention: 
a. Inflatable splint 
b. standardised IOT 
c. Control: best 
conventional 
therapy 
 
Fugl Meyer arm motor 
score P<0.001 
TEMPA P=0.0363 
Moderate 
2+ 
C 
Shaw et al
9
 
(2010) 
Botulinum toxin for the 
Upper Limb After Stroke 
(BoTULS) Trial 
RCT-Multicentre 
Single blinded 
N=333 
Adults with 
stroke 
Intervention: 
Botulinum toxin and 
4 weeks therapy 
programme 
Control: Therapy 
programme alone 
Primary measure:  
upper limb function- Action 
research arm test (ARAT) 
Secondary measures: 
Impairment, Activity 
limitation, Pain 
Results- no significant 
difference in function 
between groups P=0.232 
Significant differences in 
favour of intervention 
group in measures of 
muscle tone, strength, 
basic functional upper limb 
tasks and pain. 
Moderate to 
High 
1- 
B 
 
Turner-
Stokes, 
Ashford, 
Nair
10
 
(2010a) 
Physical Therapy and 
Botulinum toxin-A (BoNT-
A)- The temporal 
relationship between 
spasticity reduction and 
functional gain 
Prospective cohort study N=58 
Adults with 
Stroke N=30 
Other brain 
injury N=22 
Other 
neurological 
Intervention: BT, 
splinting, serial 
casting, positioning, 
functional electrical 
stimulation and 
targeted task 
practice. 
Main measures: ArmA, 
MAS, GAS. 
Results: No significant 
changes in active function 
but significant changes in 
passive function MAS 
p<0.005, GAS p<0.005, 
Moderate 
2+ 
C 
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N=6   ArmA <0.005 
Katalinic et 
al
11
 (2011) 
Effectiveness of stretch 
for the treatment and 
prevention of 
contractures in people 
with neurological 
conditions: A systematic 
review 
Cochrane review N=812 
Adults with  
varied 
neurological 
conditions in 
studies: 
Stroke, TBI 
 
Studies that 
measured stretch 
performance in 
terms of ROM (< 7 
months) 
  
(Splinting and 
casting included) 
Primary measures: joint 
mobility and quality of life 
Results (Meta-analyses 
using a random-effects 
model) 
Immediate effect: Mean 
difference 3°; (95% CI 0 to 
7) 
Short term: Mean 
difference 1°;(95% CI 0 to 
3) 
Long-term: Mean 
difference 0°;(95% CI -2 to 
2) 
For all conditions there is 
little or no effect of stretch 
on pain, spasticity, activity 
limitation, participation 
restriction or quality of life 
High to 
Moderate 
1+ 
A 
Risk of 
internal 
validity bias 
with 
confounding: 
combined 
intervention 
for prevention 
and 
treatment  
 
Usual care 
consisted of 
stretches? 
* Oxford Centre for Evidence Based Medicine (2002). Available at: www.cebm.net/index.aspx?0=1047 , Pandyan et al., (2005). RCT- randomised 
controlled trial, N- Number, ROM- Range of movement, CI – Confidence interval, PT=Physiotherapy, OT=Occupational Therapy, MAS – Modified 
Ashworth Scale, VAS- visual analogue scale, ArmA- the Arm Activity Measure, GAS- Goal Attainment Scaling. 
Table 2.3 Summary of evidence: Sub-group 2; Splinting and Dynamic Orthoses (Chronological) 
Author Title Study Design Participants 
N= 
Intervention & 
Control 
Outcome Hierarchy 
of 
evidence* 
Gracies
12
 
(1997) 
Lycra garments Designed 
for Patients with upper 
limb Spasticity: 
mechanical effects in 
Normal Subjects 
RCT Double Blind Adult 
N=10 
Intervention: Upper 
limb garment 
(orthosis) 
Control-normal 
subjects 
Paired T-test P<0.01 
Donning technique 
important 
 
Moderate 
2+ 
C 
External 
validity 
treatment not 
representing 
current 
practice 
Gracies 
 
et Short term effects of Cross-over design Adults  Intervention: Upper ROM using goniometry  Moderate 
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al
13 
(2000) Dynamic Lycra Splints on 
Upper Limb in Hemiplegic 
patients 
Inclusion exclusion 
criteria specified 
18-85 years 
N=16 
 
limb garment 
(orthosis) 
No control 
P<0.01 (Shoulder) 
P<0.05 (Fingers)  
Questionnaire on comfort 
Circumference of arm 
Resting posture 
proprioception 
Spasticity at shoulder 
2+ 
C 
 Internal 
validity- 
threat of co-
intervention 
bias 
External 
validity 
treatment not 
representing 
practice  
Brownlee 
and 
McLeman
14
 
(2002) 
Edinburgh Dynamic Lycra 
splinting trial-assessment 
of hand function 
Pre-experimental design 
Pre/post test 
 
Adults 
N=20 
Intervention: 10 Suit 
10 Upper limb 
garments (8 weeks) 
No control  
Measures of hand function 
Tool non-standardised 
Questionnaire: quantitative 
and qualitative data  
 Low 
3 
C 
Lannin et al
15 
(2003) 
Splinting of the hand in 
the functional position 
after brain impairment: A 
randomized, controlled 
trial 
RCT Adults 
N=28 
Intervention: Static 
splint 
Control: routine 
training (upper limb 
use and stretches) 
Motor Assessment Scale: 
Favoured control: P< 0.2 
Pain favoured Intervention 
group:(95% CI -4.6 to 2.2) 
Results non-significant 
and clinically unimportant 
Moderate 
1+ 
B 
Internal 
validity- 
threat of co-
intervention 
bias 
Lannin and 
Herbert
16 
(2003) 
Is hand splinting effective 
for adults following 
stroke? A systematic 
review and 
methodological critique of 
published research 
Systematic review Adults 
N=230 
19 studies 
 21% RCT(4)  
63% reports of 
case series 
RCT’s analysed by 
Two independent 
raters 
Insufficient evidence to 
support or refute 
effectiveness of splinting 
the hand post stroke 
Moderate 
1+ 
B 
Internal 
validity bias 
risk 
Pizzi et al
17
 
(2005) 
Application of a volar 
static splint in post-stroke 
spasticity of the upper 
limb 
Pre-test post-test Adults with 
stroke 
N=40 
Intervention: static 
splint 
No control 
Passive ROM: P=0.001 
MAS: P=0.002 
Pain: P=0.04 
Spasms: P=0.08 
Splint well-tolerated 
Low 
2- 
C 
Internal 
validity bias 
risk 
Sheehan et  
al
18
 (2006) 
A randomized controlled 
pilot study to obtain the 
best estimate of the size 
of effect of a 
thermoplastic resting 
RCT Adults with 
stroke 
N=14 
Both groups 
received 
intervention of splint 
with differing timing 
of interventions 
Insufficient period of 
contrast between splint 
wearing and non-wearing 
with clinically relevant size 
effect unable to be 
Low 
2+ 
C 
Internal 
validity bias 
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splint on spasticity in the 
stroke-affected wrist and 
fingers 
established risk 
Matthews et 
al
19
 (2007) 
A pilot study of multiple 
case reports to 
investigate the effects of 
dynamic Lycra orthoses 
on gait in children with 
diplegic Cerebral Palsy 
Case series reports 
Repeated measures 
Children  
3-14 years  
N=8 
Intervention: Lower 
limb garment 
(orthosis) 
No control 
10 metre timed walk test 
Physiological cost index 
Patient specific functional 
score 
Questionnaire 
Daily diary 
Low 
3 
C 
Internal 
validity bias 
risk 
Lannin et al
20
 
(2007) 
Effects of splinting on 
wrist contracture after 
stroke. A randomized 
controlled trial. 
RCT 
Blinded assessor 
Adult with 
stroke 
N=63 
Intervention: 
1. Neutral splint 
2. Extended 
splint 
Control: no splint 
Both groups 
received usual 
treatment with 
exception of 
stretches of the 
wrist and long finger 
flexors 
Extensibility of wrist using 
standardised torque 
1. (95% CI -5.4° to 
8.2°) 
2. (95% CI -4.9° to 
2.4°) 
Functional measures 
non-significant 
splinting does not prevent 
loss of range compared to 
no splinting in early stroke 
Moderate to 
High 
2+ 
B 
Watson et 
al
21
(2007) 
An evaluation of the 
effects of a dynamic 
Lycra orthosis on arm 
function in a late stage 
patient with acquired 
brain injury 
Case study Adult 
N=1 
Upper limb garment 
(orthosis) 
 
Patient specific functional 
score 
Writing tests  
Nine hole peg test 
 
Low 
3 
C 
Robinson et 
al
22 
(2008) 
No difference between 
wearing a night splint and 
standing on a tilt table in 
preventing ankle 
contracture early after 
stroke: a randomised trial 
Randomised Trial Adults with 
stroke 
N=30 
Intervention: 
1. Tilt table 
2. Ankle splint 
 
No control 
Both groups 
received 
rehabilitation 
Ankle passive range: 
(95% CI -2.8° to 9.8°) 
 (95% CI -0.4° to2.6°) 
Moderate to 
Low  
2- 
C 
Internal 
validity: threat 
of co-
intervention 
bias 
Lai et al
23
 
(2009) 
Dynamic splinting after 
treatment with botulinum 
toxin type-A: a 
randomized controlled 
pilot study 
RCT Adults with 
stroke 
N=30 
Intervention: Elbow 
Extension 
Dynasplint
®
 
Control: Manual 
therapy and OT 
Elbow active ROM: 
Intervention group 
displayed a mean 33.5% 
change in active ROM 
compared to the control 
Moderate to 
Low  
2- 
C 
Internal 
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Both groups 
received 
rehabilitation 
group (18.7% 
MAS: intervention group 
mean 9.3% improvement 
versus 8.6% in control 
validity: high 
risk of co-
intervention 
bias 
Coghill and 
Simkiss 
24 
(2010) 
Question1. Do Lycra 
garments improve 
function and movement in 
children with cerebral 
palsy (CP) 
Systematic Review 2 RCT’s 
Several case 
studies 
Children with 
CP 
N=76 
Intervention: 
Wearing various 
Lycra
®
 based 
garments 
Mostly case series 
or small numbers in 
studies 
Results: improved 
proximal stability and 
function in some children, 
toileting problems and 
discomfort 
Moderate to 
Low 
2- 
C 
External 
validity risk of 
bias 
Elliott, Reid, 
Alderson, 
Elliott 
25
 
(2011b) 
Lycra arm splints in 
conjunction with goal 
directed training can 
improve movement in 
children with CP 
Randomised parallel 
group trial with waiting 
list control 
Children with 
CP  
N=16 
 
Intervention: 25 
minutes of daily 
active task practice 
related to functional 
goals 
 
No statistical analysis  
After 3 months significant 
improvements were seen 
in 20/28 measures 
Low 
3 
C 
Internal 
validity bias 
risk 
Jung et al 
26 
(2011) 
The effect of a stretching 
device on hand spasticity 
in chronic hemiparetic 
stroke patients. 
RCT Adults with 
stroke 
N=21 
Intervention: splint 
stretching device 
Control: content of 
management not 
reported  
 
 
 
MAS: ANOVA P<0.001  
Overconfident reporting of 
significance by researcher 
Low 
3 
C 
External 
validity bias:  
not current 
practice 
Shamili, 
Amini, 
Forough et 
al
27
 (2011) 
 
Botulinum toxin injections 
or application of splints: 
Impact on spasticity, 
range of motion and 
function of upper 
extremity in chronic 
stroke patients. 
Non-randomised 
Comparison study 
Adults with 
stroke 
N= 28 
Intervention:  Volar-
Dorsal Wrist/Hand 
Immobilization  
splint  
Control: Botulinum 
toxin   
N=18 completed study 
Results: Outcome 
measures (MAS) improved 
in both groups but no 
significance (P<0.05) was 
found between the groups 
Low 
3  
C 
Internal 
validity bias 
risk 
Lannin and 
Ada
28
  (2011) 
Neurorehabilitation 
splinting: Theory and 
principles of clinical use 
Review and theoretical 
rationale 
4 RCTs 
Splinting in 
Adult stroke 
N=112 
Intervention: 
Splinting post stroke 
Static splinting: evidence 
suggests is not effective in 
decreasing spasticity, 
preventing contracture or 
improving activity 
Moderate 
1+ 
B 
* Oxford Centre for Evidence Based Medicine (2002). Available at: www.cebm.net/index.aspx?0=1047 , Pandyan et al., (2005), N= number, 
RCT=randomized controlled trial, CI= confidence interval, MAS= Modified Ashworth Scale, VAS= visual analogue scale, ROM= range of movement, 
OT= Occupational Therapy. 
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2.4 Data synthesis 
The summary of evidence is presented by PICOS evaluation, (in Table 2.4) 
 
Table 2.4 PICOS Summary of findings  
 
PICOS 
Evaluation 
Summary of Evidence 
Population The 28 studies provided data for analysis for a total of (6,028) of the population studied. These comprised total 
of (5,928) adult participants with stroke or neurological conditions. There were (100) children studied in a 
combined number of small studies (case studies or case series) with Cerebral Palsy. (one study also occurred 
in a review, it was not double counted). 
 
Intervention The interventions studied ranged from:  
splinting, orthosis or casting: Tolfts and Stiller1 (1997), Stark5 (2001), Hellweg and Johannes7(2008), Platz et 
al
8
 (2009), Turner-Stokes, Ashford, Nair
10
 (2010a), Katalinic et al
11
 (2011), Gracies
12
 (1997), Gracies 
 
et al
13
 
(2000), Brownlee and McLeman14 (2002) Lannin et al15 (2003) Lannin and Herbert16 (2003), Pizzi et al17 (2005), 
Sheehan et al18 (2006), Matthews et al19 (2007), Lannin et al20 (2007), Watson et al21 (2007), Robinson et al22 
(2008), Lai et al23 (2009), Coghill and Simkiss24 (2010), Elliott et al25 (2011b), Jung et al26 (2011), Shamili, 
Amini, Forough et al27 (2011), Lannin and Ada28 (2011)  
taping Reiter et al2 (1998), Stark5 (2001)  
physiotherapy Tolfts and Stiller1 (1997), Hyman et al3 (2000), Richardson et al4 (2000b), Stark5 (2001) 
Giovannelli et al6 (2007), Platz et al8 (2009), Shaw et al9 (2010), Turner-Stokes, Ashford, Nair10 (2010a) 
Katalinic et al11 (2011), Lannin et al15 (2003), Lannin et al20 (2007), Robinson et al22 (2008);  
muscle stretches and home programme Stark5 (2001), Giovannelli et al6 (2007), Katalinic et al11 (2011), 
Lannin et al15 (2003), Lannin et al20 (2007), Robinson et al22 (2008);  
functional training and task practice Hellweg and Johannes7 (2008), Turner-Stokes, Ashford, Nair10 (2010a), 
Elliott et al25 (2011b);  
fitness training Hellweg and Johannes7 (2008);  
sensory stimulation Hellweg and Johannes7 (2008).  
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Control/ 
comparators 
Control of interventions varied from:  
usual care Reiter et al2 (1998), Hyman et al3 (2000), Richardson et al4 (2000b), Platz et al8 (2009), Katalinic et 
al11 (2011), Lannin et al15 (2003), Lannin et al20 (2007), Lai et al21 (2009) Jung et al26 (2011), Shamili, Amini, 
Forough et al27 (2011);  
timing delay or manipulation Sheehan et al
18
 (2006);  
cross-over design Gracies  et al13 (2000);  
independent raters Lannin and Herbert16 (2003);  
waiting list control Elliott et al25 (2011b);  
none Tolfts and Stiller1 (1997), Stark5 (2001), Gracies  et al13 (2000), Brownlee and McLeman14 (2002), Pizzi et 
al17 (2005) Matthews et al19 (2007) Watson et al21 (2007), Robinson et al22 (2008).  
In addition Gracies12 (1997) used ‘normal subjects’. 
 
Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measures of outcome were assessed with a wide range of evaluation tools   
Standardised measures:  
Goal Attainment Scale (GAS) Stark5 (2001), Turner-Stokes, Ashford, Nair10 (2010a);  
Barthel Stark5 (2001);  
Functional Independence Measure (FIM) Stark5 (2001);  
Fugl Meyer Arm Motor Score Stark5 (2001), Platz et al8 (2009);  
Frenchay Arm Test Stark5 (2001);  
Arm Activity Measure (ArmA) Turner-Stokes, Ashford, Nair10 (2010a);  
Nine hole peg test Watson et al21 (2007);  
Patient specific functional score Matthews et al19 (2007), Watson et al21 (2007);  
Modified Ashworth Scale (MAS) Tolfts and Stiller1 (1997), Giovannelli et al6 (2007), Turner-Stokes, Ashford, 
Nair10 (2010a), Lannin et al15 (2003), Pizzi et al17 (2005), Lannin et al20 (2007), Lai et al23 (2009), Coghill and 
Simkiss 24 (2010);  
Spasm scale Stark5 (2001), Pizzi et al21 (2005);  
VAS for pain Richardson et al4 (2000b), Stark5 (2001), Giovannelli et al6 (2007), Shaw et al9 (2010), Lannin et 
al
15 
(2003), Pizzi et al
17
 (2005);  
VAS for attention to task Richardson et al4 (2000b);  
Action Research Arm Test (ARAT) (Stark5 (2001), Shaw et al9 (2010);  
EQ-5D Katalinic et al11 (2011);  
Goniometry Tolfts and Stiller1 (1997), Hyman et al3 (2000), Richardson et al4 (2000b), Stark5 (2001), 
Giovannelli et al6 (2007), Hellweg and Johannes7 (2008), Katalinic et al11 (2011), Gracies  et al13 (2000), Pizzi et 
al17 (2005), Robinson et al22 (2008), Lai et al23 (2009);  
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Outcomes 
(cont’d) 
Ten metre timed walk test (10MTT) Reiter et al2 (1998), Richardson et al4 (2000b), Stark5 (2001), Matthews et 
al19 (2007);  
Physiological cost index (PCI) Matthews et al19 (2007).  
 
Non-standardised measures:  
General goals Stark5 (2001), Elliott et al25 (2011b);  
Hand function Gracies  et al13 (2000), Brownlee and McLeman15 (2002) Lannin et al20 (2007);  
Quality questionnaires Gracies  et al13 (2000), Brownlee and McLeman14 (2002);  
Daily diary Matthews et al19 (2007);  
Donning technique Gracies12 (1997).  
 
Study design The findings of the study designs reported above included:  
one Cochrane review Katalinic et al11 (2011);  
five reviews Tolfts and Stiller1 (1997), Hellweg and Johannes7 (2008), Lannin and Herbert16 (2003), Coghill 
and Simkiss 24 (2010) Lannin and Ada29  (2011);  
twelve RCT’s Reiter et al2 (1998), Hyman et al3 (2000), Giovannelli et al7 (2007), Platz et al9 (2009), Shaw et 
al10 (2010), Gracies13 (1997), Lannin et al16 (2003) Sheehan et al19 (2006), Lannin et al21 (2007), Lai et al24 
(2009) Elliott et al25 (2011b) Jung et al 26 (2011), which included blinding in Reiter et al2 (1998), Hyman et al3 
(2000), Giovannelli et al6 (2007), Platz et al9 (2009), Shaw et al10 (2010), Gracies12 (1997), Lannin et al20 
(2007), Lai et al23 (2009);  
five experimental intervention designs without randomisation or control Gracies  et al14 (2000), Brownlee 
and McLeman14 (2002), Pizzi et al17 (2005), Robinson et al23 (2008), Shamili, Amini, Forough et al27 (2011); 
one prospective cohort study Turner-Stokes, Ashford, Nair10 (2010a);   
two case report studies Richardson et al4 (2000b), Stark5 (2001);  
one case series Matthews et al19 (2007);  
one case study Watson et al21 (2007).  
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Synthesis of methodological quality 
 
Heterogeneity of the study design, methods and interventions and outcomes 
meant it was not possible to pool data. Meta-analysis of this review was 
problematic. Firstly it was not possible due to the lack of consistency in the 
treatment techniques used. There were many approaches used to treat 
neurological patients with limited evidence of consistency or components of 
usual care. What was clear from the review was that splinting or casting for 
spasticity or contracture management was commonly practiced. Secondly the 
review provided evidence of a wide range of measures for outcome with limited 
consistency in use. Measures varied from those proven valid and reliable in the 
clinical setting to others which were non-standardised. This demonstrated the 
difficulty of evaluating or analysing outcome across studies in neurological 
rehabilitation. Consequently assessment of heterogeneity was not performed. 
Therefore, a synthesis of the best evidence based was presented on the 
GRADE levels of evidence.  
 
Evidence of search summary by GRADE 
 
As shown in the summary table 2.5 the majority of this evidence was assessed 
as low grade (grade C), followed by moderate-level evidence (grade B), only 
one high-level study (grade A) and no very low-level evidence (grade D): 
 
Table 2.5 Summary table of evidence by GRADE 
 
Grade of evidence Number of studies Percentage 
Grade A n= 1 3% 
Grade B n= 7 25% 
Grade C n= 20 72% 
Grade D n= 0 0% 
 
 
The implications of the findings are now discussed specifically with reference to 
physiotherapy and splinting in context of the Spasticity Guidelines (RCP et al., 
2009). According to guidelines the need for provision of orthotics or splinting 
following BT should be reviewed once the clinical effect of BT has occurred 
(RCP et al., 2009, Intercollegiate Stroke Working Party, 2012).  
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Synthesis of intervention outcomes  
 
Interventions in the studies are critically appraised for their contribution to 
evidence for splinting in relation to spasticity management and physiotherapy in 
relation to spasticity management. 
 
 Splinting, orthosis or casting and taping 
 
The theoretical rationale for splinting is based on neurophysiological and 
biomechanical approaches and the supporting scientific evidence (Lannin and 
Ada, 2011). Each study provides evidence on the main constructs; to decrease 
spasticity, decrease contracture and to improve activity. The search on splinting 
and orthotics found studies of casting included in the reviews. Although non-
removable casts were originally excluded in the search criteria a pragmatic 
decision was taken to include studies only if they were within the reviews but 
not in primary studies.  
 
The study by Tolfts and Stiller (1997) of the evidence for physiotherapy in 
people with traumatic brain injury highlighted the lack of good quality evidence 
on which to verify clinical practice. There was inconsistency in splint or cast 
provision and of duration from 2 hours to six months. In summary all ten studies 
evaluated for splinting or casting indicated improved passive range of 
movement, although often of small change, of limited duration and the validity 
and clinical significance was uncertain. This evidence was assessed as 
moderate level (Grade B) due to a low risk of bias in systematic errors. However 
in the study there were individual primary studies of single case studies that 
were likely to have been of a lower Grade.  
 
Stark (2001) argues for the role of physiotherapy in spasticity management but 
that further research is indicated to establish the effectiveness of splinting in 
conjunction with BT. This study was assessed at low level (Grade C) however it 
provides useful clinical detail on outcomes. Clinical treatment options were 
identified following BT that included splint and orthotic provision, stretching and 
serial casting. Two case studies are detailed providing clinical direction. It was 
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identified at the time that national spasticity guidelines for were needed for 
equity and efficacy.  
 
According to Lannin and Herbert (2003) despite the widespread clinical use of 
splints few studies have examined the effect of splinting in a rigorous manner to 
either refute or support its efficacy. The authors conclude that splinting the hand 
in a functional position post-stroke was not effective in the management of 
contractures in the presence of a regular stretching programme. However, there 
was insufficient evidence to support or refute hand splinting in the same 
population, not receiving a stretching programme. In a further study by Pizzi et 
al., (2005) the theoretical basis was explored with reflex inhibitory splinting by 
application of a volar splint. This study was assessed for evidence and 
determined as low (Grade C) due to design characteristics including risk of 
internal validity bias and lack of a comparative control for the intervention.  
 
In the RCT by Sheehan et al., (2006) there was a predictable finding in the 
small sample for the estimation of the best effect-size of the effect of a 
thermoplastic splint on spasticity in the hand. This study was assessed at a low 
level of evidence (Grade C) due to methodological and design issues; with 
timing issues and insufficient period of contrast between splint wearing and non-
wearing with clinically relevant size effect unable to be established. The internal 
validity of the study was also considered at risk of bias.  
 
A study by Robinson et al., (2008) explored if wearing a night splint was a viable 
alternative to using a tilt table as a potential treatment to prevent contracture in 
the ankle following stroke. The findings were inconclusive with both groups 
yielding similar results and both of limited clinical significance <10 degrees 
(mean difference 4 degrees 95%CI -3 to 10). The study was assessed at a 
moderate to low level of evidence (Grade C) due to the study design limitations 
with lack of control and co-intervention bias.   
 
The review by Hellweg and Johannes (2008) included primary studies of 
orthosis and serial casting with some verifiable evidence (Grade B) for 
improvement in passive range of movement, but limited evidence (Grade C) for 
correlation between a reduction in spasticity and serial casting or provision of 
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orthosis. However the studies reviewed did not conduct follow-up and there 
were limitations in rationale for the decision making process of when to apply 
splints or casts. It was also reported there was only verifiable evidence (Grade 
A) to support the recommendation that overnight splinting does not lead to a 
reduction in contracture formation. This corresponds closely to clinical 
experience. Further discussion points raised included negative perceptions of 
patients towards splinting and if splinting plays a role in learned non-use of the 
limb. In conclusion the evidence for proof of efficacy was limited with recognition 
that the evidence should be integrated into clinical reasoning and practice 
decisions.  
 
The RCT study presented by Platz et al., (2009b) investigated the use of an 
inflatable splint versus best conventional motor therapy or impairment-oriented 
training (IOT). The evidence was assessed at a moderate level (Grade C) but 
provides evidence of efficacy in IOT specificity with important clinical 
implications for directed motor recovery rather than static splinting. 
 
Following BT in a study by Turner-Stokes, Ashford and Nair (2010a) the 
physical therapy interventions based on clinical judgement including splinting or 
serial casting. Physical interventions also included positioning, electrical 
stimulation and task practice which introduced a number of variables. The study 
was assessed at moderate level (Grade C) as the design was at risk of bias in 
internal validity due to the heterogeneity of the interventions. 
 
A splint providing a prolonged stretch to the hand in chronic stroke was 
evaluated in a study by Jung et al., (2011). The study was based on the 
neurophysiological theoretical rationale for splinting to reduce hypertonicity.  
The potential for type I error was considered likely due to over-confident 
reporting of the clinical effect (p<0.001) in a small study (n=21). Also the study 
was assessed at a low level (Grade C) due to the risk of bias for external 
validity with the unlikely generalization to routine practice. To date there is 
strong evidence that prolonged wearing a splint (all night) has no additional 
effect in reducing spasticity (Lannin et al., 2007). 
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Despite the lack of consensus over the use of splinting a small number of the 
RCTs were found to be of quality and provided guidance for clinical practice. 
For example, one quality study (Lannin et al., 2007) compared splinting with the 
wrist in neutral overnight versus splinting in an extended position overnight 
versus no splint in 63 stroke participants. The findings indicated no difference 
between groups (mean difference 1 degree, 95%CI 2 to 5) with the clinical 
implication; splinting alone is insignificant. This finding was reinforced by a 
review of splinting Lannin and Ada, (2011) which suggests is not effective in 
decreasing spasticity, preventing contracture or improving activity.  
 
This finding is verified in the (Grade A) Cochrane review (Katalinic et al., 2011). 
It was discovered there was currently no evidence to support the use of a splint 
in comparison to other means to prevent contracture. Of the thirty-five studies it 
was reported stretch over a seven month period does not have a clinically 
important effect on joint mobility, pain, spasticity, activity limitation, participation 
restriction or quality of life.  
 
The study (n=28) by Shamili et al., (2011) used a non-randomized comparison 
of BT and a volar-dorsal immobilization wrist splint. The findings showed 
improvements in both groups in the Modified Ashworth Scale (MAS) but of no 
significance of between group effects. The implications of this are unclear as 
there was a significant rate of attrition with (n=18) completing the study. A risk 
of bias in reporting was considered and evaluated as low level of evidence 
(Grade C).  
 
Despite the paucity of high level quality evidence in the use of splinting, a 
pragmatic approach suggests clinical trials can be used to guide and inform 
future clinical decisions. Furthermore, Lannin and Ada (2011) recommended a 
timely re-focus on the rationale for clinical use of splints with greater emphasis 
to enable activity and improve muscle performance. Two small trials of 
moderate quality by Gracies et al., (1997; 2000) investigated the short term 
effects of dynamic Lycra® splints in adults with upper limb spasticity and both 
indicated promising results. Likewise, the case study by Watson et al., (2007) 
demonstrated patient specific benefits. However in this study there was no 
dynamic splint found in combination with BT. The dynamic splint evaluated by 
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Lai et al., (2009) although classified dynamic was actually a hinged elbow splint 
which was set at a constant range with a constant spring loaded force. The 
study had a number of limitations including a high level of withdrawal and non-
compliance. It was consequently assessed as moderate to low level of evidence 
(Grade C). 
 
A number of studies of effects of Lycra® in children with cerebral palsy indicate 
both acceptability and positive functional outcomes (Matthews et al., 2007; 
Coghill and Simkiss, 2010; Elliott et al., 2011b). However there were some 
compliance and acceptability issues reported (around temperature related 
discomfort, donning and toileting access). The small study using Lycra® based 
garments by Brownlee and McLeman (2002) also provided useful clinical 
procedural detail however it was assessed as low level of evidence (Grade C) 
due to its limitations in lack of control and non-validated outcomes with resultant 
bias of internal validity. Unfortunately there were a number of methodological 
weaknesses in the studies reviewed such as small numbers and lack of valid 
and reliable measures. Indeed evaluation and synthesis of the literature was 
difficult due to the limitations in the evidence base, the methodological 
shortcomings and study inconsistencies in heterogeneity. This is a commonly 
reported issue in studies in rehabilitation. The absence of evidence highlighted 
the gap in the existing knowledge base, which was a key finding that informed 
the direction of the research.                                     
 
Taping was used as an alternative to splinting as an intervention in two studies 
Reiter et al., (1998) and Stark, (2001). The findings were assessed as moderate 
to low (Grade C) but were clinically significant with the recommendation for 
combination treatment of selective BT and ankle-foot taping to optimise foot 
position and gait. 
 
Physiotherapy interventions for spasticity  
 
Physiotherapy is widely acknowledged to have a key role in spasticity 
management (RCP et al., 2009). Although this is primarily anecdotal it was 
evaluated by Stark, (2001) who cited treatment options of: stretching and 
mobilizing; positioning; electrical stimulation; strapping and use of splints or 
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casts in combination with BT. This study also stressed the need for a multi-
disciplinary approach to capitalize on the potential for successful outcome. 
Stark, (2001, p.391) surmised physiotherapists can ‘play a lead role’ in the 
management of spasticity and in particular with the use of BT for focal 
spasticity. She explained, because of their detailed knowledge of neuro-
anatomy and rehabilitation physiotherapists can ensure effective assessment, 
goal setting and direct, or deliver appropriate treatment. However it was detailed 
that further research was needed to clearly identify efficacy of timing and 
specific interventions.  
 
Physiotherapy is evaluated for evidence of beneficial effect on range of 
movement, muscle tone, quality of movement, balance and conscious level in 
traumatic brain injury by Tolfts and Stiller, (1997). The study findings identify the 
limited evidence for efficacy in this area with the exception of splinting and 
casting. The study was assessed as a moderate level (Grade B) despite the 
author’s acknowledgement that the research in this area is limited. One of the 
difficulties was highlighted as the heterogeneity of people with brain injury 
making it difficult for comparison. The paucity of RCTs in this area was 
reasoned to be due to the unethical use of control groups; however it was 
argued it should be possible to compare different treatments for relative 
effectiveness. The absence of evidence does not mean physiotherapy is not 
effective, but highlights the need for well-designed research trials. 
 
A prospective cohort study by Turner-Stokes, Ashford and Nair, (2010a) was 
assessed as moderate level (Grade C). This study included a number of 
combined physical interventions based on clinical judgement rather than by 
design. The study reported no significant change in active function but claimed 
prolonged levels of improvement of passive function (p<0.005). Implications 
drawn included the need for evaluation of the contribution of individual physical 
interventions following BT. 
 
The routine physiotherapy intervention outlined in Lannin et al., (2003) 
comprised of upper-limb motor training and stretching of specific muscles 
identified at risk of developing contracture. This study was assessed as a 
moderate to high level (Grade B) due to its methodological internal validity. The 
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RCT findings showed the hand resting splint does not produce clinically 
significant benefits. However one of the criticisms is that the splinting 
intervention was only of four weeks duration with the implication that longer 
follow-up could provide more meaningful results.  
 
The study by Lannin et al., (2007) began because of a lack of high quality 
evidence to support or refute the use of hand splints to prevent the development 
of contracture in the clinical setting. This was assessed as moderate to high 
level (Grade B) evidence as the trial was well designed and although each 
group only consisted of twenty-one participants the results of between groups 
differences indicated clinically significant effects were unlikely. It can be argued 
splints are usually provided in combination with other therapies and in this study 
the stretches and active upper limb training that usually accompany BT were 
not included. This was considered a design limitation. Hence the study was 
downgraded from a high level (Grade A) to a moderate (Grade B). 
 
A case report by Richardson et al., (2000b) outlined four case studies with lower 
limb spasticity and ‘positive support reaction’ affecting foot placement and 
weight bearing. The evidence was assessed at low level (Grade C) with 
implications for clinical relevance although the specific physiotherapy 
intervention was not detailed. Similarly best conventional therapy was described 
as based on the ‘therapists past experience’ and tailored to the ‘individual 
patient characteristics’ in one arm of the RCT by Platz et al., (2009, p.708). This 
study was assessed at a moderate level (Grade C) but it was able to 
demonstrate specificity of active training was more clinically significant than 
intensity. 
 
Despite general consensus (RCP et al., 2009) on the relevance of combined 
physiotherapy treatment with BT for improved efficacy; what this consisted of 
was not specified. Indeed the evidence for the combination of physiotherapy 
with BT is rather weak; primarily based on the study findings of Giovannelli et 
al., (2007). Intervention in this study was described as stretching exercise; both 
passive and active for 40 minutes, for fifteen consecutive days. This study had a 
risk for both external and internal validity bias. It would not be typical to have 
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this intensive intervention in standard practice. Therefore its findings are not 
generalizable.  
 
Whilst details of components of physiotherapy are underreported a number of 
studies in the review provided clinical direction on the use of muscle stretches 
and identified the benefits of a home programme (Stark, 2001; Richardson, 
2002; Giovannelli et al., 2007; Katalinic et al., 2011; Lannin et al., 2003; Lannin 
et al., 2007; Robinson et al., 2008). Specifically the study by Giovannelli and 
colleagues (2007) recommended treatment with stretching. The efficacy of this 
intervention for the prevention and management of contractures for people with 
neurological conditions has since been reported ineffective in the Cochrane 
review (Katalinic et al., 2011). This review was assessed as a high to moderate 
level of evidence (Grade A) due to its systematic rigor yet there was a risk of 
internal validity bias with confounding: combined intervention for prevention and 
treatment.  
 
The Botulinum Toxin for the Upper Limb after Stroke (BoTULS) trial by Shaw et 
al., (2010) was assessed at a moderate to high evidence level (Grade B). The 
findings of this multi-centre RCT provided valuable insights into clinical efficacy 
and cost-efficiency in physiotherapy treatment of the upper limb post stroke. 
Despite clinical benefits the addition of BT in an upper limb therapy programme 
was found to be not cost-effective. Furthermore there remains considerable 
doubt in the relationship between spasticity and functional limitation. Again this 
raises the question over the efficacy of repeat cycles of BT. 
 
Although re-learning of functional skills is one of the main tasks of 
physiotherapy it is underreported. Modalities of functional training and task 
practice were also evaluated with positive clinical outcomes (Hellweg and 
Johannes, 2008; Turner-Stokes, Ashford, Nair, 2010a; and Elliott, Reid, and 
Alderson, 2011b). There was a high level of agreement of efficacy in clinical 
practice. The evidence was assessed as moderate to low (Grade B and C) for 
these studies. 
 
Another under reported modality of treatment is sensory stimulation. This was 
investigated in a combination of interventions by Hellweg and Johannes, (2008). 
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Both studies included in the review that addressed sensory stimulation indicated 
that insufficient information is available due to poor recording of clinical details. 
Therefore clinical evidence of efficacy cannot be verified. Fitness training was 
further investigated by Hellweg and Johannes, (2008). This review evaluated 
two studies which showed there was a moderate to high level of evidence 
(Grade B) to support this modality however it was unable to find evidence of 
transfer of cardiovascular fitness into levels of activity and participation. 
 
Further evidence is sadly lacking as details of physical therapy modalities 
reported by Tolfts and Stiller, (1997); Hyman et al., (2000) and Stark, (2001) 
demonstrate a lack of consistency in approaches to treatment of neurological 
patients. 
 
 
2.5 Discussion of the findings  
 
From the findings there was little consensus over the directed use of 
physiotherapy or splinting and there was an inadequate evidence base on 
which to inform effective practice. The literature review is discussed on its 
strengths, limitations and implications of the findings. 
 
Strengths of the review 
 
The literature was systematically reviewed and the findings have provided 
direction for this study. A gap in the evidence base was discovered which 
identified a need for further investigation of a dynamic splint intervention. The 
review set out specific study aims, criteria and methods for search strategy, 
data extraction and synthesis of the findings. Critical appraisal discovered the 
majority of the findings provided low grade evidence (grade C), followed by 
moderate-level evidence (grade B) on the use of splinting and or physiotherapy 
for the management of spasticity. There was only one study (Katalinic et al., 
2011) that was assessed at high to moderate level of evidence (Grade A). This 
finding provided evidence of little or no clinical effect of stretch on range of 
movement. The review findings indicated a wide variation in practice and 
measures used. There was no evidence of mixed method studies or in depth 
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qualitative studies on the use of dynamic movement orthoses for spasticity 
management. 
 
Limitations of the review 
 
Limited availability of literature dictated the decision to be inclusive of studies 
with wider aetiology than spasticity alone. The decision to include reviews was 
taken based on the study meeting the inclusion criteria of studies with 
populations of >40% people with spasticity. For example the Cochrane review 
(Katalinic et al., 2011) included people with different neurological conditions that 
presented with movement disorders including spasticity. Primary studies within 
the reviews could have been scrutinised in more depth. The strict eligibility 
criteria was also difficult to maintain as several studies included additional 
interventions or combined approaches (Tolfts and Stiller, 1997; Stark 2001; 
Hellwegg and Johannes, 2008; Turner-Stokes, Ashford and Nair, 2010a; 
Katalinic et al.,2011) some of which were not detailed. In addition some of the 
reviews included primary studies with serial-casting as well as splinting which 
was identified as a further limitation in this review. This demonstrated the 
complexity of evaluating clinical research using multi-modal approaches.  
 
Many of the studies did not have rigorous designs including randomization or 
case control (Gracies et al., 2000; Brownlee and McLeman, 2002; Pizzi et al., 
2005; Robinson et al., 2008; Shamili et al., 2011), or did not report what usual 
care consisted of (Hyman et al., 2000; Richardson et al.,2000b; Lai et al., 2009; 
Jung et al., 2011). In addition few of the studies admitted bias, (Shadish et al., 
2002) from selection, blinding, assessment, or attrition.  
 
A number of the studies were case series or case reports consisting of small 
numbers with limited population, or ecological generalizability. In addition, only 
one person graded the evidence which does not provide a high level of 
credibility. This review was over-inclusive and should have adhered more to the 
eligibility criteria; however it could be argued the findings provided valuable 
insight for the proposed study. 
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It was worth noting that even though the hierarchy of evidence was graded it 
used an idealised system and therefore cannot be definitive. Thus an RCT of 
excellent quality could be more reliable than a systematic review of average 
quality primary studies. It is acknowledged there was some difficulty in 
application of the evidence level consistency in reporting systematic reviews 
which included poor quality studies. Thus conclusions of systematic reviews are 
often limited by low methodological quality of included trials and the absence of 
key comparisons for clinical use. This is seen in reviews and in summaries of 
evidence such as in clinical (evidence based) Guidelines and Database of 
Abstracts of Reviews of Effects (DARE). By implication the GRADE of the 
evidence could be raised or lowered. There is therefore a need to design trials 
with more sensitive measures of treatment effect and to identify patients who 
will obtain most functional benefit. In addition to grading evidence the 
summaries should clearly identify methodological components and bias. 
 
Implications of the findings 
 
Due to insufficient evidence and some ambiguous reporting on effectiveness of 
both splinting and physiotherapy practice it was identified that a pragmatic 
research approach was needed. The findings are now discussed in light of the 
identified gaps in the knowledge and implications for this study. 
 
The gap is closing between scientific understanding of spontaneous recovery of 
the CNS and the extent to which it can be translated into effective rehabilitation 
techniques. This review aimed to bring neuroscience (Chapter 1. p.24) closer to 
everyday clinical practice for the combined benefit of patients and the delivery 
of healthcare. A framework for neurorehabilitation should integrate theory, 
scientific evidence and clinical experience tempered by patient values (Sackett, 
2002).  Systematic review of the available scientific evidence and critical 
analysis of the findings were integrated using a pragmatic clinical approach to 
provide direction for further investigation.  
 
A gap in the knowledge was identified to be the lack of reported scientific 
evidence in the combination of BT and dynamic splinting for the management of 
limb spasticity. Scientific evidence proposes the rationale for prolonged stretch 
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(as applied by splinting) to modify spasticity (Chapter 1.). Further consideration 
is required on a clinical level for optimizing motor performance. Several studies 
propose further research is needed to explore the efficacy of dynamic splinting 
(Gracies et al., 2000; 2007; and Lannin and Ada, 2011). In addition the 
components of physiotherapy conventional treatment that contribute to the 
rehabilitation of muscles following spasticity are not fully understood. Some of 
the concerns of splinting study limitations documented by Lannin and Herbert, 
(2003) include: splinting acceptability and adherence; type and position of 
splints used and variance in splint protocols. Acceptability and patient 
experience was found lacking and good qualitative studies are required 
(Andringa et al., 2013). 
 
The evidence base for providing splints is both conflicting and contentious 
causing much debate around efficacy in clinical practice (Adrienne and 
Manigandan, 2011). Whilst revised national splinting guidelines provide 
theoretical rationale and clinical guidance (Kilbride et al., 2015) the evidence 
base remains inadequate. Studies to date have commonly investigated static 
(rigid) splints but there is some potential for future research in the efficacy of 
dynamic splints and active muscle performance. Emerging literature suggests a 
need to reconsider splinting rationale to a practice that embraces the potential 
benefit of newer technologies that deliver ways of improving muscle 
performance (Lannin and Ada, 2011). Dynamic orthoses have the potential to 
offer this benefit to the adult population with focal spasticity; by directing optimal 
re-alignment of functional muscle activity rather than restricting movement.  
 
The theoretical basis of using Lycra® in the management of spasticity (as 
opposed to movement disorders) is that DEFO provides prolonged stretch and 
compression ‘for stability with directive forces for optimising postural control’ 
(Matthews, 2008). The evidence for splinting in this client group is founded on 
the neurophysiological and biomechanical mechanisms of deep pressure and 
improved proprioception leading to ‘improved positional limb and body 
awareness, improving muscle activation and movement control’ (Matthews, 
2008). The DEFO provides the possibility to reduce velocity dependent hyper-
reflexia in spasticity, a positive feature associated with UMNL. The theoretical 
basis for this is the direct modulating effect of normalisation on the neural and 
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non-neural components of muscle tone. The former neural components include 
proprioceptive reflexes (stretch reflex) and the latter non-neural components of 
tone include visco-elastic properties, muscle fibre type and muscle length-
tension relationship. DEFO also provides flexibility and allows movement with 
proprioceptive sensory feedback (Gracies et al., (2000) on posture and 
performance. This interactive characteristic is an advantage over rigid splints 
considering spasticity is a velocity-dependent ‘sensori’-motor disorder (Pandyan 
et al., (2005). Thus it can be argued it is worth considering the use of Lycra® in 
spasticity management in addition to its use in movement disorders. 
 
Further research is required to determine the long term effects of dynamic 
splinting and which specific patient groups might benefit. The small study by 
Elliott et al., (2011b) suggested upper limb Lycra® splints were of some benefit 
with carryover however there were limitations to the study methodology, 
reporting and the findings should be treated with caution. The need for further 
evidence based research is reiterated in a Scoping report (by Calvert and Kelly, 
2013) with studies determining larger numbers, longer follow-ups and 
homogeneity in the type of garment design. Although this report included adults 
there was no published evidence available either to support or refute clinical 
benefit or cost-effectiveness in this population. There is a noticeable gap in the 
research with little evidence available for DEFO Lycra® worn as a splint in the 
treatment of adults with cerebral palsy and limited evidence available for 
neurological conditions such as stroke and multiple sclerosis.  
 
A review of physical therapy interventions for improving motor function in adults 
with neurological impairments following BT is needed. The studies in this review 
provided direction for the proposed research design. In addition five of the 
studies excluded provided further direction in that they were used to inform a 
data capture form for the physiotherapy modalities in this study (Stephenson, 
1993; Richardson; 2002; Teasell et al., 2003; De Wit et al., 2007 and Donaldson 
et al., 2009). Further search of the literature discovered a recent review of 
rehabilitation therapies after BT by Kinnear et al., (2014) which again could be 
used to inform future studies on best practice after BT. 
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2.6 Summary   
 
In this review the physiotherapy and splinting topics were critically appraised 
and assigned into two sub-groups of summary tables: Table 2.2 Spasticity 
management with Physiotherapy and Table 2.3 Splinting and Dynamic 
Orthoses. The evidence presented from the systematic review confirmed the 
need for further research both in the management of spasticity following BT and 
to determine the potential role of dynamic orthoses. There was also a gap in the 
existing evidence to determine which physical interventions are of most benefit 
in achieving a clinical outcome and reducing patient burden. 
 
Whilst it was not possible to undertake formal meta-analysis of the evidence 
reviewed due to heterogeneity, there were some conclusions to be drawn. 
There was clearly a gap in the existing body of knowledge to explore which 
clinically relevant treatment is best delivered following BT during this time-
limited ‘window of opportunity’. Whilst there is some evidence of efficacy and 
acceptability in the use of dynamic Lycra® orthoses with children there is limited 
evidence in the adult population and this is worth exploring further.  
 
There are potential gains from transitional research in the use of dynamic 
orthoses in neurology and this warrants further exploration. These studies 
provide direction to ‘re-focus’ on muscle performance and functional activity 
(Lannin and Herbert, 2003; Gracies et al., 2000) rather than inhibiting abnormal 
reflex activity with splints. This review identified dynamic splinting as a possible 
adjunct to usual care and physiotherapy following BT. This review informed a 
pilot feasibility study to investigate the efficacy of DEFO intervention and 
physiotherapy following intramuscular injection of BT in the adult population. 
The justification for the chosen methodology for this study is presented in 
Chapter 3. 
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Chapter 3  
Methodology  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
 
This chapter presents the rationale for the chosen research methodology, with 
justification for the design of this study. Scientific and clinically relevant literature 
was reviewed systematically (in Chapter 2) providing context and relevance to 
this feasibility study. This outlined gaps in the current research evidence for the 
management of limb spasticity in adults with dynamic splinting.  
 
This study has built on evidence for the need to evaluate a potential new 
treatment to effectively direct muscle activity in limb spasticity (Lannin and 
Herbert, 2003; Gracies et al., 2000). The DEFO is proposed as an intervention 
with the potential to deliver this by dynamic prolonged stretch of muscle for both 
active and passive care in adults with limb spasticity. In this chapter the 
methodology is considered that would provide greatest rigor in evaluation of the 
DEFO intervention in a clinical setting.  
 
Research deficiencies directed the need to evaluate the DEFO intervention from 
a qualitative perspective. The literature identified a need to gather not only 
quantitative data but to explore results in more depth and detail from the 
Key points: 
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participant and wider stakeholder perspectives (Hanley et al., INVOLVE, 2003). 
The methodology was chosen to provide practical insights into the feasibility, 
potential efficacy and acceptability of DEFO as a likely new treatment following 
BT. The design for each component was guided by the research problems. 
 
 
3.1 Research considerations  
 
Research in healthcare is widely acknowledged to be multifaceted with complex 
interventions based in complex clinical environments (Medical Research 
Council (MRC), 2008; Richards and Borglin, 2011; Thompson and Clark, 2012; 
Richards et al., 2014). Accordingly the research was founded on a theoretical 
basis of the (MRC, 2000; 2008) ‘Complex Intervention Framework’. This 
Framework provided guidance for a phased approach by clearly defining the 
steps in the research process. Key elements of the MRC Framework include: 
‘development, feasibility/pilot work, evaluation and implementation’.  
 
The complexity of clinical research requires an approach that can evaluate its 
constituent components and their inter-relationships. Accordingly adequate 
development and pilot work is considered important. Consequently this study is 
informed by the Framework (MRC, 2000; Craig et al., 2008) with due 
consideration for the methodological and practical issues that arise in clinical 
research. It provides the research approach to examine methodological, clinical 
and procedural unknowns. 
This phased model (Figure 3.1). tests the key elements of uncertainty, namely 
the practical procedures and thus enables the researcher to identify the 
common components that could influence outcome. The Framework is 
considered appropriate to examine a complex clinical area, such as 
neurological rehabilitation. In short, for clinical research to be useful it is 
important to establish clinical feasibility, compliance and acceptability. 
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Figure 3.1 Flow chart: The revised MRC Complex Interventions Framework 
(Craig et al., 2008, p. 980) 
 
All phases are intrinsically linked but may not follow cyclical sequential steps. 
The MRC framework has been further refined and updated. It is summarised to 
include a number of key points;  
 
 The phased processes may not follow a linear sequence 
 Experimental designs are preferable to observational studies but 
may not be practicable  
 The understanding of processes and outcome evaluation are 
important  
 Local context can influence standardisation, study reports must be 
sufficiently detailed for replication and add to knowledge.  
                                                                          Craig et al., (2008, p. 979) 
 
The research study presented followed the first two phases of ‘development’ 
and ‘feasibility testing’ in the revised MRC (Craig et al., 2008) phased process 
of ‘development-testing-evaluation-implementation’. This Framework was used 
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as a modelling process to inform feasibility for a larger study. Both a pragmatic 
and iterative approach was adopted to identify the main interacting components 
in the study and identify weaknesses of the design for further refinement. It was 
not within the scope of a small feasibility study to assess cost-effectiveness 
from a health economics perspective. Thus, this study aimed to build on the 
existing evidence, and follow the early developmental and feasibility testing 
research phases as a precursor to inform a larger study. A pilot study was 
proposed to test the identified complex intervention (DEFO), addressing all the 
unknown feasibility, acceptability, and recruitment, adherence and effect-size 
components.  
 
Mixed method approaches are increasingly being used together in the context 
of health and health service research (Pope and Mays, 2006). Quantitative 
methodology involves research that is protocol driven and designed, so that it 
can be replicated. By contrast, qualitative methodology requires sufficient 
flexibility to enable the researcher to respond actively to discoveries during the 
research process (Holstein and Gubrium, 2011). By combining the two 
approaches greater depth and understanding can be ascertained with the sum 
of the whole greater than its constituent parts (Onwuegbuzie and Teddlie, 2003; 
Pope and Mays, 2006; Johnson et al., 2007; O’Cathain, et al., 2010; Wisdom et 
al., 2012). This was considered an appropriate methodological approach for 
clinical research as in this study.  
 
Furthermore in a modern health service it is essential to look at the perspective 
of different stakeholders. Patient experience provided valuable insight into how 
care should be delivered. Perspectives of patients and carers were used to 
inform clinical care and research design of this study (Hanley et al., INVOLVE, 
2003). The pilot study explored what could be feasibly delivered and identified 
whether there was any burden effect on those involved. Certainly the issues of 
clinical acceptability and adherence were critical to understanding the feasibility 
of the research study. In addition to the considerations above, the specific 
design was tailored to the identified research questions. The research 
governance followed ethical practice including Good Clinical Practice and the 
Research Governance Framework for Health and Social Services (2005), NHS 
Trust R&D approval, Data Protection Act, (1998). 
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3.2 Study methodology and rationale 
 
Methods considered 
 
Quantitative method alone (pilot RCT) 
 
Initially a quantitative pilot RCT was considered appropriate to answer the 
research questions. This was in line with MRC (Craig et al., 2008) 
developmental methodology; using a pilot RCT with the primary objective of 
testing the feasibility of an intervention protocol. The RCT method is placed in 
the medical and science research hierarchy of the ‘Rolls Royce’ gold standard 
for rigour and construct validity. In this method the researcher, by control, has 
deliberately attempted to remove the effects of any variable other than the 
independent variable (the intervention to be tested) that might affect the 
outcome. However, this method alone would provide insufficient data to 
evaluate the intervention in a complex healthcare setting. Although it was 
possible to answer the primary question of likely health benefit it was unable to 
explain the results. The pilot RCT method alone was unlikely to fully answer 
important research questions of participant and clinician acceptability. It was for 
this reason that further qualitative methodology was selected for analyses of 
acceptability and identified health benefit from the participant and clinician 
perspectives.  
 
Qualitative method alone (focus groups and interviews)  
 
A qualitative design alone could be used to provide meaningful data (Charmaz 
and Bryant, 2011) on the acceptability of the DEFO intervention through focus 
groups and interviews. However it was likely this would have led to further 
developmental work as the qualitative method would have been insufficient to 
fully address the research problems. This iterative method could have been 
developed to inform a protocol based on the information gathered. It supports a 
phased approach based on the MRC (Chapter 3.1.) Framework. However, it 
was unlikely the findings from this method alone would have answered all of the 
complex intervention uncertainties that were needed to inform a larger study. 
Additional factors would not be identified such as likely recruitment rates, 
73 
 
retention rates and adherence (Thabane et al., 2010). This design would not 
provide data for estimating effect-size for a larger study. Consequently it was 
unlikely evidence from a qualitative study alone would provide sufficient 
justification to support research funding for a larger study. 
 
Single study or case-series 
 
Further research methods considered were single case study or case-series 
design. Both designs are considered applicable in the field of neurological 
rehabilitation research (Tolfts and Stiller, 1997; Richardson, 2000a). These 
methods acknowledge the likelihood of small numbers eligible for recruitment to 
a study in people with spasticity that would meet the eligibility criteria. A case 
study or single case-series design was less likely to have had impact on service 
demands including clinical capacity. Both were recognised as clinically feasible 
for that reason. This study model could have provided an alternative approach 
with optimal recruitment and increased potential for procedural application in the 
clinical area of study. However, the researcher considered both had lower 
construct validity from a research hierarchy stance when compared to the gold 
standard RCT.  
 
This design and methodology did not acknowledge the developmental MRC, 
(2000; 2008) Framework approach for fully testing complex interventions in 
feasibility and pilot work for health evidence. Although a case study would 
provide valuable clinical detail of specificity it has less construct validity for 
generalizability to a relevant population. Neither this design, nor the case series 
model would test all of the procedural and unknown constituents of the 
intervention in a clinical setting. A defined objective for this study was to 
determine what effect-size is needed for this. This outcome would not have 
been provided from either a case study or a case-series design. Consequently 
this methodology and designs were not considered appropriate for this study. 
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Mixed methods 
 
A mixed methodology was chosen to evaluate the DEFO intervention in a new 
population (adults with focal spasticity) and address the uncertainties for a 
larger study. Justification for this is detailed below. 
 
Although this methodology is not new in healthcare research (Morgan, 1998), it 
is considered by leading researchers in the field (Collins and O’Cathain, 2009; 
Johnson, Onwuegbuzie and Turner, 2007) as still in the developmental phase 
and accordingly open to individual interpretation. There has been an increasing 
popularity in the use of mixed methods since the late 20th century challenging 
Howe’s (1988) incompatibility thesis that quantitative and qualitative research 
should not be mixed. Howe argues that each methodology has its own 
paradigm or worldview which is based on differing philosophical assumptions. 
Howe (2004) challenges mixed methodology further in that it marginalizes 
qualitative interpretive approaches yet privileges post positivism. The basis for 
this mixed methodology’s recent popularity in healthcare has been supported by 
the MRCs interest (Craig et al., 2008) and indeed recognition of the importance 
of qualitative research designs. There are a number of contrasting definitions for 
practice guidance that are informed by either philosophy and/or methodology 
(Teddlie and Tashakkori, 2009; Creswell and Plano Clark, 2007; 2011). This 
study research methodology was based on the definition by Creswell and Plano 
Clark, (2007, p.5) in which;  
 
‘mixed methods are characterised by the integration of a qualitative and 
quantitative approach (at any phase in the research process)’.  
 
The mixed methods approach is based on a worldview of pragmatism which is 
founded on an epistemology of knowledge that is formed by both subjective and 
objective human values (Creswell and Plano Clark, 2011). The pragmatic 
perspective for this study with a focus on ‘what works’ was based on the ideas 
by Tashakkori and Teddlie, (2003, p.713) who also acknowledge the role and 
values of the researcher in the process of interpretation. This method is justified 
to address the complex reality of healthcare research (MRC, 2008; Richards 
and Borglin, 2011; Richards et al., 2014). It has been highlighted by others 
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(Johnson and Onwuegbuzie, 2004; O’Cathain, et al., 2007; O’Cathain, 2009) 
that regardless of ideology, pragmatic mixed methods approaches are justified 
in health services research.  
 
The rationale for choosing a quantitative pilot RCT study component is that it is 
widely acknowledged to be sufficiently robust for analysis of a potentially 
relevant and clinically practicable driven protocol. The RCT method is described 
as the ‘gold standard’ of evaluation. However, it is important to make clear that 
this study component was deliberately designed as a ‘feasibility’ pilot RCT. In 
essence a small scale feasibility study is not fully powered and therefore 
unlikely to produce a statistically significant outcome of efficacy. Accordingly 
this study design was deliberately chosen to address relevant research 
feasibility questions on the estimation of recruitment rates, refusal rates, 
retention rates and adherence rates (Thabane et al, 2010) for a larger study. A 
feasibility study which is not powered provides the possibility for effect-size 
estimates based on evidence of feasibility rather than a definitive effect-size 
calculation such as in a fully powered study.  
 
The pilot RCT was purposefully designed with blinded randomization to address 
the four main problems of potential study systematic bias (Shadish et al., 2002). 
The potential for selection, performance and detection bias were addressed by 
randomization and blinding. One of the outcomes of this study was to evaluate 
 the rate of withdrawals (attrition bias) from the study. Quantitative quality 
criteria are commonly agreed to include internal validity, external 
validity/generalisability, reliability and objectivity (Lincoln and Guba, 1985). 
These criteria are reviewed in Chapter 8.3. 
 
A qualitative phase was established to address uncertainties around the DEFO 
intervention. The quantitative method alone would provide insufficient data to 
answer the research questions of participant and clinician acceptability. The 
rationale for using a qualitative phase was to explore the research procedural, 
methodological and clinical issues after completion of the intervention phase of 
the quantitative design. This combines feasibility and acceptability detail 
provided a rich qualitative supplemental data strand (Creswell and Plano Clark, 
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2011) for analysis of the procedural, methodological and clinical issues 
experienced by participants and clinicians. 
 
A mixed methodology was deliberately chosen in this study to explain and 
strengthen the findings of each method through integration (Onwuegbuzie and 
Teddlie, 2003). In this method the data sets from quantitative and qualitative 
results are analysed separately, then integrated (Chapter 3.5) by triangulation 
of the findings (Silvermann, 2011; Farmer et al., 2006; O’Cathain et al., 2010). 
This provides the opportunity for more depth and breadth to the analysis and 
interpretation (Denzin and Lincoln, 2000; Johnson et al., 2007; Wisdom et al., 
2012). Fundamentally this was why the research methodology chosen was both 
quantitative and qualitative in the study design. The multiple advantages of the 
mixed methods approach are similarly outlined by Creswell, (2003); 
credibility/trustworthiness, practicality, complimentary (naturalistic and post-
positivist) and incremental in terms of building a knowledge base.  
 
A mixed method was the most appropriate approach in this study based on the 
rationale that ‘feasibility’ was the key objective for this study. The reason for 
selecting this method was determined on the basis of exploring the important 
feasibility issues. The underlying aim of this research was to explore 
implications for a larger study.   
 
 
3.3 Rehabilitation and health related measures 
Rehabilitation involves an interdisciplinary team approach with a distinct 
structure and delivery (Wade, 1992) of holistic patient-centred goals based on 
an underlying knowledge of the International Classification of Functioning (ICF) 
(WHO, 2001) domains of functioning; body function, activity limitation and 
participation restriction. Accordingly it was planned to assess potential clinical 
efficacy by health-related measures in each domain. Objective markers and 
outcome measures should be selected as both reliable and valid (Wade, 1992).  
It has been widely acknowledged that measuring effectiveness in neurological 
rehabilitation is problematic due to factors including changing baseline, disease 
progression and co-morbidity (Wade, 1992; Turner-Stokes, 1999; Tyson et al., 
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2008; Wissel, et al., 2009). The dual role of a researcher and clinician is to 
formulate clearly focused and relevant questions (Straus and Sackett, 1998). 
Outcomes were selected for measurement of potential clinical importance to 
identify the effect-size for a larger study and to identify specific health benefits. 
Hence measures were selected to find a clinical effect most likely to measure 
the DEFO intervention rather than for a definitively powered study. Of equal 
consideration was to measure the intervention from a clinical perspective for 
feasibility of protocol implementation in context of clinical practice in a 
community setting. A battery of recommended measures was chosen to assess 
functioning and disability outcomes in accordance with spasticity guidelines 
(Turner-Stokes and Ward, 2002; RCP, et al., 2009). The ICF model shown 
below, (in Figure 3.2) is accompanied by a description of each level of 
outcome. 
Figure 3.2 Representation of the model of International Classification of 
Functioning (WHO, 2001; 2002, p. 9)  
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Impairment Level 
 
Symptoms that have an impact at a physical level are often reported as a 
common concern by clinicians and patients. This is because physical symptoms 
(for example pain) can have a significant impact on wider function and 
participation levels and overall health and well-being. The measures of 
spasticity and pain were assessed as levels of impairment in this study.  
 
Activity Level 
 
The level of activity was used as a measure for specific functional activities 
such as walking, dressing and washing. This was reported as ‘active’ functional 
outcomes. Activity levels are commonly measured in terms of capacity and 
performance. 
 
Participation Level 
 
Spasticity has a significant impact on participation level by default due to the 
consequential effect of limitations imposed by impairments such as pain and 
spasms. Participation has been explained by the societal and personal roles 
and interaction that the person fulfils including such activities as work, 
parenting, self-care and relationships. The most commonly reported difficulty 
was in the ability to care for a limb which has altered movement. This was often 
at risk of developing secondary complications such as contractures and 
pressure ulcers, leading to increased carer burden (Bhakta et al., 2000; RCP, et 
al., 2009). Literature evolving in this area has helped to demonstrate the 
importance of measuring the impact of an intervention that takes into account 
not only the effect on the patient but also their associated care and burden or 
costs (Shaw et al., 2010; Ashford, Slade and Turner-Stokes, 2013). To date the 
exponential development of measures has also helped to categorize disability in 
terms of burden.  
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Selecting measures for the evaluation of predicted health benefits    
 
The selection of outcome measures was based on the predicted likely added 
health benefits from the DEFO intervention. These were identified by the 
researcher to include measures that correlated with rehabilitation aims to 
maximise functional potential and minimise secondary complications (RCP et 
al., 2009). The evidence to support the relationship between reduced spasticity 
and functional gain is weak (Sheean, 2001; Francis, et al., 2004). Although the 
reduction in spasticity following BT may not result in improved function, there 
are likely to be associated positive outcomes, which can be evaluated at levels 
of impairment, activity and participation. It can be argued the impact on carer 
burden can also be significant (Bhakta et al., 1996; 1999; 2000) and should be 
used as a measure of benefit. Accordingly, the measures for this study were 
selected based on a rationale of specificity and relevance to the predicted likely 
health benefits associated with the DEFO intervention during the window of 
opportunity following BT. 
 The likely health benefits were identified as reduction in pain (Bergfeldt et al., 
2006; RCP et al., 2009) and associated comfort, reduction in care burden 
(Bhakta et al., 2000; Ashford et al., 2013; 2014), improved upper and lower limb 
function and improved quality of life. More importantly the researcher 
recognised the need to evaluate potential health benefit from the patient 
perspective with identified goals for real-life outcomes. Measures for the study 
were also evaluated for reliability and sensitivity.  
Measures selected  
Although this study aimed to use valid and reliable measures it is acknowledged 
that appropriateness (relevance to research) of the measure is also important. 
Measures that could demonstrate proven sensitivity of clinical effect and 
demonstrate patient-centred outcomes of significance were considered for this 
study. 
 
The measure for ‘goal attaining’ that was first introduced in the 1960’s by 
Kirusek and Sherman has since been widely adopted by clinicians to 
demonstrate predictive clinical outcome. The primary measure (Appendix 7) 
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Goal Attainment Scaling (GAS) score was selected on the basis of reported 
predictive sensitivity for real-life outcomes which are significant to the patient 
(Ashford and Turner-Stokes, 2006; Turner-Stokes and Ashford, 2007; Turner-
Stokes, 2009). Also GAS scores were found to correlate with a reduction of 
spasticity and global benefit following BT (Ashford and Turner-Stokes, 2006). A 
further study indicated that GAS may identify functional benefits not 
demonstrated by other functional measures (Turner-Stokes et al., 2010b). 
Procedural details of this measure are explained in Chapter 4. 
 
Additional measures selected (Appendix 10) were tools previously 
administered: Visual Analogue Scale (VAS) for pain; Leeds Arm Spasticity 
Impact Scale (LASIS) (Bhakta et al., 1996); Arm Activity measure (ArmA) 
(Ashford et al., 2008) and 10 meter timed walk test (10MTT) (Watson, 2002). At 
the onset of this study the LASIS and ArmA were relatively new tools 
recommended (RCP et al., 2009) for clinical outcome and were undergoing 
evaluation for reliability. Additional measures of European Quality of Life-5 
Dimensions (EQ-5D) (EuroQol Group©, 1990) and Activity Log had not been 
used prior to the study. 
 
The symptom of pain is reported to be commonly associated with spasticity 
(Bergfeldt et al., 2006; RCP et al., 2009). Pain impairment was measured using 
the standardised nominal Visual Analogue Scale (VAS). It is reported a reliable 
measure even with modification for communication or visuo-perceptual 
problems as those that may result in stroke (Jackson et al., 2006). One such 
modification available was the Wong-Baker FACES® Pain Rating Scale 
(Hockenberry et al., 2005) with six pictorial representations of faces with 
incremental changes of happiness or sadness across the line. 
 
The European Quality of Life-5 Dimensions (EQ-5D) questionnaire is used to 
measure health benefits and this has been found both reliable and 
generalizable to neurological conditions (EuroQol Group©, 1990). It can also be 
used in the clinical and economic evaluation of health care (EQ-5D-3L 
UserGuide v5, 2013). However, in this small feasibility study there was no 
intention to use this measure for cost-analysis. This measure was selected for 
evaluation for use in a designated study population to inform procedural 
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feasibility for a larger study and for its simplicity to complete. It was registered 
with the EuroQol Group© for the trial. 
The LASIS was originally developed by Bhakta and colleagues (1996) after 
findings in an earlier BT study (Hesse et al., 1992) suggested the standardised 
measures previously used were not sensitive enough to measure change in 
areas such as hand hygiene. The LASIS was further evaluated (Bhakta et al., 
2000) and found to demonstrate increased sensitivity to change in disability 
when compared to the Barthel Index (Mahoney and Barthel, 1965). This new 
tool measured a number of items related to self-care. The LASIS was chosen to 
measure carer burden in this study based on its clinical relevance (RCP et al., 
2009). 
 
The Arm Activity measure (ArmA) was chosen for the combined purpose of 
measuring arm function and care of the arm (Ashford et al., 2008; RCP et al., 
2009). It has since been reported reliable and relevant for measuring care 
burden in people with upper limb spasticity (Ashford et al., 2013; Ashford et al., 
2014).  
 
For those with the ability to walk, the 10 meter timed walk test (10MTT) 
provided a measure of functional gait velocity (Watson, 2002, Foley et al., 
2010). For quick reference it was suggested 82m/min was the norm for a 
healthy adult. This was selected as a reliable and validated tool for the measure 
of functional impact of the DEFO intervention on gait velocity (comfortable). 
 
The Activity Log (Appendix 13) was a useful measure of functional 
performance and provided details on participant activity level throughout the 
study. Further measures for testing fidelity were used such as the DEFO 
wearing record (Appendix 9) and the Physiotherapy Intervention Data Capture 
Sheet (Appendix 8). Clinical records were made available for the purpose of 
corroborating fidelity. 
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3.4 Methodological approaches for qualitative analysis 
 
Thematic Analysis 
 
Thematic Analysis methodological approach was developed as a useful method 
in comparing sets of interviews. Thematic Analysis is widely used for analysis of 
qualitative research, but without universal agreement for how it is accomplished 
(Braun and Clarke, 2006). It has been described as ‘a method for identifying, 
analysing and reporting patterns (themes) within data’ (Braun and Clarke, 2006, 
p.79). It also involves interpretation of aspects within the research topic 
(Boyatzis, 1998). With this qualitative methodology it was reasoned appropriate 
to use a thematic coding method with both a theoretical deductive (Boyatzis, 
1998) and interactive inductive (Frith and Gleeson, 2004) analytic approach for 
transparency and to go beyond just reporting emergent themes (Bazeley, 
2009). In this approach the researcher is positioned actively in the process yet 
is able to use an analytic narrative approach to make sense of the data (Braun 
and Clark, 2006). This fits with the researcher’s worldview as a pragmatist with 
orientation in real-world practice, problem focussed, pluralistic in approach and 
able to recognise that actions lead to consequences (Creswell and Plano-Clark, 
2011). Thematic Analysis by a six phased process of analysis (Table 3.1) is a 
method for identifying, analysing and reporting patterns (themes) within data.  
 
Table 3.1 Six phases of Thematic Analysis (Braun and Clarke, 2006) 
 
 
 
  
 
 
 
 
 
 
The coding of the data is an inherent part of the analysis and is thus reported on 
below in more detail using a Framework analytic approach (Appendix 16). 
 
 
 
1. Familiarisation of data  
2. Generating initial codes  
3. Search for themes  
4. Refine and naming of themes   
5. Integrate findings by triangulation 
6. Producing a report with extracts embedded in analytic narrative 
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Framework Analysis Methodology 
 
A ‘Framework’ analysis methodology is increasingly appropriate as a coherent 
approach using an inclusive and systematic methodology in Health studies 
(Ritchie and Lewis, 2003). The Framework analytic approach (Ritchie and 
Spencer, 1996) is used for the data categorization in this study. In this method a 
process called constant comparison is used to check and compare all of the 
categorized data with the rest of the findings as each category is established. 
The data sets are coded with an analytic process: named common and 
distinctive categories (open coding), which involves analysis to see if they fall 
into common groups (axial coding) which are then analysed further (selective 
coding) both keeping the core and rich data detail (Ritchie and Lewis, 2003). 
The organisation of the groups is then further interpreted actively by creating 
links as the researcher makes sense of them, considering details of the context. 
Thus the overarching analytic methodology was Thematic Analysis with a 
Framework analytic approach for the categorization of the qualitative data.  
 
Thematic Networks 
 
Attride-Sterling (2001, pp. 387-91) further outlined the process for ‘Thematic 
Analysis’ using a web-like systematisation of the key themes, ‘thematic 
networks’. This process provides a method for organizing qualitative data 
captured as; 
 
 ‘it simply provides a technique for breaking up text, and finding within it 
explicit rationalizations and their implicit signification’.  
                                                                    (Attride-Sterling, 2001, p. 388)  
 
Semantic content analysis is used to inform evaluation of findings; by defining 
and refining the themes as the patterns of meaning became increasingly 
coherent. This descriptive thematic content is then interpreted for further 
meaning. The thematic methodology follows good Thematic Analysis’ (Attride-
Sterling, 2001) using a coding system that links to the original data sets. This 
method is illustrated below (Figure 3.3) in which data was systematically and 
thematically organised and coded from ‘basic’ to ‘organizing’ to ‘global themes’. 
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Figure 3.3 Thematic Analysis (Attride-Sterling, 2001, p. 388)  
 
In this study a Framework analytic approach was used to the Thematic Analysis 
for coding of the findings but also followed good Thematic Analysis (Attride-
Sterling, 2001) with the themes displayed visually by networks and interpreted 
in the text. 
  
 
 
3.5 Methodology of integration 
 
Integration is the ‘interaction or conversation between the qualitative and 
quantitative components of a study’ (O’Cathain et al., 2010).  Three techniques 
for integrating data in mixed methods studies are described by O’Cathain and 
colleagues (2010): mixed methods matrix, following a thread and triangulation 
protocol. The former techniques are applied at the point of analysis whereas the 
latter is applied at the point of interpretation. Although the triangulation protocol 
was originally developed for multiple qualitative methods (Farmer et al., 2006) it 
is also relevant to studies of mixed methods.  
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Triangulation is when data is both integrated and interpreted in a later phase. 
The triangulation protocol is used for example to assess the efficacy of a 
healthcare intervention and semi-structured interviews with participants and 
clinicians to provide a real-world analysis. This technique was considered to fit 
with the researcher’s worldview as a pragmatist. Triangulation can be used to 
establish validity of combined quantitative data and qualitative findings. This 
methodology combines the multiple theories, methods and empirical materials 
which adds ‘rigor, breadth, complexity, richness and depth’ (Denzin and Lincoln, 
2000, p. 5).  
 
The process of triangulating findings from mixed methods takes place at the 
interpretation stage after both data sets have been separately analysed. The 
methods for this process are described by O’Cathain and colleagues (2010). 
This depends on whether there is overall agreement, (convergence), 
complimentary information (complimentary) or disagreement by conficting 
findings (discrepancy or dissonance). Indeed, exploration of contradictions can 
lead to a better understanding of the issues (O’Cathain et al., 2010).  
 
In mixed methods approach individual data analysis can be planned in parallel 
or sequentially then through integration of the two methods to produce meta-
inference (Teddlie and Tashakkori, 2009) thus resulting in a sum greater than 
the individual components (Pope and Mays, 2006). The concept refers to the 
conclusions drawn from mixed methods study in terms of credibility of the 
qualitative component and internal validity of the quantitative component. The 
inferences drawn from the integration are legitimised and used to formulate 
generalisations.  
 
Integration brings together data from quantitative and qualitative components of 
mixed methods studies (Bryman, 1992; 2006; Onwuegbuzie and Teddlie, 2003; 
Polit and Beck, 2012). It is justified on the basis of providing a more 
comprehensive picture of the findings in the study (O’Cathain et al., 2010). By 
integration and triangulation (O’Cathain et al., 2010; Silvermann, 2011) of the 
qualitative and quantitative findings it offers a strategy for greater breadth and 
quality of findings (Denzin and Lincoln, 2000; Johnson et al., 2007; Wisdom et 
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al., 2012) resulting in inference transferability (Teddlie and Tashakkori, 2009). 
Inference transferability is underpinned by the combined concepts of external 
validity (from the quantitative perspective) and transferability (from the 
qualitative perspective) and refers to generalisability of the integrated findings 
from the mixed methods study to a specified population and context. Thus a 
mixed method study has benefit in combining both approaches into a single 
study adding credibility (qualitative) and external validity (quantitative). Teddlie 
and Tashakkori (2009) propose integrated findings can be explained in 
concepts of overarching quality and transferability (generalisability to a similar 
population).  
 
In mixed methods research a number of quality frameworks have emerged to 
address rigour. Firstly a set of four criteria was developed that includes;  
 
 Truth value (credibility vs. Internal validity) 
 Applicability (Transferability/Fittingness vs. External 
validity/Generalizability) 
 Consistency (Dependability vs. Reliability) 
 Neutrality (Confirmability vs. Objectivity) 
(Sale and Brazil, 2004, pp.358-360) 
Secondly the essential components developed by O’Cathain, Murphy and 
Nicholl, (2008, p.92) provide useful criteria for reporting mixed methods 
research; Good Reporting of a Mixed Methods Study (GRAMMS). This six-item 
framework provides a useful procedural checklist. The method of integration 
and inferences drawn are key components that demonstrate methodological 
congruence. Conflicts in findings justify further investigation (Moffat et al., 
2006). Further recently developed procedural checklists for mixed methods 
research include the ten point checklist by Collins and O’Cathain, (2009) and 
another by Andrew and Halcomb, (2009) which informs the design elements. 
The integration of findings in this study and quality framework for rigour are 
presented in Chapter 7. 
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3.6 Summary  
 
There was clearly an identified gap both in rigor and of clinical relevance in 
studies for the treatment of adults with focal spasticity following BT. Intervention 
of the DEFO has not been rigorously evaluated in the adult population with focal 
spasticity.  
 
One data source in an exploratory study is believed to be insufficient to answer 
the research questions fully. The chosen methodology has informed the mixed 
methods study design (Figure 4.1). This chapter provides justification for the 
chosen methodological approach. How this was implemented is made explicit in 
the next chapter (Chapter 4; Methods).  
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Chapter 4  
 
Methods  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 Background  
This chapter provides a detailed account of the research method conducted and 
follows the CONSORT standards of reporting (Schultz et al., 2010) for a 
randomized trial. This study also follows ‘Good Reporting of a Mixed Method 
Study’ (GRAMMS) developed by O’Cathain et al., (2008).  
 
The scientific background for the study is presented in Chapters 1 and 2 setting 
out the research problem and uncertainties. The justification and rationale for 
the research methodology is detailed, in Chapter 3, which informed the mixed 
methods design of this feasibility study. This chapter delivers detailed 
descriptions of the procedural methods and protocols used whilst investigating 
the multiple research feasibility questions. The results of this study are 
presented in Chapters 5 and 6 with the findings integrated in Chapter 7. The 
study findings are then interpreted in light of strengths, weaknesses and 
generalisability by discussion in Chapter 8 with study conclusions drawn in 
Chapter 9. The following method was submitted and gained ethical approval 
(12/SC/0518, Appendix 1) and is detailed, in Chapter 4.9 and Chapter 8.1.1. 
 
 
Key Points: 
 
 Background and objectives 
 Methods and trial design 
 Participants and setting 
 Interventions 
 Outcomes 
 Recruitment, randomization, allocation, concealment and blinding 
 Statistical methods and analysis 
 Data management, withdrawals, adverse event recording 
 Ethical process, Research Reference Group 
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Study aim, objectives and research questions 
Study aim 
The study aimed to investigate the feasibility, potential efficacy and acceptability 
of DEFO and physiotherapy as a new treatment of focal spasticity following BT 
in an adult population.  
 
Objectives 
  
 To identify the likely added patient health benefit in providing DEFO 
compared to usual care as a primary intervention as an adjunct to usual 
care following BT in the management of focal spasticity.  
 
 To provide detail of clinical feasibility and acceptability in order to find the 
likely recruitment rate and estimated effect-size for justification of a larger 
study. 
 
 To contribute to the existing knowledge base to inform clinical decisions 
for focal spasticity management. 
 
The primary research question was formulated after identification of a gap in 
knowledge about the management of limb spasticity in adults following BT. 
Equally important questions were identified to provide practical insights into the 
feasibility, potential efficacy and acceptability of DEFO as a likely new treatment 
following BT.  
 
Research questions 
 
This study identified three equally important questions to explore the uncertainty 
of this intervention following BT for focal spasticity in adults:  
 
 What is the likelihood of health benefits of treatment with DEFO and 
physiotherapy (as required) and usual care, compared to usual care 
alone? (primary question) 
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 What is the feasibility of the protocol to inform the design of a larger 
study? 
 
 How acceptable is the DEFO intervention in clinical practice? 
 
An important consideration in the study was to identify health benefits. The 
likely health benefits (Chapter 3.3) were identified to be associated with 
potential reduction in limb spasticity which can impact on pain, deformity and 
impaired function (Bergfeldt et al., 2006; RCP et al., 2009).  A range of valid and 
reliable measures (Chapter 4.5) were used to identify health related benefits of 
the intervention and examine any uncertainties.  
 
Alternate hypothesis- Following BT: There is added health benefit from the 
intervention with DEFO with physiotherapy and usual care compared to 
physiotherapy and usual care alone. 
 
Null hypothesis- Following BT: There is no added health benefit from the 
intervention with DEFO with physiotherapy and usual care compared to 
physiotherapy and usual care alone.  
 
 
4.2 Study design  
 
Mixed methods embedded design 
 
A mixed methodology with a ‘mixed methods embedded design’ (Creswell and 
Plano Clark, 2011, pp. 90-96) was used to evaluate the DEFO intervention. This 
embedded design integrated quantitative and qualitative methods, each 
informing the other. This can be exampled by the development of the topic 
guided (semi-structured) interview questions, which were specifically based on 
the early findings of the pilot randomized controlled trial (RCT) adherence and 
informed by research participant experience. This qualitative design component 
was considered as an important modification to the research protocol 
(Appendix 1). This study design consisted of two interconnected phases; 
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quantitative followed by qualitative method. The quantitative component was 
with an experimental feasibility single-blind randomized controlled study. The 
qualitative component was designed with topic guided interviews for a nested 
sample of the participants (Campbell et al., 2003; Onwuegbuzie and Collins, 
2007). This nested sample was with the subgroup (intervention group) of the 
pilot RCT participants and clinicians who provided feedback on the intervention 
experience. This provided qualitative findings for external validation of the 
study. A procedural diagram (Figure 4.1) is used to describe the mixed method 
embedded design used in this study. 
 
Figure 4.1 Procedural diagram of the mixed methods embedded study 
design  
 
 
 
The research quantitative and qualitative design components are presented 
sequentially in a phased framework. The first phase was a quantitative 
comparative (pilot RCT) design followed by a second qualitative phase to 
describe the experience ‘what and how’ the intervention was delivered.  
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Mixed method phase I: Quantitative design  
 
Single-blind pilot RCT  
 
The quantitative design (phase I) of the mixed method research was designed 
to investigate the potential efficacy and acceptability of the DEFO intervention 
following BT. It was specifically designed to assess the feasibility of introducing 
this intervention in clinical practice.  
Following development work (testing the measures and meetings with DM 
Orthotics Ltd© clinicians, Chapter 8.1) a feasible protocol was designed and 
replicated in the clinical setting. All participants had BT intramuscular injection 
of identified targeted muscle(s) following recommended guidelines (RCP et al., 
2009) and received usual care as required. The intervention protocol pathway is 
shown in Figure 4.2. The intervention protocol (Appendix 6) was devised and 
tested to address procedural feasibility. A DEFO wearing protocol (Appendix 9) 
was established for the intervention group and both protocols were followed for 
consistency. All participants were given a diary ‘Activity Log’ (Appendix 13) to 
record their weekly activities which was used to capture any group variance 
over the twelve weeks. In addition the physiotherapy clinicians were given a 
Physiotherapy Data Capture sheet (Appendix 8) to record intervention 
modalities for all of the participants over the twelve weeks.    
 
Intervention Group (A): DEFO (intervention) and physiotherapy and usual 
care. 
Delivered as: six weeks intervention, physiotherapy (as required) and usual 
care followed by six weeks removal of the intervention but continued 
physiotherapy (as required) and usual care. 
 
Control Group (B): physiotherapy and usual care (control). 
Delivered as: twelve weeks physiotherapy (as required) and usual care. 
 
Justification for the time of wearing for the DEFO intervention was based on the 
potential for efficacy within a twelve week window following BT (RCP et al., 
2009; Wissel et al., 2009). Optimal impact of BT is from approximately two 
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weeks when therapy and splinting is considered to be of most benefit. The 
reason for removing the DEFO at six weeks was to measure the specific impact 
of the added intervention with a planned further six week follow up to measure 
for any carry-over effect.  
 
Figure 4.2 Intervention pathway for protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intervention Pathway for Protocol 
 
 
Identify population with spasticity assessment and eligibility criteria  
↓ 
Informed consent 
↓ 
Recruitment and concealed allocation 
↓ 
Randomization to 2 groups (intervention: Group A and control: Group B) 
↓ 
Attend Spasticity Clinic and BT intervention 
↓ 
1. Baseline assessment (blinded researcher)  
↓ 
Group A: Measurement for fitting of DEFO* (within 2 weeks).  
DEFO Intervention (up to 8 hours daily) and physiotherapy (as required) and 
standard care** for 6 weeks 
 
Group B: physiotherapy (as required) and standard care** for 6 weeks  
↓ 
2. Post-intervention assessment (6 weeks) 
↓ 
Group A withdrawal of DEFO intervention and both groups continue standard 
care** (as required) for 6 weeks 
↓ 
3. Final assessment (12 weeks)  
↓ 
Data analysis/ evaluation and feedback 
  
DEFO* is the Dynamic Elastomeric Fabric Orthosis  
Standard care** is the usual care following Botulinum toxin administration and is 
tailored to the individuals needs but includes: advice on positioning, hygiene, 
muscle stretches, splinting, and pain management. Physiotherapy may not be a 
part of care (RCP et al., 2009). 
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Mixed method phase II: Qualitative design  
 
The qualitative design (phase II) of the mixed method research was intended to 
explore the experience of the DEFO intervention and provide supplementary 
data for analysis. Following the feasibility RCT intervention the group of 
participants who received the intervention and the clinicians who delivered the 
protocol were interviewed.  Research questions on feasibility and acceptability 
of the intervention were used to provide critical discussion points.  
 
This qualitative strand explores and explains the pilot RCT findings to determine 
the feasibility and acceptability of the DEFO intervention for further study. The 
scope and focus of the research questions provide a well-defined area for 
study. The topic guided questions were expanded following an iterative 
framework; using probe questions to follow further lines of interest and 
uncertainties (Appendices 11 and 12). This design strategically guided the 
interviewee to identify accounts of their experiences. These were later 
authenticated by Thematic Analysis of the data (Braun and Clarke, 2006). The 
analytic methodology is presented in Chapter 3.7. This data was collated and 
the findings presented (Chapter 6) and integrated with the quantitative data 
(Chapter 7). 
 
 
4.3 Participants and setting, eligibility, recruitment and consent 
 
Potential participants were identified for recruitment on referral for spasticity 
management with BT at the regional Spasticity clinic. Participants possibly 
eligible were identified from an adult, heterogenic population with an established 
neurological upper motor neuron condition (including Multiple Sclerosis, Stroke, 
Acquired Brain Injury, and Spinal Cord Injury) presenting with symptoms of focal 
or multi-focal spasticity in the upper limb or calf. Details of the community 
setting and level of carer support was documented. The study was conducted in 
a community setting with physiotherapy and usual care delivered either in 
participant homes or therapy gyms. The inclusion and exclusion eligibility 
criteria were chosen to be deliberately inclusive and representative of the 
population studied (Appendix 15).  
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The following were integral to the research: Principal researcher, Consultant 
Physician in Rehabilitation Medicine, two Specialist Neuro-Physiotherapists 
(postgraduate M-level qualification in spasticity management and provided 
delivery of physiotherapy interventions) and DM Orthotics Ltd© clinician 
(appropriately DMO® skilled and provided DEFO intervention; assessment and 
fitting) and a research administrative support worker. Roles and responsibilities 
were established for the study and monitored (Research Reference Group, 
Chapter 8.1.3). 
 
The Consultant Physician was responsible for the identification of potentially 
eligible participants in his spasticity clinic. He also administered the BT for 
spasticity management as a prerequisite to the study intervention.  
 
Eligibility 
 
Potential eligibility of participants was pre-determined by an identified treatment 
plan with BT in place and a spasticity clinic appointment. The eligibility 
assessment was conducted by the principal researcher. 
 
Measure of spasticity for eligibility to the study 
 
Measurement of biomechanical and neural components in spasticity is difficult 
to quantify. Both the Modified Ashworth Scale (MAS) introduced by Bohannon 
and Smith (1987) and the Tardieu Scale recommended by Patrick and Ada, 
(2006) are commonly used in practice. Despite evaluation by Mehrholz et al., 
(2005); Haugh et al., (2006); and Fleuren et al., (2009) that the Tardieu Scale is 
more reliable for test-retest and has closer adherence to velocity-dependence in 
spasticity (Lance, 1980), they concede it has reduced timely application in the 
clinical setting. The MAS has been widely adopted by clinicians for the 
measurement of spasticity and was used as a guide for eligibility in this study. A 
predictive change in the level of spasticity is well evidenced as attributed to BT 
and not the purpose of this study. Accordingly; it was used as an assessment 
measure for eligibility and not a measure for intervention effect in the study. 
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The MAS consists of a five point scale where: 0= no change in muscle tone and 
4= affected part is rigid. In practice it is common for BT to be most effective in 
MAS 2-3. It is not clinically indicated at MAS 1 or MAS 4. Hence this was a 
consideration for eligibility to the study.  
 
Inclusion criteria 
 
Participants recruited were adults (over 18 years) living in the community with 
full capacity to provide informed consent, presenting with identified focal or 
multi-focal spasticity of one limb (in upper or lower limb) present for at least 
three months. In addition a treatment plan with BT was identified and consented 
for people with a spasticity score of MAS 2-3 in flexor muscles of the forearm 
and elbow of the upper limb or gastro-soleus muscles of the lower limb.  
   
Exclusion criteria 
 
Those who were unable to co-operate in a rehabilitation programme (co-
morbidity of dementia or mental health disorder), fixed joint contracture, 
pregnancy, inflammatory arthritic condition, fracture and neuromuscular 
diseases did not meet the criteria.  
 
Ethical considerations included the selection and recruitment of participants 
from an inclusive perspective; access to information for those with aphasia; 
from different ethnic and cultural backgrounds.  
 
Participants who met the above eligibility criteria were invited to be recruited for 
the feasibility study. Participants recruited and randomized by concealed 
allocation to the intervention group were automatically eligible for the qualitative 
topic guided interviews. The participants recruited and randomized to the 
control group had not experienced the intervention and so they were not 
interviewed for intervention acceptability. The clinicians who provided the DEFO 
intervention assessment and fitting and delivery of the physiotherapy 
interventions were also interviewed.   
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Recruitment 
Prospective potentially eligible participants were invited to participate in the 
study and provided with the Participant Information Sheet (PIS), (Appendix 4). 
All potentially eligible participants were given at least 24 hours for due 
consideration of the PIS. Alternative forms of information were available (for 
example large print and digital recording) and provided if needed. A further 
opportunity was provided to discuss any issues independently prior to consent. 
If interested in participating in the study they were offered an eligibility 
assessment. This was to provide the opportunity to discuss any research 
issues, informed consent and recruitment based on the eligibility criteria. Clear 
participant information for the potential participants to make a fully informed 
decision was deemed essential to ensure realistic expectations in study 
participation.  
 
Consent 
The consent format was outlined in a two part process (Appendix 5). The first 
part of the consent form was for the main study and was completed by the 
participant and signed by the principal researcher. The second part was 
optional but was for the participant’s consent to a follow-up semi-structured 
interview whether they participated in the study, or decided to withdraw from the 
study intervention. This was also completed by the participant and signed by the 
principal researcher. Participants were recruited with full capacity following 
informed consent. Participants were also able to revoke consent at any time 
without affecting their usual care. Copies of the signed consent forms were sent 
to the participant and their GP.  
 
 
4.4 Intervention and comparator groups 
 
The feasibility RCT was designed with a research intervention protocol 
(Appendix 6). The intervention protocol and pathway (Figure 4.2) was 
developed by the principal researcher and informed by discussion with DM 
Orthotics Ltd© clinicians and Neuro-physiotherapists.  
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Intervention group  
 
After BT the intervention group participants were assessed and provided with 
an individually customised DEFO. Once fitted this was worn up to eight 
hours/day following a wearing protocol (Appendix 9). The wearing time protocol 
for the orthoses was followed to clarify implementation of the intervention and 
was guided by the seven day protocol for wearing dynamic Lycra® garments 
(Matthews, 2008).  
 
A ‘cricket sensor’ was suggested by the company to be inserted into the 
orthoses for confirmation of wearing times. This comprised a digital pressure 
sensor that could be sewn into the orthosis to record pressure when worn and 
data transferred to an electronic database (Rahman et al., 2010). It was made 
clear to the participants that the wearing protocol (Appendix 9) was flexible to 
their individual needs but any variance must be recorded. The participants were 
given an information leaflet detailing (DEFO) washing instructions and 
cautionary advice on when to remove it. The participants were also provided 
with contact numbers for the physiotherapy clinician and the research secretary.  
 
The rationale for the chosen time of wearing the DEFO intervention was based 
on the potential for efficacy within a twelve week window following BT.  The 
window of treatment opportunity was identified between two-eight weeks. This 
was based on the optimal weakening of the injected muscle. Optimal impact of 
BT is from approximately two weeks when therapy and splinting is considered 
to be of most benefit. The protocol was planned for the assessment for the 
provision of the orthoses within two weeks after the BT injection. The 
subsequent six weeks intervention was considered appropriate to measure the 
specific impact of the added DEFO intervention as the independent variable 
with a planned further six week follow up to measure for any carry-over effect 
after withdrawal of the intervention.  
 
After administration of BT usual care was delivered according to recommended 
Spasticity Guidelines (RCP et al., 2009) by standard optimal rehabilitation: 
physiotherapy as required; postural management; passive and active home 
exercises; splint provision and review. Usual care delivered was recorded by 
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the physiotherapist in the clinical field notes and interventions record. 
Standardised physiotherapy (as required) was delivered up to a maximum of 40 
minutes contact twice weekly for six weeks with home exercises, usual care and 
advice. The intervention was withdrawn after six weeks but usual care was 
continued for a further six weeks following the intervention protocol (Figure 
4.2). At twelve weeks the participants were reunited with their customised 
DEFO.  
 
Comparator group 
The participants in the control group followed the study protocol for the 
feasibility RCT. Usual care following BT was delivered according to the 
recommended Spasticity Guidelines (RCP et al., 2009; Sheean et al., 2010) for 
standard rehabilitation (as described above). The usual care delivered was 
recorded by the physiotherapist in the clinical field notes and interventions 
record. Standardised physiotherapy was delivered (as required) up to a 
maximum of 40 minutes contact twice weekly for six weeks with home 
exercises, usual care and advice. A further period of usual care (including 
physiotherapy as required) was delivered over the next six week s (Figure 4.2).  
 
 
4.5 Outcome measures  
 
Blinded assessments followed the pilot RCT design; at baseline assessment, 
six weeks post intervention, and again at twelve weeks. The assessments 
coincided with the optimal time for the effect of BT to provide the ‘window of 
opportunity’ in which the intervention was tested. The measures consisted 
mainly of pencil and paper tests with only one clinical measure for gait velocity 
(lower limb participants) that required an appropriate clinical setting. The 
measures were conducted in community settings (participants home or therapy 
department in a community hospital). In practice the pen and paper tests were 
conducted after clinical measures and followed a set order from the 
researcher’s measures folder. The tests took between 30 minutes to 45 minutes 
to complete with the consequence of minimal participant burden.  
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Measures for the study were evaluated for reliability and sensitivity to answer 
the research questions. The following measures were selected based on a clear 
rationale of specificity and relevance to the predicted likely health benefits 
(Chapter 3.3). 
 
Primary measure: The Goal Attainment Scale 
 
The Goal Attainment Scale (GAS) (Appendix 7) was selected as the primary 
measure for this study (Turner-Stokes, 2009). The construct of this measure is 
to measure goal attainment and thus all ICF levels depending on the goal. In 
practice this measure was used to set and measure objectives or ‘goals’ which 
were chosen through collaboration between the clinician and the participant or 
their carer before the intervention commenced. Three or more goals were set 
for each participant. The goals were weighted by applying a factor of 
importance  the difficulty of achievement: 
 
Importance                         Difficulty 
1= fairly important                1= probable 
2= very important                 2= possible 
3= extremely important        3= doubtful 
 
Baseline scores were also attributed depending on the functional level of the 
participant (where -1 represented the current state unless the current state 
could not be any worse and in this instance the score was attributed -2). Goal 
attainment was measured over a set time. In this study the set time was at six 
weeks and again later scored at twelve weeks. The scores were attributed 
where: 
 
+2= much better than expected 
+1= somewhat better than expected 
 0= goal achieved as predicted 
-1= no change below the expected level 
-2= worsening below the target level 
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Secondary measures 
 
A measure of pain: Visual Analogue Scale (VAS)  
 
Pain is subjective therefore the aim of this measure was to compare the 
individual’s perception of pain over time to assess for any change. Pain was 
scored using the numerically rated ten point scale: Visual Analogue Scale 
(VAS). This scale used a calibrated horizontal single ruled line of ten 
centimeters with an indication of zero being ‘no pain’ and ten representing ‘the 
worst pain ever’. In practice the participant was invited to put a vertical line to 
cross the horizontal line at the level that most represented their pain today. All 
participants were assessed using this measure. 
 
European Quality of Life-5 Dimensions (EQ-5D) 
 
This research intended to measure any additional health benefits that were not 
addressed by the specific outcome tools used for evaluation of rehabilitation in 
spasticity management. The European Quality of Life-5 Dimensions (EQ-5D) 
measure (EuroQol Group©, 1990) was chosen as a valid and reliable 
questionnaire in health-related research (Appendix 10). It provided a 
descriptive profile and a value for health status which was easily administered 
face to face.  It was cognitively simple requiring only a few minutes to complete.  
 
It consists of five dimensions: mobility, self-care, usual activities, pain and 
discomfort, anxiety and depression. The classifier had different levels for the 
problems (scale 1=no problem 2=some problems, 3=extreme problems and a 
health status rating tool the EQ VAS. The health state was determined by a five 
figure code (for example: 11212). The instruction for completing the EQ VAS 
was to; draw a line from a box to intersect a vertical, visual analogue scale 
where the endpoints were labelled ‘best imaginable health state’ and ‘worst 
imaginable health state’. This study was registered with The EuroQol Group© 
and was granted permission for use. This measure was assessed in all 
participants. 
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Upper limb measures 
 
The Arm Activity measure (ArmA) 
 
The Arm Activity measure (ArmA) was used in the participants with upper limb 
spasticity in the study (Appendix 10). It is a 20 item measure for the upper limb 
divided into two sections for the combined purpose of measuring arm function 
and care of the arm (Ashford et al., 2008; RCP et al., 2009; Ashford et al., 
2014). Whilst the former section A (13 items) was specified for activity, the latter 
B (7 items) were classified as measures of participation. The proforma required 
the recording of who had completed the form: the participant alone; the carer 
alone or the participant and carer in combination. The participant was asked to 
complete all the questions based on their activity over the last seven days 
whether they were actual or estimated.  
 
For each of the activities listed the participant was asked to indicate if the task 
was possible or not, either for them, or their carer and to measure the level of 
difficulty from a scale when: 
 
0= No difficulty 
1= Mild difficulty 
2= Moderate difficulty 
3= Severe difficulty 
4= Unable to do activity 
 
Section A was designed to measure caring for the affected arm such as ‘cutting 
finger nails’ and Section B on using the affected arm in activities such as ‘brush 
your teeth’. Together the measures provided relevant specific detail on both 
care and activity levels of the upper limb. This measure was recently reported 
by Ashford, et al., (2014) to have a low burden for completion for patients and 
caregivers.  
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Leeds Arm Spasticity Impact Scale (LASIS) 
 
A measure of care burden was used in the participants with upper limb 
spasticity in the study (Appendix 10). It is the Leeds Arm Spasticity Impact 
Scale (LASIS). This outcome measure follows a five point Likert scale in which: 
 
0= No difficulty 
1= A little difficulty 
2= Moderate difficulty 
3= A great deal of difficulty 
4= Unable to do this activity 
 
To complete the measure the subject was asked to rate eight disability items 
whilst the caregiver was asked to complete the four carer burden items. A 
summary of disability score was provided by adding together the items scored 
by the patient and dividing them by the number of items answered (0= no 
disability, 4= maximum disability). Similarly this method was used to summarize 
the carer burden score (0= no carer burden, 4=maximum carer burden). In 
practice it was recorded whether the participant was living alone, in receipt of a 
package of care or lived with a partner and/or an additional package of care. 
This influenced how this measure was administered.  
 
Lower limb measure 
 
10 Meter Timed Walk Test  
 
For ambulant participants, the 10 meter timed walk test (10MTT) (Appendix 10) 
provided a reliable and validated tool for the measure of functional impact of the 
DEFO intervention on gait velocity (Watson, 2002, Foley et al., 2010).  
 
In practice it was easy to administer with a calibrated ten meter (33 feet) flat 
surface along a corridor or in a physiotherapy gym. To administer the test a line 
of tape was placed at either end of the measured ten meters. The participant 
was instructed to stand approximately three feet behind a taped line. They were 
asked to walk at a comfortable rate until they passed the end tape by 
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approximately three feet. This was in order to minimize the effects of 
acceleration and deceleration. The participant was asked not to talk when 
performing the test as this can slow performance from dual task interference. 
The measure of elapsed time was recorded in seconds and the number of steps 
taken over the ten meters. This measure was repeated three times and an 
average time taken. Velocity was calculated by dividing the average time by the 
ten meters and multiplying by sixty. This provided a measured speed of meters 
per minute which was compared to a healthy population reference table shown 
below, (Table 4.1).  
 
Table 4.1 Normal healthy gait velocity (comfortable m/min) (Watson, 2002) 
 
Gender/Decade Men Women 
20s 83.6 84.4 
30s 87.5 84.9 
40s 88.1 83.5 
50s 83.6 83.7 
60s 81.5 77.8 
70s 79.8 76.3 
 
 
Measures of intervention fidelity 
 
Further measures of fidelity in the protocol delivery were recorded by the 
participants and the clinicians. For the participants this included a DEFO 
wearing record (intervention group participants only) and an ‘Activity Log’ for all 
participants (Appendix 13) to record participation activities during the six weeks 
intervention period.  This provided a diary record of activity and participation 
levels variance for analysis of impact by the intervention. The physiotherapy 
clinicians were tasked with completing a physiotherapy intervention data 
capture (Appendix 8).  
 
DEFO Intervention: Record of wearing 
 
The participants in the intervention group were asked to complete a DEFO 
wearing record whilst following the six weeks intervention phase of the protocol. 
The DEFO wearing record is shown below, (in Table 4.2). 
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Table 4.2 DEFO: Record of wearing* 
Week Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
1 1 hour 2 hours 4 hours 8 hours 8 hours 8 hours 8 hours 
2        
3        
4        
5        
6        
Total 
Hours 
       
*Additional comments also recorded 
 
The Activity Log (Appendix 13) was a useful measure of functional 
performance and provided details on participant activity level throughout the 
study. Further measures for testing fidelity were used such as the DEFO 
wearing record (Appendix 9) and the Physiotherapy Intervention Data Capture 
Sheet (Appendix 8). Clinical records were made available for the purpose of 
corroborating fidelity. 
 
 
4.6 Randomization, concealment of allocation, and blinding 
 
The quantitative research design was planned as a pilot RCT. In this design 
there were three components delivered; randomization, concealment and 
allocation. The recruited participants were randomized into two groups. This 
was done by the following method.  
 
The research administrative support worker (the randomizer) had 30 opaque 
sealed envelopes containing 15 (intervention) and 15 (control) cards. These 
envelopes were shuffled by a person independent to the study before 
recruitment. The envelopes were stored in a secure cabinet only accessible to 
the research administrative support worker. As each participant was recruited 
they were randomly allocated by the randomizer to either group as each 
envelope was opened in random sequence from the pile. Once recruited the 
participants were informed which group they were allocated to and a record of 
their randomization was coded and entered on a password protected database. 
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The participants were reminded of the importance of not discussing their 
allocation group with the principal researcher to maintain blinding. The treating 
physiotherapist and DM Orthotics Ltd© clinician were informed (by referral) of 
the participant’s allocation. This concealed and encoded participant data was 
made available to the principal researcher at the end of the interventions phase 
in the study for evaluation. The concealed allocation of participants was 
anonymised to the principal researcher but in this kind of study it is not possible 
to blind the participants or the clinicians. 
 
The research participants were clearly identified on their notes of their research 
participation in the study but not of their respective allocation. This was with a 
participant code sticker (provided by R&D) and placed on the front of the 
patient’s record sheet. All assessment and outcome sheets had the participant 
codes for identification and this data was entered in coded format onto an 
electronic database. The research secretary was responsible for maintaining 
the password protected encoded database of allocation which was collated 
separately from the outcomes database. 
 
On completion of the quantitative intervention phase of the study (after twelve 
weeks) and outcome data entered on the excel spread-sheet there was a 
sequential reveal of the participant’s allocation to the principal researcher. The 
intervention group participants were followed up by the principal researcher 
with face to face topic guided interviews. The interviews were conducted either 
in the person’s own home or in a community hospital setting. A paper topic 
guided script was used (Appendix 11) with the topics outlined and a digital 
voice recorder (Olympus DM-650) to tape the interview. The environment was 
prepared to minimise interruption, ensure the participant was comfortable and 
remind them of the purpose of the interview. Then the recorder was turned on 
and used for as long as the interview lasted. At the end of the interview the 
participant was asked if there were any further comments they wished to add 
and if so this was also recorded. Following the interview, the details were 
transcribed to an electronic encoded database for qualitative analysis. 
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On completion of the feasibility RCT, at twelve weeks, the participants in the 
control group were revealed to the principal researcher. They were not 
interviewed but additional data from the Activity log and clinical records was 
collated. The comparator (control) group provided a constant in standard 
practice. Although standard practice was seen as an appropriate practice for 
control, data was captured to account for variance in both groups. Participants 
were formally thanked and informed they had completed their part in the study 
and would receive a report on the study findings. 
 
 
4.7 Sample size and statistical methods 
The study design followed the guidance provided in the Medical Research 
Methodology publication by Thabane et al., (2010) which suggested a pilot 
study can be used to assess feasibility to guide a larger study rather than 
merely inform sample-size calculation.  Hence this feasibility pilot study was 
used to: inform the estimation of recruitment rates, retention rates, refusal rates, 
adherence rates and appropriateness of the eligibility criteria. It therefore aimed 
to assess the recruitment potential from an annual spasticity clinic of 180 
patients; often with repeated BT. An estimated sample size of 30 participants 
from the clinic were considered likely to meet the eligibility criteria and consent 
for the feasibility study. Recruitment was planned to run over a period of twelve 
months with feasibility ‘stopping rule’ in the event of less than ten patients 
recruited in eight months. Similarly protocol modification was considered if 
feasibility was threatened. Alternately if recruitment had slowed down 
significantly with saturation of potential recruits, recruitment was planned to 
cease. This stopping rule was based on capacity in the recruitment procedure 
and considered as a pragmatic approach for delivering a small scale feasibility 
study within a specific timeframe. 
The mixed methods data analysis (Chapter 3.7) was conducted in parallel then 
through integration of the two methods. Descriptive data captured was analysed 
for difference of demographics and standard deviation of age by group.  
 
The pilot RCT provided three data sets from the chosen outcome measures for 
repeated measures analysis. The primary measure of the GAS T score was 
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analysed by Statistical Package for Social Sciences (SPSS) (IBMv19) analysis 
of co-variance (ANCOVA) using difference between-groups effects with 
adjusted baseline means to determine a change score analysis at six weeks 
and twelve weeks with a summary of significance on the effects. The GAS, EQ-
5D and the VAS for pain were measures used for all of the participants. The 
GAS data set was used to provide an estimated effect-size for a larger study. 
The remaining measures (ArmA, LASIS, 10MTT) were dependent upon upper 
and lower limb spasticity presentation and conducted accordingly. The upper 
limb measures provided data sets that were analysed using the same method 
(ANCOVA between-groups effects). Both the ArmA and the LASIS consisted of 
‘active’ and ‘passive’ components that required separate analysis due to 
difference in construct validity. The lower limb measure (10MTT) was analysed 
descriptively for gait velocity due to likely small numbers. 
 
The GAS T score was calculated by applying the Kiresuk and Sherman formula 
(1968) cited in Turner-Stokes (2009, p.3), (in Table 4.3) to the aggregated 
scores for each goal using an Excel data spread-sheet: 
 
Table 4.3 GAS T formula, (Kiresuk and Sherman, 1968) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall GAS   = 50 +       10 Ʃ(wixi) 
                                    [(1- þ) Ʃwi
2+ þ(Ʃ(wi)
2]1/2 
Where:  
wi  =  the weight assigned to the ith goal (if equal weights, wi = 1) 
xi   =  the numerical value achieved (between –2 and + 2) 
þ = the expected correlation of the goal scales  
 
For practical purposes, according to Kirusek and Sherman (Turner Stokes, 
2009 p. 3), þ most commonly approximates to 0.3, so the equation simplifies 
to: 
 
Overall GAS   = 50 +    10 Ʃ(wixi) 
                                √(0.7Ʃwi
2 +0.3(Ʃwi)
2 
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This calculated GAS T score formula provided interval-level data with a normal 
distribution around a mean of 50 and standard deviation of ten. This means a 
change in GAS T score of ≥ 10 is needed to provide a measure of achievement 
of the combined goals set. This formula was based on the findings of Kirusek 
and Sherman (1968). A predictive value of ≥10 GAS T score was used for 
sensitivity of change in measurement of clinical efficacy (Ashford and Turner-
Stokes, 2006; Turner-Stokes et al., 2010b).  Demonstration of a mean T score 
around 50 was used to provide feedback relating to the accuracy of the goal 
setting.  
 
Additional data including the DEFO wearing results, physiotherapy data and 
Activity log was analysed for variance by group comparison. Additional data 
from clinical records and the DMO clinician was analysed for fidelity.  
 
Thematic Analysis (Chapter 3.7) of the interview data (participant and clinician) 
followed a Framework analytic approach (Ritchie and Lewis, 2003) using a 
coding system that links to the original data sets (exampled in Appendix 16) 
and the findings are thematically represented by Thematic networks (in Chapter 
6).  
 
 
4.8 Data management 
 
The data from both design components was collated in two databases, one that 
was encrypted (secure from the blinded research assessor) with data from the 
randomization and a second that only had the encoded databases for the 
research assessors data entry of the participants outcome measures. The 
research secretary managed the data entry in the former and the blinded 
research assessor managed the data entry in the latter. All demographic details 
and a timeline of appointments for the research protocol were managed on the 
securely encrypted database by the research secretary.  
 
Following assessments data was entered onto the spread-sheet on a weekly 
basis or according to recruitment needs. This was to ensure the data was 
entered in a timely fashion. Data was double entered by the research secretary 
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for the pilot RCT data sets to optimise consistency reliability according to good 
research practice.  
 
The participant’s group allocation was revealed to the principal researcher on 
completion of the data entry in this database. This was to enable follow-up topic 
guided interviews to take place for qualitative evaluation. The digitally recorded 
interview data was transcribed and participant coded. Additional paper data 
such as the Physiotherapy Intervention Data Capture sheet, Activity Log and 
DEFO wearing records were also coded and filed in a secure cabinet until the 
allotted reveal. The Physiotherapy clinical notes were also made available for 
further analysis of clinical variance and other issues of each participant once the 
study was completed. 
 
Recording withdrawals and adverse events 
 
Spasticity is prevalent in people with co-morbidities and thus there is a high risk 
that participants recruited were likely to withdraw for medical reasons. All 
participants were followed up with permission in the instance of withdrawal from 
the study or adverse event. This was outlined in part two of the participant 
consent form (Appendix 3). The proposed follow-up of the participant was by 
interview as outlined on the consent form, unless they were unable to co-
operate and medical notes were then reviewed as ethically appropriate. By this 
method all reasons for withdrawal from adverse events were recorded. A 
CONSORT flow diagram (in Figure 5.1) provides details of recruitment and 
retention on the study (Boutron et al., 2008; Schulz et al., 2010). 
 
 
4.9 Ethical process 
 
The study (12/SC/0518) was ethically approved from Berkshire-B South Central 
Research Committee (NRES) in September 2012 and registered with local NHS 
R&D and Exeter University ethics committee (PREC) in October 2012. 
Following approval all clinicians involved in the research were informed and the 
research study commenced in October 2012. Protocol amendments with the 
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qualitative research component were submitted and approved in July 2013 
(Chapter 8.1.1).  
 
The research processes followed the ‘good clinical practice’ (Research 
Governance Framework for Health and Social Care, 2005). Research ethical 
considerations were founded on rigor, respect and responsibility and are 
reflected on at the end of the thesis. All data gathered and stored followed strict 
NHS Data governance protocols.  
 
Further ethical considerations are discussed in Chapter 8.1. including how a 
Research Reference Group (Chapter 8.1.3) was established with the aim for 
ethical monitoring and to establish research peer support. Essentially the 
purpose of the group was to keep the research on track with patient and public 
involvement (INVOLVE, Hanley et al., 2003) and stakeholder engagement. 
 
 
4.10 Summary 
 
This chapter outlined the procedural content of process delivery through mixed 
methodology. The researcher identified critical elements of method for data 
capture and analysis, together with key ingredients and important relationships 
in the research process.  
 
The pilot and developmental work covered practical and technical issues. These 
are explored in Research Reflections (p. 256) with rationale for research 
decisions. The overarching study protocol was clearly defined with descriptive 
pathways based on the rationale for delivery of each phase in the research 
design of mixed methods. It is explained how the measures were used in the 
assessments at baseline, following the DEFO intervention and after withdrawal. 
The procedural delivery describes the method of recruitment, retention and 
recording attrition. In addition procedural issues of data capture and analysis 
are described. Monitoring the research process delivery was not 
underestimated. This was supported by a Research Reference Group of key 
stakeholders. 
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This section provided transparent accounts of delivery stage by stage including 
pathways, roles and responsibilities. The method presented provides a detailed 
description of the investigation of the feasibility, potential efficacy and 
acceptability of the DEFO as a new treatment following BT. As an exploratory 
feasibility study its purpose was to test the research design and method used as 
a developmental phase in the research process; with potential for this study to 
inform further research based on the findings. Results of the two phases are 
presented in Chapters 5 and 6 with the findings integrated in Chapter 7.
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Chapter 5 
 
Results I (Quantitative)  
 
 
 
 
 
 
 
 
 
5.1 Overview of data presented 
This is the first of two Chapters (5 and 6) to present results. It sets out the 
baseline categorical data and quantitative pilot RCT data gathered. This 
Chapter (5) includes how and why it was presented in the chosen format. The 
qualitative data is presented in the next Chapter (6). This data was collated 
sequentially but was analysed in parallel to the quantitative results with both 
results integrated and interpreted in the discussion, (in Chapter 7). 
Data presented in this chapter includes: baseline characteristics of the 
participants; summary of flow participant recruitment and attrition; quantitative 
data from the (pilot RCT) primary and secondary measures; fidelity; adherence 
and variance data.  
 
 
5.2 Baseline characteristics of participants  
Twenty-five participants were recruited to the study with an overall age range of 
29-78 years (median age of 56 years) with a mean age of 56.28 years. The age 
range of the intervention group was from 29-69 years (median age of 47 years) 
and a mean age of 50.5 years. The age range of the control group was from 30-
78 years (median age of 61 years) and a mean age of 61.6 years. There were 
Key points: 
 Results overview- how data is presented and why? 
 CONSORT (flow summary of recruitment/retention/attrition and 
completion of study) 
 Baseline characteristics of participants 
 Quantitative data: tables of results (primary measure, secondary 
measures)  
 Fidelity, adherence and variance data: DEFO Wearing Log; Activity 
Log; Physiotherapy Interventions Data Capture; Clinical data  
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twelve female participants and thirteen male participants. Following 
randomization the two groups were found to be evenly distributed with twelve 
participants in intervention group and thirteen in the control group. In the 
intervention group there were six (50%) male and six (50%) female participants, 
in the control group seven (53.8%) male and six (46.2%) female participants. 
Eighteen participants presented with diagnosis of Stroke (>3/12), three had 
suffered Traumatic Brain Injury (>2 years), and one participant was diagnosed 
with Multiple Sclerosis, one participant had a Spinal Cord Injury, one reported 
an Acquired Brain Injury and one with brain haemorrhage associated with Brain 
Tumour. All participants presented with spasticity in one or more limbs with 
planned management according to the study protocol; with BT and standard 
care. Twenty-two participants presented with upper limb spasticity for treatment 
with BT intramuscular injection of the forearm flexors and biceps. Three of the 
participants recruited had lower limb spasticity with planned treatment for BT 
intramuscular injection of the calf muscles.   
All participants lived in the community and of those nine lived alone, with one 
person fully independent (one in control group) and the other eight in receipt of 
varying packages of care (four in control group, four intervention group). The 
remaining sixteen participants lived with partners (eight in control group, eight in 
intervention group) who provided informal care and support. Of these 
participants a further fourteen (seven in control group, seven in intervention 
group) had additional packages of care with the remaining two participants (one 
in control group, one in intervention group) in receipt of informal care.  
Four of the participants recruited had speech difficulties following stroke with 
varying levels of expressive aphasia (two in control group, two in intervention 
group). All had capacity (Mental Capacity Act, 2005). A summary of the 
baseline characteristics of the participants is presented, in (Table 5.1).  
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Table 5.1 Baseline characteristics of participants 
Characteristic Intervention 
group n=12 
Control group 
n=13 
Total  
n=25 
Sex     
Male n=6 n=7 n=13 
Female n=6 n=6 n=12 
Age (years)    
Mean (SD) 50.5 (12.60) 61.6 (14.46) 56 (14.47) 
Median 47 61 65 
Range 29-69 30-78 29-78 (49) 
Ethnic origin    
White British n=12 n=13 n=25 
Other  n=0 n=0 n=0 
Diagnostic group    
Stroke n=8 n=10 n=18 
TBI n=2 n=1 n=2 
ABI n=0 n=1 n=1 
Brain Tumour n=1 n=0 n=1 
Multiple Sclerosis n=1 n=0 n=1 
Spinal Cord Injury n=1 n=0 n=1 
Affected limb    
Upper limb n=9 n=13 n=22 
Lower limb n=3 n=0 n=3 
Communication    
Aphasia n=2 n=2 n=4 
Verbal  n=10 n=11 n=21 
Care support    
Living alone n=4 n=5 n=9 
Married/cohabiting n=8 n=8 n=16 
Package of care n=7 n=7 n=14 
Key: SD=Standard Deviation, TBI=Traumatic Brain Injury, ABI= Acquired Brain Injury 
 
5.3 Recruitment and attrition pathway 
A CONSORT (Boutron et al., 2008; Schulz et al., 2010) flow diagram (Figure 
5.1) was used to provide a summary of the participant recruitment, concealed 
allocation and randomization and attrition pathway. This was in order to display 
the number of potential participants recruited to the study, those eligible and 
providing consent and the rate and rationale for attrition.  
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Recruitment 
Sixty-two potential participants attending the spasticity clinic were invited to the 
study. Of those invited, 37 were excluded: 30 potential participants declined; six 
were not eligible based on the assessment criteria and one person was 
recruited to another study and unable to commit to the study protocol. The 
remaining 25 eligible participants consented to participate in the study and were 
recruited. Over twelve months, this was at an initial rate of more than three per 
month, falling to a regular rate of two per month and in the last two months 
(eleven and twelve) of the study there was none. This was due to saturation of 
recruits from the Spasticity clinic.  
Delivery and receipt of the intervention  
Following concealed randomization and allocation of the 25 participants 
recruited who met the eligibility criteria: Twelve participants were in the DEFO 
intervention group; and thirteen in the control group. Of those in the intervention 
group; eleven received delivery of the DEFO intervention and one participant 
withdrew consent and consequently did not receive the intervention.  
Attrition 
The rate of attrition was recorded including the rationale and reason for loss to 
the study accounted for. In the intervention group one participant dropped out of 
the study due to delays in recruitment following a missed appointment from ill-
health, then decision to withdraw consent.  In the control group one participant 
failed to attend a number of appointments and was lost to the study with no 
forwarding contact. In the intervention group one further participant did not fully 
complete the intervention due to unrelated medical reasons and was lost to the 
study. All randomized patients n=25 had their ‘observed’ data analysed even if 
they did not receive the intervention. This was for ‘intention to treat’ analysis. 
The total number to complete the study was n=22.  
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Figure 5.1 CONSORT flow diagram (Schulz et al., 2010)  
* Intention to treat (ITT) analysis (n=25) of all observed data. 
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5.4 Quantitative pilot RCT data 
Data handling and statistics is now presented. Data were transferred to the 
Statistical Package for Social Sciences (IBM SPSS, Version19).  
An adjusted mean baseline was conducted on all of the participants. The results 
of the measures conducted on all the participants (n=25) are presented first. 
This includes the primary measure the GAS, followed by the VAS for pain and 
EQ-5D. Next the upper limb measures are presented for those participants with 
upper limb spasticity (n=22). Of those there were (n=9) in the intervention group 
and (n=13) in the control group. Lastly the three participants with lower limb 
spasticity were all in the intervention group. Data was presented accordingly. 
Any missing data was accounted for and reported within the results.  
 
5.4.1 Primary Measure 
The Goal Attainment Scale (GAS) T score was used as the primary measure in 
the pilot RCT to assess the health benefit of the DEFO intervention in the 
intervention group in comparison with the control group. Justification for using 
the GAS T score is based on the assumption of its sensitivity as a measure of 
patient centred meaningful outcome following BT (Turner-Stokes et al., 2010b). 
It was also considered representative as a measure of clinical outcome for all of 
the participants when compared to specific limb measures. The GAS T score 
was measured in all participants by a baseline adjusted ANCOVA for between 
groups over time (at six weeks and twelve weeks).  
Goal Attainment Scaling (GAS)  
The primary outcome measure GAS T score statistics by group over time is 
presented in Figure 5.2. The predictive value of the GAS T score for a positive 
overall clinical outcome was set at a change ≥10. The mean GAS for a study 
population around 50 is a useful quality check of GAS scoring. This is because 
if a clinician attempts to inflate results by scoring overcautiously the mean score 
is >50, whereas if they are overly ambitious the score will be <50.
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Figure 5.2 Chart of GAS T score by group over time (SD) 
 
SD= standard deviation 
 
The data from the GAS T score at the six weeks primary measure presents a 
statistically significant difference in the score. This is presented in the chart 
above, (Figure 5.2) with a GAS T score by group over time with standard 
deviations shown.  
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Table 5.2 ANCOVA for the change (from the baseline) in GAS T score between intervention and control at six and 
twelve weeks  
 
GAS T  Intervention 
Mean(SD) 
N 
Control 
Mean(SD) 
N 
Adjusted 
mean  
difference  
between  
intervention 
and 
control* 
N=24 
95%  
Confidence 
Interval  
 
p-value Effect size  
(95%CI) 
(standardised) 
 
Baseline 
  
6 weeks 
  
12 weeks 
  
33.69 (5.53) 
N= 12 
58.92(10.93) 
N=11 
51.21(13.21) 
N=10 
  
30.98(6.69) 
N=13 
47.05(10.08) 
N=12 
44.49(11.77) 
N=12 
 
  
  
  
12.17 
  
6.14 
 
 
 
3.16 to 21.18 
  
-4.6 to 16.97 
 
 
 
 
0.014 
  
0.28 
 
 
 
1.21(0.3 to 2.1) 
  
0.52(-0.4 to 1.4) 
SD= standard deviation; N=number of participants; CI=confidence interval 
*Based on 12 patients per group, i.e., 24 patients in total 
 
As can be seen from Table 5.2 there was a statistically significant improvement in GAS T score for the intervention group 
when compared to the control. The change from baseline was 12.17 units of GAS (or 1.21 standard deviations) higher in the 
intervention than that of the control group (95%CI: 3.16 to 21.18; p=0.014). This difference equates to a standardised effect-
size of 1.21 (95% confidence interval 0.31–2.10). This effect-size of the DEFO intervention demonstrates an important clinical 
effect, however with a small study the large effect-size should be interpreted with caution.  
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It can be argued that the effect-size can be directly attributed to the DEFO 
intervention as the goals set were correlated with the previously identified likely 
health benefits associated with the DEFO (in Chapter 3.3). In addition the 
effect-size of 1.21 is likely to be representative of the intervention due to the 
principle of randomized control. The results are indicative that the treatment 
was clinically significant at the six weeks of intervention delivery, but there was 
no worthwhile longitudinal effect after the intervention was withdrawn after the 
six weeks. How meaningful this measure was as an outcome in this study is 
discussed in Chapter 8.5. 
 
5.4.2 Secondary Measures 
Additional measures were used to assess the outcomes of the DEFO 
intervention in the pilot RCT by comparison of the between groups. Both the 
VAS for pain and the EQ-5D was measured in all participants. 
VAS score 
The VAS score was measured in all participants by a baseline adjusted 
ANCOVA for between groups over time (at six weeks and twelve weeks). As is 
shown in Table 5.3 there was no significant change from the baseline between 
the intervention and the control group at any time point. In addition the large 
standard deviation is presented in Figure 5.3. Both groups showed a reduction 
in pain scores at six weeks but the score change was small.  
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Figure 5.3 Chart VAS by group over time (SD) 
 
SD= standard deviation
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Table 5.3 ANCOVA for the change (from the baseline) in VAS between intervention and control at six and twelve 
weeks 
.                                            
 
VAS Intervention 
Mean(SD) 
N 
Control 
Mean(SD) 
N 
Adjusted 
mean  
difference  
between  
intervention 
and 
control* 
N=24 
95%  
Confidence 
Interval  
 
p-value Effect size  
(95%CI) 
(standardised) 
 
Baseline 
  
6 weeks 
  
12 weeks 
  
3.30(2.69) 
N= 12 
2.40(2.21) 
N=11 
2.42(1.90) 
N=10 
  
2.85(3.36) 
N=13 
1.73(1.70) 
N=12 
2.60(2.22) 
N=12 
 
  
  
  
0.48 
  
-0.32 
 
 
 
-0.66 to 1.63 
  
-2.05 to 1.40 
 
 
 
 
0.41 
  
0.72 
 
 
 
1.21(0.3 to 2.1) 
  
0.52(-0.9 to 0.6) 
SD= standard deviation; N=number of participants; CI=confidence interval 
*Based on 12 patients per group, i.e., 24 patients in total. 
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EQ-5D 
The EQ-5D was measured in all participants by a baseline adjusted ANCOVA 
for between groups over time (at six weeks and twelve weeks). The summary of 
statistics of the EQ-5D by group over time is presented, in Figure 5.4. As is 
shown in Table 5.4 there was no significant group differences from the baseline 
between the intervention and the control group at any time point. This is shown 
in the chart below, (Figure 5.4) illustrating the large standard deviations. 
Figure 5.4 Chart of EQ-5D summary statistics by group over time (SD) 
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Table 5.4. ANCOVA for the change (from the baseline) in EQ-5D between intervention and control at six and twelve 
weeks.                                              
 
EQ-5D Intervention 
Mean(SD) 
N 
Control 
Mean(SD) 
N 
Adjusted 
mean  
difference  
between  
intervention 
and 
control* 
N=24 
95%  
Confidence 
Interval  
 
p-value Effect size  
(95%CI) 
(standardised) 
 
Baseline 
  
6 weeks 
  
12 weeks 
  
0.41(0.27) 
N= 12 
0.45(0.27) 
N=11 
0.42(0.23) 
N=10 
  
0.44(0.27) 
N=13 
0.42(0.34) 
N=12 
0.45(0.27) 
N=12 
 
  
  
  
0.03 
  
-0.04 
 
 
 
-0.22 to 0.28 
  
-0.24 to 0.16 
 
 
 
 
0.79 
  
0.73 
 
 
 
0.08(-0.65 to 0.82) 
  
0.15(-0.8 to 0.6) 
SD= standard deviation; N=number of participants; CI=confidence interval 
*Based on 12 patients per group, i.e., 24 patients in total. 
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Results for upper limb measures 
The following results are presented for the participants recruited and 
randomised with upper limb spasticity using the appropriate outcome measures 
the ArmA and the LASIS. Both are reported to measure ‘active’ and ‘passive’ 
functional components. 
ArmA 
The ArmA was measured in all upper limb participants by a baseline adjusted 
ANCOVA for between groups over time (at six weeks and twelve weeks). The 
following results for the ArmA are presented with the ‘active’ components score 
followed by the ‘passive’ (care) function components score. This is due to the 
difference in construct in each component for the purpose of analysis. 
ArmA (Active) 
Table 5.5 Summary statistics for ArmA (Active) by group over time 
Group Baseline 6 weeks  12 weeks 
Intervention 
Mean(SD) 
N 
 
 
49.33 (0.87) 
9 
 
48.22(3.99) 
9 
 
47.38(4.63) 
8 
Control 
Mean(SD) 
N 
 
 
48.69(1.44) 
13 
 
48.08(1.62) 
12 
 
47.08(3.89) 
12 
SD= standard deviation; N=number of participants 
 
Figure 5.5 Chart for ArmA (Active) by group over time (SD) 
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Table 5.6 ANCOVA for the change (from the baseline) in ArmA (Active) 
between intervention and control at six and twelve weeks 
Outcome Adjusted mean 
difference between 
intervention and 
control 
95% Confidence 
Interval 
p-value Effect size  
(standardised) 
ArmA- 
Active 
n=22 
6 weeks 
 
12 weeks 
 
 
 
 
-0.46 
 
-0.39 
 
 
 
-2.88 to 1.96 
 
-4.08 to 3.29  
 
 
 
0.71 
 
0.83 
 
 
 
0.28 (-1.8 to 1.2) 
 
0.10 (-1.0 to 0.8) 
 
The summary of statistics for the ArmA (Active) by group over time is in Table 
5.5. As is shown in the table above, (Table 5.6) there was no significant 
difference from the baseline between the intervention and the control group at 
any time point. There was a small change in both groups with reduced scores 
over time. As is shown in the figure above, (Figure 5.5) both the intervention 
and control groups demonstrated a small decrease in score over time (from the 
baseline). 
ArmA Passive  
Table 5.7 Summary statistics for ArmA (Passive) by group over time 
Group Baseline 6 weeks  12 weeks 
Intervention 
Mean(SD) 
N 
 
 
16.11 (4.54) 
9 
 
17.67(5.31) 
9 
 
6.5(2.32) 
8 
Control 
Mean(SD) 
N 
 
16.46(2.93) 
13 
 
16.83(3.66) 
12 
 
6.42(2.19) 
12 
 
SD= standard deviation; N=number of participants 
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Figure 5.6 Chart for ArmA (Passive) by group over time (SD) 
 
SD= standard deviation 
 
Table 5.8 ANCOVA for the change (from the baseline) in ArmA - Passive 
between intervention and control at six and twelve weeks 
Outcome Adjusted mean 
difference between 
intervention and 
control 
95% Confidence 
Interval 
p-value Effect size  
(standardised) 
ArmA- 
Passive 
n=21 
6 weeks 
 
12 weeks 
 
 
 
 
1.53 
 
-0.89 
 
 
 
-1.35 to 4.41 
 
-2.56 to 0.78  
 
 
 
0.31 
 
0.30 
 
 
 
0.42 (-0.4 to 1.2) 
 
0.41 (-1.2 to 0.4) 
 
The summary of statistics for the ArmA (Passive) by group over time is in Table 
5.7. As is shown in the table above, (Table 5.8) there was no significant change 
between the intervention and the control group at any time point as both groups 
provided an increased score at six weeks followed by a decreased score at 
twelve weeks. Both groups provided a change score (decrease) in the ArmA 
(Passive) between baseline and each time point as shown in the chart above, 
(Figure 5.6). There was a drop in for the ArmA (Passive) score for both groups 
which increased over time.  
 
129 
 
LASIS 
The LASIS was measured in all upper limb participants by a baseline adjusted 
ANCOVA for between groups over time (at six weeks and twelve weeks). The 
following results are presented for the LASIS for the participants and also for 
the carers. This is due to the separate constructs for analysis. 
LASIS (Participant) 
Table 5.9 Summary statistics for the LASIS (Participant) by group over 
time 
Group Baseline 6 weeks  12 weeks 
Intervention 
Mean(SD) 
N 
 
 
1.97 (0.67) 
9 
 
2.03(0.48) 
8 
 
1.71(0.53) 
7 
Control 
Mean(SD) 
N 
 
 
1.69(0.37) 
13 
 
1.70(0.64) 
12 
 
1.59(0.51) 
12 
SD= standard deviation; N=number of participants 
 
The summary of statistics for the LASIS (Participant) by group over time is in 
Table 5.9. 
 
Figure 5.7 Chart for LASIS (Participant) score by group over time (SD) 
 
SD= standard deviation 
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Table 5.10 ANCOVA for the change (from the baseline) in LASIS 
(Participant) between intervention and control at six and twelve weeks  
Outcome Adjusted mean 
difference between 
intervention and 
control 
95% Confidence 
Interval 
p-value Effect size  
(standardised) 
LASIS (P) 
n=20 
6 weeks 
 
12 weeks 
 
 
 
0.21 
 
0.11 
 
 
-0.26 to 0.68 
 
-0.34 to 0.57  
 
 
0.39 
 
0.63 
 
 
0.33 (-0.4 to 1.06) 
 
0.21 (-0.7 to 1.1) 
 
As is shown in the table above, (Table 5.10) there was no significant difference 
from the baseline between the intervention and the control group at any time 
point. This can be seen in Figure 5.7 with added standard deviations. 
LASIS (Carer) 
Table 5.11 Summary statistics for LASIS (Carer) by group over time 
Group Baseline 6 weeks  12 weeks 
Intervention 
Mean(SD) 
N 
 
 
2.21 (0.78) 
6 
 
2.36(0.57) 
6 
 
2.22(0.86) 
5 
Control 
Mean(SD) 
N 
 
 
2.46(0.86) 
9 
 
1.78(0.78) 
8 
 
2.64(0.98) 
8 
SD= standard deviation; N=number of participants 
 
The summary of statistics for the LASIS (Carer) by group over time is in Table 
5.11. The low numbers (intervention group n=6 and n=9 in the control group) 
analysed was due to some of the participants not having a ‘carer’. They were 
independent.  
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Figure 5.8 Chart for LASIS (Carer) score by group over time (SD) 
 
SD= standard deviation 
 
Table 5.12 ANCOVA for the change (from the baseline) in LASIS (Carer) 
between intervention and control at six and twelve weeks 
Outcome Adjusted mean 
difference between 
intervention and 
control 
95% 
Confidence 
Interval 
p-value Effect size 
(standardised) 
LASIS (C) 
n=14 
6 weeks 
 
12 weeks 
 
 
 
0.57 
 
-0.73 
 
 
-0.17 to 1.31 
 
-1.88 to 0.43  
 
 
0.14 
 
0.23 
 
 
0.73 (-0.2 to 1.7) 
 
0.74 (-1.9 to 0.4) 
 
As is shown in the table above, (Table 5.12) there was no significant difference 
from the baseline between the intervention and the control group at any time 
point. There was a small reduction in the LASIS score in the control group at six 
weeks but this returned to baseline by twelve weeks. There was no 
measureable difference in the LASIS score in the intervention group at any time 
point. This is demonstrated above, (in Figure 5.8). 
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Results for lower limb measures 
The following results are presented for the participants recruited and 
randomised to the study with lower limb spasticity. The outcome measure for 
gait velocity was used.  
The Ten Meter Timed Walk Test (10MTT) 
Results from the 10 meter timed walk test are presented as descriptive data 
below, (Table 5.13). Three participants with lower limb spasticity recruited and 
allocated to the intervention group provided insufficient data for statistical 
analysis for significance. There were no participants allocated to the control 
group with lower limb spasticity. The participants were demographically 
representative of three diagnostic groups. One person had been diagnosed with 
stroke (P18), another presented with spasticity following traumatic head injury 
(P10) and the third presented with a progressive neurological disease, Multiple 
Sclerosis (P11). The latter participant’s general medical condition deteriorated 
and the participant was unable to walk the necessary distances (ten meters 
repeated three times) for the third assessment at twelve weeks. 
Table 5.13 Ten Meter Timed Walk Test: Descriptive Data (Intervention 
Group) 
ID:10 1st Assessment 2nd Assessment 3rd Assessment 
Trial Steps Seconds Steps Seconds Steps Seconds 
1 28 50.2 24 34.8 26 44 
2 28 48.5 23 35.4 25 45 
3 27 52.4 24 40.3 25 45 
Average 27.66 50.36 23.66 36.83 25.33 44.66 
Meters/Min 11.45 14.88 13.33 
ID:11 1st Assessment 2nd Assessment 3rd Assessment 
Trial Steps Seconds Steps Seconds Steps Seconds 
1 37 85 42 92  -  - 
2 36 70 36 71  -  - 
3 36 71 38 70  -  - 
Average 36.33 75.33 38.66 77.66 - - 
Meters/Min 8.45 8.57 - 
ID:18 1st Assessment 2nd Assessment 3rd Assessment 
Trial Steps Seconds Steps Seconds Steps Seconds 
1 19 15.8 17 11.5 16.5 11.9 
2 18 15.2 17 11.8 17 10.9 
3 18 15.5 17 11.9 15 9.7 
Average 18.33 15.5 17 11.73 16.16 10.83 
Meters/Min 38.70 50.42 61.85 
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Figure 5.9 Summary of results for ten meter timed walk test 
 
 
As can be seen in the figure above, (Figure 5.9) participants 1 (P10) and 3 
(P18) made improvements in gait velocity at six weeks however this 
improvement was not maintained by twelve weeks following the removal of the 
DEFO. There was no change in the gait velocity in participant 2 (P11) at six 
weeks and retest at twelve week was not performed due to deterioration of her 
progressive condition. 
 
5.5 Fidelity, adherence and variance data  
Data presented here is a record of procedural fidelity, adherence and variance. 
It includes a summary of the DEFO wearing record, a summary record by group 
of the physiotherapy interventions and contact time data, the Activity Log 
summary by group, and clinical data including goals set by group and protocol 
variance. Clinical data is coded for data protection. 
DEFO wearing record 
A summary of the DEFO wearing record (Table 5.14) is presented for the 
purpose of analysis of adherence, tolerance and fidelity of the intervention 
protocol.  
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Table 5.14 Summary of DEFO wearing record (Total participants n=11) 
Week Daily 
wearing  
<8 hours 
Daily 
wearing 
>8 hours 
Preferred 
range 
daily 
(hours) 
Recommended 
Wearing 
Total hours 
Recorded 
mean 
Total hours 
1 1-4 hours 8 hours 1-13 39 35.8 
2 0 hours* 8 hours 5-13 56 54.5 
3 0 hours* 8 hours 6-13 56 58 
4 0 hours* 8 hours 5-13.5 56 57.5 
5 0 hours* 8 hours 6-13 56 60 
6 0 hours* 8 hours 6-13 56 59.5 
* Two participants chose to not wear DEFO (1 participant refused, 1 didn’t wear at the weekend) 
 
The ‘cricket sensor’ for use as a wearing record was not forthcoming from DMO 
Ltd®. The DEFO wearing record was completed by all the participants in the 
intervention group who followed the protocol (n=11) and the raw data was 
collated by the researcher. The combined records were compared to the 
wearing protocol (Chapter 4). The combined data was then analysed to provide 
the preferred range of number of hours the DEFO was worn each day followed 
by the mean number of hours actually worn. The findings show a significant 
level of adherence and tolerance. The records also indicate wearing fidelity 
although the sensor could have further verified the written records. 
As can be seen in the table above the DEFO was acceptable to wear in ten 
participants with one declining to wear it and a second person who chose not to 
wear it at weekends. This was reported in additional comments ‘for washing’ at 
weekends (worn daily at work). The DEFO protocol was closely adhered to in 
weeks three, four, five and six with some participants preferring to wear it longer 
than eight hours (13.5 hours). The wearing protocol was not fully adhered to in 
weeks one and two, however the recorded mean total hours did not vary 
greatly: week one: 35.8 hours out of 39 hours; week two: 54.5 hours out of a 
recommended 56 hours. It was noted that one participant was hospitalised in 
week six resulting in her reduced total wearing record. 
Physiotherapy interventions 
A clinical record of physiotherapy interventions for each participant was 
captured over the twelve weeks study protocol. This demonstrated total contact 
time and individual treatment components delivered. A summary of the 
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interventions delivered over the protocol duration to participants in both groups 
together with respective contact time are presented below, (in Table 5.15).  
From the recorded mean physiotherapy contact time it can be seen that the 
intervention group had less total contact (185.9 minutes) compared to the 
control group (237.5 minutes). It can also be seen the modalities of intervention 
were similarly matched for both groups. Participants from each group were 
evenly distributed between the clinicians. The results are analysed and 
discussed further in Chapter 7. 
Table 5.15 Summary of physiotherapy interventions and contact time (in 
twelve weeks) 
 Intervention 
group n=11 
Control group 
n=12 
Total 
participants 
n=23 
Intervention    
Sensory 
stimulation 
n=4 n=4 n=8 
Splinting 
or casting 
n=8 n=7 n=15 
Strength 
training 
n=7 n=7 n=14 
Fitness/ 
Aerobic training 
n=3 n=4 n=7 
Stretches 
a)Static 
b)dynamic 
a) n=9 
b) n=9 
a) n=8 
b) n=9 
a) n=17 
b) n=18 
Functional 
training (task 
related) 
n=10 n=8 n=18 
Other training: 
FES 
CIMT 
n=4 n=6 n=10 
Other: 
Fatigue 
management 
n=4 n=4 n=8 
Advice and 
carer advice 
n=6 n=6 n=12 
Clinician    
C2 n=5 n=6 n=11 
C3 n=6 n=6 n=12 
Contact time   Total contact 
time 
Mean (minutes) 185.9 237.5 212.8 
Range (minutes) 45-420 45-500 45-500 
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Activity Log 
A table summary of themes from recorded activities in the ‘Activity Log’ is 
presented in the table below, (Table 5.16). It demonstrates the variety of 
activities by group. 
Table 5.16 Research Activity Log (by group) 
Activity recorded Intervention 
group 
n=11 
Control group 
n=12 
Total 
participants 
n=23 
Work n=2 n=1 n=3 
Housework n=2 n=2 n=4 
Gym, practised exercises n=3 n=2 n=5 
Walking n=3 n=3 n=6 
Gardening n=1 n=0 n=1 
Swimming, Hydrotherapy  n=2 n=3 n=5 
Computer n=1 n=0 n=1 
Saebo-stretch splint worn at 
night 
n=1 n=0 n=1 
Relaxation class, meditation n=1 n=1 n=2 
Clubs: Speaking club, golf 
club, stroke club, school 
reunion, dancing 
n=1 n=3 n=4 
Driving, school run n=3 n=2 n=5 
Shopping n=4 n=10 n=14 
Visiting bank, citizens advice n=0 n=1 n=1 
Hairdressers n=0 n=1 n=1 
Looking after pets: going to 
vets, walking dog, visit 
horses, looking after cats 
n=2 n=1 n=3 
Social outings: Cinema 
out for lunch, pub, BBQ 
n=3 n=5 n=8 
Appointments: GP, hospital, 
dentist, podiatry, wheelchair 
assessment 
n=3 n=5 n=8 
Medical events: fall, seizure, 
infection requiring antibiotics 
n=3 n=3 n=6 
Holidays, weekend trip n=2 n=2 n=4 
Moved house n=0 n=1 n=1 
Respite in care home n=0 n=1 n=1 
Total activities  36 46 82 
 
As can be seen from the table above, (Table 5.16) there was a wide variety in 
activities recorded over the study period. This varied from activities of 
participation and roles: working (intervention group n=2, control group n=1); 
shopping (intervention group n=4, control group n=10); driving and school run 
(intervention group n=3, control group n=2), to more passive activities: 
attending appointments (intervention group n=3, control group n=5); relaxation 
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and meditation (intervention group n=1, control group n=1). From a position of 
variance the control group recorded more activities than the intervention group. 
This is descriptively analysed and discussed in Chapter 7. Participants also 
recorded physiotherapy sessions which were captured and presented 
elsewhere, (Table 5.15). 
Clinical data 
As clinical data was embedded in both quantitative and qualitative results it is 
presented separately. The clinical data was sourced from the physiotherapy 
records and where necessary medical notes for verification of variance data.  
From the clinical records two participants were hospitalised, (n=1 control group, 
n=1 intervention group). This meant one participant was lost to the study after 
six weeks (P09) with extended immobilisation for a medical condition unrelated 
to the study; however the other participant (P13) continued with the protocol 
and returned home. In addition there were six medical events recorded (n=3 
control group, n=3 intervention group) including: a fall (P06); seizures in two 
participants (P16, P20) and three participants (P02, P05, P11) requiring 
antibiotics for infections. Two participants (P11 and P21) received diagnostic 
news on disease progression. Additional issues of clinical impact included level 
of carer support provided and dependency. The former was reported in the 
participant baseline characteristics (Table 5.1) but the latter was only gathered 
from the clinical records and not quantified. Social issues which impacted on 
individual participants included: roles and responsibilities for dependents; 
financial pressures and relocation.  
Goals identified 
The goals identified by all the participants in the study are summarised by group 
for variance and presented in the table below, (Table 5.17). There were 69 
goals set (three per participant) and of these 14 common themes emerged and 
were categorised. There was no significant difference between the groups in the 
number or category of goals set.  
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Table 5.17 Summary of goals set (by group)  
Goal Intervention 
Group 
Control 
Group 
Total Goals 
(69) 
ASSOCIATED REACTION 
(AR): e.g. To walk 50 
meters outdoors on flat 
ground with elbow 
extension maintained  
4 3 7 
PASSIVE RANGE: e.g. To 
maintain passive ROM in 
wrist extension of 30 
degrees with fingers neutral  
2 0 2 
EXERCISE RELATED: e.g. 
To be able to do strength 
exercises independently 
weekly 
2 3 5 
WALKING: e.g. To walk 
independently indoors 15 
meters with a stick 
4 5 9 
SPLINT: e.g. To put splint 
on daily with ease 
3 4 7 
FUNCTIONAL 
INDEPENDENCE: e.g. 
Independent dressing 
6 4 10 
PAIN (VAS): e.g. To 
subjectively decrease in 
pain by 2 points  
3 4 7 
MUSCLES TENSION: e.g. 
To reduce feeling of 
tightness in leg 
2 0 2 
POSTURE: e.g. To rest 
forearm on table 15 minutes 
at meal times 
2 2 4 
BALANCE: e.g. 
Unsupported stand 3 
minutes  
1 1 2 
FALLS: e.g. To fall less 
than 2 times in 6 weeks 
0 1 1 
CONFIDENCE: To increase 
confidence VAS score by 2 
points 
1 1 2 
HAND FUNCTION: e.g. To 
hold plastic drinking cup in 
hand and take to mouth for 
a drink 
2 3 5 
HAND HYGEINE e.g. To 
allow safe nail care 
3 3 6 
Key: AR = Associated Reaction (Posture of arm when walking), VAS= Visual Analogue Scale  
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Variance data 
Additional data was captured from the DM Orthotics Ltd© clinician. This data 
was collated from the intervention group participants. There were two recorded 
timing delays in the protocol delivery for the assessment for fitting of the DEFO. 
Both of these resulted from cancelled appointments due to illness. Another 
delay in fitting of the DEFO of two participants was caused by unforeseen travel 
difficulty (from flooding). There were further delays in the fitting process with 
three participants as additional modifications were made in the customised 
DEFO. This meant the six week intervention period was considerably delayed 
for participants (P16) and (P19). In the former a second DEFO was provided as 
the first was extremely tight and difficult to put on. This participant (P16) took a 
‘dislike’ to it and even when provided with another refused to wear it. In the 
latter case (P19) a second cycle of BT was awaited before the participant could 
be successfully recruited. Further delays due to participant illness resulted in 
one recruited participant rescinding his consent to the study. He was offered 
recruitment after his second cycle of BT, but he declined. Further variance 
included two incidents of revealed allocation. 
 
5.6 Data Summary  
In summary the baseline characteristics of the participant two groups were 
found to be evenly matched. This was however, with the exception of mean 
(SD) age difference: 50.5 (12.60) years (intervention group); 61.6 (14.46) years 
(control group). 
Of the (n=25) participants recruited (n=23) completed the study. Two of the 
participants recruited (intervention group n=1, control group n=1) did not 
proceed with the study and their data was not analysed. One participant 
(intervention group, n=1) was lost to the study for medical reasons unrelated to 
the study. 
A summary table of the results analysis of primary and secondary outcomes at 
six weeks and twelve weeks for difference between groups is presented below 
(in Table 5.18). The lower limb measures are presented descriptively for those 
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participants in the intervention group. There were no participants allocated to 
the control group with lower limb spasticity. 
Table 5.18 Summary of findings: pilot RCT (primary and secondary 
measures) 
Outcome Adjusted mean 
difference 
between 
intervention 
and control 
95% 
Confidence 
Interval 
p-value Size effect (95%CI) 
(standardised) 
ANCOVA     
Primary measure     
GAS  
6 weeks 
 
12 weeks 
 
12.17 
 
6.14 
 
3.16 to 21.18 
 
-4.68 to 16.97  
 
0.014 
 
0.28 
 
1.21 (0.3 to 2.1) 
 
0.52 (-0.4 to 1.4) 
Secondary 
measures 
    
VAS 
6 weeks 
 
12 weeks 
 
0.48 
 
-0.32 
 
-0.66 to 1.63 
 
-2.05 to 1.40  
 
0.41 
 
0.72 
 
0.28 (-0.4 to 0.9) 
 
0.14 (-0.9 to 0.6) 
EQ5D 
6 weeks 
 
12 weeks 
 
0.03 
 
-0.04 
 
-0.22 to 0.28 
 
-0.24 to 0.16  
 
0.79 
 
0.73 
 
0.08 (-0.65 to 0.82) 
 
0.15 (-0.8 to 0.6) 
Upper limb     
LASIS-Participant 
6 weeks 
 
12 weeks 
 
0.21 
 
0.11 
 
-0.26 to 0.68 
 
-0.34 to 0.57  
 
0.39 
 
0.63 
 
0.33 (-0.4 to 1.06) 
 
0.21 (-0.7 to 1.1) 
LASIS-Carer 
6 weeks 
 
12 weeks 
 
0.57 
 
-0.73 
 
-0.17 to 1.31 
 
-1.88 to 0.43  
 
0.14 
 
0.23 
 
0.73 (-0.2 to 1.7) 
 
0.74 (-1.9 to 0.4) 
ArmA- Active 
6 weeks 
 
12 weeks 
 
-0.46 
 
-0.39 
 
-2.88 to 1.96 
 
-4.08 to 3.29  
 
0.71 
 
0.83 
 
0.28 (-1.8 to 1.2) 
 
0.10 (-1.0 to 0.8) 
ArmA- Passive 
6 weeks 
 
12 weeks 
 
1.53 
 
-0.89 
 
-1.35 to 4.41 
 
-2.56 to 0.78  
 
0.31 
 
0.30 
 
0.42 (-0.4 to 1.2) 
 
0.41 (-1.2 to 0.4) 
Lower limb 
10MTT 
 
Trial 1  
Baseline 
Meters/Min 
Trial 2  
6 weeks 
Meters/Min 
Trial 3  
12 weeks 
Meters/Min 
 
Participant 1 (P10) 
 
Participant 2 (P11) 
 
Participant 3 (P18) 
11.45 
 
8.45 
 
38.70 
14.88 
 
8.57 
 
50.42 
13.33 
 
- 
 
61.85 
All participants had 
demonstrated 
improvements in 
gait velocity at 6 
weeks.  
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The DEFO wearing record supported the tolerance and adherence of the 
wearing protocols. The DEFO protocol was closely adhered to in four of the six 
weeks with wearing preferences and tolerance of eight hours or more (13.5 
hours). In addition the procedural fidelity was established with the majority of 
participants ten choosing to wear the DEFO and one declining to wear it. 
A summary of physiotherapy intervention and contact delivery time found the 
modalities of intervention were similarly matched for both groups however the 
intervention group had less total contact (185.9 minutes) compared to the 
control group (237.5 minutes). Modalities most commonly used included: 
stretches (both active and passive); functional training; splinting; strength 
training and advice. 
Analysis of the Activity Log provided a snapshot by group of the varied activities 
of the participants during the study. Shopping appointments and social outings 
were commonest activities recorded and both groups recorded similar levels of 
activity.  
Goal setting and analysis by group was reported for variance in clinical practice. 
Of the 69 goals set there were 14 common categories. On analysis there was 
no significant difference either between the groups or in the number or category 
of goals set.  
The clinical findings reported procedural variance data on timing of fitting and 
protocol implementation. Reasons included illness and environmental issues 
beyond the control of the researcher. These findings are addressed by the topic 
guided interviews, which were analysed and presented in Chapter 6 and the 
combined findings discussed in more detail in Chapter 7.   
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Chapter 6 
Results II (Qualitative) 
 
 
 
 
 
 
 
 
6.1 Overview of findings presented 
After the quantitative phase (pilot RCT) was completed topic guided interviews 
were conducted and provided qualitative data to explore the results (Chapter 5) 
and address the research questions (Chapter 3.2). 
Topic guided interviews 
The topic guided interview questionnaires for the participants and clinicians are 
presented in Appendices 11 and 12, respectively. One (n=1) participant in the 
intervention group was not interviewed due to removal from the study for non-
related medical reasons at six weeks but was followed up and contributed to the 
development of the interview questions). The experiences of intervention group 
participants (n=10 of the n=25 recruited to the study) and clinicians (n=3) were 
captured by digitally recorded topic guided interviews. Data was transcribed, 
anonymised and collated onto an NHS electronic database.  
Examples of the Framework analytic approach used for coding participant and 
clinician data extracts are shown in Appendix 16. Each of the coded themes 
was able to be traced back to participant quotes for reference and authenticity. 
A colour coding system was used to explore issues and descriptives which were 
interpreted into sub-themes (basic themes) and further analysed into themes 
(organizing themes) and finally superordinate themes (global theme). The 
Thematic Analysis findings are presented, in a series of ‘thematic maps’ 
Key points: 
 Results overview of findings presented  
 Qualitative findings analysis of topic guided interview accounts of 
participants and clinicians 
 Thematic Analysis- basic, organizing and global themes presented 
in ‘Thematic maps’, theming of quotes, and critical analysis of 
themes.  
 Summary of themes 
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(Figures; 6.2, 6.3, 6.5 and 6.6). They were generated in order to provide 
transparency in the method used for thematic interpretation of participant and 
clinician feedback, (in Chapter 3.6). Each of the data sets is presented below 
under the relevant headings. 
 
6.2 Participant feedback 
The semi-structured interviews with the participants were steered by topic 
guided questions (Topic Guided Interview of Participants, Appendix 11) to 
answer specific feasibility and acceptability issues in the research study 
including rationale for compliance, adherence, clinical applicability, and to 
identify any specific health benefits and adverse effects. A probing technique 
was used in the interviews. Specific topics covered: positive and negative 
experiences of; the research feasibility; acceptability of the DEFO intervention; 
and wearing preferences. For this reason the findings were likely to be 
deductive, however the conversations also provided interesting and inductive 
themes which were explored. The Thematic Analysis findings are presented, (in 
Figure 6.1). The figure depicts the underlying issues and descriptives which 
were colour coded into sub-themes, then categorized into themes and finally 
superordinate themes.  
 
6.2.1 Global Participant theme: (GP.1) Research Experience: Acceptability  
The following organizing themes that underpin the global theme (GP.1) 
‘Research experience: Acceptability’ are presented below. These sub-
ordinate themes comprise; Organizing Participant themes: (OP.1): Research 
expectations; (OP.2): DEFO acceptability; (OP.3): Protocol feasibility; 
(OP.4): Health benefits and (OP.5): Adverse effects. Each sub-theme is 
analysed with evidenced references from the original textual data (quotes from 
the transcriptions). The findings are synthesized from the relevant and 
interesting themes and they are presented diagrammatically in a ‘Thematic 
network map’ (Figure 6.2). The findings are presented and interpreted with 
evidence theme by theme. 
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Figure 6.1 Thematic Analysis of participant interview findings; colour coded for categories 
  Issues and descriptives                       Sub-themes                                Themes                             Superordinate Themes 
 
 
 
Perceptions 
on disability:  
Impact on Research  
(GP.2) 
Generalizability to 
condition 
(OP.1) 
 
• Health benefits for self/others 
• Opportunity/hope 
• Expectation/Access to resources 
• Motivation 
• Wearing time > 8 hours 
• Wearing issues  
• Colour preference  
• Cosmetic appearance  
• Protocol clear 
• Protocol consistency 
• Delays in timing 
• 6 weeks ‘not long enough’ 
• Delays in fitting 
• Social (support) impact 
• Pain relief 
• Comfort 
• Felt more normal/awareness 
• Posture improved 
• Reduced tension in 
muscles/relaxed 
• Movement Function improved 
• Appearance more normal to 
others 
• Sweating in warm climate 
• Tightness of DEFO 
• Pulling of hairs (on fitting) 
 Impact on activity 
 Timing preferred earlier in 
condition management 
 Optimal timing in BT treatment 
cycle  
 Self-image perception of disability 
 Perception of society on disability 
(community)  
 Motives for research participation  
Research expectations 
(OP.1) 
  
 
 
 
 
 
 
DEFO acceptability 
(OP.2) 
 
 
Protocol feasibility 
(OP.3) 
 
Health Benefits 
(OP.4) 
 
Adverse Effects 
(OP.5) 
Differing perceptions 
on disability 
(OP.2) 
Health benefits for self 
and others. 
Appearance and 
wearing issues.  
 
Timing delays and 
protocol acceptability. 
 
Physical health benefits 
and psychosocial health 
benefits.  
 
Physical adverse effects 
and impact on activity. 
Timing preferences and 
generalizability to 
specific conditions. 
Self-perceptions on 
disability, societal 
perceptions on 
disability and motives in 
research. 
Research 
experience: 
Acceptability 
(GP.1)  
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Figure 6.2 ‘Thematic map’ for Global Participant theme: (GP.1) Research Experience: Acceptability 
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6.2.1.1 Organizing Participant theme (OP.1): Research expectations 
 
Participants raised a number of issues around their expectations and underlying 
motives for participating in the research. These were categorized into two 
further sub-themes. Firstly participants considered their own expectations on 
likely benefits. Secondly a number of participants proposed likely benefits for 
others, for example funding opportunities and service delivery improvements. 
   
Sub-theme: Health benefits for self 
 
The examples from the texts below include differing perceptions of how the 
research or the intervention in particular could benefit them specifically as an 
individual. Differences in the expectations were often linked to their experiences 
as the interviews were after the pilot RCT.  
 
One participant gave an interesting viewpoint in that they accepted anything 
offered. This could have been because he had reached the end of his 
rehabilitation phase, was perhaps not accepting of his level of disability and was 
still highly motivated to make improvements:  
 
‘Just because it was there it was offered …I like to say yes to everything 
so… I just went for it!’ (P01) 
 
This raises the underlying concept of patient motivation in rehabilitation. 
Motivation is a term commonly used by clinicians when linked to performance 
and outcomes. The impact of a life-changing disability and how people adjust as 
individuals is likely to have an effect on attitudes and behaviours in therapy and 
research. There is much debate about the individual (intrinsic) and social 
(extrinsic) concepts of motivation (Maclean and Pound, 2000).  A similar 
viewpoint of another participant with a progressive condition expressed a 
personal need to grasp every chance for potential improvement and hope at the 
opportunity to join the research. Understanding the concept of hope is relevant 
to rehabilitation clinicians (Bright et al., 2011). This expression of ‘hope’ was 
echoed by other participants: 
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‘…I think in a situation like that, you would try anything really’. (P11) 
 ‘An opportunity to sort of try something…as part of research.’ (P04) 
‘… sometimes you can go on week by week,  month on month and not 
see anything has been done… that is a positive like a feeling of hope like 
something was being done… it will improve.’ (P18) 
The underlying motives of individuals can be interpreted in light of their 
experience of a life-changing illness to which they have had to adjust both 
physically and emotionally. The importance of apathy and motivation for 
meeting the challenges of the recovery process are surprisingly undervalued 
(Mayo et al., 2009). The problem of apathy post stroke is an issue that deserves 
further study. According to Mayo and colleagues it is linked to motivating factors 
and low mood that can impact negatively on ability to participate in promising 
therapies.  
Another viewpoint was considered from a person-centred stance outlining the 
possible benefits offered by the research with access to further therapy. There 
is a suggestion of a link between both hope and motivation, and expectation 
and reward: 
‘…to see if there was any long term benefit to myself’. (P18) 
 ‘Well…selfish... that it was going to get me better quicker- with a bit of 
luck. I suppose you get access to physiotherapy quicker- whether that is 
true or not I don’t know!’ (P20) 
Two further participants were clear about what they expected from the research 
and how these were realised. In the examples below the benefits gained were 
realised suggesting that the expectations for both individuals were well founded. 
 
 ‘…to see if these things work. It worked for me’. (P24) 
 
 ‘…I was glad to be helping you in your research and thought it would be 
good for me to help me to be beneficial in my progression to my target… 
it was like helping my mind as well it was definitely helping me too’. (P10) 
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The sentiment of helping oneself and others at the same time was commonly 
reported demonstrating consideration for other people in a similar predicament. 
This was further complemented by the suggestion of evidence influencing 
decisions: 
‘…you do it to help yourself and other people…. and get the arm moving’. 
(P19)  
‘…it might be available if it proves successful for us to try later on 
because we would know a bit more about it.’ (P16) 
Sub-theme: Health benefits for others 
 
Consideration for others was seen as a priority for some participants 
demonstrating insight into the underlying aim of the research; to find if the 
DEFO intervention had any added health benefit. This altruistic sentiment was 
expressed in a number of ways; from general, to more condition specific and for 
a similar younger population: 
 
‘I decided to take part because if you do anything like that it helps other 
people’. (P19) 
 
 ‘Anything that can help to alleviate the suffering of stroke has got to be a 
good thing’. (P20) 
 ‘Just thought it would be helpful to other young people... to see if these 
things work’. (P24) 
 
There was a further viewpoint that considered others (people with stroke) from a 
perspective of the level of motivation required to comply with the research 
expectations. This personal insight is evidenced in the literature as ‘apathy’ post 
stroke (Mayo et al., 2009). 
 
‘High level of motivation, effort and time needed. Question whether 
people with stroke have the level of motivation required’. (P21) 
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In addition a specific issue was raised on funding decision opportunities that 
could arise from the research findings. This was from a participant with previous 
experience in research and who had a broader perspective on potential health 
benefits:  
 
‘…get me better quicker…with a bit of luck and if it helps people to make 
a decision about where they spend NHS funding that is good for me’. 
(P20) 
 
This was an unexpected finding from the participants and demonstrated the 
added value of qualitative research. The literature supports the importance of a 
person’s motivation in determining the outcome of rehabilitation (Maclean and 
Pound, 2000; Nicholson et al., 2012). In summary the categories of hopes, 
expectations and motives of participants were interpreted for significance into 
sub-themes of health benefits for self and others and subsequently synthesised 
into the theme (OP.1): expectations in research. 
 
 
6.2.1.2 Organizing Participant theme (OP.2): DEFO Acceptability 
 
The topic of DEFO wearing acceptability was presented overtly in the 
participant interviews with the intention of finding out details of importance to the 
participants. From the data analysis two issues were found significant for 
acceptability and adherence; appearance and wearing issues. 
 
Sub-theme: Appearance 
 
The appearance of the DEFO was considered from differing perspectives 
depending on the individual. It was important for some participants that it was 
not conspicuous as they did not wish to draw attention to their disability; to 
others it was an important medical emblem for others to identify a need for 
assistance. In contrast to the above, two participants suggested the appearance 
should reflect their personality with vivid statement colours.    
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The appearance of the DEFO was firstly considered from a self-image, 
‘normalising’ perspective. This was considered an important aspect for reasons 
to wear the orthotic from a personal stance. It links with perceptions of social 
acceptability and wanting to fit in. Two participants were clear on their rationale 
for finding the DEFO acceptable: 
 
‘…you could hardly see it …and for the colour of it …just blended in’. 
(P19) 
‘My arm felt straighter, when I was wearing it, much straighter and more 
normal…’ (P24) 
 
Secondly, one participant viewed the DEFO appearance helpful in respect of 
cueing others. She raised the importance of social roles and responsibilities by 
openly declaring disability with a visual cue: 
 
“…as a physical cue for other people for if you have something wrong 
with your limb to be helpful for other people ’cause if you have nothing on 
they are not aware you have a problem. Splints in general serve as a 
visual aid to third parties which prompts the public to be more helpful in 
social situations e.g. shopping bag packing’. (P21) 
 
Lastly there was a different perspective from participants who fully embraced 
their DEFO as an extension of their apparel. It was suggested that in order to be 
acceptable to them personally the colour of the orthosis needed to be 
customised: 
 
 ‘A choice of colours might have been nice…’ (P21) 
‘…it was flesh coloured even with the tones… he wanted ‘Orange!’ (P04) 
‘…just part of the stroke. I would just wear it anyway…so…I dyed it 
purple…more me’. (P01) 
 
The issues raised were not so much about the specific colour preferences but 
more about the need for customising the appearance of the DEFO to optimise 
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the acceptability from an individual’s perspective. This is presented from 
another viewpoint on perceptions of disability (GP.2; OP.1: Differing 
perceptions of disability, self-perceptions of disability). 
Sub-theme: Wearing issues 
There were a number of participants who raised the important issue of 
acceptability from the experiences on wearing the DEFO. There were both 
positive and negative experiences. The positive findings identified flexibility, it 
was lightweight, able to be worn under clothing and was easy to remove.  
 
‘Definite benefits are that it is more lightweight, and flexible… can put on 
clothing…like a coat…more easily especially in winter and prefer 
compared to rigid thermoplastic splints…especially coming into the 
winter, more accessible.’ (P21) 
 
‘…taking it off was no trouble…’ (P19) 
 
‘Putting it on every day it got easier and easier and easier and we could 
actually do it within a couple of minutes’. (P04) 
‘…splint allows movement whilst being worn so all daily exercises can 
still be undertaken without the need to remove and reapply. Therefore 
increasing the likelihood of doing physio exercises as less hassle’. (P21) 
 
From these findings suggest DEFO offers a real alternative to existing rigid 
splints with evidence of acceptability and compliance based on real-life issues. 
However the negative findings included: difficulty with donning, tightness or too 
slack, wear and tear, and uncomfortable in the summer. Adverse effects were 
also reported. (GP.1; OP.5: Adverse effects). 
 
‘It’s become a little loose in a certain area …around the left little toe 
which obviously reduces the benefit of wearing it to be honest. The only 
slight negative I would say is that it seems to wear quite quickly’. (P18) 
‘…it did slip down a bit I remember it was loose just around the heel’. 
(P10) 
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‘…it’s  a combination (name’s) hand  and being stiff and this thing being 
extremely tight and…getting one into the other was hugely difficult’. (P16) 
 
 ‘…it was tight and uncomfortable to wear, with swelling, sweating, 
marking and it ached’. (P21)  
 
‘There was a few times when I felt like giving in because the… erm sling 
was quite hard to get on… but I persevered and carried on’. (P24) 
 
From the experiences above there are some important factors raised for 
consideration by the orthotics company. These findings on colour, fit, function 
and wearing experience are similar to those reported in the literature (Kuipers et 
al., 2009; Coghill and Simkiss, 2010; Calvert and Kelly, 2013) which have been 
shown to influence compliance. In summary cosmetic appearance including 
colour, function and optimal fit are significant findings for acceptability and 
adherence of the DEFO. 
 
 
6.2.1.3 Organizing Participant theme (OP.3): Protocol feasibility 
 
Experiences described by the majority of participants demonstrated a high level 
of procedural feasibility of the research. The key issues analysed were from the 
procedural issues around protocol timing and its acceptability.  
 
Sub-theme: Timing issues 
 
The timing element was especially important in this protocol as was the co-
ordination between the research team to assess and fit the DEFO. From a 
procedural perspective the majority of the participants reported positive 
experiences with no variance or difficulty in following the protocol: 
 
‘… just followed what it said a few hours at first and then yeah no 
problems. Just did what it said’. (P01) 
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‘I wore it all day… every day ….for the first six weeks. I did everything I 
should have done’ (P11) 
‘It was good to be selected, I was more than happy to take part there was 
no trouble throughout. Everyone has been helpful.  I appreciate being a 
part of the study. I think the fitting went well you know the timing’. (P18) 
The views of the above were particularly insightful in that they reported key 
procedural elements of the research; consent, a clear protocol, compliance and 
good communication between the researchers and participants. However there 
was an alternative perspective which resulted from a delay in the DEFO fitting 
and delivering the protocol for two participants: 
“… that comes back to the fitting, everything else has been OK! Just the 
fitting took a bit too long”. (P19) 
‘By the time we got it, it was pretty much six weeks, after the event. I 
think the idea was to get it within a few days whilst the hand was still 
supple. No. It was unfortunate there was delay. The timings went 
haywire.’ (P16) 
It was the experience of the latter participant (P16) that the first DEFO was too 
tight and required modifications which caused the delay in timing. The result of 
this was that it impacted negatively on the participant experience, so much so, 
that when it finally came she refused to wear it. From the literature (RCP et al., 
2009) the optimal time for a review of the need for splinting is suggested at two 
weeks post injection, once the toxin (BT) has taken effect.  
 
Sub-theme: Protocol acceptability 
 
In the research it was important to find out about the participant’s experiences 
of following the protocol. The protocol was analysed in terms of how it impacted 
on the participant’s daily routine and whether this was acceptable or not. 
 
‘…no problem just sticking to it’. (P01) 
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‘It’s all gone smoothly. I have an early morning start- it takes a little bit 
longer to get it on in the mornings to get ready’.  (P18) 
 
 ‘No problem with the protocol, able to keep records to make sure I was 
doing it accurately’. (P21) 
 
‘It all went fine… just got into a routine in the morning and put it on, I took 
it off when I went to bed’. (P24) 
 
The protocol was found not to be a burden. Experiences described above were 
common and corroborated the results of adherence in terms of the DEFO 
wearing record and the clinical records. One participant worked night shifts and 
managed to fit his protocol around his work pattern. This participant also chose 
to remove the DEFO at weekends when he was not working so he could wash 
it. This was reported in the clinician feedback (Chapter 5.5). (OC.2): DEFO 
intervention acceptability)  
 As previously reported there was one participant (P16) who was compliant with 
everything in the protocol, with the exception of wearing the DEFO. She was 
aphasic and despite several attempts to communicate with augmentation it was 
difficult to ascertain the reason why she chose not to wear it: 
 
“I tried to explain but would not even try it on. She took one look at it and 
refused…Just took a dislike to it! (carer of P16) [shakes head and 
grimaces (P16)]  
 
To summarise the overall feedback from the participants indicated the protocol 
timing went well (n=9) in comparison to with those who reported delays (n=2) 
and the protocol delivery was adhered to in (n=10) compared to (n=1). 
 
6.2.1.4 Organizing Participant theme (OP.4): Health benefits 
The findings on the positive effects of wearing a DEFO were categorised into 
two sub-themes; physical and psychosocial. These were analysed to form the 
theme of (OP.4): Health benefits. 
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Sub-theme: Physical benefits 
The issues raised by the participants were vivid and demonstrate real insights 
into the experiences of wearing the DEFO. These included; pain relief, comfort, 
benefits on improved posture, muscle tension and functional activity. 
Firstly two participants found the DEFO had the added benefit of specifically 
reducing their pain:  
‘I found when I put the sleeve on that: I get pain at the top of the arm but 
as soon as the sleeve was on the pain went ….and it took the tightness 
away’. (P19) 
‘….and when walking wearing it is what gives the relief of pain. It felt very 
comfortable, very supportive’. (P20) 
This was reinforced by the similar findings of added comfort reported by others. 
The combination effect of warmth, posture and comfort were all seen as positive 
justifications for wearing the DEFO. 
‘I felt positive yeah! Sort of …like comfort’. (P01) 
‘No discomfort, no…very good’ (P18) 
‘It was fine it was comfortable’. (P24) 
‘It kept my hand warm … and it stopped my thumb from sticking in too 
much. …will probably wear it when it gets cold- ‘cause it keeps my hand, 
my arm warm’. (P24) 
Additional findings demonstrated a link between wearing the DEFO and 
improvements experienced in the positioning of joints and limbs: 
‘There was definitely a difference in the first three or four weeks…The 
foot was in shape more… so I thought it was great’. (P11) 
 ‘One of the positive things is it did …did ...did do the job to keep my 
thumb out’ (P24) 
This was further evidenced in that the DEFO was perceived to reduce muscle 
tension which impacted not only on the comfort but was also a consideration 
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affecting posture of the limb. This is particularly important for people with 
spasticity that results in ‘associated reaction’ (AR) in the hemiplegic limb. The 
AR in the affected limb is an abnormal postural reaction commonly due to effort 
and instability (Macfarlane et al., 2002). This finding was most applicable for 
those who set goals related to AR in the upper limb.  
‘My arm felt straighter, when I was wearing it, much straighter and more 
normal… than being across my chest all the time’.  (P24) 
 ‘I just found it was better for my arm it took away a lot of the tightness 
and that and that’s all I can say’. (P19) 
In addition to reducing unwanted tension the DEFO was reported to have 
beneficial effects on movement in several participants: 
‘More than anything else I can straighten my arm… straighten it, see. 
[Raises arm]…and a bit more movement in my fingers’. [wiggles fingers] 
(P01)  
 ‘…and it just felt like I was able to lift it a bit better.’ (P11)  
‘I can straighten me arm more with it on’. (P19) 
‘…the stability wise…my…at the ankle tended…the foot drop...wasn’t as 
bad as it usually is…It stabilised it so I do feel the benefit … it hasn’t 
cured it, don’t get me wrong but it is better than it used to be’. (P18) 
A further benefit reported was joint stability provided by the DEFO which had a 
knock on effect on the functional activity as participants described the 
differences made to their confidence and participation in social activities: 
‘I found in the beginning it did help with that I couldn’t believe how good I 
was walking.  I couldn’t believe the difference… I would have kept it… on 
to use’. (P11) 
‘I wore it on nights out … when I go bowling’. (P18) 
‘a walking frame that I walk with especially when I go food shopping 
…because it is flexible (DEFO) so I can get my hand to hold on and use 
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the frame to walk, …but with the fixed splints you can’t… so I have to 
take it off so then I have no splints on at all’. (P21) 
The importance of participation level activity was highlighted when participants 
were deliberately choosing to wear the DEFO during social activities and finding 
the added health benefits. Participant (P21) indicated this splint (DEFO) offered 
something new; the added value of using her hand in a real-life situation whilst 
shopping. This is reflected in individual goals that are important to the person 
and have real-life meaning (Ashford and Turner-Stokes, 2006). This was 
demonstrated in the specific goals chosen in the pilot RCT for example one 
participants goal was to be able to walk without her arm flexing (more than 45 
degrees) into an associated reaction and causing distress when she was out 
socially at the community centre.  
Sub-theme: Psychosocial benefits 
There were several issues raised on the impact of wearing the DEFO that were 
unexpected. Firstly the feeling of ‘normality’ was referred to by several 
participants. Secondly it was hailed as providing more awareness so that the 
limb became a part of the person again. This is linked to the evidence for 
proprioception which helps with postural awareness and movement control. 
This was seen as a particularly important finding when compared to rigid splints 
that commonly restrict movement and sensory feedback (Lannin et al., 2007; 
Lannin and Ada, 2011). Thirdly two participants were keen for the physical 
appearance to be acceptable from a social perspective. This is analysed further 
in global theme (GP.2: OP.1: Differing perceptions of disability, societal 
perceptions of disability). 
 ‘I felt like I was missing it when I … when I did not have it on’. (P01) 
‘More relaxed. More awareness. It was the awareness and the 
interaction... could do things with it. …awareness was much… much 
better’. (P04) 
 ‘…you could hardly see it …just blended in’. (P19)  
‘…when I was wearing it, much straighter and more normal…’ (P24) 
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Again the lived experience of ‘normality’ is what many of the participants were 
keen to point out as an unexpected health benefit that is also difficult to explain 
or quantify. The cosmetic acceptability of the DEFO contributed to the overall 
high level of compliance. Continuous stretch of the spastic muscles resulted in 
reduced tension and improved levels of muscle tension similar to the findings of 
Gracies et al., (2000). Although this may be considered a physiological 
response there is a correlation between muscle tension levels and emotional 
anxiety in stressful social environments.  
It could be argued that the benefit of feeling more ‘normal’ allows the person to 
consciously or unconsciously adjust to their disability and relate better to the 
social environment. This perspective could be from the individual who wishes 
not to be seen as different due to their disability. There is a link between 
appearance and what individuals and society perceive as normal (Wa Munyi, 
2014). The psychological impact of disability and perceptions of ‘normality’ can 
in turn impact on motivation in goal attainment (Seigert and Taylor, 2004). Thus 
the interviews provided the most relevant tool to explore this important aspect of 
health benefit which could easily have been missed in quantitative research 
methodology.  
In summary the categories discussed and analysed for most significance 
included were pain relief, comfort, more normal, more awareness, benefit 
realised by improved posture, muscle tension and functional activity. These 
positive and tangible health benefits were interpreted to have had a significant 
impact on individual daily living experiences in real-life contexts which were 
valued by the majority of participants in the DEFO intervention group. These 
were themed into physical and psychosocial benefits for the sub-theme (GP.1; 
OP.4: Health benefits). 
 
6.2.1.5 Organizing Participant theme (OP.5): Adverse effects 
The sub-theme Organizing theme (OP.5): Adverse effects is presented 
comprised of the negative physical impact of the DEFO and its effect on usual 
activity. The findings presented here provide an interesting dissonance with the 
mainstay of findings but deliver a balanced approach.  
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Sub-theme: Physical effects 
The experience of one participant was that she experienced real discomfort with 
the DEFO which was reported with reference to the climate: 
‘Unusually hot this summer there was a lot of swelling that made it tight… 
tight and uncomfortable to wear, swelling, sweating, marking and ache. 
Skin pinched and bruised during application’. (P21) 
The above findings corroborate the evidence in the literature on compliance 
(Coghill and Simkiss, 2010; Calvert and Kelly, 2013) in which parents of 
children who wore Lycra® body suits reported discomfort in warm weather. A 
further concern reported was the tightness of the DEFO, which for most 
participants was something they became accustomed to but for one participant 
this was unacceptable. Participant (P16) refused to wear the DEFO. 
‘…this thing being extremely tight…refused…Just took a dislike to it!’  
(P16) 
There was a similar experience in another subject but this was more related to 
the process of donning the DEFO: 
‘…this corset material pulls the hairs…not whilst it is on… but whilst 
putting it on.’ (P20) 
‘Putting it on was a big problem- third party had to put it on…reducing 
independence’ (P21) 
From the findings above the key physical issues were primarily based around 
the customised fitting of the DEFO and how it was applied. With experience the 
therapists, carers and participants all reported this became easier.  
Sub-theme: Impact on usual activity 
There were a number of occasions when the DEFO impacted on usual activity. 
This was surprising as the inherent flexibility suggested it could be worn much 
like usual clothing. One of the instances that stood out is when it impacted on 
hand function in a negative way by loosening the grip: 
‘There was only the gym side of it where I couldn’t hold on…’ (P19) 
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On the other hand it was obvious that it was not suitable to wear for activities 
like swimming/ hydrotherapy, although this finding could be seen as a potential 
design feature modification with the orthotics company informed. Similarly it was 
necessary to be removed for activities and therapies involving skin contact like 
massage and acupuncture: 
‘…do hydro quite regularly so that is another instance when I wouldn’t 
wear it’. (P04)  
‘When was having acupuncture- had to remove it, and when having 
physio massaging hand’. (P20) 
One further interesting and significant personal point raised was the negative 
aspect that one participant liked to sunbathe and felt the DEFO was interfering 
with his overall appearance by blocking the sun to his skin. This was something 
not previously considered or observed in the literature but it does contribute to 
insight in the overall findings as to why splints are worn or not.  
‘…likes the sun…It would detract from that...I suppose that would be a 
concern …very much short sleeves exposing the skin’. (P04) 
In summary the issues discussed comprised discomfort, fitting, donning and 
individual preferences of wearing or not during activity. Significant findings 
included reducing independence and physical appearance or discomfort from 
tightness especially in warmer months. These were synthesised into categories 
of physical and impact on usual activity which were analysed into the sub-theme 
(OP.5): Adverse effects. 
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Summary 
From analysis of the findings there were a number of relevant and interesting 
themes. A summary of the key points in each Organizing theme is presented 
below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary Global Participant theme (GP.1) Research experience: 
Acceptability 
Organizing Participant theme (OP.1): Research expectations 
Themes of hopes, motives and expectations in regard to health benefit and 
improved access to resources were interpreted for significance. 
Organizing Participant theme (OP.2): DEFO acceptability 
Cosmetic appearance including colour and optimal fit are significant findings 
for DEFO wearing acceptability and adherence. 
 
Organizing Participant theme (OP.3): Protocol feasibility 
  
Overall the protocol timing went well (n=9) despite reported delays (n=2) and 
the protocol delivery was adhered to in (n=10) compared to (n=1). 
Organizing Participant theme (OP.4): Health benefits  
Health benefits analysed for most significance and interpreted to have had an 
impact on individual daily living experiences in real-life contexts included; 
pain relief, comfort, more normal feeling and awareness, benefit realised by 
improved posture, muscle tension and functionality. 
Organizing Participant theme (OP.5): Adverse effects 
Significant findings included difficulty with donning thus reducing 
independence and physical appearance or discomfort from tightness 
especially in warmer months. 
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Figure 6.3 ‘Thematic map’ for Global Participant theme (GP.2): Perceptions of disability: impact on research 
 
163 
 
6.2.2 Global Participant theme (GP.2): Perceptions of disability: impact on 
research 
The sub-themes (organizing themes) that underpin the superordinate (global) 
theme (GP.2: Perceptions of disability: impact on research) include two key 
categories. These sub-themes are presented as Organizing themes: (OP.1) 
Differing perceptions of disability; and (OP.2) Generalizability to condition. 
A ‘Thematic map’ for Global Participant theme (GP.2): Perceptions of 
disability: impact on research is presented (in Figure 6.3) for clarification of 
the analytic categorisation used. The themes are subsequently presented and 
analysed below. 
 
6.2.2.1 Organizing Participant theme (OP.1): Differing perceptions of 
disability 
In analysis of the transcript data it was found the differing perceptions of 
disability had an impact on the study experience. The sub-theme (OP.1): 
Differing perceptions of disability was comprised of three distinct categories 
of perceptions in disability: self-perception, societal perceptions and perceptions 
within research itself.  
Sub-theme: Self-perceptions of disability 
Firstly it was found significant that people with disability viewed themselves from 
different perspectives. Several participants were concerned with their 
appearance as a means of expressing their personality and how the orthotic 
should complement this. This was presented earlier, (in GP.1; OP.2: DEFO 
Acceptability, Appearance) with regards to acceptability and the importance of 
a choice in colour of the DEFO. Another sentiment raised was of wanting to be 
‘accepted’ for who they are, regardless of any difference. Indeed for some the 
personalised concept was extended in that they were happy to wear the DEFO 
as an emblem. It demonstrated individuality and clearly identified their needs to 
other people. Others indicated their frustration at being different and keen to be 
seen as ‘normal’. Another person’s perspective of her disability was one of 
reluctant acceptance. The findings highlighted different attitudes towards people 
with disability. Findings were also analysed in light of how self-perception in 
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disability is linked to personal motivation and how this impacts on realistic goal 
setting (Seigert and Taylor, 2004).  
 
One participant was quite clear his disability was a part of him, another facet of 
his persona. It rankled with him that people he knew appeared to view him 
differently since his stroke: 
‘It’s more what people might say… this is just part of the stroke… But, I 
would just wear it anyway. I coloured it to show it is a part of me’. (P01) 
This participant was keen to embrace the DEFO as an extension of his 
personality in terms of choice of colour, purple (Figure 7.2). This participant 
was keen to promote his personality and was recognised by the local 
community for his usual flamboyant appearance. This was in direct contrast to 
one participant’s perspective it appeared she was keen to ‘fit in’ with nothing 
drawing attention to her disability (P19) (p.150). 
Equally it should not be underestimated how people reacted to ‘feeling more 
normal’ when wearing the DEFO. Two participants were clear that it had a 
beneficial effect of enhancing awareness and making their limb feel ‘good’: 
‘…seemed to be much more aware of it. It obviously felt good… ’ (P04) 
‘… it was... beneficial and yeah, it was like helping my mind as well it was 
definitely helping me too’. (P10) 
One participant’s comments can be interpreted as resignation to her acquired 
disability and a matter of coming to terms with this predicament. This is ‘how it 
is’, significant change is unlikely: 
‘…it was not able to keep my hand straight enough to paint my nails, but 
then I think this will never happen’. (P24) 
This could be further explored; how individuals with different perceptions on 
their own disability are able to select achievable goals in the GAS. The work by 
Ashford and Turner-Stokes, (2006) suggests goal setting requires skill. This is 
explained further by Wade and Bovend’Eerdt, (2010) in that the goal is ‘SMART’ 
(Chapter 3.6). Clinicians who use the GAS in clinical practice report an initial 
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learning curve in selecting and guiding appropriate goals. This skill was 
reported to become easier with experience and routine use.  
Self-perception in people with a long term condition is difficult, with reported 
need for specialist care to guide and assist in developing strategies for 
adjustment (Korwin-Piotrowska et al., 2010). It can be argued social acceptance 
of disability is equally challenging. 
Sub-theme: Societal perceptions of disability 
Findings also introduced the impact of societal perceptions on disability. This 
was discovered in the comments by participants on how the wearing of the 
DEFO had a different impact on the people around them. It was proposed an 
invisible line was drawn between what was socially (and culturally) acceptable 
and what was not. Judgments in society are often based on physical 
appearance and society is keen to categorise people accordingly (Wa Munyi, 
2014). It also appeared to be important to the individual how others (in society) 
saw them. This relationship between the individual and where they fitted in 
society is both interesting and worth exploring further. 
There were positive and negatives findings in how the DEFO was received 
within the local community. These perspectives are viewed through the eyes of 
people with disability and in one case (with aphasia) his partner. Some reported 
curiosity and interest, some reported blatant bias when confronted by difference 
and others described reactions that were more embracing with appropriate 
offers of help. 
‘There is always this thing… people would look …I know it was flesh 
coloured even with the tone…throughout summer…it would not be as 
acceptable if you had got short sleeves. It was OK! …if … at home but if 
… outside in the summer without a jacket…There is always this thing… 
people would look’. (P04) 
The reaction to the participant wearing a DEFO by friends and others in the 
community was surprising in that although they knew he had a disability, they 
saw the new splint as something for an orthopaedic condition with potential to 
be fixed. It links to his previous role as a sportsman. Perhaps this was seen as 
more ‘acceptable’ in that it was something people could understand.  
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‘It’s like people say what have you done? I’ve had a stroke and they 
know that but this is just part of the stroke and that’s why I’m wearing it 
and they all thought I had done something to my arm like broken it or 
something’. (P01) 
The concept of wearing the orthosis for reasons of cueing the public was raised 
by one participant. This medicalisation of the DEFO was seen in a positive light 
in that it provided an appropriate visual aid for people to respond in an 
acceptable way. 
 ‘…as a physical cue for other people for if you have something wrong 
with your limb to be helpful for other people ’cause if you have nothing on 
they are not aware you have a problem’. (P21) 
Although this was seen as a positive by the participant above there is still an 
invisible line. This in essence is who to help and how much help people with 
disability want, or need. The dialogue continues to be difficult with each 
situation and individual perceptions on disability. The reluctance from both 
parties to confront this issue openly perpetuates the societal categorisation of 
‘them and us’. This is entrenched in the natural order of society as it continues 
to categorise us all.  
Sub-theme: Perceptions of disability and motivation in research 
From the collective comments on rationale for joining the research study a 
number of categories emerged. This varied from being pleased to be even 
considered and taking it as an opportunity that could serve of benefit personally 
and to others. This was interpreted to mean that the profile of disability was 
raised by involvement in research. The suggestion of appreciation yet 
accountability to represent others with disability was encountered. It was also 
suggested that research should mirror real life for someone with disability.  
‘…life has been quite complicated so….then it has been a true indication 
of like life…’ (P21) 
This sentiment was interpreted to mean that it is important to participate in 
research as living with acquired disability is complicated; so this is worth 
measuring. This was in contrast to her belief that people with stroke do not have 
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the level of motivation required to undertake research that involved following a 
protocol (p. 148). This understanding is supported by the findings of stroke 
services Maclean and colleagues (2000) which suggest the personality trait 
model of motivation prevails in rehabilitation. However recent studies on stroke 
rehabilitation have reported the benefits of ‘lived motivation’ using methods of 
interactive technologies to tap into the underpinning theoretical models of 
motivation (Balaam et al., 2011).  
 
Participant motivation is worth exploring in all research studies and should be 
reported as it is likely to impact on compliance and bias in the findings. It was 
also suggested in an expectation by two participants (P18) and (P20) (p.147) in 
terms of access for more therapy. This was a further consideration in how the 
research study was perceived by participants who considered the physiotherapy 
research component important in the management of their disability.  
‘I thought it went well, except for like I said, I didn’t have no physio with it. 
…but I think it would have been better to have had physio more often 
definitely. …’cause I don’t think it would work unless you was having 
physio anyway’. (P11) 
This participant had pre-conceived ideas on how much therapy the research 
entailed despite clear indications in the PIS (Appendix 4). Her findings were not 
corroborated with the physiotherapy intervention record and clinical records. In 
fact, she had regular contact with the physiotherapist (210 minutes). Again this 
links back to expectations in research and how experiences are reported from 
different perspectives. 
In contrast the link identified between undertaking research now and how it 
helps others in the future was underlined as previously reported (P19) and 
(P20) in GP.1; OP.1 Research expectations, Health benefits for others.  
 
 ‘It was good to be selected, I was more than happy to take part there 
was no troubles throughout. Everyone has been helpful.  I appreciate 
being a part of the study. …to benefit others in the future that was the 
main reason.’ (P18) 
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The sub-theme of differing perceptions of disability was exampled by real-life 
issues of complexity in clinical research. The underlying issues of expectations, 
motivation, self-image, self-perception, societal perspectives and research 
perceptions were all explored. 
 
6.2.2.2 Organizing Participant theme (OP.2): Generalizability to condition 
Participants had strong opinions on how the intervention should be optimally 
delivered, to whom and when. The sub-theme (OP.2): Generalizability to 
condition was comprised of two distinct categories; diagnostic condition and 
timing. 
Sub-theme: Condition specific 
The experience of one participant with a progressive condition was significant. 
Despite reporting early improvements, it became apparent that her underlying 
progressive condition had an impact on research experience. She recognised 
her condition was deteriorating which contributed to the negative experience. 
‘It was good, it would have been really good if I hadn’t been in such a 
bad condition. I think I wish I had had it before it got that bad. …If I didn’t 
have a problem like I did at the end that would have been fine to wear 
it… That would have been good.’ (P11) 
 
She says ‘if it worked’ with the inference that it had not. In fact it did help 
initially. This finding is a further example of the difficulty in undertaking research 
in progressive conditions like those in neurological conditions with moving 
baseline and pattern.   
‘There was definitely a difference in the first three or four weeks…The 
foot was in shape more…and it just felt like I was able to lift it a bit better 
and shape, so I thought it was great’. (P11) 
This finding is relevant in that it points out the rationale for condition specific 
intervention with the idea that early intervention may be more useful in some 
conditions or with stratification. 
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Sub-theme: Timing 
Timing of the intervention was highlighted for relevance with optimal 
generalizability of the intervention. Timing for the intervention was considered 
firstly from the perspective of when it was likely to be of optimum benefit in the 
broader sense in a condition within a progressive disease trajectory. Secondly it 
was considered within a more specific treatment programme for those with time-
limited rehabilitation potential. The above were highlighted by participants with 
long-term conditions:    
‘I think people should have it a bit earlier … It was a bit late for mine 
because if I had had it earlier I think it would have been fine’. (P11)  
‘…at six months the benefits are more obvious… there is a lot more to it. 
It feels like it has done some good…like I said a greater timespan would 
have been better’.  (P01) 
As the intervention was introduced within a time-dependent window of 
opportunity it was not surprising the generalizability was linked to the effects of 
the BT. Timing of the combined intervention was deemed crucial. The long term 
effect of the DEFO was reported to have a positive effect. It was inferred that 
the orthotic effect should have been measured for a longer period. The 
argument could be taken further; to investigate the DEFO intervention in 
spasticity prior to dependency on BT.  
‘Yes it worked for me but now it has umm tightened up again as Botox 
has worn off. It was great because my arm was nice and straight to start 
off with but now the Botox has been wearing off, so it is closing back 
down again’. (P24) 
‘By the time we got it, it was pretty much six weeks, after the event. I 
think the idea was to get it within a few days whilst the hand was still 
supple’. (P16) 
In order for the intervention to be acceptable to people with a wide range of 
conditions and for use in a wide variety of settings it was deliberately 
customised to the individual. This was supported by earlier evidence (GP.1: 
(OP.2): DEFO Acceptability, (OP.4): Health benefits) on acceptability and 
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health benefits for example with participant (P21) using her hand on a frame 
whilst out food shopping. 
Summary  
From analysis of the findings there were a number of relevant and interesting 
themes. A summary of the key points in each Organizing theme is presented 
below:  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary Global Participant theme (GP.2): Perceptions of disability: 
impact on research 
Organizing Participant theme (OP.1) Differing perceptions of disability 
The significant findings included underlying issues of self-perception, image 
and acceptability of disability. Societal and research attitudes and 
behaviours based on perceptions in disability were found to have an impact 
on the acceptability of the DEFO. 
Organizing Participant theme (OP.2) Generalizability to condition. 
From the findings; timing was preferred earlier in treatment cycle, for a 
longer period and earlier in condition management. 
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6.3 Clinician feedback  
Data is presented from the follow-up qualitative Topic Guided interviews 
(Appendix 11) of the clinicians (C1), (C2) and (C3), who delivered the 
physiotherapy and clinical management of the intervention in the pilot RCT.  
Of the clinicians two were experienced specialist stroke and neurorehabilitation 
physiotherapists with advanced postgraduate knowledge and skills in spasticity 
management with BT. They provided delivery of physiotherapy interventions as 
required to all participants in the pilot RCT component of the study. Both were 
employed by the community NHS health company provider. The third clinician 
had knowledge and skills in paediatric physiotherapy and was a trained 
assessor and fitter of DMO and provided the DEFO intervention in the study. 
This clinician was employed by the Health technology company (Chapter 4.1 
Participants and setting). 
Framework analytic approach for Thematic Analysis is exampled in Appendix 
15. The topics discussed in the interviews were on the clinician experiences: 
motives in joining the study, their clinical experience of the protocol delivery and 
DEFO intervention. Feedback, both positive and negative, was asked of them. 
A representation of the Thematic Analysis of the clinician interview findings is 
presented, (in Figure 6.4). 
 
 6.3.1 Global Clinician theme (GC.1): Research impact on clinical practice 
The topic guided interviews of the clinicians revealed a depth of critical thinking 
and reflective practice on the impact of the research on their practice. This is 
presented diagrammatically as a ‘Thematic map’, (in Figure 6.5) of the key 
themes drawn from the analytic approach: basic to organizing to global themes. 
The sub-themes are comprised of the Organizing Clinician themes (OC.1): 
Research expectations, (OC.2): Ethical issues, (OC.3): Clinical practice, 
(OC.4): Research experience. The findings are presented and interpreted with 
evidence theme by theme.  
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Figure 6.4 Thematic Analysis of clinician interview findings; colour coded for categories 
  Issues and descriptives (sub-themes)                     Themes                                                               Superordinate theme 
 
Feasibility 
and Acceptability 
of DEFO in a 
clinical setting 
(GC.2) 
 
DEFO Acceptability 
(OC.2) 
 
• Participant expectations      
• Clinician expectations 
• Research communication 
• Recruitment eligibility 
• Fidelity 
• Clinical risk 
• Rehabilitation potential 
• Usual practice 
• Active vs passive function 
• Capacity and priorities 
• Positive experience 
• Negative experience 
• Clinical research role 
• Impact of co-morbidity 
• Variance in timing 
• Variance in fitting 
• Availability of  DMO clinician 
• Comfort 
• Compliance and wearing issues 
• Difficulty with donning 
 
Research Expectations 
(OC.1) 
 
Ethical issues 
(OC.2)  
 Clinical practice 
(OC.3) 
 
Research experience 
(OC.4) 
 
Research impact 
on clinical 
practice 
(GC.1) 
 
Protocol feasibility 
(OC.1) 
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Figure 6.5 ‘Thematic map’ for Global Clinician theme (GC.1): Research impact on clinical practice 
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6.3.1.1 Organizing Clinician theme (OC.1): Research expectations  
 
Sub-theme: Clinician expectations 
 
Expectations were raised by the clinicians from personal, professional and 
participant perspectives. This was a recurrent theme across all three clinicians 
as it was reported to impact on their ‘therapeutic relationship’ with the 
participant.  
 ‘…discussing expectations and making it clear what it can and can’t do 
and that is something I was unable to discuss with them’. (C1) 
It could be linked to what is taken as usual clinical practice in that expectations 
are part and parcel of planning therapeutic intervention. This expectation was 
possibly heightened due to the opportunity to try something new. This was the 
BT injection in some cases and in others the research:  
‘…elevated expectations on what being on a research project might 
achieve…sometimes with passive function there is elevated expectations 
about what the injection might achieve… it was a matter of managing 
those expectations’. (C2)  
She went on to explain her role as she understood it. She described from an 
observed participant perspective with the understanding that her role was also 
to provide clarity in managing elevated expectations:  
‘…people saw this new opportunity and wanted to grasp it… they… just 
hold on to hope, and just hold on to anything that’s going’. (C2) 
This level of expectation was also observed by her colleague:  
‘…they had already trawled through all the other options and this was 
something novel and new that could help them… they were intrigued by 
the actual product some of them…What’s this sleeve? sort of thing and 
what can it do for me?’ (C3) 
These concerns were tempered in that she was aware the research had a 
process for managing over ambitious expectations. This was done through the 
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participant information sheet (Appendix 4) and opportunities for discussion 
prior to commencing the study and clinical feedback throughout.  
‘…which I know was done at every step of the research anyway’. (C2)  
Sub-theme: Participant expectations 
 
Although it was considered that all participants recruited were willing (by 
consent) and enthusiastic to undertake the research there was an undercurrent 
of disappointment in some of the control group following news of group 
allocation:  
 ‘…those you did recruit they were all willing, certainly the ones I met and 
wanted to be a part of it erm…and of course some were disappointed 
when they were not in the intervention group’. (C3) 
From another perspective there was possibly added pressure on the 
participants from the carers.  
‘…all the carers I worked with were quite positive, as positive as the 
participant and sometimes even more positive than the participant’. (C2) 
From the above it was important to acknowledge that pre-conceived 
expectations could influence the study experience from both the clinician and 
the participant perspective. It was considered particularly relevant that both 
could openly discuss what, if any, likely outcome could be achieved as in 
normal clinical practice (in a therapeutic relationship) and this was not possible 
in the research as it was perceived as a potential bias for the outcome. 
 
6.3.1.2 Organizing Clinician theme (OC.2): Ethical issues 
From an ethical perspective there were three issues raised by the clinicians that 
were categorised: eligibility, clinical risk, research communication and fidelity. 
These comprised the sub-theme (OC.2): Ethical issues. The emergent themes 
are analysed and presented below. 
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Sub-theme: Eligibility 
From early stage implementation of the research in clinical practice discussions 
around criteria for study eligibility took place. This was of particular concern for 
the DM Orthotics Ltd© clinician as she was applying the DEFO to a new client 
group.  
‘…little things that we ironed out at the beginning’ (C1) 
The eligibility criteria ‘little things’ presented a potential stumbling block to 
further recruitment but were sorted out by further clarification in the Research 
Reference Group (RRG). This was with definitions of the inclusion and 
exclusion criteria (Appendix 15). This important issue was carefully considered 
and is presented in a reflective diary (p.256). The role of effective 
communication in research was taken seriously and RRG (Chapter 8.1.2 and 
8.1.3) meetings helped with the communication between clinicians and the 
principal researcher. 
Sub-theme: Clinical risk 
A further ethical consideration was raised from a clinical perspective when the 
dichotomy of continuing with the research protocol or clinical need was 
discussed. An issue of potential clinical risk was raised when one participant 
highlighted a clinical need in a joint (hyperextending knee) above his DEFO. 
Another potential clinical issue of risk was raised in a participant with higher 
levels of spasticity.  
‘it was unlikely the sock would help that and it was a concern’ (C1) 
‘Holding her ankle I didn’t feel the DEFO could achieve that’. (C1) 
‘it was one issue…knowing what was safe and what not …so the study 
follows the clinical needs and that is fine. It was just that this is the first 
time I had done anything like this and I wasn’t sure if I was upsetting the 
research study and that clarifies it’. (C3) 
Potential clinical safety issues were prioritised. The uncertainty of how this 
should be managed in clinical research was ethically clarified by supervision; 
clinical risk taking precedence over any research protocol (Chapter 8.1). 
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Sub-theme: Fidelity 
 
Two issues of fidelity were discussed. The first was around the delivery of usual 
care and physiotherapy and the second was when one participant absolutely 
refused to wear the DEFO. 
 
‘I tried to just deliver just standard physiotherapy that I would normally 
do’. (C2) 
 
‘one that just did not get on with the splint and said that she was not 
going to wear it’ (C2) 
The former example of fidelity reinforces the clinicians understanding of her role 
in the research delivery. This is supported by examples of her clinical practice in 
promoting self-efficacy and not dependency which are presented below. The 
latter example was a disappointing result for both the clinician and the 
participant. It was previously presented from the participant’s perspective 
(OP.5): Adverse effects (P16)) and clinician’s perspective of non-compliance. 
Proof of fidelity is an important reflection of how feasible the intervention was in 
clinical practice.  
Sub-theme: Research communication 
All clinicians described a good level of communication between the research 
secretary and from the RRG (Chapter 8.1.3). This was essential from a 
feasibility perspective for the timely delivery of the protocol. The procedural 
impact of good communication meant things could run smoothly: 
 
‘…the communication was good’ (C1) 
 
‘…on the whole I think it was fine, it went well and the communication 
meetings helped as well. Erm… and we were in regular phone contact...’ 
(C2) 
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‘I think I was quite fortunate in that I have close links with the consultant 
clinics so I knew who was going to and coming out of the clinic and it was 
just knowing those patients, being ahead of the game. That helped.’ (C3) 
 
However this was not always the experience of one clinician. From her 
perspective the communication was ‘hit and miss’ with reliance on Spasticity 
Clinic letter for specific details on the BT injection. In some instances she was 
reliant on participants or carers informing her. This was not ideal as details may 
have been unreliable. 
  
‘I didn’t always get the clinic letter in the most-timely fashion... I didn’t always 
have the clinic letter telling me where the injection was so I was often reliant 
upon the erm… the research subject or their partner to tell me and that was 
sometimes a bit vague.’ (C2) 
A further issue on communication was raised regarding the difficulty of 
communication due to the blinding. The issues of research uncertainty were 
directed to the supervisor for clarity and clinical issues had to be resolved by the 
clinicians. 
 
6.3.1.3 Organizing Clinician theme (OC.3): Clinical practice 
There were a number of significant issues discussed and analysed as 
complexity in clinical practice. These categories included: clinical perspectives 
on rehabilitation, motivation, activity levels, models of delivery and practice 
issues of capacity and interface with private physiotherapy. These are grouped 
into the sub-theme (OC.3): Clinical practice. 
  
Sub-theme: Usual practice  
 
Discussion on clinical practice raised issues on the content of usual practice 
and individual perspectives on rehabilitation and its delivery. For instance one 
clinician was clear that her normal role was being extended in the research 
study:  
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‘…to learn my role which was different from my normal role and to see 
the use of the DEFO’S being used in a slightly different client group was 
still I think beneficial’. (C1) 
 
She was explicit in that the clients she normally saw in her role had different 
criteria than in the study. She was also used to seeing clients with more activity. 
In addition she was used to assessing and providing the orthotics in a less 
prescriptive way from the restrictions of the study protocol:  
 
‘…99 percent of the time I would only prescribe the orthosis if I saw 
activity or a level of activity and many of the participants did not’. (C1) 
 
‘I was only able to go in to supply a sock or glove and not look more 
centrally…more centrally rather than distally’. (C1) 
 
This raises the possibility of conflicting expectations and tensions in research 
that is collaborative with industry. How this was managed is discussed in 
Chapter 8.2 and reflected on at the end of the thesis.  
 
From a perspective of usual practice the clinicians described difficulty and 
awkwardness in not being able to discuss the treatment intervention and 
expected outcome(s) with participants.   
 
‘…not to put ideas into people’s minds so it was completely neutral’ (C1) 
 
‘promoting self-efficacy and self-management strategies, yet: … just 
knowing when it is appropriate to do more hands on erm and just 
explaining every step of the way, and hopefully educating people as 
much as possible so they can understand the perspective I am coming 
from’. (C2) 
The clinician (C2) was clear about her usual practice role and this was 
unchanged in the research delivery. It is ‘normal’ practice for a clinician to 
discuss care based on the evidence about what is likely to help with a specific 
condition and the rationale why an intervention is done.  
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Sub-theme: Active versus passive function 
 
Clinical practice in common terms was repeatedly described from a reflection of 
usual practice and supported by evidence of efficacy in the literature. Both (C1) 
and (C2) explored practice issues around ‘active’ versus ‘passive’ function and 
respective treatment options. One clinician (C2) repeatedly emphasised her 
preferred practice: working more actively at function. On the other hand she was 
dismissive of her role in more passive care.  
‘…nice to have seen more participants who were injected for active 
function. …one chap that I didn’t know from before the study and his 
goals were in fact for active function so I found that exciting and really 
enjoyed treating him…I felt he did really well with the combination of 
physiotherapy, injection and DMO (DEFO)’.(C2)  
 ‘…the majority of participants were being injected for passive function 
and there was a slightly limited role that physiotherapy could play…my 
input was always going to be fairly limited… someone that was injected 
for passive function only, rather than more active function’. (C2)  
This was not the view of another clinician (C1) who appeared more open to 
change in practice:  
‘…if there was a perceived benefit from wearing it that opens up my 
practice again’. (C1) 
 Sub-theme: Rehabilitation potential 
However in this respect the further issue of rehabilitation potential was 
introduced opening up the debate around ‘how useful is physiotherapy in people 
with passive function only’?  
 
‘…patients I have seen in the past and I knew what their rehab potential 
and their capacity for participating in a rehab programme was’. (C3) 
The rehabilitation potential for each individual was also considered from a wider 
perspective acknowledging the importance of belief systems and the ethical role 
and responsibility of the clinician. This was supported by the evidence that links 
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rehabilitation to behavioural motivation and goal setting (Seigert and Taylor, 
2004; Broetz and Birbaumer, 2013).  Reflections of her colleague appear to 
support this:  
‘you are hailed as somebody who might help them get back to pre-
morbid level of ability…and I have always tried to be realistic with people 
erm… without shattering their hopes and dreams… because there is a lot 
of evidence in stroke rehab in terms of the benefit of hope in maintaining 
peoples motivation and things like that’. (C2) 
A further theme that emerged from the interviews was on the usual practice of 
promoting self-efficacy rather than dependency.  
 
‘I try to steer away from creating dependency for people I work with’. (C2) 
In addition it was problematic for the clinicians to have to discuss goals with 
participants who had been following a programme before and the rehabilitation 
phase in their care was completed. This was challenging:  
‘I had to still generate goals with people that I had very recently 
discharged. … sometimes that felt a little bit awkward’. (C2)   
This aspect of rehabilitation was possibly more participant focussed by one 
clinician she recognised therapy was not the only drive for setting goals.  
‘…based on what the patients wanted to do.’ (C3) 
Indeed many of the goals for people with ‘passive function’ or care needs were 
centred on opening out their hand for hygiene care and social reasons (painting 
nails). This is evidenced in the summary table of goals set, (Table 5.17, in 
Chapter 5.5). 
Sub-theme: Interface with private physiotherapy 
In addition the issue of impact of the research was raised on the interface 
between usual practice roles of private physiotherapy providers and NHS 
physiotherapy. This provided a potential conflict in practice:  
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‘injection for passive function…patients were already seeing private 
physiotherapists and sometimes that brings a few challenges with 
itself…we are going down a more maintenance, passive function route 
and sometimes other people may have slightly different goals that are 
slightly more optimistic’. (C2) 
This tension was especially challenging for this clinician whose practice 
promoted self-efficacy. This was particularly in participants who were injected 
for ‘passive’ function only, rather than more ‘active’ function. A potential conflict 
in professional practice was raised with clinical accountability and 
communication of clinical reasoning. 
‘I would get in touch with the private practitioner and that was standard 
practice anyway –if you know that somebody else is treating someone 
you are treating …so I just stuck to my guns and did what I thought was 
the right thing to do and particularly if I had seen the patient fairly 
recently’. (C2) 
This raises the issue of defining the focus of the practice, from the 
participant/patient or from the service provider. This provides a link to treatment 
efficacy and professional practice issues in rehabilitation. Clarity around 
treatment effects and defining achievable goals are important physiotherapy 
roles. Interface tensions were also echoed by the participants in experiences of 
conflicts around access to therapy and funding for equipment. There was also 
an underlying theme raised around perceptions of disability and different 
perspectives. These issues are discussed further in Chapter 8.  
Sub-theme: Capacity and priorities 
 
A theme that links closely with protocol feasibility includes: capacity and 
prioritisation. The capacity of one clinician (C1) was pre-set with agreement for 
planned clinics. However this was not the experience of another clinician:  
‘…the time with the constraints of trying to shoe-horn patients in because 
(DMO clinician name) as you know could only visit the area on certain 
days…trying to meet the deadlines especially due to having to liaise with 
someone who was only part time and not in the area’. (C3) 
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 ‘…the patient needed to be available for treatment to follow the protocol 
and it didn’t always suit their diary or mine…I had other commitments 
elsewhere, I had leave or meetings elsewhere’. (C3) 
A similar experience highlighted the importance of research team 
communication:  
‘I didn’t always get the clinic letter in the most-timely fashion…so I was 
often reliant upon the erm… the research subject or their partner to tell 
me and that was sometimes a bit vague’. (C2) 
This added another level of pressure on the clinicians as new systems were 
introduced by the research and were not always found reliable. The increased 
pressure on capacity for one clinician resulted in her seeing participants that 
she was not expecting referrals for.  
‘I wasn’t able to attend them all so some of the recruits came from clinics 
I hadn’t been at’. (C2) 
The research was considered to have a significant impact on the existing 
clinical role and capacity of the clinicians, which required careful monitoring and 
management.  
 
6.3.1.4 Organizing Clinician theme (OC.4): Research experience 
Next the coded data provided emerging themes from the lived research 
experience and these are analysed. They are primarily reported from a 
perspective of clinicians with limited previous experience in clinical research. 
They include categories of positive and negative experiences and difference in 
existing roles and inform the sub-theme (OC.4): Research experience. 
 
Sub-theme: Positive experiences: Learning experience and Clinical 
research role 
 
All three clinician’s reported positive feedback in emotional terms as well as with 
a ‘learning experience’. This provides evidence of professional and personal 
development. It was reflected on by one clinician from an emotional touch-point:  
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‘I think it has boosted my confidence and increased my interest to get 
back onto my research’. (C3) 
 
‘I am also very proud and I do think we should be promoting it (research) 
in our service as clinicians’. (C3) 
 
She also explained her sense of belonging to an area of clinical practice as an 
experienced clinician:  
 
‘It was just nice to be part of a developing world…as such… cause the 
field of neurology is developing all the time and it’s nice to feel a part of it 
and it’s nice to be a part of your development’. (C3) 
 
An alternative experience was expressed by another clinician. This ‘research’ 
was a new experience for her. However two clinicians were a little more 
experienced and saw research as integral to their roles:   
‘…the first time I have been involved in that particular role and it was 
great to do it and I would like to do more’. (C1) 
 ‘…interesting to be actually a part of a local research project and I see it 
as part of my role as clinical specialist to take up these opportunities as 
they arise’. (C2) 
 ‘…as a clinical specialist I should be up there doing research whether it 
is data collection or analysis or clinical intervention and whatever it 
should be should be part of my job role… it made more sense to my 
working practice being involved in research’ (C3) 
 The latter clinician went on to explain how it made more sense of her practice. 
This introduces the idea of critical thinking in practice as an important 
component which can be used to bridge the research practice gap. She outlines 
her ambition:  
‘I would like to build links between clinicians and researchers, ‘cause I 
think that interface…is lacking’. (C3) 
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Sub-theme: Different from usual role 
 
In one clinician’s interview she described learning in a research role that was 
different from her current role and provided a real opportunity: 
 
‘… a number of ways but one way was to just to learn my role which was 
different from my normal role… at times that was complicated for my 
mind so it took a bit of time to understand the reason for the research’. 
(C1) 
 
‘…to see the use of the DEFO’S being used in a slightly different client 
group was still I think beneficial…it opens up my thoughts and my 
practice and that is really good’. (C1) 
 
Learning experience was valued by the clinicians in that the research was 
supportive with good communication in the RRG. 
 
 ‘…it felt nice to be part of a team’. (C2) 
 
 ‘I felt it was a novel idea so it was going to be a learning experience for 
me about the research as well as the product and how it can be used’. 
(C3) 
 
This introduces the idea of humility required as the expert clinicians are 
immersed in an unfamiliar learning situation and become a ‘novice’ in the 
research world along the continuum towards being an expert (research) 
practitioner (Benner, 2001). Certainly this experience outlines the journey for 
continuing professional development and learning towards enhanced skills of 
critical thinking (Hawkins and Shohet, 2011) and reflective practice (Schon, 
1980) needed in research. 
 
The complexity and difficulty of undertaking research in real-life; clinical practice 
was also highlighted in examples of maintaining blinding and non-bias.  
 ‘I did find difficult was trying to talk about the research without un-
blinding it for you’. (C3) 
186 
 
It was apparent that each clinician held a personal perspective from which the 
research was experienced.  
 
‘…very interested in research so want to promote good research in the 
area and DEFO’s because that is the area I am involved in’. (C1) 
 ‘…it was also nice to be involved with a new product that I had not been 
familiar with so that was a positive… to think there are new things 
coming through all the time’. (C3) 
 
‘I tried to just deliver just standard physiotherapy that I would normally 
do’. (C2) 
There were differences in experience of the skills needed to undertake clinical 
research.   
Sub-theme: Negative experiences: Recruitment, eligibility and 
capacity issues 
 
There were few negative experiences reported, however these were commonly 
linked to recruitment pressures, clinical capacity and debate around the study 
eligibility criteria previously outlined.  
The most significant negative experience was reported as a sudden increase in 
new participants following recruitment at the beginning of the study. This was 
subsequently monitored and managed:  
‘5 new referrals came in that did feel initially quite a lot to fit in with the 
existing caseload… the first couple of months just felt quite busy… it 
seemed to even out’.. (C2) 
  ‘…stress came from the time constraints of the protocol and I 
understand the protocol has to have time constraints but there were 
times when I got frustrated because of my other caseload was being 
sacrificed for the protocol and we can’t stop the research protocol 
because of caseload but it was difficult sometimes to fit it in’. (C3) 
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This negative experience was reported with competing tensions in capacity from 
practice and research. The experiences were interpreted as emotive reactions 
to uncertainty and loss of control with conflicting priorities from caseload and the 
research input. This is again linked to the unfamiliar territory as a ‘novice’ 
undertaking clinical research whilst doing the day job.  
‘to start with it was all a bit like oh my goodness I’ve got all of this to do 
on top of everything else, but it did settle down as I became more 
proficient with the paperwork and I worked out what we had to do and 
what we didn’t have to do’. (C3) 
Summary  
From analysis of the findings there were a number of relevant and interesting 
themes. A summary of the key points in each Organizing theme is presented 
below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of key points: Global Clinician theme (GC.1): Research impact 
on clinical practice 
Organizing Clinician theme (OC.1): Research expectations  
Personal, professional and participant expectations and motives were 
analysed of which the most significant finding was the elevated expectations 
of the participants and sometimes carers.  
Organizing Clinician theme (OC.2): Ethical issues  
Key findings of significance included ethical research clarification on eligibility 
criteria and clinical risk. The communication was effective in keeping the 
research on track and there was evidence of procedural fidelity reported. 
Organizing Clinician theme (OC.3): Clinical practice 
Clinicians showed an overall preference for clinical practice with people who 
have more active vs passive function and rehabilitation potential and delivery 
by promotion of self-efficacy. Both clinical capacity and clinical risk 
prioritisation were found to impact on the research delivery. Interface with 
private therapies suggested conflicting priorities (active vs passive). 
Organizing Clinician theme (OC.4): Research experience 
Significant findings included the learning opportunities in research, how the 
research provided a difference from the usual role and uncertainties around 
clinical priorities. 
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6.3.2 Global Clinician theme (GC.2): Feasibility and acceptability of DEFO 
in a clinical setting 
The themes that are outlined below address the research questions on 
feasibility and acceptability of the DEFO intervention. The issues discussed in 
the clinician interviews included topics of protocol procedural delivery and 
variance, and compliance, tolerance and acceptability preferences. These were 
grouped into two categories that naturally informed the feasibility and 
acceptability sub-themes. The sub-themes presented include Organizing 
Clinician themes: (OC.1): Protocol feasibility and (OC.2): Intervention 
(DEFO) acceptability. The presenting themes are evidenced and analysed 
accordingly. 
A ‘Thematic map’ generated from the clinician interview data for Global 
Clinician theme (GC.2) Feasibility and acceptability of DEFO in a clinical 
setting is presented below, (in Figure 6.6). 
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Figure 6.6 ‘Thematic map’ for Global Clinician theme (GC.2): Feasibility and acceptability of DEFO in a 
clinical setting 
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6.3.2.1 Organizing Clinician theme (OC.1): Protocol feasibility  
Sub-theme: Availability of the DMO Ltd© clinician 
 
The procedural feasibility of delivering the protocol in a timely fashion was 
primarily dependent on the availability of the DMO clinician. Clinics were pre-
arranged on a bi-monthly basis; however there were additional environmental 
and personal factors that influenced this. 
 
‘the flooding’… ‘when I was ill’ (C1) 
‘…constraints of trying to shoe-horn patients in because (DMO clinician) 
as you know could only visit the area on certain days’ (C3)   
Sub-theme: Variance in timing 
 
This availability subsequently had an impact on the timing of the protocol 
delivery: 
  
‘…it was difficult to keep to the times in the protocol within 2 weeks post 
BT to have assessed the patient’. (C1) 
This sentiment of pressured timing was repeated by (C3) in that there were 
competing pressures as a clinician from the clinical caseload. She implied the 
research protocol took precedence. However this resulted in frustration that she 
was not in control of her own prioritisation of workload (C3) (pp.186-7). The 
timing posed a further challenge for (C2) in that the majority of recruits were 
from the Spasticity clinic in the west of the county which were more frequent. 
She was unable to attend all of these clinics due to caseload capacity issues:  
‘I wasn’t able to attend them all so some of the recruits came from clinics 
I hadn’t been at’. (C2) 
‘…the hardest thing about the protocol was just adjusting to basically this 
patient needed to be seen within a fairly set time frame’. (C2) 
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This clinician also received five new recruits in a short space of time which 
added pressure from a timely delivery perspective. This proved very challenging 
and raised the issue of controlling recruitment flow: 
‘…it was the first couple of months just felt quite busy… it seemed to 
even out’. (C2) 
The important issue of protocol timing feasibility was resolved with the protocol 
amendment of the wording and thus the ‘assessment ‘for’ fitting’ was within two 
weeks (Chapter 8.1).  
Sub-theme: Variance in fitting 
 
A further issue raised that had an impact on the protocol feasibility was the 
delivery and variance in fitting of the DEFO. Although the DMO clinician was 
experienced in assessing and fitting the other clinicians were not. They gave 
clinical guidance on fitting requirements from a therapeutic perspective and 
reassurance around trying something new:  
 
‘I was there for every new fitting DMO (DEFO) and without giving bias I 
was acknowledging it was a bit tricky to get it on. A bit tricky in the very 
first attempt, but that it generally gets a bit easier- so trying to reassure 
people that probably with a bit more practice it will get a bit easier’. (C2) 
 
Variance due to the modifications for customised fitting had a further impact on 
protocol timing delays:  
 
‘…actual garment itself bunching up a little bit… but in that occasion I 
think a modification was made. Things like zips could be put in and 
seams could be addressed’. (C2) 
 
One participant who had significant issues with the fitting of the DEFO resulted 
in a predicament for the clinicians. The first DEFO did not fit and the second 
when it arrived after some delay; she refused to wear it:  
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‘…one that just did not get on with the splint and said that she was not 
going to wear it’ (C2) 
‘…the participant absolutely didn’t want to try it and that was quite 
difficult’ (C1) 
It was within the participant’s right to choose not to wear the DEFO. She had full 
capacity to make the decision. 
 
Sub-theme: Impact of co-morbidity 
 
A further theme for consideration was the impact of co-morbidity on the protocol 
delivery. A number of participants had underlying health problems requiring 
medical intervention including antibiotics for urinary infections and seizures 
requiring modification of medication. This impacted at a clinical level with 
increased liaison with other health care professionals. This issue resulted in 
modifications of the physiotherapy interventions depending on the individuals’ 
health and ability to participate.  
 
‘…the individual health of the participant e.g. seizures and pressure sore’ 
(C2) 
As outlined in all the previous issues above there was an impact on the protocol 
feasibility which was categorised as a theme (OC.1): Protocol feasibility.  
 
6.3.2.2 Organizing Clinician theme (OC.2): DEFO intervention acceptability  
Sub-theme: Comfort, compliance and wearing issues 
 
One of the primary concerns in the study was the question of DEFO 
acceptability. The findings by one of the clinicians supported that this orthosis is 
comfortable: 
 
‘…most people would suggest they are comfortable.’ (C1) 
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This was considered by one clinician in more general terms in that she was 
interested in their experiences both positive and negative: 
 
‘I enjoyed seeing patients experience new treatment and what they found 
about their experience and whether they thought it was a good idea or 
not’. (C3) 
Comfort is important for compliance. Poor compliance is commonly reported in 
wearing of splints and orthotics (Lannin et al., 2007; Kuipers et al., 2009). The 
findings of this study are positive in general terms for compliance, as was 
verified by the DEFO wearing log and the comments below: 
‘I would have said the compliance was… with the patients I met, really 
good. They were very compliant with it. They were keen to be a part of it 
and give it a jolly good go’. (C3) 
This issue on compliance was expressed from another perspective by: 
 ‘…in terms of compliance I think it affected them in terms of having 
someone around to help them put it on’. (C2)  
‘…there were some concerns about getting it on particularly when they 
were living alone’. (C3) 
 
Essentially in order to be compliant with the protocol and putting on the DEFO 
in some cases with increased dependency levels they were reliant on others 
both in fitting and wearing times: 
 
‘…she really struggled getting the carers to help her to put it on and it 
was difficult for her to put it on by herself due to the severity of her tone 
… and then having somebody around at the right time to take it off’. (C2) 
 
A further issue around wearing was raised by a clinician in that one participant 
worked night shifts which did not impact on wearing compliance but confused 
him about wearing times. The clinician clarified this. This demonstrated the 
importance of PPI (INVOLVE, Hanley et al., 2003) for the development phase of 
informing protocol design to optimise compliance and acceptability.  
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The option for different colours was raised in the research proposal during the 
developmental stage. However a neutral colour DEFO was decided upon for 
consistency. This finding on compliance was raised as some participants were 
interested in other colour options: 
  
‘…only provided the beige and there is possibility that some may not like 
that colour and would have preferred a different colour.’ (C1) 
The option of different colours was not discussed by the other clinicians who 
were perhaps used to the medical appearance of splints and orthotics provided 
in the NHS.  
Sub-theme: Difficulty with donning 
A specific finding was raised on difficulty with donning of the DEFO. This was 
either by participants as individuals or with assistance (C2) (p.193). This 
important issue contributed to the overall acceptability and adherence in 
wearing the DEFO and following the wearing protocol. It was demonstrated to 
be dependent on the level of disability and associated carer support. 
 
 ‘A bit tricky in the very first attempt, but that it generally gets a bit easier- 
so trying to reassure people that probably with a bit more practice it will 
get a bit easier’. (C2) 
All the above issues raised were categorised and analysed thematically into the 
theme (OC.2): DEFO intervention acceptability.  
Summary  
From analysis of the key findings there were a number of relevant and 
interesting themes. A summary of the key points in each Organizing theme is 
presented below:  
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6.4 Summary 
From the findings of participants and clinicians reported experience there is 
some evidence to support the DEFO as an acceptable intervention in the 
clinical setting. In addition the protocol was found acceptable in a clinical 
setting, however the clinicians also reported constraints on capacity due to 
competing demands from clinical and research practice. The findings provide 
direction for protocol modification to improve procedural delivery and reduce 
burden on clinicians involved in clinical research. These are discussed in 
Chapter 8. The narratives tell a vivid account of research experiences. The 
qualitative analysis provides a storyline of the impact of research in real-life 
situations. A summary table of the themed topics from the combined interview 
data findings is presented below, (in Table 6.1). Significant findings include 
differing perspectives in disability that impacted on the research and the 
learning opportunity for research experience gained by the clinicians. Further 
significance was surmised from interpretation of the participant accounts of 
DEFO physical and social cosmetic acceptability. The findings of both 
participant and clinician data sets are integrated and analysed further, (in 
Chapter 7). 
Summary of key points: Global Clinician theme (GC.2): Feasibility and 
acceptability of DEFO in a clinical setting 
Organizing Clinician theme (OC.1): Protocol feasibility 
Overall protocol was found to be feasible in the majority of participants. 
However the availability of the DMO clinician had a direct impact on the 
protocol delivery with variances in timing and in fitting (n=2). Also co-morbidity 
had a negative impact on protocol feasibility.  
Organizing Clinician theme (OC.2): Intervention (DEFO) acceptability 
The DEFO was acceptable in the majority of participants with good 
compliance due to comfort and colour. Wearing issues included early difficulty 
with donning together with reliance on carers. 
 
196 
 
Table 6.1 Summary of qualitative findings (Thematic Analysis of participant and clinician Topic guided interviews) 
Topics 
 
 
Participant themes Participant findings  Clinician themes Clinician findings  
Health benefits (GP.1) (OP.4) Health 
Benefits 
Physical and 
Psychosocial benefits: 
positives > negatives 
No emergent theme Not evidenced directly 
Feasibility (GP.1) (OP.3) Protocol 
feasibility 
Timing: 
delays in n=2 
no delays in n=9 
Protocol:  
acceptable in n=10 
not acceptable n=1 
(GC.2): (OC.1) Protocol 
feasibility 
 
Research communication 
kept things on track 
Variances: in timing and in 
fitting (n=2) 
Availability of DMO clinician 
had a direct impact on 
protocol delivery 
Co-morbidity had a negative 
impact on protocol feasibility 
Overall protocol was found to 
be feasible in the majority of 
participants for both 
intervention and control 
groups (n=22) 
The protocol was not 
acceptable in (n=1) 
Acceptability (GP.1) (OP.2) DEFO 
acceptability 
Appearance: 
acceptable in n=10 
not acceptable n=1 
(GC.2):(OC.2) DEFO 
Acceptability 
 
The DEFO was found 
acceptable in the majority of 
participants with good 
compliance due to comfort 
and colour. Wearing issues 
included early difficulty with 
donning together with 
reliance on carers. 
Other 
 
 
 
(GP.1) (OP.1) Research 
Expectations  
 
 
 
Hope and motives 
expressed for self and 
others. Individual 
expectations realised. 
 
(GC.1):(OC.1) Research 
Expectations 
 
 
 
Personal, professional and 
participant (elevated) 
expectations and motives 
expressed. 
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Other (cont’d) (OP.5) Adverse Effects 
 
 
 
 
(GP.2) (OP.1) Differing 
perceptions of 
disability)  
 
 
 
 
(OP.2) Generalizability 
to Condition 
Physical discomfort 
(sweating, tightness and 
difficulty with donning. 
Impact on usual activities. 
 
Self-perception, image and 
acceptability of disability. 
Societal and research 
attitudes and behaviours 
based on perceptions in 
disability.  
 
Timing preferred earlier in 
treatment cycle and earlier 
in condition management. 
 
(OC.3) Clinical practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(OC.4) Research 
experience 
 
 
 
 
 
 
 
(OC.2) Ethical issues 
 
Practice issues were cited 
including usual practice, 
rehabilitation perspectives 
and delivery (promoting self-
efficacy). Clinicians showed 
an overall preference for 
clinical practice with people 
who have more active vs 
passive function. Both clinical 
capacity and clinical risk 
prioritisation were found to 
impact on the research 
delivery. Interface with 
private therapies suggested 
conflicting priorities (active vs 
passive). 
 
Both positive and negative 
research experiences 
described: learning 
opportunities in research; 
difference from the usual role 
and clinical impact on the 
research with uncertainties 
explored. 
 
Ethical issues were analysed 
for research clarification on 
eligibility criteria and clinical 
risk. The research was found 
to have internal integrity with 
evidence of fidelity in practice 
reported. 
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Chapter 7 
Data Integration  
 
 
 
 
 
 
 
 
Introduction 
In this chapter the study findings are considered. This was by integration and 
interpretation of the findings from both quantitative and qualitative data sets. 
The former data from the pilot RCT was used to assess the potential 
effectiveness and feasibility of the DEFO intervention. The latter comprised of 
key themes gathered from participant and clinician interview feedback. This 
provided rich and valuable insights of the research feasibility and DEFO 
acceptability and tolerance. In this chapter the mixed methods approach using 
embedded design demonstrates how the qualitative findings provide an 
enhance understanding of the quantitative results. 
The reporting of the mixed methods study followed the six-item guidance 
framework; Good Reporting of a Mixed Methods Study (GRAMMS) (O’Cathain 
et al., 2008, p.92). The findings follow the method of triangulation protocol 
(O’Cathain et al., (2010) for consideration of integrated findings regarding 
agreement or dissonance of the data components. Rigour and quality of both 
the data sets was established by following a procedural checklist for mixed 
methods research as advocated by Collins and O’Cathain, (2009, pp.2-6) and 
Andrew and Halcomb, (2009, p.35). Combined quantitative quality criteria and 
qualitative study criteria were assessed for truth value, applicability, consistency 
and neutrality (Sale and Brazil, 2004). In addition each data set was scrutinised 
by research tutors and statisticians before being presented. The findings were 
Key points: 
 Integration of findings 
 Health benefits 
 Feasibility 
 Acceptability and tolerance of the DEFO 
 Quality framework for study integrated findings 
 Summary of key findings 
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reviewed for how they addressed the objectives (Chapter 4.2) and research 
questions: 
 What is the likelihood of health benefits of treatment with DEFO and 
physiotherapy (as required) and usual care, compared to usual care 
alone? (primary question) Addressed by pilot RCT data and Topic guided 
interview data combined. 
 
 What is the feasibility of the protocol (as a small feasibility pilot RCT) to 
inform the design of a larger study? Addressed by pilot RCT data and 
Topic guided interview data combined.  
 
 How acceptable is the DEFO intervention in clinical practice? Addressed 
by Topic guided interview data together with specific wearing data and 
clinical records.  
 
In light of the study findings, (in Chapters 5 and 6) the integrated key issues are 
presented: health benefits; feasibility of the protocol; and acceptability of the 
DEFO intervention. Each of these sections is divided into a typology or set of 
categories which are analysed by combining the quantitative data and 
qualitative findings, data comparison and integration using a triangulation 
approach. These are presented in tables 7.1, 7.2 and 7.3. 
 
7.1 Health benefits 
Uncertainty of the health benefit of DEFO intervention was addressed by 
findings of the pilot RCT outcome measures and qualitative data which was 
gathered and analysed from the participant and clinician interviews. They are 
discussed in terms of: person-centred goals; physical benefits and adverse 
effects; psychosocial benefits; quality of life and carer burden. The summary of 
these integrated findings for health benefit are presented, (in Table 7.1) and 
discussed. 
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Person centred goals 
Findings of the primary measure (GAS) for the pilot RCT indicated a tangible 
health benefit in achievement of health related goals that was significantly 
different in the DEFO intervention group (95%CI: 3.16 to 21.18; p = 0.014). This 
difference equates to a standardised effect-size of 1.21 (95% confidence 
interval 0.31–2.10). In this study it cannot be reported with any precision if the 
effect size is small or large. Due to the wide 95% confidence intervals 
surrounding this effect-size this is conservatively interpreted as a statistically 
significant large effect to a non-significant one. In order to improve the precision 
of the effect-size (i.e. reduce the 95% CIs to a narrower band) there will need a 
larger population in a future study. As this is a small scale study there is a 
potential risk of a type I (false positive) error. Further, the effect, although 
statistically significant, may not be clinically important.  An RCT should be 
powered to detect the smallest effect-size that is of clinical importance (p.244); 
for instance significant effect-size for the GAS. 
Goals identified were personalised to the individual’s needs reflecting 
importance and difficulty (Turner-Stokes, 2003; 2009). The summary table of 
goals by group (in Table 5.17, Chapter 5. 5) provides a snapshot of the goals 
selected by the participants. From the total of 69 goals there was a similar 
distribution for both groups which included 14 categories. There were a number 
of commonly themed goals. These included: goals for gaining functional 
independence; walking; and splint application; reducing associated reactions, or 
pain and hand hygiene. The GAS provided a useful reflection of outcome that 
was both critically important and found to be in context of the person’s own life 
(Ashford and Turner-Stokes, 2006; Ashford, Slade and Turner-Stokes, 2013).  
Physiotherapists as clinicians delivering the intervention were best placed in the 
study to discuss and agree the participant goals, rationalise difficulty and score 
the baseline. Recovery following brain injury becomes a continuum and needs 
careful monitoring and challenging to ensure the goals set are realistic and 
achieved. This was sometimes difficult if the participant was previously known 
to the physiotherapist and alignment of the goal was not functionally directed or 
within the clinicians perceived role (C2) (p.180). Issues of rehabilitation 
potential, activity versus passive function and motivation were all discussed as 
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factors that influenced goal setting (C3) (p.180) (GC.1): (OC.3): Clinical 
practice, Active versus passive function, Rehabilitation potential).  
This is supported by evidence that links rehabilitation to motivation and goal 
setting (Seigert and Taylor, 2004). Equally there was difficulty with setting goals 
in previously unknown participants. However (C2) was clear in her approach 
with participants who demonstrated more activity (p.180).  
A skill is required to implement this tool (GAS) (Appendix 7). Measurement was 
conducted and variance in goal attainment was recorded if not achieved. 
Considerations included: transport difficulties and financial constraints in 
attending a gym; even personal factors including level of motivation. This detail 
of variance was captured in the clinical records and presented as an important 
factor in the feasibility of the protocol (Chapter 7.2). The findings showed 
person-centred goals were mostly achieved, with a significant positive 
difference in achievement of DEFO group. 
Physical benefits  
Health benefits reported by participants were thematically analysed as (GP.1); 
(OP.4): Health benefits and grouped into two categories: physical and 
psychosocial. The findings in the physical category included benefits of 
collective significance for instance pain relief which was linked to reducing 
tension in the spastic muscles (P19) and even further benefit in normalising 
posture (P24). The feeling of comfort and the perception of normalising 
awareness was also repeatedly described as an added benefit of wearing the 
DEFO (P01, P04) (p.157). This was considered important in terms of 
acceptability. In addition there were accounts of increased movement which 
was supported by increased functional use of the limb in individuals where 
activity was present (P01, P11, P19) (p.156). 
There was further evidence to support positive and tangible physical health 
benefits in real-life contexts which were valued by the majority of participants in 
the DEFO intervention group. A striking example is that of one participant (P21) 
who found it provided flexibility so she could ‘hold and use the frame’ with her 
hand whilst out shopping (p. 157). 
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Findings of the secondary measures of the pilot RCT data were corroborated by 
the clinical records. The VAS (for pain) in both groups showed a reduction in 
pain scores at six weeks, but the score change was small, with no significant 
difference between groups. The reduction in score was collectively less than 
two points, but in individual participants there was a change score of more than 
two points in three participants (P13, P20 and P23) in the intervention group. 
For those participants the pain score was particularly relevant measure of 
health benefit. For one participant his medication for pain management was 
reduced resulting in health benefit.  
Three participants were randomized to the intervention group with lower limb 
spasticity, none into the control group. This was predicted likely with few 
potentially eligible participants with lower limb spasticity at the clinic. The 
participants with lower limb spasticity were required to walk over ten meters and 
present with spasticity of the calf muscles. These were prerequisites for 
recruitment. Most of the people with lower limb spasticity at the clinic received 
BT injection for adductor muscle spasticity and were unable to walk. 
Subsequently only descriptive results were reported for the 10MTT measure.  
Some improvement in gait velocity (at six weeks) was indicated in two 
participants (P10 and P18) however this was not maintained (by twelve weeks) 
following the removal of the DEFO. There was minimal improved change in the 
gait velocity in (P11) at six weeks. However, retest at twelve week was not 
performed due to the progression of her long-term condition.  She was unable 
to walk the necessary distances (ten meters repeated three times) at twelve 
weeks. The deterioration was duly noted and corroborated by the clinical 
records. Progression of the participant’s neurological condition was considered 
to have had a negative impact on her participation in the study.  
This is exampled by comments made by participant (P11) (p.168). The 
inference was interpreted that she wished this intervention had been offered 
earlier in her own condition and also that it should be available earlier for people 
with similar progressive conditions. From the combined findings of the walk test 
and the themes gathered by interview this is a valid viewpoint.  
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Table 7.1 Summary table of combined quantitative and qualitative findings: for health benefit 
Health benefits 
Category/typology 
Quantitative data Qualitative data Integrated findings 
Person-centred 
goals (with level of 
difficulty and 
importance) 
GAS significant difference 
between groups with positive 
outcomes in the DEFO 
intervention group (95%CI: 
3.16 to 21.18; p = 0.014). 
 
Summary of goals set 
(Table 5.17) 
Global Participants theme: (GP.1); 
Organizing theme (OP.1): Research 
expectations 
Hopes and motivations for self and others 
evidenced. 
 
Global Clinician theme: (GC.1): (OC.1) 
Clinical practice, Active versus passive 
function and Clinical practice, 
Rehabilitation potential. 
Rehabilitation potential, activity versus 
passive function and motivation influenced 
goal setting 
Goals set and achieved that were of critical 
importance and in context in the individuals 
own life. 
Key findings: 
 Person-centred goals 
achieved with significant 
difference in achievement 
in the DEFO group. 
 Factors including 
rehabilitation potential and 
motivation influence how 
goals set are realistic. 
 
Level of agreement: The 
combined findings are 
congruent with qualitative 
findings supporting 
quantitative data. 
Physical benefits 
 
 
 
 
 
 
 
 
 
 
Adverse effects 
 
VAS pain levels small 
reduction in both groups but 
of no significant difference 
between groups  
DEFO Wearing record 
supports tolerance of comfort, 
appearance and functionality  
10 Meter timed walk  
All participants improved gait 
velocity at 6 weeks (P11) 
retest at 12 week was not 
performed. 
DEFO Wearing record (n=1) 
non-compliance  
Global Participants theme: (GP.1) 
Research Experience: Acceptability 
Organizing Participants theme (OP.4): 
Health benefits; Physical benefits  
 Pain level reduced 
 DEFO supportive and comfortable 
 More relaxed 
 Posture more normal and improved 
functional activity 
Organizing Participants theme (OP.5): 
Adverse effects; Physical:  
tightness, sweating and swelling in hot 
weather, dislike, reliance on others, difficulty 
with donning (initially) 
Impact on usual activity: 
A block to sunbathing and therapies/ 
swimming. 
Key findings: 
1. Positive and tangible 
health benefits in real-life 
contexts which were 
valued by the majority of 
participants in the DEFO 
intervention group.  
2. This negative findings 
were related to a few 
reported individual fitting 
and wearing issues. 
Level of agreement: The 
combined findings are 
congruent with greater depth 
of understanding provided by 
the qualitative findings. 
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Psychosocial 
benefits 
 
Wearing record 
compliance in (n=10) 
Summary of goals set 
(Table 5.17) 
Person-centred goals 
included appearance of upper 
limb in social settings 
Global Participants theme: (GP.1) 
Research Experience: Acceptability; 
Organizing Participants theme (OP.4): 
Health benefits; Psychosocial health 
benefits: 
 Appearance acceptable from a health 
perspective with social cues 
 More ‘normal’ 
 More awareness 
 Appearance socially acceptable 
Key findings: 
Combined evidence to 
support psychosocial health 
benefit in wearing compliance 
and thematic analysis of 
health benefit. 
 
Level of agreement: The 
combined findings are 
congruent. 
Quality of life EQ-5D  
No significant difference 
between groups. 
Global Participants theme (GP.2);  
Organizing Participants theme (OP.1): 
Differing perceptions of disability: 
Quality of life benefits 
Self-image and self-awareness issues raised 
by participants (links with psychosocial health 
benefits evidenced above and perceptions of 
disability). 
Key findings: 
No evidence of significant 
difference between groups for 
improved quality of life but 
some evidence of improved 
self-perception of normality 
and awareness. 
 
Level of agreement: The 
combined findings are 
congruent. 
Carer burden 
 
 
 
 
 
 
 
 
 
 
ArmA Active  
No significant difference 
between groups. A small 
change in both groups with 
reduced scores over time. 
ArmA Passive 
Both groups demonstrated a 
moderate drop in the score 
over time with no significant 
difference between groups.  
LASIS Participant 
Positive  findings: 
Global Participants theme: (GP.1); 
Organizing Participants theme (OP.2): 
DEFO Acceptability; Wearing issues: 
Donning gets easier. 
Organizing Participants theme (OP.3): 
Protocol feasibility; Protocol acceptability: 
Fitted in with routines. 
Global Clinicians theme (GC.1); 
Organizing Clinicians theme (OC.4): 
Research experience; Different from usual 
role: New client group. 
Organizing Clinicians theme (OC.3): 
Key findings: 
1. Combined evidence of 
reduced carer burden in 
both groups but not of 
significant difference 
between groups.  
2. The findings indicated a 
generalizability of the 
DEFO to a new client 
group.  
3. Rehabilitation potential, 
motivation and 
compliance were factors 
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Carer burden 
(cont’d) 
No significant difference 
between groups with a drop in 
score in both groups over 
time. 
LASIS Carer 
No significant score difference 
between groups at any time 
point. A small score reduction 
in the control group at 6 
weeks returned to baseline by 
12 weeks.  
Clinical practice; Active vs passive 
function: clinical practice issues 
Rehabilitation potential: motivation 
Promote self-efficacy: not dependency 
 
Negative findings:  
Global Participants theme: (GP.1); 
Organizing Participants theme (OP.5): 
Adverse effects; Impact on usual activity 
and reliance on carers  
Global Clinicians theme: (GC.1); 
Organizing Clinicians theme (OC.3): 
Clinical practice; Interface with Private 
Physiotherapy: 
Linked to realistic goals, and level of 
dependency 
Global Clinicians theme (GC.2); 
Organizing Clinicians theme (OC.2): DEFO 
intervention acceptability; 
Compliance and wearing issues; Difficulty 
with donning 
Reliance on carers and donning issues 
 
suggested to influence 
likely outcome. 
4. Reliance on carers linked 
to level of dependency. 
(Level of dependency was not 
categorised at baseline) 
 
Level of agreement: The 
combined findings are 
congruent with greater depth 
of understanding provided by 
the qualitative findings. 
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7.1 Health benefits (continued) 
Adverse effects 
This is in contrast to the negative findings which were related to a few reported 
individual fitting and wearing issues. One participant (P16) refused to wear the 
DEFO (possibly due to tightness) but she was unable to explain her decision 
due to aphasia. Two other participants tolerated the DEFO and found it 
comfortable apart from its application (P20) and during hot weather (P21) 
(p.152). 
Psychosocial benefits  
There was evidence to support psychosocial health benefit in wearing 
compliance and thematic analysis of health benefit. This was demonstrated 
from the perspective of cosmetic acceptability; fitting in and providing some with 
the feeling of ‘normality’ (P04), (P10), (P19), and (P24). Participants reflected 
on how their appearance was seen by others (P19) (p.150). This particular 
issue of health benefit was also analysed for the impact of differing perceptions 
and attitudes towards disability. 
Quality of life 
An alternative view on cosmetic acceptability was expressed by one participant 
with regard to the DEFO restricting his sunbathing. There was no evidence of 
significant difference between groups for improved quality of life. However there 
was some evidence of improved self-perception of normality and ‘more 
awareness’ (P04) (p.157). 
The EQ-5D as a measure of quality of life did not provide any findings of 
significance with little change in score in either group in any time point. This was 
not surprising since the small numbers for a feasibility study were likely to be 
insufficient for prediction of significant difference. The EQ-5D was used in this 
small study to test clinical procedural feasibility for use in a larger study which 
could test economic benefit rather than for statistical benefit for calculation of 
sample size. From the clinical records there were a number of variances in 
participant’s lives which impacted on their perceptions of health. This included 
external factors of difficulty with finances, problematic relationships and 
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receiving bad news of scan results. Medical complications were also recorded 
in the clinical records which impacted on the general health of participants in 
both groups equally (Chapter 5.5). 
Carer burden 
Upper limb measures (ArmA and LASIS) were reported each having separate 
constructs for ‘active’ and ‘passive’ function/care components. The LASIS and 
ArmA were relatively new tools at the onset of this study recommended for 
clinical applicability (RCP et al., 2009). Both have been recently evaluated for 
reliability. They were found to have relevance and specificity for the purpose of 
measuring care burden in people with spasticity with the ArmA most reliable 
(Ashford et al., 2014). This measure was found to closely correlate with goals 
for care burden.  
It was found there was reduced carer burden in both groups but this was not of 
any significant difference between the groups.  It could be argued that the 
finding of reduced carer burden in both groups was the result of the 
rehabilitation philosophy of the physiotherapist (C2) in promoting self-efficacy 
(p.181). 
Small levels of health benefit were found in the ArmA (Active) measure, but the 
difference was insignificant between groups with a reduction in scores in both 
groups over time. This finding was interpreted as a small benefit in the reduction 
of carer burden over time from the combined BT, usual care and physiotherapy 
intervention. 
The ArmA passive score which represented carer burden, showed a similar 
pattern of reduced scores in both groups over time. This is interesting in that the 
carer burden appeared substantially reduced in both groups equally by the 
twelve week time point. This was reasoned as resulting from the combined 
effects of physiotherapy and BT, rather than the DEFO intervention. 
Alternatively it could be interpreted as a carry-over effect. 
In the LASIS (Participant) measure there was no significant difference from the 
baseline between the intervention and the control group at any time point. There 
was a very small difference in both groups at week twelve indicating slight 
improvement in active levels of function. The findings of the LASIS (Carer) was 
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analysed with the proviso of small numbers due to not all participants having a 
‘carer’. There was no significant difference from the baseline between the 
intervention and the control group at any time point. There was a small 
reduction in the LASIS score in the control group at six weeks but this returned 
to baseline by twelve weeks. There was no measureable difference in the 
LASIS score in the intervention group at any time point. This could be 
interpreted in the slight difference in level of baseline age and dependency in 
the control group. Another factor that was considered was the level of 
dependency on carers for donning the DEFO (P21), p.159 and (C2), p.193. 
From the above findings the combined physiotherapy and BT showed a small 
beneficial impact of health benefit on the carer burden.  
Summary of key points 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Person-centred goals were achieved with significant difference in 
achievement in the DEFO group. Factors that influence goal setting 
include rehabilitation potential and motivation. 
 The health benefits from the DEFO intervention were found to include 
both physical and psychosocial benefits (pain relief, comfort, more normal 
feeling and awareness, benefit realised by improved posture, muscle 
tension and functionality). These benefits were of varying significance to 
the individual depending on the critical importance and context to the 
person’s life.  
 Adverse effects were also recorded for physical discomfort (sweating, 
tightness and difficulty with donning and impact on usual activities), but 
these were analysed to be of lesser significance when compared to the 
generalizable health benefits realised.  
 There was no evidence of significant difference between groups for 
improved quality of life however some evidence of improved self-
perception of normality and awareness.  
 There was evidence of reduced carer burden in both groups but not of 
significant difference between groups.  
 Reliance on carers was possibly correlated to a level of dependency, 
though this was not formally measured. 
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The strategy used for interpreting the connected results of the quantitative data 
and qualitative findings was by distinct categories. These categories included 
person-centred goals, physical benefits, adverse effects, psychosocial benefits, 
quality of life and carer burden. Integrated findings provided a moderate level of 
congruence with meta-inference gained from a better understanding of the 
quantitative results by explaining and exploring with the qualitative findings. The 
findings indicated a generalizability of the DEFO to a new client group. 
Furthermore rehabilitation potential, motivation and compliance were factors 
suggested to influence likely outcome.  
 
7.2 Feasibility of the protocol 
The feasibility of the protocol procedural delivery in a clinical setting was 
established. The integrated findings are presented, (in Table 7.2) in terms of 
protocol delivery, fidelity, variance and other factors that were found to impact 
on feasibility. These included baseline characteristics, expectations and ethical 
issues raised.  
Protocol delivery 
The protocol feasibility was evidenced by the integrated findings of: retention, 
delivery and adherence (CONSORT, in Figure 5.1); the measures of the pilot 
RCT; and the combined thematic data from the participant and clinician 
interview feedback. The DEFO wearing record (Table 5.14) also supported 
protocol feasibility with adherence of wearing times. Wearing was adhered to in 
four of six weeks and with recorded tolerance of eight hours, or more (13.5 
hours).  
The results of recruitment show that of potential participants (n=62) there were 
(n=30) who declined to participate. Furthermore saturation of recruitment level 
was achieved two months early with n=25 of a desired n=30 participants. This 
provides indicative levels of the difficulty in recruitment to a study in a 
population with spasticity from a clinic setting. The CONSORT diagram (p.118) 
of recruitment and attrition showed the overall retention level was high with 
merely two participants, one from each group, who revoked consent. The study 
protocol was delivered in (n=23) of (n=25) participants recruited. Thus 
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procedural delivery and acceptability was established. The DEFO intervention 
was fully delivered to ten of the eleven participants in the intervention group and 
was partially delivered to the remaining participant. The protocol followed usual 
care for the twelve control group participants. In essence the adherence level 
was good with a high proportion of the participants following the study protocol. 
From the participant interviews the protocol was found to be both feasible and 
acceptable (GP.1; OP.3: Protocol feasibility; Protocol acceptability). It was 
reported to fit in well with routines of everyday life (P01, P18, P21 and P24) 
(pp.153-4) and no problems in following the protocol in ten participants with one 
exception. This was further evidenced from the participant perspective in the 
acceptability of the wearing protocol with a high level of tolerance and 
compliance.  
 
Specific wearing issues were found to contribute to the feasibility of the 
protocol. This included reliance on carers for donning the DEFO. Again this was 
influenced by the level of dependency of the participant and whether their care 
was delivered by a care agency or partner. Thus participant compliance was 
found to depend both on the level of dependency and subsequent reliance on 
carers (C2) (p.193). 
 
Co-morbidity and rehabilitation potential were found to impact on clinical 
practice and protocol delivery. This finding was presented from the clinician’s 
feedback and introduced the importance of motivation, and not creating 
dependency (C2) and (C3) (p.180-1). This finding is similar to findings of 
Maclean and Pound, (2000) with insights into the importance of understanding 
the role of motivation in rehabilitation and professionals attitudes (Maclean et 
al., 2002). This finding highlights the potential impact of motivation in health 
research. Accordingly it provides direction in future studies on incorporating 
assessment of motivation as a baseline measure.  
The protocol was reported acceptable and tolerated by both clinicians and 
participants with no identified burden in data capture. However, it was found for 
the clinicians there was a conflict in competing priorities of clinical caseload and 
capacity with delivery the research protocol. This finding challenged the 
feasibility of the protocol in a clinical setting (C3) (p.186-7) (GC.1; OC.4: 
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Research experience; Negative experiences: Recruitment, eligibility and 
capacity issues. 
 
Agreement on eligibility and potential clinical risk were also identified as factors 
that could impact on procedural clinical research feasibility. These are 
considered further in relation to ethical practice (Chapter 8.1). The clinician was 
given clear instruction to follow professional guidelines on clinical accountability 
and ensured a risk assessment and plan was in place (as is usual practice). 
212 
 
Table 7.2 Summary table of combined quantitative and qualitative findings: for feasibility of the protocol  
Feasibility 
Category/typology 
Quantitative data Qualitative data Integrated finding 
Protocol delivery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data capture 
CONSORT flow diagram 
Figure 5.1 of recruitment and 
attrition shows (n=25) 
recruited from a potential 
(n=62) with (n=30) declined 
to participate. The study 
protocol was delivered in 
(n=23) with attrition of (n=2). 
An intention to treat (ITT) 
analysis was conducted. 
  
No added burden of data 
captures recorded 
(measures). 
 
DEFO Wearing record 
(Table 5.14) supports 
protocol feasibility with 
adherence of wearing times: 
adhered to in 4 of 6 weeks 
and tolerance of 8 hours or 
more (13.5 hours). 
 
DEFO Wearing record  
Delays in (n=2) 
No delays in (n=9) 
 
Compliance in (n=10) 
Non-compliance in (n=1) 
Global Participants theme: (GP.1); 
Organizing theme (OP.3): Protocol 
feasibility; Protocol acceptability 
Fitted in well with routines, no 
problems with following protocol 
(n=10) with (n=1) exception. 
Global Participants theme (GP.2); 
Organizing theme (OP.1): Differing 
perceptions of disability; 
Generalizability Timing and 
diagnostic condition were considered 
factors in protocol feasibility and 
application to a similar population. 
 
Global Clinicians theme: (GC.1);  
Organizing theme (OC.2): Ethical 
issues; Eligibility and recruitment, 
and potential clinical risk. 
Organizing theme (OC.3):  Clinical 
practice; Rehabilitation potential 
and practice factors affecting protocol 
delivery. 
Organizing theme (OC.3): Clinical 
practice; Capacity and priorities 
Impact of research on existing 
caseload. 
Organizing theme (OC.4): Research 
experience; Recruitment and 
eligibility and potential clinical risk. 
Global Clinicians theme (GC.2); 
Organizing theme (OC.2): Protocol 
feasibility; 
- Research communication 
Key findings: 
1. Feasibility of the protocol 
delivery was established in 
clinical practice with a high 
level of adherence and 
tolerance with compliance in 
the DEFO wearing protocol.  
2. Recruitment was saturated early 
from a small pool of possible 
participants (from a desired 
n=30: n=25 successfully 
recruited). 
3. No added burden in data 
captures (measures). 
4. Specific wearing issues 
contributed to feasibility of 
protocol including reliance on 
carers for donning DEFO.  
5. Co-morbidity and rehabilitation 
potential were found to impact 
on clinical practice and protocol 
delivery.  
6. The protocol was acceptable 
and tolerated by both clinicians 
and participants.  
7. Clinical capacity, priorities, 
agreement on eligibility and 
potential clinical risk were 
identified as factors that could 
impact on procedural clinical 
research feasibility. 
8. Participant compliance was 
found to depend on level of 
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Protocol delivery 
(cont’d) 
- Availability of DMO clinician 
- Variance in protocol timing 
- Variance in fitting 
- Impact of co-morbidity 
Compliance and donning issues, 
reliance on carers, level of 
dependency, research and clinic 
communication. 
 
dependency and reliance on 
carers. 
 
Level of agreement: The combined 
findings are congruent with greater 
depth of understanding provided 
by the qualitative findings. 
Fidelity 
 
Protocol Delivered in (n=23). 
DEFO Delivered (n=10) 
Not fully delivered (n=1). 
Physiotherapy data (Table 
5.15) 
Modalities of intervention 
were similarly matched for 
both groups. Most commonly 
used interventions: stretches 
(both active and passive); 
functional training; splinting; 
strength training and advice. 
Intervention group time: 
185.9 minutes 
Control group time:  
237.5 minutes. 
 
Global Participants theme: (GP.1); 
Organizing theme (OP.3): Protocol 
feasibility; Timing issues and 
Protocol acceptability evidenced 
fidelity. 
 
Global Clinicians theme: (GC.1); 
Organizing theme (OC.2): Ethical 
issues; Fidelity and eligibility 
Usual practice of clinicians and 
clarification of eligibility criteria. 
 
 
 
 
 
Key finding: 
The protocol was found to have 
delivered fidelity.  
 
Level of agreement: The combined 
findings are congruent. 
Variance 
 
 
 
 
 
 
 
 
 
 
Variance data: 
Timing variance 
Delays in (n=2) 
Fitting variance  
Delays in (n=2) 
Activity log: A wide variety 
of activities reported with 
similar levels of activity in 
both groups with exception of 
shopping (Intervention group 
n=4; control group n=10). 
Global Participants theme: (GP.1); 
Organizing theme (OP.3): Protocol 
feasibility; 
Protocol acceptability: (n=10); 
Not acceptable (n=1) 
Timing variance- Delays (n=2) 
Fitting variance- Delays (n=2) 
Global Clinicians theme (GC.2); 
Protocol feasibility; Availability of 
DMO Ltd clinician, Variance in 
timing, Variance in fitting. 
Key findings: 
1. High level of protocol 
compliance in (n=10) with Non-
compliance (n=1). 
2. There was minimal variance 
reported in protocol delivery 
(with delays in timing and fitting 
n=2) and level of activity 
between groups. 
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Variance (cont’d)  Illness and flooding 
 Time constraints of protocol 
 Modifications of DEFO delays 
 
Level of agreement: The combined 
findings are congruent. 
OTHER 
Baseline 
characteristics 
 
 
 
 
 
 
Expectations 
 
 
 
 
 
 
Ethical Issues 
 
Characteristics evenly 
matched following 
randomisation with 
exception of age difference 
between groups (Table 
5.1): control group 
approximately 11 years older 
(mean age difference). 
 
Expectations reported in 
terms of aspirations in goals 
set. Goal setting established 
person centred expectations 
(Chapter 5, Table 5.17). 
 
 
Protocol amendment 
submitted and agreed for 
procedural feasibility. 
Potential clinical risks 
highlighted and managed but 
no adverse events reported. 
 
Global Participants theme (GP.2); 
Organizing theme (OP.1): Differing 
perceptions of disability; 
Generalizability Progressive 
condition- earlier. Treatment cycle 
earlier and DEFO for longer. 
 
Global Participants theme (GP.1) 
Organizing theme (OP.1): Research 
expectations; 
 Participant  
 Clinician  
 Research  
Expectations, motives and aspirations 
acknowledged and met (in some). 
 
Global Clinicians theme (GC.1); 
Organizing theme (OC.1): Research 
expectations 
 Participants 
 Clinicians 
Research expectations and learning 
opportunities support practice 
development. 
 
Key findings: 
1. Baseline characteristics evenly 
distributed as expected 
following randomisation (except 
age difference). 
2. The participants suggested the 
protocol was likely to be 
generalizable to a population 
earlier for use in progressive 
conditions and earlier and 
longer in a BT treatment cycle. 
3. Expectations were identified 
and met (in some). 
4. Protocol amendment was 
submitted to improve 
procedural feasibility and 
ethical approval was obtained. 
5. Potential clinical risks were 
highlighted and managed 
clinically. No adverse events 
were reported. 
 
Level of agreement: The combined 
findings are congruent. 
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7.2 Feasibility of the protocol (continued) 
Fidelity 
The protocol was found to have demonstrated internal validity and reliability for 
fidelity. The delivery of the study protocol was reported consistent with delivery 
to (n=23). The DEFO was delivered to ten participants but not fully delivered to 
one due to non-compliance. There was also reported protocol variance in two 
participants in delayed timing and fitting. The components of DEFO wearing 
record, standardised physiotherapy (Table 5.15) and usual care supported 
protocol fidelity. Modalities of intervention were similarly matched for both 
groups. However there was a reported difference between groups in contact 
time (Intervention group time: 185.9 minutes Control group time: 237.5 
minutes). This is evidenced further in (GC.1); (OC.3) Clinical practice as (C2) 
(p.186) delivered standard physiotherapy. The evidence of fidelity in the 
protocol delivery supports feasibility of the DEFO intervention (DEFO) in a 
clinical setting. 
Generalizability  
Participants suggested the protocol was likely to be generalizable to a 
population earlier in progressive condition management and earlier and longer 
in a BT treatment cycle. This was from two participants: one with a progressive 
neurological condition (P11) and another who found benefit from prolonged 
wearing of the DEFO (P01), (p.169). 
Variance 
There was a high level of DEFO wearing (Table 5.14) with compliance in ten 
participants and non-compliance in one. In addition there was minimal variance 
reported in protocol delivery (with delays in timing and fitting in two) and level of 
activity between groups. It should be acknowledged, however that there were 
time pressures reported by the clinicians involved in the protocol delivery 
(GC.2); (OC.1): Protocol feasibility; Variance in timing, Variance in fitting 
(C1, C2), (pp.190-1). 
 
 This finding was reported by two participants from their experience of delays in 
the timing of the protocol. One participant had to wait for a second cycle of BT 
216 
 
before being successfully recruited and the other participant refused to wear her 
DEFO. This was following a delay in assessment and then further delays for 
repeat fitting of a second customised orthosis (P16) (p.154). The protocol was 
designed around the guidelines (RCP et al., 2009) for spasticity management 
with BT in adults. The delays for this participant resulted in a less than optimal 
time to trial the intervention. The second participant followed the protocol 
without further delays, after a second cycle of BT. 
 
Baseline Characteristics 
 
The baseline characteristics of the participants were evenly distributed as 
expected following randomization (with exception of age difference). The mean 
age difference of control group participants was of eleven years older. The 
impact of this was considered insignificant when compared with the group 
activity levels reported in the Activity Log. Indeed the control group was 
analysed to be more active than the intervention group. 
 
Expectations  
 
The hopes, aspirations, motives and expectations for the research were 
identified by clinicians and participants. It was useful to explore how participants 
and clinicians saw the research as an opportunity for improvement as 
individuals and for others. Clarifying expectation in both was seen as integral to 
the research compliance. The clinicians appeared to understand their role and 
research responsibilities (C3) (p.184) but some of the participants had elevated 
expectations (GC.1); (OC.1): Research expectations (C2) (p.174); and (GP.1); 
(OP.1): Research expectations; Health benefits for self (P18) (P20), (p.147). 
It was considered a positive finding that the protocol was clear and the 
participants understood the rationale for the pilot RCT even if they were not 
allocated to the intervention group (C3) (p.175). Good communication was 
analysed to be essential for the successful delivery of the protocol, contributing 
to feasibility.  
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Ethical issues  
The protocol amendment, eligibility and clinical risk are discussed separately in 
(Chapter 8.1 Ethical considerations) to avoid repetition.  
Summary of key findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Feasibility of the protocol delivery was established in clinical practice with a 
moderate to high level of adherence and tolerance with compliance in the 
DEFO wearing protocol.  
 Recruitment was saturated early from a small pool of possible participants 
(from a desired n=30: n=25 successfully recruited). 
 There was a high level of protocol compliance with non-compliance of only 
one participant. Participant compliance was found to depend on level of 
dependency and reliance on carers. The protocol was found to have 
delivered with fidelity. There was minimal variance reported in protocol 
delivery (with delays in timing and fitting n=2) and level of activity between 
groups. There was no added burden in data capture (measures).  
 Specific wearing issues contributed to feasibility of the protocol including 
reliance on carers for donning DEFO. Co-morbidity and rehabilitation 
potential were found to impact on clinical practice and protocol delivery. 
Clinical capacity, priorities, agreement on eligibility and potential clinical risk 
were all identified as factors that could impact on procedural clinical 
research feasibility.  
 Baseline characteristics were evenly distributed, as expected following 
randomization (except age difference).  
 Expectations were identified and met (in the majority). Participants 
suggested the protocol was likely to be generalizable to a population earlier 
in progressive condition management and earlier and longer in a BT 
treatment cycle.  
 A protocol amendment was submitted to improve procedural feasibility and 
ethical approval was obtained.  
 Potential clinical risks were highlighted and managed clinically. Importantly, 
no adverse events were reported. 
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The connected results of the quantitative data and qualitative findings were by 
distinct categories. These categories included protocol delivery, fidelity, 
variance, baseline characteristics, expectations and ethical issues that impacted 
on the feasibility of the study. Following integrated analysis of the above data 
the study protocol was found to be both clinically feasible and acceptable. The 
qualitative findings added value to the RCT data to provide greater 
understanding of the procedural feasibility. It showed that clinicians should have 
dedicated and funded research time to release them from competing caseload 
and other capacity demands. It also provided useful procedural detail on timing 
modifications and variance for future implementation of a larger study in a 
clinical setting. 
 
7.3 Acceptability of the DEFO intervention 
The acceptability of the DEFO intervention in a clinical setting was established. 
The integrated findings are presented, in Table 7.3. The findings are presented 
in categories/typology terms of clinical practice acceptability, DEFO wearing 
experiences, acceptability and adverse effects and ethical issues which had an 
impact on acceptability. 
Clinical practice acceptability  
Acceptability of the DEFO in the clinical setting is presented from the 
participants and clinicians perspectives. There was a clear preference for the 
DEFO intervention in combination with physiotherapy; earlier in condition 
management; also in BT cycle; and to be worn for a longer period following BT 
(GP.2); (OP.1): Perceptions of disability in research (P11) (p.168); (OP.2): 
Generalizability; Diagnostic condition and Timing (P01); (P24) (p.169). 
DEFO acceptability was considered from clinician’s perspectives founded in 
previous knowledge and experience. This was exampled by potential bias in 
predictive clinical effect and preferences for application. This included 
participants with more activity rather than those with passive function and care 
needs. This could be argued from a philosophical stance of the clinician that this 
was related to the rehabilitation role of the physiotherapist, rather than that of a 
care provider. Similarly the DMO clinician was more familiar with the use of 
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DEFO in people with more activity and for whom more central stability was the 
goal. The DEFO was used in this study in a new way, for potentially managing 
muscle tone (spasticity) in limbs, often with limited movement. The potential for 
muscle shortening in people with spasticity and reduced activity is well 
established (Goldspink and Williams, 1990; Katalinic et al., 2011). Initially this 
concept was challenging but was acknowledged as a useful learning 
opportunity (GC.1); (OC.4): Research experience (C1) (p.185). 
A further theme emerged from the clinician feedback was both the rehabilitation 
potential and the impact of co-morbidity (GC.1); (OC.3): Clinical Practice, 
Rehabilitation potential (C3) (p.180). This was corroborated with the six 
medical events and two participants who reported diagnostic news on disease 
progression. This was recorded in the clinical records previously reported, in 
Chapter 5.5 (clinical data). 
Clinical practice acceptability  
The clinicians also considered DEFO acceptability dependant on caregiver’s 
availability for donning. Both levels of dependency and reliance on carers were 
believed an important factor in acceptability and compliance (GC.2); (OC.2); 
DEFO intervention acceptability; Comfort, Compliance and wearing issues 
(C2) (p.193). Compliance was an important consideration as previous studies 
have indicated poor compliance in long term splint wearing (Lannin and Harvey, 
2003). 
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Table 7.3 Summary table of combined quantitative and qualitative findings: for acceptability of the DEFO intervention  
Acceptability 
Category/typology 
Quantitative data Qualitative data Integrated finding 
Clinical practice 
acceptability 
 
 
Physiotherapy data 
and clinical records 
 
 
DEFO Intervention 
Delivered in (n=10) 
Not fully delivered in 
(n=1) 
Compliance in (n=10) 
 
DEFO Wearing 
record supports 
tolerance of wearing 
time protocol. 
(Table 5.14) supports 
protocol feasibility 
with adherence of 
wearing times: 
adhered to in 4 of 6 
weeks and tolerance 
of 8 hours or more 
(13.5 hours). 
 
Global Participants theme (GP.2); 
Organizing Participants theme (OP.1): 
Differing perceptions of disability 
Perceptions of disability in research 
(P11) Physiotherapy plus DEFO 
Global Participants theme (GP.2); 
Organizing Participants theme (OP.1): 
Differing perceptions of disability; 
Generalizability; Diagnostic condition 
and Timing 
(to conditions and timing in BT cycle (P24) 
Wearing DEFO for longer (P01) 
  
Global Clinicians theme (GC.1); 
Organizing Clinicians theme (OC.3): 
Clinical practice: 
Active vs passive function 
Usual practice 
Rehab potential and motivation 
Clinical practice considerations 
Global Clinicians theme (GC.2); 
Organizing Clinicians theme (OC.1): 
Protocol feasibility; Impact of co-
morbidity 
Organizing Clinicians theme (OC.2): 
DEFO intervention acceptability; 
Comfort, Compliance and wearing 
issues. 
 
Participant findings: Wearing 
compliance and tolerance evidenced; 
preference of DEFO in combination 
with physiotherapy; earlier in 
condition management; also in BT 
cycle; and to be worn for a longer 
period following BT. 
 
Clinician findings: Clinical bias over 
active vs passive function and central 
over distal application; 
DEFO acceptability tempered by co-
morbidity and rehabilitation potential. 
 
Key findings: 
Both clinicians and participants 
provided evidence of DEFO 
acceptability in practice/setting (with 
caveat of stratification of participants 
based on the above findings). 
 
Level of agreement: The combined 
findings are congruent with greater 
depth of understanding provided by 
the qualitative findings. 
DEFO Wearing 
experiences 
Acceptability and 
adverse effects 
Clinical records 
DEFO Wearing 
record supports 
tolerance of comfort, 
Global Participants theme (GP.1) 
Organizing Participants theme (OP.1): 
Research expectations; 
 Participant  
Both positive and negative wearing 
experiences with substantive physical 
and psychosocial benefits reported. 
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DEFO Wearing 
experiences 
Acceptability and 
adverse effects 
(cont’d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
functionality and 
appearance.  
 
DEFO Wearing 
record showed 
Compliance in (n=10) 
non-compliance 
in(n=1) 
 
 Clinician  
 Research  
Hope, opportunity, expectations. 
 
Global Participants theme: (GP.1) 
Research Experience: Acceptability 
Organizing Participants theme (OP.4): 
Health benefits; 
Physical benefits  
 Pain level reduced 
 DEFO supportive and comfortable 
 More relaxed 
 Posture more normal and improved 
functional activity 
Psychosocial health benefits 
 Appearance acceptable from a health 
perspective with social cues 
 More ‘normal’ 
 More awareness 
 Appearance socially acceptable 
 
Organizing Participants theme (OP.5): 
Adverse effects; 
Physical: tightness, sweating and swelling 
in hot weather, dislike, reliance on others, 
difficulty with donning (initially) 
Impact on usual activity 
A block to sunbathing and therapies 
 
Organizing Participants theme (OP.2): 
DEFO Acceptability;  
Appearance and wearing preferences- 
colour  
 
 
 
Key findings: 
1. Appearance was considered a 
significant factor in 
acceptability. 
2. Physical benefits were 
established. 
3. Psychosocial benefits were 
established. 
4. Functionality of the DEFO was 
found beneficial in comparison 
to rigid splints.  
5. A moderate level of compliance 
was established. 
6. Poor fitting was found to 
detract from acceptability. 
7. Negative findings included 
difficulty and/or reliance with 
donning of the DEFO. 
 
 
Level of agreement: Both findings 
agreed with the deviant outlier of non-
compliance in n=1 and adverse 
effects. The combined findings are 
therefore congruent with greater 
depth of understanding provided by 
the qualitative findings. 
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DEFO Wearing 
experiences 
Acceptability and 
adverse effects 
(cont’d) 
 
Wearing issues 
Flexibility, it was lightweight, able to be 
worn under clothing, easy to remove, or 
difficulty with donning, tightness / too 
slack, wear and tear, and uncomfortable in 
the summer. 
 
Global Clinicians theme (GC.1); 
Organizing Clinicians theme (OC.1): 
Research expectations 
 Participants 
 Clinicians 
Elevated expectations of participants and 
possibly carers. Research expectations 
and learning opportunities support practice 
development.  
 
Ethical issues Pilot RCT 
Recruitment and 
eligibility criteria 
Inclusive of conditions 
with spasticity rather 
than condition 
specific. 
 
Global Clinicians theme: (GC.1);  
Organizing Clinicians theme (OC.2): 
Ethical issues;   
Eligibility - inclusion/ exclusion criteria 
clarification with definitions.  
Clinical safety - potential clinical risk 
(n=2) reported to the Research Reference 
Group and risks managed clinically. No 
adverse events reported. 
 
Key findings: 
Ethical considerations included 
clarification of eligibility criteria and 
research guidance on potential 
clinical risks. 
 
Level of agreement: The combined 
findings are congruent. 
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7.3 Acceptability of the DEFO intervention (continued) 
DEFO wearing experiences 
 
The DEFO wearing experiences are considered from situations in real-life 
contexts. The findings showed both positive and negative wearing experiences. 
These are presented in terms of acceptability of the DEFO intervention and the 
adverse effects (GP.1); (OP.2): DEFO Acceptability Wearing issues; (OP.4): 
Health benefits and Adverse effects. One of the most vivid accounts 
supporting acceptability of the DEFO intervention suggested benefits in 
functionality over more rigid standard splints (P21) (p.151). Again this was an 
important consideration for compliance and acceptability. There were additional 
considerations in support of the physical and psychosocial benefits previously 
presented, (in Chapter 7. 2: Health benefits). 
 
Adverse effects   
Findings of the adverse effects were centred on acceptability of fitting including 
issues of tightness, or too loose. The orthoses were customised to the individual 
needs of the participants and this sometimes resulted in additional, minor 
modifications for optimal fitting. This is illustrated in the complexity of a fitting a 
lower limb orthosis with the posterior compartment removed for comfort, (as in 
Figure 7.1). 
 
In contrast the DEFO was often referred to as ‘tight’ or as the DMO clinician 
preferred to call it ‘snug’. A fine line was drawn between acceptably tight and 
comfortably supportive and unacceptably tight and constrictive. This also had 
an impact on carer acceptability for donning the orthosis (GP.1; OP.5: Adverse 
effects; Physical and refusal to wear it (P16) (p.159). 
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Figure 7.1 Photograph showing DEFO fitting (with participant consent and 
Trust policy) 
 
 
One further participant reported the DEFO uncomfortable to wear, but this was 
in the summer heat, however she was compliant in wearing the DEFO and 
followed the wearing protocol. It was noted from the clinical records she also 
gained weight over the study period which could have impacted on her 
experience (P21). However, this finding was in alignment with previous studies 
(Coghill and Simkiss, 2010; Calvert and Kelly, 2013).  
 
Wearing preferences 
From the wearing records it can be surmised there was a high level of wearing 
tolerance. Although included with the tolerance, there was variability in the 
individual preferences for timing of when and where the DEFO was worn. These 
preferences took into account various factors including dependency on carer 
support for donning and personal choices for example: sun tanning, or weekend 
washing routines.   
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In addition to timing preferences the choice of colour was considered important 
(Figure 7.2) as a factor for cosmetic acceptability (GP.1; OP.2: DEFO 
Acceptability; Appearance (P04), (P19) (p.150). Whilst the majority preferred 
the neutral tones, one participant preferred the colour orange whilst another 
decided to dye the DEFO (purple). This was interpreted as a personal 
expression to reflect his personality. Both participants reported they would have 
preferred a choice in the colour of the DEFO. In the development of the study it 
was agreed by DM Orthotics Ltd© to provide neutral DEFO’s to reduce bias and 
simplify production. The following examples provide support for the significance 
of appearance in the acceptability of the DEFO.  
 
Figure 7.2 Photograph of DEFO colour preference (with participant 
consent and Trust policy) 
 
 
The cosmetic appearance of the DEFO was also considered important to many 
of the participants from a perspective of self-image and self-perception and how 
they were seen and accepted by others in society. This was related to both 
individual and collective views on disability and the reactions of others in a 
social setting. Again the physical appearance of someone is the most 
commonly reported factor in recognising disability. Indeed judgments in society 
are often based on physical appearance as society is keen to categorise people 
accordingly (Wa Munyi, 2014). 
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Collectively the early categories of DEFO ‘colour’ and ‘physical appearance’ 
were analysed thematically to inferences on appearance, self-image and self-
perceptions. A number of threads were examined from appearance and DEFO 
acceptability to more complex analyses of societal attitudes and behaviours. 
Colour was considered to impact on psychosocial acceptance for being able to 
blend in (P19) (p.157) (GP.1 Research Experience: Acceptability; OP.4 
Health Benefits; Psychosocial). Appearance was also considered to impact 
on perceptions (GP.2 Perceptions on disability: impact on research; OP.1 
Differing perceptions of disability). 
 
Ethical issues 
 
Ethical considerations included clarification of eligibility criteria and research 
guidance on potential clinical risks. These are discussed as important 
considerations that impacted across the study on all levels for safe clinical 
practice, research communication and clarity of the protocol for recruitment and 
delivery. The ethical issues are discussed further in Protocol feasibility and 
Ethical considerations respectively (in Chapters 7.1 and 8.1) and reflected on 
at the end of the thesis.  
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Summary of key findings 
The integrated findings supported the acceptability of the DEFO intervention 
with a moderate level of agreement from the quantitative data and qualitative 
findings:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4  Quality framework for study integrated findings 
The credibility of this study is shown in the quality framework below (table 7.4). 
The inferences drawn from the study findings are further analysed for insights 
and credibility gained by the mixing of methods in Chapter 8. 
 Appearance was considered a highly significant factor in acceptability and 
a moderate level of compliance was established.   
 Physical and psychosocial benefits were established with a significant 
finding of improved functionality of the DEFO. It was found beneficial in 
comparison to rigid splints.    
 Poor fitting was found to detract from acceptability. Negative findings 
included difficulty with donning of the DEFO and reliance on carers.  
 Compliance and tolerance was evidenced by participant adherence in the 
DEFO wearing record.  
 There was a preference of the DEFO in combination with physiotherapy, 
earlier in condition management, also in BT cycle, and to be worn for a 
longer period following BT.  
 There was a clinical preference in DEFO application for participants with 
more active vs passive function and central over distal presentation.  
 Both clinicians and participants provided evidence of DEFO acceptability 
in a clinical setting.  
 DEFO acceptability was tempered by co-morbidity and rehabilitation 
potential.  
 Ethical considerations for acceptability included clarification of eligibility 
criteria and research guidance on potential clinical risks, (in Chapter 8.1).  
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Table 7.4 Mixed methods quality framework for integrated findings (Sale 
and Brazil, 2004) 
Credibility of 
findings 
Quantitative    Qualitative   
Truth value of 
Health benefits 
Study protocol  
Feasibility 
DEFO acceptability 
Internal validity of credible 
procedural method (blinded 
RCT), data and measures 
collected and analysis in 
reporting. 
Thematic Analysis method was 
verified with a degree of 
confidence that the findings 
are credible- able to trace 
themes back to original coded 
data. Independent verification 
by a research tutor. 
Applicability of 
Health benefits 
Study protocol  
Feasibility 
DEFO acceptability 
 
RCT findings were limited 
due to an underpowered 
feasibility study. The study 
protocol was feasible (with 
modifications) for external 
validity with generalizable 
findings to inform a larger 
study.   
Thematic Analysis of findings 
was able to explain and 
explore in depth the 
participants and clinicians 
reactions and experiences of 
the RCT. The findings provided 
credible detail for transferability 
to a similar population.  
Consistency of 
Health benefits 
Study protocol  
Feasibility 
DEFO acceptability 
 
The RCT procedural delivery 
was detailed sufficiently to 
be replicated using study 
and DEFO wearing 
protocols. Consistency was 
also achieved by 
standardised physiotherapy 
components and usual care.  
The topic guided interviews 
followed a questionnaire 
format that was both deductive 
and probing to explain and 
explore participant and 
clinician experiences in the 
study. 
Neutrality of 
Health benefits 
Study protocol  
Feasibility 
DEFO acceptability 
RCT-recruitment, 
randomization, blinding, 
delivery of intervention by a 
protocol and usual care. 
Also reporting was unbiased 
with independent statistician 
support. 
Acknowledge difficulty in 
maintaining un-biased 
accounts in data synthesis and 
interpretation of findings. 
Clinician data was verified by 
the clinicians, both data sets 
were independently verified by 
a research tutor, but participant 
findings were not verified by 
themselves.  
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7.5 Summary 
In summary the integrated quantitative and qualitative findings corroborate the 
feasibility and acceptability of the DEFO intervention in clinical practice. The 
combined findings provided evidence of health benefits identified further by 
specific examples in the qualitative findings. There was a moderate level of 
congruence across all categories with some inferences intended for direction for 
future study into the combined benefits of DEFO and BT. The qualitative 
findings demonstrated a coherent level of adherence and provide guidance for 
improving compliance based on preferences for appearance and functionality. 
The meta-inferences from further interpretation of this study are presented in 
the next two chapters. The study is discussed in light of its strengths, limitations, 
research implications and implications for practice from an ethical perspective. 
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Chapter 8  
Discussion 
 
 
 
 
 
 
 
 
 
Introduction 
In this chapter the study findings are considered and critically analysed in light 
of strengths and limitations. The critical analysis followed the underpinning 
methodology for complex interventions in the developmental and feasibility 
phases. In addition the research and DEFO intervention was considered from 
an ethical perspective.  
The systematic review (Chapter 2) identified a gap in the evidence for the 
management of people with focal spasticity following BT. This gap was the 
basis for the study. It highlighted the need to evaluate a potential new treatment 
for dynamic prolonged stretch of muscle for optimal active and passive care in 
adults with limb spasticity. The study aimed; ‘to investigate the feasibility, 
potential efficacy and acceptability of DEFO and physiotherapy as a new 
treatment of focal spasticity following BT in an adult population’. (Chapter 4.2) 
Similarly the objectives for the study (Chapter 4.2) were set out: to identify likely 
added health benefit of the DEFO intervention; provide clinical feasibility and 
inform acceptability. These were in order to find the likely recruitment rate and 
estimated effect-size for justification of a larger (phase III) study and contribute 
to the existing knowledge base to inform clinical decisions.  
 
Key points: 
 Clinical research delivery and complexity 
 Ethical procedural considerations 
 Collaboration with health technology industry 
 Recruitment, attrition and retention 
 Strengths of study findings and implications (Generalizability) 
 Limitations of study 
 Implications for practice  
 Summary of key learning points 
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The study addressed the gap by a mixed method approach of quantitative pilot 
RCT methodology and qualitative Thematic Analysis of interviews for integrated 
analysis (O’Cathain et al., 2010). The findings are triangulated into a cohesive 
report providing direction for future clinical practice and implications for further 
research. 
 
 
8.1 Ethical procedural considerations 
Ethical considerations include rigor, responsibility and respect. In this section 
the research procedural considerations are presented from an ethical stance.  
The ethical submissions and considerations for practice include: recruitment; 
randomization method; concealment; data governance and analysis; clinical 
capacity; and communication; reporting and monitoring by the Research 
Reference Group (RRG).  
 
8.1.1 Ethical submissions   
Research ethical application 
All the paperwork for the ethics application was prepared and reviewed with the 
assistance of the local R&D supporting officer. The study research ethics 
application and IRAS electronic submission on 28
th
 August 2012 was received 
by NRES South Central Berkshire B Committee and approved on September 5th 
2012 (12/SC/0518). The approval was obtained subject to simplifying and 
combining the two part Patient Information Sheet (PIS) into one. This was 
resubmitted and accepted prior to the study commencing. Further approval was 
gained and registered with the School of Psychology, University of Exeter and 
NHS organisations. Once all written approvals were obtained the study 
commenced on October 4th 2012.  
Ethics substantial amendment for protocol  
Firstly the need for ethical submission for a protocol amendment became 
apparent from monitoring the protocol delivery. After the study protocol had 
been running for four months it was reviewed by the RRG (Chapter 8.1.3) and 
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discussion on the process delivery resulted in the suggestion for a modification 
in the protocol that would have a significant impact on feasibility. The specific 
timing of the intervention group referral to assessment to fitting of DEFO as a 
two week timeframe was undeliverable. However it was more realistic to set the 
assessment within the two weeks target and the subsequent fitting as a no 
specified date as this would vary depending on availability of participant or 
clinician for appointments, production and even further modifications following 
fitting. Hence the protocol was submitted for minor amendment in the wording to 
allow for the feasibility of the delivery of the intervention; ‘assessment for fitting 
within two weeks’.  
Secondly it became apparent that further consideration should be given to the 
method of qualitative research to capture and provide a robust method to 
analyse the feedback from the participants and clinicians. The qualitative 
element of the research had always been considered integral in the study 
design however had not been given the equal procedural attention of the pilot 
RCT. As a consequence a series of topic related questions were piloted around 
the research questions for health benefit, feasibility of the protocol and 
acceptability of the DEFO. The piloting was done with a participant who 
withdrew from the intervention due to medical reasons and was unable to fully 
complete the study. This participant agreed to have a follow-up interview and 
helped with the development of the questions for the interview format. They 
were discussed with the research supervisor, remodelled and subsequently 
formed into the Topic Guided Interview format (Appendix 11 and 12). The 
proposal for the qualitative method was submitted for Thematic Analysis of the 
transcript interviews using Framework analytic approach (Chapter 3.4, p.83).  
The protocol amendment was submitted together with the qualitative 
amendment in April 2013. The amendments were both subsequently agreed 
with ethical approval by the NRES committee.  
 
8.1.2 Ethical considerations in clinical practice   
As a researcher situated in clinical practice it is clear that decisions can be 
biased by previous clinical knowledge and thus cloud decisions. Clinical bias 
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has the potential to incur the Hawthorn effect.  There is a need to follow 
guidelines and keep true to method design and for measurement to be 
conducted in a rigorous manner. The research principle is to be transparent in 
conducting and reporting methodology. This is based on the rationale for doing 
credible research with construct validity and must follow ‘good clinical (research 
ethical) practice’ (Research Governance Framework for Health and Social Care, 
2005) in methods proven for validity and reliability.  
Responsibility was taken seriously for keeping all those involved with the study 
fully informed. By careful monitoring and putting effective reporting systems in 
place the potential risks and variances were captured and where necessary 
modified for optimal study and intervention delivery. This monitoring and 
reporting system was delivered by setting up the RRG (Chapter 8.1.3). Respect 
from a research perspective was also given due consideration for each 
participant and all those involved in the research. 
Clinical practice has a responsibility not to place a patient at risk and this is also 
true for the research participant. Potential clinical risks were highlighted for two 
participants and managed clinically. Ethical discussions clarified the 
prioritisation of clinical safety over delivery of the research protocol. No adverse 
events were reported. Again, good communication monitoring and reporting 
systems in research were valued and integral to good clinical research ethical 
practice (Research Governance Framework for Health and Social Care, 2005).  
Clinical risk takes precedence over any research decision. Hence when clinical 
risk was raised it was dealt with appropriately using a clinical risk assessment 
and strategies for minimising risk. Tension between research and clinical 
practice was explored in the clinician interviews (in Chapter 6.3.1 (GC.1): 
(OC.2):  Ethical issues; Eligibility (C1) (p.176) and Clinical risk (C3) (p.176). 
 
In the early phase of recruitment clarity was also sought around eligibility 
criteria. Definitions for the inclusion and exclusion criteria provided to ensure all 
clinicians and the Research Reference Group were fully informed of the 
recruitment eligibility criteria (Appendix 15). A further issue raised in the 
protocol delivery was the difficulty of maintaining blinding (C3) (p.185). 
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During the study delivery the RRG was informed of two incidents of revealed 
allocation. The first was when a participant had completed his six week 
measures and as he was going out the of the therapy department door he 
turned and asked ‘when can I put my splint back on again?’ This was 
unintentional. He was asked to refer to his information sheet and contact his 
physiotherapist if further clarification was needed. The second reveal occurred 
as a result of a participant being seen for a six week measure at short notice 
prior to a physiotherapy session and he had forgotten to remove his DEFO. It 
was due to be taken off that week but he was still wearing it and it could be 
seen beneath his clothing. The participant appeared unaware of the un-blinding 
and it was not discussed during the assessment. 
 
Both of the issues above were considered under the banner of ethical issues 
due to the impact on ethical rigor and responsibility in reporting. This was 
considered essential procedure for transparent reporting (GRAMMS) in mixed 
methods (O’Cathain et al., 2008).  
 
8.1.3 Research Reference Group 
A Research Reference Group (RRG) was established prior to the 
implementation of the research and commenced with the protocol meeting 
before ethical approval. Regular meetings every four to six weeks were 
established with alternate venues at the Researchers base and DM Orthotics 
Ltd© offices. Meeting agendas were circulated and notes written with key action 
points recorded.  
The meeting dates were planned to coincide with the DMO clinician visits to 
optimise travel arrangements. The agenda was circulated prior to the meeting 
for additional issues to be raised aside of the standard agenda items. A record 
of the meeting was written up and disseminated to the group members. 
Standard agenda items included; protocol delivery, ethical issues, intervention 
delivery, new knowledge, and communication with a further opportunity to 
discuss individual cases by the clinicians in the absence of the researcher. 
Fundamentally the purpose of the group was to keep the research on track, 
provide the opportunity for ethical monitoring and establish research peer 
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support. The reference group meeting notes were disseminated to the 
researcher’s supervisor and field supervisor for monitoring of progress and to 
provide a steer on procedural or ethical issues raised. This was found beneficial 
when the discussion on eligibility criteria was raised by the DMO clinician.  
 
The pivotal role of this clinician was acknowledged when recruitment was 
paused whilst clarification of the study criteria was gained. It was a significant 
moment in the research when the clinician questioned her role in delivering the 
intervention to participants that had been recruited who met the eligibility criteria 
but did not fit with her usual practice model (C1) (p.179). This was explored 
further in a meeting with the supervisor and resulted in clarification of the 
research, individual’s roles and responsibilities and a full explanation of 
eligibility criteria was subsequently defined for the clinicians. 
 
An additional issue was raised by a clinician regarding the potential safety of a 
participant with moderate to severe spasticity. The physiotherapist was advised 
independently by the supervisor to keep the researcher blinded. This was a 
clinical issue and followed safe clinical practise as discussed previously, (in 
Chapter 8.1.2).  
 
8.2 Collaboration with health technology industry  
Research in dynamic Lycra® based orthotic garments for people with Multiple 
Sclerosis was introduced at a workshop by a colleague (Betts, 2006). This new 
technology was again presented at two training days which raised consideration 
for its potential use as a treatment option for people with spasticity. 
From the literature review there was an identified gap in the research and 
dynamic splinting was suggested as a likely area for further research. It became 
apparent that collaboration with an industry that produced dynamic orthoses 
would be beneficial. This was considered both as a funding opportunity and to 
build on previous knowledge and skills within the industry. This was in 
alignment with National Institute of Health Research (NIHR, 2011) and UKCRC 
Guidelines (2009) on collaboration with industry and model agreements such 
as; model Industry Collaborative Agreement (mICA). It was recognised 
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collaboration with industry provides innovative partnering to ‘speed up 
translation of scientific ideas and observations into therapeutics and benefits for 
patients’ (MRC and NIHR, 2011, p.4).   
Two companies were contacted. DM Orthotics Ltd© responded first and an 
appointment was made with the Director to discuss my research and potential 
involvement. An appointment made with the company Director and a research 
proposal for the feasibility study was presented. The company was formally 
asked to collaborate in the provision of the specialist clinician assessment, 
fitting and supply of the customised DEFO’s.  
Roles and responsibilities, benefits and risks were considered including 
intellectual property, tax benefits, publication acknowledgement, shared data 
findings and so on. It was agreed by the company that the study would be in 
alignment with their business. A formal letter was requested stating the 
agreement for the assessment, fitting and supply of DEFO’S for the feasibility 
study and when received (Appendix 2) the research was able to proceed for 
ethical approval.  
There was potential for bias in the research and it was important to explore 
different perspectives that might influence research decisions. From the 
company’s perspective it was explained the research contributions in the form 
of time for clinical assessments and fitting and the equipment would provide tax 
relief. Furthermore the Director reported it was in the company’s long term 
interest to support research towards evidencing the benefits of the DM Orthotics 
Ltd© products as this could influence future funding decisions. Any research 
findings of benefit or otherwise and recommendations would be made explicit 
and published with acknowledgement of the company’s role (provision of the 
assessment, fitting and equipment). It was further discussed that as a feasibility 
study this could direct future larger research projects such as a multi-centre 
trial. 
Selection bias was raised as a potential issue in that some of the participants 
meeting the criteria for the study were not typical of the usual patients that 
would benefit from the orthosis (C1) (p.180). This challenging perspective was 
from the clinician from DM Orthotics Ltd© based on a perception that all 
participants should have dynamic movement for the orthotic to be effective.  
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This bias in perspective was possibly founded in wanting the participants ‘to do 
well’. It highlights the need for a research knowledge base and communicating 
effectively the aims and purpose of the intended research. Indeed the research 
is explicitly planned as a feasibility study to explore acceptability from the 
participant’s perspective and the feasibility of implementing the research in a 
clinical setting. These considerations were explored further in the RRG 
meetings (Chapter 8.1.3). This collaborative stakeholder group was formalised 
to discuss and plan the protocol development and procedural feasibility for the 
study implementation and monitoring. 
In additional issue raised in collaboration with industry was that the factory 
production was closed over the Christmas period for two weeks and this had an 
impact on the protocol timings of two participants. This together with unplanned 
leave of the assessor clinician due to illness demonstrated the dependency of 
the protocol on one person. As the weakness in delivery of the protocol was 
raised a contingency plan was drawn up for a further DM Orthotics Ltd© trained 
clinician to be involved in cover for the fitting of the orthosis. This allowed for 
consistency in the measurement of the DEFO but provided sufficient flexibility 
for pragmatic feasibility to deliver the protocol. 
 
8.3 Recruitment, attrition and retention 
Recruitment was estimated at a likely 30 participants from the local spasticity 
clinic over a twelve month timeframe. It was initially underestimated how the 
flow of recruitment could impact on clinical capacity. In the first month five 
potential participants were assessed as eligible and recruited whilst a further 
three did not meet the study criteria. After the second month recruitment flow 
became steady, to a more manageable two recruits per month. Issues around 
eligibility was raised in the RRG (8.1.3) and resolved by defining the criteria 
(Appendix 15).  
By six months, 15 participants had been recruited with the study on target. A 
stroke rehabilitation trial was running simultaneously and potential participants 
chose to participate in that instead. At nine months the numbers of recruits 
dropped. Awareness of the study profile was raised by local teaching and 
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feedback. At nine months it was clear from the clinic list that potential 
participants had been previously recruited, asked and declined, or was not 
eligible. This meant recruitment from new patients only. As only one participant 
was recruited in the last two months, the point of recruitment saturation was 
considered likely with 25 participants. The decision to stop recruitment was 
informed by an understanding that assessments and analysis would continue 
for a further six months. This pragmatic decision was considered appropriate for 
a small feasibility study; however, by implication it provided indicative evidence 
for a multi-centre phase III trial with a wider pool of potential participants for 
recruitment.     
From the perspective of retention two participants recruited did not continue: 
one was unwell and the consequential delay resulted in his withdrawal of 
consent; a second participant moved house and left no forwarding contact. A 
further participant only completed part of the study as she became unwell and 
hospitalised. The participants all had long-term health conditions with likelihood 
of secondary complications. Therefore the rate of retention was considered 
good for this type of study.  
 
8.4 Strengths of the study findings and implications 
There is much to consider when embarking on a research study. The study was 
founded on a perspective of clinical relevance to further the knowledge base in 
which it exists. It is critical to acknowledge this stance as it has influenced the 
approach. This approach is to provide evidence that can be used to inform and 
influence clinical practice decisions. From a perspective of rigor the research 
provided evidence by using Complex Intervention Framework methodology 
(MRC, 2008). Although this provided a sound methodological framework it is 
unlikely that this early phased development and testing feasibility study could 
provide categorical evidence. The strengths of this study are now discussed on 
scope, methodology, design and analysis and relevance for clinical practice and 
patient benefit.  
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Scope 
The scope of this study was deliberately kept small, as a feasibility study. The 
research proposal was designed for an optimal recruitment of (n=30) 
participants over twelve months. In fact recruitment was saturated at ten months 
with (n=25) participants recruited. The inclusive scope of the eligibility criteria 
was based on a pragmatic consideration for generalizability to a population with 
limb spasticity rather than by specific conditions. This was justified on an 
understanding of the difficulty in recruitment in clinical research, if the eligibility 
criteria are too narrow. The findings of the study provided participant 
preferences on possible earlier timings in conditions and earlier in the BT 
treatment cycle. The implication of this finding supports the potential for 
eligibility stratification in people with spasticity in a future study. 
Methodology, design and analysis 
To answer the research questions a mixed method approach was deliberately 
used; quantitative pilot RCT methodology and qualitative Thematic Analysis of 
interviews for integrated triangulation analysis (O’Cathain et al., 2010). The pilot 
RCT was bound by rigour in content using single-blinded method with 
concealed randomization and allocation with resultant optimal reduction in 
systematic bias (Shadish et al., 2002). In addition the RCT followed a quality 
standard of reporting by CONSORT (Schulz et al., 2010). Furthermore there 
was a formal intention to treat (ITT) analysis in the quantitative analyses which 
included all of the randomized participants regardless of their allocation, 
regardless of the treatment they actually received and regardless of any 
subsequent withdrawal from treatment or deviation from the protocol (Fisher et 
al., 1990). This method was used to provide a realistic outcome of clinical 
practice to reduce overstating the study efficacy by including non-compliers and 
deviation from the protocol (Gupta, 2011). This was considered an appropriate 
approach for generalizability to the relevant population. Further analysis by per-
protocol (PP) analysis, which provides a strategy to analyse the whole study 
population in more depth, could have provided more confidence in the study 
(Gupta, 2011) and this should be a future consideration for including in the next 
phase of a larger study. 
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The Thematic Analysis was used effectively to explain the pilot RCT findings 
and explore the research uncertainties in depth to inform a larger trial. A 
Framework approach for categorization and thematic network diagrammatic 
representation were found appropriate methods for analysis of the qualitative 
data. The qualitative component provided a supplemental data strand that 
enhanced the overall study design by providing a more complete understanding 
of the intervention acceptability and the process delivery. A more complete 
picture was established than by single method alone (Wisdom, et al., 2012). 
Both study components were given equal attention and significance in delivery 
and reporting. The component parts (quantitative data strand and qualitative 
data strand) when combined together added more to the sum of findings. 
 
The mixed methodology provided a sound methodological approach in clinical 
research. This approach acknowledged healthcare is multi-faceted with 
interventions based in complex clinical environments (MRC, 2008; Richards and 
Borglin, 2011; Thompson and Clark, 2012; Richards et al., 2014). This study 
followed the first two phases (development and testing) of the MRC, (2008) 
complex interventions Framework. The pragmatic research methodology was 
supported by an appropriate embedded design and integrated analysis 
(Creswell and Plano Clark, 2011). This method was considered appropriate as it 
provided procedural evidence of feasibility with a pilot RCT protocol and detail 
from the Thematic Analysis which demonstrated protocol feasibility and 
acceptability in a clinical setting with direction for modifications. Combined 
quantitative and qualitative analysis of the pilot RCT provided evidence of 
acceptability of the DEFO intervention with real-life health benefits in people 
with focal spasticity.  
 
In addition the qualitative research methodology provided a rounded approach 
with demonstrative proof of acceptability building on proof of concept studies. 
The integration of the two approaches provided a holistic 360° approach with 
application of detail to explain the confounding variables which enabled the 
research to tell the clinical story as it was. 
The study protocol was found feasible despite clinical challenges in a clinical 
setting.  As outlined (in Chapter 7.2) the mixed methods approach enabled 
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detailed analysis of the feasibility of the protocol. The measures selected for the 
pilot RCT were justified in that they provided valid and reliable measures of 
clinical effect and did not add to the clinical burden of the participants or 
clinicians. All the participants were measured with the GAS, VAS for pain and 
EQ-5D. Those with upper limb spasticity were measured with the LASIS and 
ArmA, the latter has since been found valid and reliable (Ashford et al., 2014). 
There were only three participants with lower limb spasticity, all in the 
intervention group and their gait velocity measure (10MTT) was analysed 
descriptively. Statistical significance in a small feasibility study was considered 
unlikely, however significant difference between groups was found in analysis of 
the primary measure (GAS). The findings provided an estimated effect-size for 
justification of a larger study (Chapter 8.6). 
The chosen method of analysis of the pilot RCT measures was considered 
appropriate with a baseline adjusted ANCOVA for between groups over time (at 
six weeks and twelve weeks). The DEFO intervention was measured for clinical 
effect at six week and was considered worthwhile longitudinally. The 
longitudinal results of the GAS T score were surprising considering the usual 
limited effect of orthotic carry-over. The protocol timing of measures was 
planned to fit into the clinical cycle of BT for effect within the window of 
opportunity. Interestingly several of the participants (P01, P11 and P24) 
reported uncertainty at the withdrawal of the DEFO after six weeks. This 
method of covariate analysis was for measurement of likely clinical significance 
with time series data. However a linear model fitted to time series data may 
produce a risk of auto-correction effects with under-estimated standard errors 
(and over-estimated t-scores).  
Both clinical practice relevance and patient benefit were identified. This study 
evaluated the DEFO intervention in a new population (adults with focal 
spasticity) and addressed the uncertainties for a larger study. This was 
evidenced in the integrated findings of health benefits realised (Chapter 7.1) 
and acceptability of the DEFO in clinical practice (Chapter 7.3). The combined 
qualitative and quantitative findings offered greater breadth and quality of the 
findings (Wisdom et al., 2012). This resulted in inference transferability (Teddlie 
and Tashakkori, 2009), meaning the study findings are generalizable to a 
similar clinical context and population. 
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8.5 Limitations of the study 
 
The limitations of the study are now considered. This was a small scale 
feasibility study which suffered from being over-ambitious in delivery from a 
part-time researcher in a clinical setting with reliance on clinicians already 
stretched by capacity, with no research funding. Whilst deliberately planned for 
recruitment purposes the study was perhaps too broad in scope resulting in 
potentially confounding variables.  
 
There were a number of variances recorded including incidents of systematic 
bias which are declared. Firstly despite randomization the age difference 
(eleven years older in the control group) between groups could be interpreted 
as a selection bias variable. Similarly all the participants with lower limb 
spasticity were recruited to the intervention group, providing no comparison for 
analysis. Secondly there were clinical philosophical differences between the 
clinicians which possibly led to different treatments between those with ‘passive’ 
function (care needs) and those with ‘active’ functional needs. This could have 
contributed to performance bias. Also a difference in the level of dependency 
was suggested by the presence of carers or a package of care in the baseline 
characteristics. This level of dependency was not formally analysed and is 
acknowledged as a limitation of this study. Next there was the potential for 
variance in participant compliance depending on the level of motivation. In 
addition there were two incidences of hospital admissions and a number of co-
morbidities recorded. Two participants withdrew consent and a further 
participant was lost to the study at six weeks, but further attrition was not 
reported as a bias. Finally there were two incidents of altered timing in the 
protocol delivery which could have impacted on the measures. The delivery of 
the measures could have resulted in detection bias.  
The findings of this small feasibility study are likely to present with a type I error 
from over stating the importance of the pilot RCT findings of the group 
difference in the GAS T score. It was also likely that with intention to treat 
analysis of the study findings cautious interpretation could have been 
susceptible to type II error. This is more likely in a small scale study with the 
potential to under report findings as their significance may be missed. However, 
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it was deliberate that the ANCOVA was chosen as a method of analysis to 
reduce potential in bias from confounding variables.  
A further limitation in the study was from the limited input from PPI (INVOLVE, 
Hanley et al., 2003) in the development of the study and in the RRG. The 
research pilot RCT had an unnecessary design feature with the removal of the 
DEFO intervention at six weeks. The original intention was to measure any 
carry-over of the intervention; however as an orthotic this was unlikely and 
previous studies have not shown this carry-over effect (Bridges, 2004; 
Matthews et al., 2009).  
Also there was a limitation in the research procedural delivery from over-
reliance of another service, namely in collaboration with industry. It was 
reported by clinicians that the availability of a part-time clinician who was based 
out of county was not ideal. The availability of the DM Orthotics Ltd© clinician 
was reduced over school holidays and consequently assessment and fitting 
clinics were reduced. The DMO Ltd® factory also closed over the Christmas 
period for two weeks which resulted in production delays.   
 
8.6 Implications for practice and further research 
From the findings in this study it is possible to draw both theoretical and clinical 
implications for future practice. The evaluation showed success in the 
procedural feasibility of the DEFO intervention. The protocol was found feasible 
with recruitment, randomization and delivery of the intervention as planned. 
Both clinicians and participants found the protocol acceptable but suggested 
procedural modifications. The DEFO intervention was found acceptable with 
positive health benefits established. This study suggests DEFO has the 
potential to be used to provide an acceptable strategy for the management of 
focal spasticity in combination with BT and usual care. Further investigation is 
justified to understand clinical efficacy. 
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Estimated effect-size  
 
In this study it has been possible to demonstrate a clinical effect with n=23 
subjects with the GAS T score at six weeks (12.17) although this result should 
be interpreted with caution for clinical importance for a larger study. The primary 
measure GAS showed significant difference in achievement in the DEFO 
intervention group. From the results of the GAS sample size calculation the 
answer is: to be able to detect an effect-size of 0.3 standard deviations between 
the intervention and the control group with 80% power at 5% level of 
significance you would need 200 patients per group (400 in total). This takes 
into account an attrition rate of 20%. It is however, important to note that a 
potential randomized clinical trial should be powered to detect the smallest 
effect-size that is of clinical importance. In this case, there was enough power to 
detect an effect-size of 1.2 standard deviations with 80% power.  
 
The pilot RCT provided sufficient evidence to warrant further investigation in the 
use of the DEFO intervention following BT and in the wider use of combined 
interventions for spasticity management. The findings from the GAS score 
provided estimated effect-size for justification of a larger study. Analysis of the 
pilot RCT data suggested potential stratification of participants for future 
evaluation. This could be taken a step further by focussing further research on 
participants with upper limb spasticity and stratifying participants by level of 
dependency.  
Physiotherapy components 
Physiotherapy was evaluated to be integral to the follow-up therapy whether for 
‘active’ or ‘passive’ function. This finding is in alignment with the Spasticity 
Guidelines (RCP et al., 2009). The role was interpreted as primarily for people 
with rehabilitation needs but was also interpreted as having an important role to 
play in providing education, advice, monitoring and promoting self-efficacy. 
Practical issues included optimal timing, carer support and access to a trained 
DEFO assessor. From the physiotherapy data capture (Chapter 5.5, Table 
5.15) it was seen the modalities were similarly matched for both groups. Most 
commonly delivered interventions were categorized: stretches (both active and 
passive); functional training; splinting; strength training and advice. This finding 
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can be used to inform future practice decisions. There was some variance 
between groups in contact time with the control group receiving 237.5 minutes 
and the intervention group 185.9 minutes. Additional private therapy was 
recorded within the contact time. In future studies physiotherapy modalities and 
contact time should be specifically collated after BT.  
Measures 
The chosen measures were considered appropriate; the GAS was found to be a 
meaningful measure of health benefit from the patient perspective. The ArMA 
was found most meaningful for upper limb spasticity. However a dependency 
measure would have provided further validity. In addition a larger trial should 
incorporate cost-benefit analysis using the EQ-5D, thus following the later 
implementation and evaluation phases of the MRC Framework (2008).  A future 
study should include an ITT analysis and a PP analysis to provide increased 
confidence in findings. Analysis of procedural feasibility provided sufficient detail 
to recommend protocol modification in assessment for the DEFO prior to the BT 
(to reduce the timing delays) and for wearing of the DEFO for a longer period 
(twelve weeks) with longer follow-up. 
Clinical feasibility and DEFO intervention acceptability 
Feasibility of the protocol delivery was established in clinical practice with a high 
level of adherence and tolerance with compliance in the DEFO wearing 
protocol. The feasibility on procedural timing was enhanced by the intervention 
protocol amendment. The protocol was acceptable and tolerated by both 
clinicians and participants. There was no added burden in data captures 
(measures). It was found there were specific wearing issues which contributed 
to feasibility of protocol including reliance on carers for donning DEFO. It was 
also found co-morbidity and rehabilitation potential impacted on clinical practice 
and protocol delivery. Further factors were found to impact on the research 
feasibility in a clinical setting; clinical capacity, priorities, agreement on eligibility 
and potential clinical risk. 
There was a high level of wearing compliance evidenced by the wearing record. 
Both clinicians and participants provided evidence of DEFO acceptability in a 
clinical setting (with a caveat of stratification of participants for earlier in 
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condition and BT treatment cycle). Most significant was the cosmetic 
acceptability of the appearance of the DEFO. This was acceptable in most 
participants with further customisation identified such as for a choice in colour. 
The findings also showed there were many health benefits identified in the 
provision of the DEFO intervention. These physical benefits were identified as; 
pain level reduced, supportive and comfortable, more relaxed, posture more 
normal and improved functional activity. Additional psychosocial benefits were 
found including; appearance acceptable from a health perspective with social 
cues, more ‘normal’, more awareness and appearance socially acceptable. 
These findings were reinforced by positive perceptions of disability (self-image 
and acceptability). A further finding of significance was in the functionality of the 
DEFO in comparison to rigid splints. Findings that detracted from acceptability 
included poor fitting and difficulty or reliance with donning the DEFO. 
 
8.7 Summary of key learning points 
The study methodology was reviewed if it had fully addressed the research 
uncertainties identified (in Chapter 4.) The mixed methodological approach was 
considered appropriate and fully met the objectives. This was by identifying 
likely added health benefits of the DEFO intervention and further evidence of 
procedural clinical feasibility and acceptability. The likely recruitment rate and 
estimated effect-size was identified for justification of a larger study. This study 
has contributed to the existing knowledge base to inform future clinical 
decisions.  
 
In summary the findings suggest the DEFO intervention was procedurally 
feasible and acceptable in a clinical setting providing evidence of added health 
benefit. The findings provide useful guidance on future recommendations for 
optimising feasibility of a larger study. Modifications of the protocol were based 
on the study findings. This study was a small feasibility study and the results 
should be interpreted with caution but provided useful insights into recruitment, 
refusal, retention rates, and adherence with delivery of the intervention. The 
next chapter concludes with a review of the key findings and learning points in 
relation to the research.  
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Chapter 9 
Conclusion 
 
 
 
 
 
 
 
 
Introduction 
This research study was planned to open and unpack the ‘black box’ on 
spasticity management following BT. It is openly acknowledged there is 
complexity in maintaining control of the research process in clinical research. 
The developmental work in this feasibility study has contributed to the 
successful testing of a research design, its delivery and early phase analysis 
providing direction for a further larger research study.   
 
From a review of the literature there was an identified gap both in rigour and of 
clinical relevance in studies for interventions of adults with focal spasticity. This 
innovative intervention of DEFO had not been rigorously evaluated in the adult 
population. Neither had the explicit components of physiotherapy been 
evaluated in standardised practice following BT intervention. Importantly this 
study was a preliminary pilot RCT to allow testing for feasibility before a larger 
study is planned. Implications were drawn for clinical practice with patient 
benefit demonstrated. It is hoped this could result in access to resources 
previously not commissioned. 
 
 
 
Key points: 
 Summary of key findings and learning points  
 Research evidence evaluation; to test a research design for a further 
larger study 
 Thesis provides Original contribution to new knowledge; empirical, 
theoretical and practice 
 Implications for further research 
 Strategy for dissemination 
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9.1 Summary of key findings and learning points 
 
The key findings and learning points are reviewed by the researcher for the 
research study. Therefore a summary of findings are presented in answer to the 
specific research questions identified (Chapter 4) on health benefit, feasibility 
and acceptability.  
 
The primary question, ‘What is the likelihood that there is health benefit of 
treatment with DEFO and physiotherapy and usual care compared to usual care 
alone?’ was answered by the integrated findings of the pilot RCT measures and 
Thematic Analysis of the interviews. The findings showed many health benefits 
both physical and psychosocial in the analysis of the DEFO intervention. The 
most significant finding included the attainment of goals in a real-life context as 
the primary measure GAS showed with significant difference in achievement in 
the DEFO intervention group at six weeks but not at twelve weeks. This 
measure was considered an appropriate measure to use in a heterogenic 
population with limb spasticity. Although the GAS has a construct that measures 
attainment of goals rather that a specific outcome this measure was chosen for 
its construct validity, clinical application and relevance to the participants. 
 
The most commonly identified physical benefits included pain relief, support and 
comfort, reduced muscle tension which improved postural alignment and 
enhanced functionality. The additional psychosocial benefits were found to 
include significant factors including the cosmetic acceptability of the DEFO. This 
was from its appearance and was analysed to be acceptable from a health 
perspective. It generated social cues and was found to be more ‘normal’ 
providing more awareness and the appearance was considered socially 
acceptable from different perspectives.  
 
Next the research uncertainty ‘What is the feasibility of the protocol (as a small 
feasibility pilot) for a larger study?’ was addressed by procedural analysis of the 
pilot RCT including clinician and participant feedback. There was a high level of 
adherence and tolerance demonstrated with compliance in the DEFO wearing 
protocol. Feasibility was established with tolerance and acceptability by both 
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clinicians and participants. The intervention protocol amendment contributed to 
improved procedural feasibility although delay in timing was not the only factor 
considered to impact on delivery in clinical practice. Other factors included co-
morbidity and rehabilitation potential, clinical capacity, priorities, agreement on 
eligibility and potential clinical risk. A further factor that contributed to the 
feasibility of the protocol included reliance on carers for donning the DEFO. 
From the above findings a number of recommendations are proposed to 
improve the feasibility of the protocol for a larger study. These are addressed in 
Chapter 8 and summarised in Chapter 9.2. 
Finally the question ‘How acceptable is the DEFO intervention in clinical 
practice?’ was addressed. This was answered by the combined DEFO wearing 
record data (pilot RCT), Thematic Analysis and data from clinical records. There 
was a high level of wearing compliance evidenced by the wearing record. Both 
clinicians and participants provided evidence of DEFO acceptability in 
practice/setting (with a caveat of stratification of participants earlier in condition 
and BT treatment cycle).  
 
Most significant was the cosmetic acceptability of the appearance of the DEFO. 
This was acceptable in most participants with further customisation identified 
such as for a choice in colour. Physical and psychosocial health benefits were 
established as outlined earlier. Another significant finding was the benefit of 
functionality of the DEFO in comparison to rigid splints. Findings that detracted 
from acceptability included poor fitting and difficulty or reliance with donning the 
DEFO. A summary of the key findings and learning points is presented below, 
(in Table 9.1). 
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Table 9.1 Summary of the key findings and learning points 
Topic  Key findings/Learning points 
Systematic review There was a gap in the literature with an identified need to research a potential intervention 
to optimise spasticity management following BT. 
MRC Complex Interventions 
Framework 
The study followed the early phases of development and testing for identifying the 
uncertainties and testing the study design feasibility in order to inform a larger study. 
Ethical considerations 
 
Ethical submission for approval required support (R&D) to minimise delays. 
Research followed good (research ethical) clinical practice: rigor, responsibility and respect. 
Collaboration with industry was beneficial for all those involved. 
Methodology  The mixed methods approach with embedded design of quantitative (pilot RCT) and 
qualitative (Interviews Thematically analysed) study components was considered 
appropriate for clinical research. Separate analysis of data was followed by integrated 
analysis to strengthen the findings and explain them in more depth. This method told a more 
complete research story. 
Procedural delivery Research in a clinical setting is complex. 
Several factors and people were important in successful delivery of the research protocol; 
pilot work, R&D support, research supervision (access to expertise), research 
communication including monitoring and reporting to the Research Reference Group, 
Research Support (admin.), Consultant support, clinician capacity and willingness to 
undertake research roles and Service Manager support and last but not least the compliance 
of participants and their carers. 
Concealment of allocation was difficult with (n=2) declared exceptions. 
It was useful to keep a research diary and minute notes for meetings. 
Data capture and results Setting up appropriate Excel data bases for data capture and blinded data capture for 
participant allocation was critically important. 
A study flow was captured of recruitment, refusal, retention rates, and adherence with 
delivery of the intervention (CONSORT, Figure 5.1). 
Pilot RCT method of statistical analysis was considered appropriate with an alternate 
method considered. 
Interview data ‘Thematic Analysis’ methodology with ‘Framework’ approach was considered 
appropriate. 
The combined results were analysed and the data provided information on design feasibility 
for a further larger study (Table 9.2). 
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9.2 Implications for further research 
 
There is clearly a need to design trials with more sensitive measures of 
treatment effect and to identify patients who will obtain most benefit, functional 
or otherwise. The findings are summarised with the research implications, (in 
Table 9.2). 
 
The impact of specific conditions of the participants who were in the study is 
now considered. The heterogeneity of the participant’s diagnostic conditions 
included people with stroke, acquired and traumatic brain injury, spinal cord 
injury and multiple sclerosis. In light of the inclusive study findings there is 
sufficient evidence to support further stratification of the potential population 
recruited for a larger study. The stratification could focus further on participants 
with upper limb spasticity and a clearly identified level of dependency. In this 
way the measures selected would be categorized and thus more appropriate for 
example for those with specific issues of carer burden. Similarly the level of 
dependency could be used to stratify those with progressive or stable 
conditions.  
 
As previously outlined in the analysis of the pilot RCT data the results of the 
GAS T score provided estimated effect-size for justification of a larger study. 
Although this study was small it showed an effect of clinical importance, 
however interpretation of this result should be considered with caution. For a 
fully powered potential randomized clinical trial it was estimated from the results 
of the GAS you would need 200 patients per group. For an estimated effect-size 
to be detected there would need to be an effect-size of 0.3 standard deviations 
between the intervention and the control group with 80% power at 5% (taking 
into account a rate of 20% attrition). 
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Table 9.2 Summary of research implications 
Research findings Implications for Research 
 
Eligibility considerations Stratification and generalizability need further consideration: 
 Upper limb 
 Level of dependency 
 Progressive or static condition 
Study methodology and design 
 
 
 
 
 
 
 
 
 
 
 
A mixed method approach is appropriate for research in a health care setting. 
From the pilot RCT: the results of the GAS indicated for a potential randomized clinical 
trial it was estimated you would need 400 patients (200 per group).  
From the findings of recruitment and likely attrition it is recommended a future Phase III 
study is designed for optimal feasibility as a fully funded multi-centre study. 
The Thematic Analysis of the interviews provided rich detail to identify the health benefits 
and explain feasibility and acceptability of the RCT. 
Integration of the findings provided valuable procedural detail for a future study: 
 Choice of colour could improve cosmetic acceptability. 
 Improved fitting could also improve acceptability. 
 Availability of a carer for donning improved compliance. 
Also cost-analysis should be incorporated into the design of a larger study. 
Protocol delivery Protocol modifications indicated to improve timing of assessment and delivery by: 
 Earlier assessment for fitting prior to BT. 
 Longer delivery of DEFO intervention with no need for removal. 
Physiotherapy Modalities of delivery and contact time should be specifically collated to identify what 
treatment options are of most benefit.  
DEFO assessment and fitting 
 
Clinicians could be trained as DEFO assessors to improve procedural delivery. 
Patient and Public Involvement (PPI)  PPI could be used to improve a future study design and contribute to monitoring the 
research delivery. 
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9.2 Implications for further research (continued) 
 
Sufficient information was shown in the results to justify further modification of 
the protocol. From the analysis of the protocol feasibility two areas were 
considered for improvement. Firstly to reduce the timing delays and promote 
optimal delivery in the treatment cycle, the DEFO assessment for fitting could 
be carried out prior to the BT. Secondly the wearing of the DEFO is recommend 
for a longer duration in the protocol (twelve weeks) with follow up at six weekly 
intervals and no need for removal as there was considered to be of no benefit 
from carry-over. Although BT was considered important as a prerequisite in this 
study a further study could evaluate another RCT comparator group of 
participants who did not receive this combined intervention. 
A further consideration to optimise a future research protocol was for the 
improved access to a trained DEFO assessor. Training for assessment of the 
DEFO was available but not taken up by the clinicians in this study. It is 
recommended clinicians are trained in assessment and fitting to reduce reliance 
on the provider. Allocated clinical research funding could reduce conflicts 
between clinical and research capacity. 
In future studies both physiotherapy modalities and contact time should be 
specifically collated to identify what treatment options are of most benefit in 
spasticity management after BT. The evidence gathered in this study can also 
be used to inform future practice decisions. 
The successful implementation of the protocol demonstrated intrinsic feasibility 
and acceptability by clinicians and participants. This was evidenced by the high 
retention, delivery and adherence rates. Modifications were identified to improve 
protocol feasibility and reduce clinician burden in delivery. The DEFO 
intervention was found acceptable with many positive health benefits identified. 
In summary the unique contribution to knowledge in this thesis is provided from 
a theoretical, empirical and practice-related stance.  
 
Theoretical:  Whilst clinical research is acknowledged to be complex a mixed 
methods approach with embedded design of quantitative (pilot RCT) and 
qualitative (interviews thematically analysed) study components was found to 
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be appropriate and feasible in a health care setting. In addition the hypothesis 
tested in the RCT (Chapter 4.1) provided evidence of added health benefits 
from the DEFO intervention with physiotherapy and usual care compared to 
physiotherapy and usual care alone, following BT. The findings support the 
theoretical rationale in the use of DEFO for prolonged dynamic stretch of 
muscle for improving muscle performance in people with limb spasticity 
following BT. Further investigation is warranted based on the findings in this 
study. 
 
Empirical: This small study has demonstrated an important clinical effect in the 
use of DEFO intervention following BT. The results of the pilot RCT primary 
measure GAS T score provided estimated effect-size for justification of a larger 
study into the clinical efficacy of DEFO intervention for the treatment of people 
with limb spasticity. To be able to detect an effect-size of 0.3 standard 
deviations between the intervention and the control group with 80% power at 
5% level of significance you would need 200 patients per group (400 in total). 
This finding indicates further investigation by a multi-centre fully-funded 
research trial. 
 
Practice-related: This thesis provides procedural detail with analysis on 
feasibility and acceptability of the DEFO intervention. The protocol was feasible 
with protocol modifications identified by the findings for a future study. The 
DEFO intervention was found potentially acceptable and of clinical benefit for 
the treatment of adults with limb spasticity following BT. Findings on splint 
acceptability suggested compliance could be improved by choice of colour and 
fit and the support of a carer for donning. In future studies physiotherapy 
modalities and contact time should be specifically collated to identify what 
treatment options are of most benefit. The GAS primary measure was reported 
clinically acceptable and relevant as a patient-centred measure for change for 
people with limb spasticity. 
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9.3 Strategy for dissemination 
Dissemination is planned by timely presentation of the findings to local 
clinicians, stakeholders and patient support groups. Participants have received 
a summary report of the findings. Strategic and wider dissemination is planned 
with publication of the protocol and study findings in peer-reviewed journals 
(Clinical Rehabilitation) and by poster presentation of findings at ACPIN, 
Physiotherapy and Stroke National and International Conferences.  Findings will 
be presented to commissioner stakeholders for service commissioning. 
 
 
9.4 Conclusion 
 
Spasticity that is predominantly focal has been evidenced to be managed 
effectively with BT for many years. The effect is however reversible requiring 
repeated cycles of care. A long-term strategic model is worth considering for the 
early detection of spasticity and a stepped approach in management to reduce 
the potential of more severe spasticity. The role of splinting and physiotherapy 
in focal spasticity are yet to be proven, however this study presents the option 
of a new dynamic approach to splinting that was evaluated both clinically and 
from the perspective of the patient.  
The study has met the planned objectives with a mixed methods embedded 
study design. This has addressed many of the uncertainties of this intervention 
and evaluation of the findings has informed an estimated effect-size for 
justification of a larger study. The findings of this developmental study indicate 
that it is both feasible and acceptable for replication in the clinical setting (with 
modifications). It has identified likely added health benefits and factors that 
influence cosmetic and wearing acceptability. In addition it has contributed to 
the existing knowledge base to inform clinical decisions. It provides the basis for 
a larger DEFO trial to inform clinical-effectiveness and cost-effectiveness. 
The combined implications from the above suggest with further investigation 
DEFO is a new and promising treatment option which can be used to provide a 
realistic and acceptable strategy for the management of focal spasticity in 
combination with BT and usual care.  
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Reflections on research 
 
This reflective piece is intended to provide an account of research delivery from 
the perspective of a novice researcher. The reflective pieces are captured from 
a twelve month research diary of the planning and delivery stages of the clinical 
research. It covers personal perspectives on the complexity of implementing 
research in clinical practice and the learning mapped along the research 
journey. 
I present my worldview as a pragmatist and with a professional and clinical lens. 
Research requires discipline. Physiotherapy clinical practice also requires 
discipline but it is a mix of science and art based on knowledge and skills and 
underpinned by hard won autonomy. The tensions and conflicts that these 
create are explored. 
Clinical experience in spasticity management has led me to question the 
efficacy of static splinting following BT when spasticity is a complex dynamic 
and velocity-dependent positive feature of the UMN syndrome. The nature of 
spasticity is that it is a sensori-motor disorder meaning that it is influenced by 
sensori-motor feedback. Spasticity is associated with reduced movement and 
altered muscle pattern generation often leading to complications such as pain, 
deformity and altered function. Spasticity pathway evaluation identified repeat 
cycles of BT which it could be argued leads to dependency.  
 
The systematic review clearly identified gaps in the current research evidence 
for management of adults with limb spasticity following BT. Leading authors in 
the field Lannin and Ada (2011) suggest the need to investigate the rationale for 
clinical use of splints and a re-focus on muscle performance. The review found 
evidence of splints and orthoses for spasticity management but no evidence of 
the use of dynamic splints or orthoses in combination with BT in adults. This 
study builds on theoretical evidence to evaluate a potential treatment using 
dynamic prolonged stretch of muscle. The focus of the research was to optimise 
active and passive care for patient benefit following the window of opportunity 
provided by BT. The DEFO intervention was identified as a potential treatment 
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option that had not previously been rigorously tested for limb spasticity 
management in an adult population.  
 
The diary was a useful research tool to capture procedural issues and 
discussion points of significance that influenced research decisions. What is 
ethical and what is right is underpinned by doing most good and least harm. 
This is the moral principle of beneficence that similarly applies to professional 
practice (Sim, 2010). Ethical decision making follows six stages and these were 
adhered to in this study; describe and clarify, apply the three ‘r’ principles, 
establish boundaries including legal/governance frameworks and consult key 
stakeholders, make difficult decisions (weigh up), implement, reflect and review 
the decision. Research experience has equipped me with a better 
understanding of the guiding principles in research; rigor, respect and 
responsibility. I divided this chapter of reflections on the research journey into 
these three topics.  
 
Rigor  
 
The rationality and rigor of research was a challenge to my intuitive practice. 
However I understand the need to follow guidelines and keep true to method 
design and for measurement to be conducted in a rigorous manner. It was 
important that I acknowledged the research principle; to be transparent in 
conducting and reporting methodology. I fully accept the rationale for doing 
credible research with construct validity. This must follow ‘good clinical 
(research) practice’ (Research Governance Framework for Health and Social 
Care, 2005) and trust in methods proven for validity and reliability.  
As a small scale research study for a part-time programme competing with 
other work priorities I was aware of the need to prioritise my time. Planning the 
research study was fundamental and a Gantt chart (Appendix 18) was used to 
provide a mapped outline of necessary steps and actions to drive the research 
forward and deliver the thesis. This was used for the monitoring of the research 
delivery by the Research Reference Group (RRG) and the supervisor to ensure 
the study was on track. 
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Other strategies used for ensuring transparency included actively reporting 
progress to my peers. This gave the opportunity to re-focus on methods used 
and whether they were delivered in the way I had intended. Updates on 
progress provided snapshots of underlying hypotheses, methods planned, tasks 
achieved, numbers recruited and uncertainties identified in the delivery process. 
Fundamentally I was able to spend some time reflecting on progress and take 
stock of any flaws in my study. One such moment was in the need to revise my 
study approach from a pilot RCT to a mixed methods study. This resulted in a 
new challenge in exploring the literature on different philosophical stances, 
approaches and methods in qualitative design and ultimately how to integrate 
the two methods. It required a leap of faith followed by a number of decisions on 
how to implement the qualitative component and thematically analyse the 
findings supported by a supervisor. 
The decision to use a primarily theoretical deductive analysis in my qualitative 
Thematic Analysis was considered appropriate to answer my research 
questions. I had weighed up other options of discourse analysis (DA) or content 
analysis (CA) and considered this theoretical deductive approach was better 
aligned with my researcher’s interest in answering specific questions of 
feasibility and acceptability of the DEFO intervention and identifying likely health 
benefits. The topic guided probe questions in the interviews also provided the 
opportunity for inductive approach to analysis. It was challenging not to be 
overly descriptive in the thematic analysis and the interpretation of the findings 
was detailed in the text. 
One of the key components to get right in research is setting up the spread-
sheets for data collection and ensuring that there is a rigorous method to 
collating the data and regular entering of the data. I used the support of an 
administrator to ensure the data bases were encrypted and that one spread-
sheet was encoded with the participants allocation concealed. This was so that I 
was blinded according to the concealed allocation and randomization. There 
were two cases of revealed allocation which I reported to the RRG and in the 
Results (Chapter 5). 
Credibility of reporting research findings is important. Therefore consideration 
was given on use of an intention to treat analysis and reporting of the data from 
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the RCT. Conflicts of interest are important to declare and this was considered 
both when collaborating with industry and when using support for quantitative 
statistical analysis. Collaboration is considered under the principle of 
responsibility. Internal validity of the RCT data analysis was a concern to me as 
I had support from two statisticians who offered conflicting advice on methods of 
analyses. In effect both methods produced very similar results however I made 
a decision to work with the University statistician and this helped to clarify my 
understanding of the method used; ANCOVA with adjusted means at baseline 
and statistical comparison between groups at six weeks and twelve weeks. 
Justification for measures of clinical effect at six weeks was based on the 
procedural window of opportunity for change following BT. A double data entry 
method was used to ensure any errors in data entry were explored and 
corrected.  
A further discipline in reporting was considered in authentication of the 
qualitative findings in that the clinicians were provided with their transcriptions 
and checked for truth. In addition the thematic findings of the participant 
transcripts were discussed with an experienced qualitative supervisor. 
Limitations in the study rigor have since been reflected on in that the 
participants could also have had copies of their transcripts for authenticated 
truth of the findings. They were given copies of the study findings and asked for 
any comments, however none were forthcoming.  
Respect 
Respect is engendered in professional practice. It follows codes of practice and 
has legal implications on how participants must be treated in research. I 
recognised the importance of respect for people from a research perspective 
with due consideration of each participant and all those involved in conducting 
the research. This was most important from an ethical stance in my aim to be as 
inclusive as possible in the study which was demonstrated by including four 
people with aphasia. It was challenging and frustrating at times however I was 
able to use augmented communication skills previously learned in an aphasia 
workshop. Two of the participants agreed for their carers to assist in 
communication and one participant used scrabble letters to spell out words. The 
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participants were respected and they were also empowered. I reflected it was 
important to give them a voice where other studies may have excluded them.  
The clinicians were also respected for their knowledge; skills and opinions were 
actively sought and valued to inform the study. Their individual contributions in 
the qualitative interviews offered insights into professional roles and 
responsibilities and conflicts between clinical practice and research. These 
tensions were raised with uncertainties in delivery with capacity and potential 
clinical risk. I addressed the capacity issue by meeting with the clinician’s 
manager and the issue was resolved by personally taking on equivalent clinical 
caseloads for each research participant. Potential clinical risk was dealt with as 
any clinical risk and prioritised with appropriate clinical modifications to reduce 
the risks identified. An example included the medical deterioration of one 
participant, rendering the participant immobile in which the DEFO was 
considered unsafe and consequently removed.  
When the question of defining eligibility criteria was resolved it was a great relief 
that the research had not been prematurely stopped. The importance of 
understanding the individual roles and responsibilities had been 
underestimated. Conflict in research practice from usual care was identified in 
the clinician in the industry in that the people she normally treated had more 
movement and DEFO was provided for more proximal management. I was 
aware there was a need for further clarification and discussion for agreement on 
the study eligibility criteria to gain trust and agreement in the recruitment 
process. This was achieved in a RRG meeting and the initial conflict between 
the clinician in the industry and the study was resolved. 
Responsibility 
Research governance was considered essential to honest and accurate 
reporting of the study. I did not underestimate my responsibility as the research 
principal investigator and the importance of keeping all those involved with the 
study fully informed. Effective communication was established with pathways 
and roles identified for the clinicians delivering the physiotherapy in the study to 
address both clinical and research uncertainties. 
261 
 
By careful monitoring and putting effective reporting systems in place the 
potential risks and variances were captured and where necessary modified for 
optimal study and intervention delivery. Ethical responsibility is an important 
consideration for clinical and research practice. Clinical practice and 
management of clinical risk takes precedence over research. This was an 
important lesson learned from the delivery of a new treatment in a clinical 
setting. 
Research is positively driven by effective communication. The exchange of 
ideas led to key decisions informing the research proposal, design and 
implementation of the study. Fundamentally this research study could not have 
been initiated without explicit communication of the research ideas to engage 
the stakeholders. The stakeholders identified were; clinicians and their 
managers, a supervisor and research field supervisor, the local Research and 
Development support staff and statistician, the DMO company manager and 
staff and participants. The stakeholders required different levels of 
communication at key stages in the delivery of the study. 
The research proposal was the starting point for early discussions with my 
supervisor for improvements and to explore what perspective the research 
should take. I was challenged to look at the research differently from another 
perspective; not as a clinician, but as a researcher. I decided that the participant 
perspective was more important in that if the DEFO was to be explored as a 
new treatment option for limb spasticity a feasibility study must also evidence 
intervention acceptability from the participant. Therefore the design chosen and 
measures selected were based on this assumption.  
It became increasingly apparent that research cannot occur in isolation and 
positively benefits from collaboration. A number of companies manufacturing 
dynamic orthoses were approached regarding potential research collaboration. 
This resulted in one definitive interest. Early meetings with the DM Orthotics® 
CEO ensured the research protocol would be deliverable and provided 
assurance that funding the assessment, fitting and provision of the splint would 
not influence intellectual property and the right to publish without interference.  It 
was also agreed that the findings would be made available to the company. 
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Written agreement was sought and provided which was necessary in 
collaborative research with industry. 
Further collaboration was established by setting up a stakeholder RRG. This 
was useful to discuss the protocol feasibility and procedural delivery. Initial 
discussion around choice of orthoses fabric colour was used to inform delivery 
of DEFO of neutral colour to control for bias. Further discussion was on the 
specific timing of the assessment for fitting of the DEFO. It was advised that 
changes in muscle tension following BT meant that it could impact on fit and so 
assessment should be after rather than before this intervention.  In addition this 
group was able to monitor the research delivery by receiving regular reports and 
providing an opportunity for feedback. Important procedural decisions were 
made on modification of the protocol to ensure it was feasible in the timeframe 
and this was submitted for ethical approval as a protocol amendment. 
Leadership in clinical research 
Knowing what you know and what you don’t know is fundamental to identity and 
reality. I consider myself as a novice in clinical research. However as a health 
care professional I am used to the concept of evidence based medicine 
(Sackett et al., 1996) and from this starting point I have developed further skills 
from professional practice to research specific skill sets. I have a strong ethical 
accountability towards professional and clinical research leadership. In truth I 
value transparency, honesty, loyalty, equality, respect, creativity, knowledge, 
fairness and generosity. These are qualities I seek personally and value in 
others.  
The paradigm shift in the patient-clinician relationship has led to the 
empowerment of the patient and this has influenced my practice. The reflective 
diary has provided a framework for learning in a logical cycle of reflection critical 
to my own learning style as a constructivist (Higgs and Titchen, 2001). The 
diary provides evidence of a journey of transformation both in research 
confidence and leadership. 
A critical learning point from my reflections is that research leadership provides 
an opportunity of power ‘through’ others. In order to be an effective leader I 
consider collaboration to be essential using a strong dynamic approach. 
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Working on tasks together helps to bind a group together, providing identity and 
common purpose as was experienced by the RRG. Even when dissonance is 
encountered it is an important lever for learning. This was experienced in the 
issues around participant eligibility and conflicting caseload and research 
priorities that threatened the research. Personal resilience is important as 
changes and challenges are common in research.  
I recognise these critical challenges influencing research design and procedural 
delivery have led to personal transformation. The key components of resilience 
were identified as resistance, recovery and reconfiguration. Resistance was 
encountered as dissonance between managing expectations of the clinician 
representing industry and ensuring the research followed an ethical framework. 
Recovery occurred with resolution of the understanding of the research 
eligibility criteria.  Reconfiguration occurred as the RRG was strengthened by 
ethical accountability.  
The research study has also provided an opportunity for developing an arc of 
influence as a leader in clinical research and confidence in collaboration with 
others. This newly gained confidence in research skills has provided the 
opportunity for collaboration in service improvements and mentoring others. It 
has also led to wider experience in dissemination of research findings at a level 
of international impact.  
Conclusion 
Reflections I considered of critical learning significance were; making ethical 
decisions and ethical practice, collaboration and developing an arc of influence. 
These components are not specific to research; however they are fundamental 
to developing leadership skills in clinical research and to influence translational 
research practice gaps. 
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Appendix 3: Example of search strategy  
A literature review included: NHS Evidence Health electronic data bases: 
Medline and CINAHL, PsychINFO, Embase, AMED; Cochrane; Clinical 
Evidence in National guidelines, Map of Medicine, DARE; Dialog DataStar; and 
hand search. The search covered a period from 1990-2013. 
 
Index words: spasticity, Botulinum toxin, splint, orthosis, dynamic splint, 
dynamic orthosis, Lycra® and physiotherapy 
Each single word or concept was initially searched and then later combined in 
the Medline database and mapped to thesaurus. The subject headings were 
then listed in a hierarchy of broader to narrower terms. Further terms were 
exploded to include all the narrower terms. The final collection for each concept 
was combined using ‘AND’ resulting in the key papers for this review. It was 
appropriate to use the search strategy wildcards to explore any truncated words 
such as ‘splint’. Each search was themed then saved, abstracts evaluated for 
relevance and papers identified as key to the research study were requested for 
scrutiny. 
 
Medline search terms 
 
1. Physiotherap* or ‘physical therap*’ 
2. Spasticity* AND Botulinum toxin* 
3. Splint* or orthos*s 
4. Dynamic splint or dynamic orthos*s 
5. (splint* or orthos*s) OR (dynamic splint or dynamic orthos*s) 
6. Lycra® AND splint OR Lycra® AND orthos*s 
7. 1 AND 2  
8. 1 AND 2 AND 3 
9. 1 AND 2 AND 4 
10. 1 AND 2 AND 6 
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Appendix 4: Research Study Participant Information Sheet  
Study title: Dynamic Elastomeric Fabric Orthoses (DEFO) and 
physiotherapy after Botulinum toxin type-A (BT) in adults with focal 
spasticity: A pilot randomised controlled study. 
Introduction 
Spasticity or over-activity of muscle is a fairly common symptom following 
damage or disease of the central nervous system (CNS). It can present in 
people with stroke, spinal cord injury, multiple sclerosis and acquired brain 
injury. It is associated with reduced movement and altered muscle control, often 
leading to pain, deformity and altered function. 
It is known that treatment of spasticity is complex and should be addressed, 
especially when it is causing problems such as alteration in function or care 
provision. The aims for treatment are to provide symptom relief, improve 
function and prevent deterioration. 
If spasticity is fairly localised this may respond better to local treatment such as 
injection with Botulinum toxin. Both the National Clinical Guidelines for Stroke 
(2004) and the Multiple Sclerosis: National clinical guideline for diagnosis and 
management in primary and secondary care (NICE, 2004) recommend that 
Botulinum toxin is used for spasticity management in selected cases. 
Evidence shows it requires a combination approach to address both the nerve-
based and biomechanical (muscle and soft tissues) components. In this study 
the nerve-based component will be medically managed by local administration 
of BT type- A.  
What is Botulinum toxin? 
Botulinum Toxin (BT) is derived from the bacterium ‘Clostridium Botulinum’. 
When injected into muscles, BT has local and controlled effects. It blocks 
transmission between the nerve endings and muscle fibres around the injection 
site, thereby causing weakness of the nearby muscle. Injections take effect 
within a few days and last until new nerve endings grow back, which typically 
takes three to four months.  
This safe and effective injection of toxin to targeted over-active muscles 
achieves temporary muscle weakness. BT offers a unique treatment opportunity 
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to inhibit specific overactive muscles whilst leaving other muscles unaffected 
(RCP 2009). This allows the ‘window of opportunity’ to direct therapy towards 
achieving a functional goal. The therapy is aimed at treating the biomechanical 
components of spasticity. 
What is a splint?  
A splint or orthosis is a removable device which provides a means of 
maintaining the specific position of a limb either providing static or dynamic 
support.  Aims for splinting commonly include: to decrease spasticity, prevent or 
reduce contractures, improve activity at a joint, protect joints, and to reduce 
pain. The splint to be used in this study is a dynamic elastomeric fabric orthosis 
(DEFO) which is customised (fitted) to the individual. It is made of an elastic-
based material which is breathable and allows movement. It is similar to an 
elasticated glove or a sock. It works by providing cylindrical pressure to cause 
increased stability of joints, dampens down external forces to improve 
movement control and improves sensory feedback to provide postural 
awareness of the limbs. It is layered to counter-act the distorting forces of 
muscle spasticity to achieve better position and function. 
 
What is the purpose of this study? 
The design of the study is to test the efficacy of a dynamic splint/orthosis and 
any added health benefits compared to standardised treatment. The therapy 
planned in this study is aimed at improving muscle control during this ‘window of 
opportunity’ by using a dynamic elastomeric fabric orthosis (DEFO) and 
standardised physiotherapy compared with standardised physiotherapy alone. 
 
How will the study be conducted? 
Following consent you will be assessed for eligibility for the study by the 
researcher and baseline measures taken. You will be allocated to one of two 
treatment groups following Botulinum toxin injection. One group will have usual 
care and the other group will have the dynamic splint in addition to usual care. 
The allocation to either group will be randomised. This is necessary to make 
sure the study is not biased. You will be asked NOT to discuss your 
treatment with the research assessor, but if you have any concerns you will 
be able to discuss these with the named physiotherapist delivering your care. 
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The treatment protocol will encourage wearing the splint for a period of up to 
eight hours daily or as tolerated. This is based on evidence in previous studies. 
Both groups will have access to usual care and rehabilitation including postural 
management, provision of equipment and advice etc. Standardised 
physiotherapy will be provided to all participants. The study will last for 12 
weeks which will include a period of 6 weeks of specific treatment followed by 6 
weeks of on-going standardised care as needed. (Please see the protocol) 
 
What are the identified benefits? 
The splint is designed to provide sensory awareness and joint position sense. It 
is also dynamic with properties that promote rather than restrict movement. 
There is some evidence from paediatric studies that this treatment offers 
improvements in movement stability and postural control with a beneficial 
impact on balance and walking. This study will provide evidence of added 
health benefits that have not been previously measured in the adult population.    
 
What are the identified risks? 
The main identified risk is that of compression on the skin resulting in reduced 
circulation. This could be an increased risk to those with poor circulation in the 
extremities or those who suffer from Diabetes. However the splint will be made 
to measure to ensure comfort and can be easily removed.  DMO can provide 
access to a skin surface pressure monitor to determine safety in those identified 
at risk. 
 
How can I participate? 
If you have read and understood the information in this form and wish to 
proceed with participation in this study you will be asked to sign a consent form. 
The study has been agreed as safe and regulated by a research ethics 
committee. If you wish to discuss any of these issues more fully from this 
information sheet you are encouraged to contact the physiotherapist/clinician 
involved in your care who will be briefed on the purpose and plan for delivery of 
the research study. If you decide to participate in the study you will be given a 
form to sign for your consent. You will then be assessed for eligibility to the 
study and allocated to either group. You will have the right to withdraw your 
consent at any time during the study and this will not affect your provision of 
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usual care. If you decide not to participate you will be provided with standard 
care. With your consent your GP and any other health care professionals will be 
contacted to inform him/her that you are participating on the research study and 
what it involves. All personal data will be password protected, securely stored 
and managed according to NHS governance and data protection regulations.  
 
ASSESSMENTS:  
The research assessor will conduct three assessments during the research 
study: 
1. Baseline Initial Assessment following BT (within 2 weeks) 
2. Post intervention assessment (at 6 weeks) 
3. Follow-up assessment (at 12 weeks) 
MEASURES: 
1. Impairment: Spasticity: Modified Ashworth Scale (MAS); pain: VAS 
2. Function: Goal Attainment Score (GAS); 10 meter timed walk. 
3. Participation: Activity log; Leeds Arm Spasticity Impact Scale (LASIS);       
EQ-5D (quality of life), participant  and clinician feedback on 
acceptability and feasibility   
 
Intervention Protocol 
 
Following consent and eligibility you will be recruited to the study and 
randomized into 1 of 2 treatment groups: 
The intervention (Group A) and control (Group B) 
 
Group A  
After clinic you will be invited to attend your local physiotherapy department (or 
if unable to travel at home) for a baseline assessment by the researcher using 
validated outcome measures and a questionnaire. This should take 
approximately one hour. Please do NOT discuss your treatment with the 
researcher. 
 
An appointment will be made with you for an assessment and measurement for 
fitting of the DEFO (within 2 weeks). This should take approximately one hour. 
This orthosis will be provided for you to wear daily for increasing periods of time 
(up to 8 hours daily within your comfort). You will be asked to keep a record of 
this time. You will also receive standard care* and physiotherapy (as clinically 
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relevant) for up to a maximum of 40 minutes twice weekly for a period of 6 
weeks. Any home exercises or activity will be recorded by you using an ‘Activity 
log’.  
 
After 6 weeks your progress will be assessed by the researcher using the same 
measures and questionnaire (approximately 1 hour). The dynamic orthosis 
treatment will be withdrawn but continued standard care for a further 6 weeks. 
After this period you will be re-assessed using the same measures and 
questionnaire by the researcher. Again this should take approximately one hour. 
You will be informed of the outcome of the study and your individual progress. 
 
Group B  
After clinic you will be invited to attend your local physiotherapy department (or 
if unable to travel at home) for a baseline assessment by the researcher using 
validated outcome measures and a questionnaire. This should take 
approximately one hour. Please do NOT discuss your treatment with the 
researcher. 
 
After 2 weeks you will receive standard care* (this may or may not include a 
splint depending on individual clinical need and this will be recorded) and 
physiotherapy (as clinically relevant) for up to a maximum of 40 minutes twice 
weekly for a period of 6 weeks. Any home exercises or activity will be recorded 
by you using an ‘Activity log’.  
 
After 6 weeks your progress will be assessed by the researcher using the same 
measures and questionnaire (approximately 1 hour). The standard care will 
continue for a further 6 weeks. After this period you will be re-assessed using 
the same measures and questionnaire by the researcher. Again this should take 
approximately one hour. You will be informed of the outcome of the study and 
your individual progress. 
 
Standard care* 
This is the usual care following Botulinum toxin (BT) administration and is 
tailored to the individuals needs but includes: advice on positioning, hygiene, 
muscle stretches, splinting, and pain management. Physiotherapy may not be a 
part of care. 
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Appendix 5: CONSENT FORM   
Study: Dynamic Elastomeric Fabric Orthoses (DEFO) and physiotherapy 
after Botulinum toxin type-A (BT) in adults with focal spasticity: A pilot 
randomised controlled study.  
Please see the consent form is in two parts, you do not have to sign both parts: 
Part 1 on Page 1: This is the main consent for your general participation in the study 
and if you agree to take part. Part 2 on Page 2: This is optional and about whether you 
would agree to being followed up by the researcher for the purpose of health research 
even if you decide to withdraw from the study. 
PART 1: MAIN STUDY CONSENT FORM 
Participant Identification No: ……………………..Site Details:  ...................................................... 
 
Consent  detail Please 
initial box 
1. I confirm that I have read and understand the information sheet 
for the above study and have had the opportunity to ask 
questions. 
 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3. I agree to my GP being informed of my participation in this study 
and updated with information from this study relevant to my 
medical care. 
 
4. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust where it is relevant to 
my taking part in the research. I give my permission for the 
individuals to have access to my records. 
 
5. I understand that data already collected as part of the research 
study can be retained for up to 20 years even if I decide to 
withdraw from the study and that it will only be used for this study.  
 
6. I agree to participate in wearing the dynamic splint or other splint 
as required. 
 
7. I agree to participate in Physiotherapy treatment as required. 
 
 
8. I agree to participate in outcome measure assessments (GAS 
and measures identified as clinically appropriate) by the 
researcher.  
 
9. I agree to complete the EQ-5D questionnaire. 
 
 
10. I agree to complete the Activity log as required. 
 
 
11. I agree to take part in the above study. 
 
 
When you have initialled the boxes above, please complete below including the 
date yourself. 
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-----------------------------------------------    ---------------------------    ------------------------------ 
Name of Participant (BLOCK CAPITALS) Date                          Signature 
 
-----------------------------------------------    ---------------------------    ------------------------------ 
Name of Researcher (BLOCK CAPITALS) Date                          Signature  
 
I have explained the study to the above patient and he/she has indicated his/her 
willingness to take part in the study 
 
Part 2: OPTIONAL CONSENT FORM 
Part 2: This section is optional; you can choose if you wish to take part or not 
and it will not affect your participation in the main part of the study. 
 
This consent form is about if you would agree to: 
 Being interviewed about your experiences of taking part in the study? 
 The data from the above in the optional consent being retained? 
 Non-identifiable data being shared for the purposes of health research only. 
 
Please only initial the boxes you wish to consent to, thank you. 
Participant Identification No: ……………………..Site Details:  ...................................................... 
 
 
Consent detail 
Please 
only 
initial the 
boxes 
that apply 
1. I am willing to be interviewed about my experiences of taking part 
in the study for research purposes only even if I decide to 
withdraw from the study. 
 
2. I agree to data being collected for this additional part of the above 
study being retained for up to 20 years and that it will only be 
used for this study. 
 
3. I agree to my data from this study being shared with other health 
researchers after my personal identifying data has been removed. 
I understand that it will only be used towards improving health 
outcomes by assessing the types of treatment that I have agreed 
to participate in for the main study. 
 
4. I agree to this additional part of the above study and consent only 
for the sections where I have clearly initialled in the boxes.  
 
 
 
 
-----------------------------------------------    ---------------------------    ------------------------------ 
Name of Participant (BLOCK CAPITALS) Date                          Signature 
 
-----------------------------------------------    ---------------------------    ------------------------------ 
Name of Researcher (BLOCK CAPITALS) Date                          Signature  
 
I have explained the additional part of study to the above patient and he/she has 
indicated which parts apply 
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Appendix 6: Research Intervention Protocol  
POPULATION:  
Inclusion: Adult (>18 years) living in the community with full capacity to undertake 
informed consent, with identified focal spasticity of one limb (in upper or lower limb) 
present for at least three months, treatment plan with Botulinum toxin identified and 
consented.  
Exclusion: Unable to co-operate in a rehabilitation programme (co-morbidity of 
dementia or mental health disorder), fixed joint contracture, pregnancy, arthritic 
condition, fracture and neuromuscular diseases.  
RECRUITMENT: Potential participants identified by clinician’s independent from the 
researcher will be invited to take part in the study and provided with the study 
information for the informed consent process. After gaining consent participants will be 
randomized to either the Intervention group or comparison group by computer 
generated randomization. The participant’s data will be encoded and stored in 
adherence with clinical and research governance for data protection. It is intended that 
30 participants will be recruited with 15 participants in each group to ensure sufficient 
power for statistical analysis. The researcher will be blinded to the randomization and 
undertake baseline assessment and outcome assessment of all the participants 
recruited. Participants in the intervention group will be referred from the spasticity clinic 
to DM Orthotics Limited for assessment, supply and fitting of the orthoses. Participants 
in both groups will be referred to the Clinical Specialist Physiotherapist for standardized 
physiotherapy and have standard care*. Heterogeneity will be evaluated for acquired 
and progressive disorders, upper and lower limb, age and gender. 
PROTOCOL: 
Intervention Group A: Intramuscular injection with Botulinum toxin type-A. 
Measurement and fitting within 2 weeks of dynamic elastomeric fabric orthoses 
(DEFO). The orthoses should be worn 7 days a week (not at night) and in the first 
week: for 1hour for the first day; 2 hours on the second day; 4 hours for the third day; 
and 8 hours daily from the fourth day. Wearing time for the orthoses will be recorded. 
Physiotherapy standardized intervention (as clinically relevant) up to a maximum of 2x 
40 minutes per week for 6 weeks. A Physiotherapists intervention log will be used to 
record delivery of commonly used components of treatment. Treatment is to be 
delivered by Clinical Specialist Physiotherapists with experience in spasticity 
management. A standardized home exercise programme is to be provided and 
standard care*. Also a Participants Activity log will be used to record activity levels. 
Control Group B: Intramuscular injection with Botulinum toxin type-A followed by 
standardized Physiotherapy intervention (as clinically relevant) up to a maximum of 2x 
40 minutes for 6 weeks. A Physiotherapists intervention log will be used to record 
delivery of commonly used components of treatment. Treatment is to be delivered by 
Clinical Specialist Physiotherapists with experience in spasticity management.  A 
standardized home exercise programme is to be provided. Also a Participants Activity 
log will be used to record activity levels. A static splint will be provided if clinically 
indicated for standard care*.  
ASSESSMENTS: (single-blinded research assessor) 
4. Baseline Initial Assessment  
5. Post intervention assessment (at 6 weeks) 
6. Follow-up assessment (at 12 weeks) 
MEASURES: 
4. Impairment: Spasticity: Modified Ashworth Scale (MAS); pain: VAS 
5. Function: Goal Attainment Score (GAS); 10 meter timed walk. 
6. Participation: Activity log; Leeds Arm Spasticity Impact Scale (LASIS); EQ-5D, 
participant and clinician feedback on acceptability and feasibility.   
Standard care* 
This is described as the usual care following Botulinum toxin administration and is 
tailored to the individuals needs but includes: advice on positioning, hygiene, muscle 
stretches, splinting, and pain management. Physiotherapy may not be a part of care.
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Appendix 7: Goal Attainment Scaling (GAS) T Record Sheet  
Participant code No:………………………………………………. 
 Patient stated goal SMART goal Imp Diff Baseline Achieved  Variance  
(Describe achievement 
if differs from 
expected and give 
reasons) 
1.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
2.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
3.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
Summary 
Baseline GAS T-score: Achieved GAS T-score Change in GAS T Score 
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Appendix 7 Goal Attainment Scaling (GAS) T Record Sheet (continued)   Participant code 
No:……………………… 
 
 Patient stated goal SMART goal Imp Diff Baseline Achieved  Variance  
(Describe achievement 
if differs from 
expected and give 
reasons) 
4.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
5.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
6.   0 
1 
2 
3 
0 
1 
2 
3 
 Some 
function 
 None 
(as bad as 
can be) 
 Yes  Much better 
 A little better 
 As expected 
 
 No 
 
 Partially achieved 
 Same as baseline 
 Worse 
Summary 
Baseline GAS T-score: Achieved GAS T-score Change in GAS T Score 
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Appendix 8:  Physiotherapy Intervention Data Form 
To complete: For each research participant please tick all that apply  
 
Intervention 
 
1 2 3 4 5 6 7 8 9 10 11 12 
Sensory 
stimulation 
 
            
Splinting/casting 
 
 
            
Strengthening 
 
 
            
Fitness/aerobic 
training 
 
            
Stretches 
(specify)  
a. Static 
b. Dynamic 
 
            
Functional 
training (specify) 
a. Sit to stand 
b. Gait training 
c. Arm ability 
training 
d. Other 
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Other training 
(specify) 
a. FES 
b. CIMT 
c. Other 
 
 
            
Other 
comments* 
(Intensity/fatigue 
etc.) 
 
 
            
Total time 
contact 
 
            
*Please use a separate sheet if needed to record any additional comments 
and include with patient data capture sheet 
Date Other Comments 
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Appendix 9: DEFO: RECORD OF WEARING LOG 
WEEK DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 6 DAY 7 
1 
 
1hr 2hr 4hr 8hr 8hr 8hr 8hr 
2 
 
       
3 
 
       
4 
 
       
5 
 
       
6 
 
       
TOTAL 
HOURS 
 
       
 
Week Comments 
1  
 
 
2  
 
 
3  
 
 
4  
 
 
5  
 
 
6  
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Appendix 10: Secondary Measures: VAS/ EQ-5D, LASIS, ArMA, 10MTT 
Pain rating scale 
 
 
Visual analogue scale (VAS)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fold paper 
------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
 
FACES® rating scale (FRS) 
 
 
  
 
 
Appendix 10: The ArMA 
 
Patient Name: ..................................................................................................... 
 
Carer Name:........................................................................................................ 
 
Date and time of completion:  ........................................................................... 
 
 
Instructions for completion: 
 
If the patient is unable to complete the questionnaire independently they may: 
 
 receive assistance from a carer or professional to either act as scribe 
 or facilitate understanding and completion question by question. 
 
Who has completed this questionnaire? 
 
 □ Patient alone 
 □  Carer alone 
 □  Patient/carer in combination 
 
 
Guidance for completion: 
 
For each of the activities listed, please indicate: 
 
1 If the task is possible for you or the carer. 
2 The amount of difficulty that you or your carer experience in doing the 
activity. 
3 Please answer every question based on your activity over the last 7 
days. 
 
If you are unable to do the task but have not done so in the last 7 days please 
estimate the amount of difficulty you would have had with each task.  Indicate if 
the score is an estimate or actual in every case.  
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ArMA – Section A (caring for the affected arm) 
In each column, please CIRCLE as appropriate 
 
 
 
 
Care activities 
(affected arm) 
 
 
 
 
Possible to do 
a task or not? 
Difficulty 
0 = no difficulty 
1 = mild 
2 = moderate 
3 = severe 
difficulty 
4 = unable to do 
activity 
 
Estimate/Actual 
(if the task was 
not actually done 
in the last 7 days, 
circle ‘estimate’) 
1 Cleaning palm 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
2 Cutting finger nails 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
3 Putting on a glove 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
4 Cleaning armpit 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
5 Putting arm through a 
sleeve 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
6 Put on a splint (if 
required) 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
7 Positioning arm on a 
cushion or support in 
sitting 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
 
ArMA – Section B (using the affected arm) 
In each column, please CIRCLE as appropriate 
 
 
 
 
Care activities 
(affected arm) 
 
 
 
 
Possible to do 
a task or not? 
Difficulty 
0 = no difficulty 
1 = mild 
2 = moderate 
3 = severe 
difficulty 
4 = unable to do 
activity 
 
Estimate/Actual 
(if the task was 
not actually done 
in the last 7 days, 
circle ‘estimate’) 
1 Do up buttons on 
clothing 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
2 Pick up a glass, bottle 
or can 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
3 Use a key to unlock the 
door 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
4 Write on paper 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
5 Open a previously 
opened jar 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
6 Eat with a knife and 
fork 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
7 Hold an object still 
while using unaffected 
hand 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
8 Effect of affected arm 
on balance when 
walking 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
9 Dial a number on home 
phone 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
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10 Tuck in your shirt 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
11 Comb or brush your 
hair 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
12 Brush your teeth 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
13 Drink from a cup or 
mug 
Yes / In part / 
No 
0    1    2    3    4 
Estimate / 
Actual 
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Appendix 10: Leeds Arm Spasticity Impact Scale (LASIS)  
 
 
Instructions for LASIS 
 
1. Investigator asks questions to the patient and carer; the responses 
are noted on a proforma.  Each question should be qualified in terms 
of the usual level of difficulty when performing the task over the 
preceding seven days.  The investigator may supplement the 
questions by demonstrating the action required for a particular 
activity.   
 
2. If either the patient or carer reports difficulty then the answer to the 
first part of each question is yes. 
 
3. The responses are chosen to the following question ‘How difficult is 
this activity?’ by the patient or carer from the rating chart. 
 
4. If patients or carers have not performed a particular activity within last 
seven days, then leave blank. 
 
5. A summary score for patient disability is obtained by adding together 
all the patient scores and dividing this total by the number of 
questions on which responses were made.  This results in a summary 
score between 0 (no disability) and 4 (maximum disability).  A 
summary score for physical carer burden can be derived in a similar 
way. 
 
6. Preliminary analysis of the psychometric properties has only been 
performed on the patient ratings thus far.  This scale has not been 
published yet so any data obtained should be analysed with caution. 
 
How difficult is this activity? 
0  I have no difficulty 
1  I have a little difficulty 
2  I have moderate difficulty 
3  I have a great deal of difficulty 
4  I cannot do this activity 
 
 
 
 
 
 
 
 
 
Patient Name: ......................................................................................................................  
 
Carer Name:.........................................................................................................................  
 
Date and time of completion:  ............................................................................................  
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Leeds Arm Spasticity Impact Scale 
1.  Cleaning the palm of the hand  
Do you or your carer have 
difficulty cleaning the palm 
of your affected hand? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
2.  Cutting fingernails  
Do you or your carer have 
difficulty cutting the 
fingernails of your affected 
hand? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
3.  Cleaning around the elbow 
Do you or your carer have 
difficulty cleaning around 
the elbow of your affected 
arm? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
4.  Cleaning the armpit – affected arm 
Do you or your carer have 
difficulty cleaning the 
armpit of your affected 
arm? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
5.  Cleaning the armpit – unaffected arm 
Do you or your carer have 
difficulty cleaning the 
armpit of your unaffected 
arm? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
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Leeds Arm Spasticity Impact Scale 
6.  Putting arm through sleeve 
Do you or your carer have 
difficulty putting your 
affected arm through the 
sleeve of your coat? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
7.  Putting on glove 
Do you have difficulty 
putting a glove on your 
affected hand? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
8.  Rolling over in bed 
Do you have difficulty 
rolling over in bed 
because of tightness in 
your arm? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
9.  Doing physiotherapy exercises  
Do you have difficulty 
doing physiotherapy 
exercises to your affected 
arm? 
Yes/No  
or 
Not 
attempted 
Who does this 
activity most of the 
time? 
 
Degree of difficulty 
experienced by 
patient 
Degree of difficulty 
experienced by 
carer 
Patient  Carer 
 
 
0 
 
0 
 
1 
 
1 
 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
10.  Balance when standing alone  
Does the position of your 
affected arm cause 
difficulty in balancing when 
you are standing by 
yourself? 
Yes/No  
or 
Cannot 
stand 
Degree of difficulty 
experienced by 
patient 
 
0 1 2 3 4 
11.  Balance when walking  
Does the position of your 
affected arm cause 
difficulty in balancing when 
you are walking by 
Yes/No  
or 
Cannot walk 
 
Degree of difficulty 
experienced by 
patient 
 
0 1 2 3 4 
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Leeds Arm Spasticity Impact Scale 
yourself (including use of a 
walking aid)? 
 
 
 
 
 
12.  Stabilising objects – with affected arm  
Do you have difficulty 
using your affected arm to 
hold objects steady while 
you use your unaffected 
arm? 
Yes/No  
or 
Cannot use 
affected arm  
Degree of difficulty 
experienced by 
patient 
 
0 1 2 3 4 
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Appendix 10: Ten-Meter Walk Test  
 
This test examines gait speed.  Gait speed is important for safe community mobility 
(e.g. crossing a street before the light changes).   
 
 
Administering the test: 
 
Measure a 10 meter (33 foot) course and mark its ends with tape on the floor. 
 
Position the subject approximately 3 feet behind the tape line. 
 
Instruct the subject to walk at a comfortable rate until s/he is approximately 3 feet past 
the tape line.  (Distance before and after the course minimizes the effect of acceleration 
and deceleration). 
 
Repeat 3 times and average the times. 
 
Instruct the subject to walk as above, but as fast as possible. 
 
Repeat 3 times and average the times. 
 
Convert to m/min: divide walking distance of 10 meters by elapsed time, then multiply 
by 60. 
 
Compare the times to the reference values in the table below (or for quick reference can 
use 82m/min norm). 
 
 
 Comfortable (m/min) Maximum (m/min) 
Gender/Decade Men Women Men Women 
20s 83.6 84.4 151.9 148.0 
30s 87.5 84.9 147.4 140.5 
40s 88.1 83.5 147.7 127.4 
50s 83.6 83.7 124.1 120.6 
60s 81.5 77.8 115.9 106.4 
70s 79.8 76.3 124.7 104.9 
 
OR 
 
1.2-1.5 m/sec healthy young adult 
0.9-1.3 m/sec older adult 
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Appendix 10: EQ-5D © 1990 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol 
Group. 
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© 1990 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group. 
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Appendix 11 
Interview Topic Guide: Qualitative data capture (participant)  
Participant Ref: 
Study: Dynamic Elastomeric Fabric Orthoses (DEFO) and physiotherapy 
after Botulinum toxin type-A (BT) in adults with focal spasticity: A mixed 
methods study. 
Recently you participated in the research study above in which you were 
assessed, measured and fitted with a fabric splint (DEFO) for wearing after 
Botulinum toxin injection(s). Please tell me about your experiences: 
 What were your experiences in joining the study (recruitment) or 
staying on the study (retention)? 
Probe areas: 
What did it feel like to take part in the study? 
Why did you decide to take part? 
Did you have any concerns and what were they? 
 Were there any positive or negative experiences in the DEFO 
treatment? 
Probe areas: 
Did you feel any different? 
Can you describe any benefits? 
Can you describe any side-effects? 
Did these effects interfere with your usual routines? 
 What was the most acceptable length of time for you to wear the 
DEFO? 
Probe areas: 
What are your views on wearing the DEFO? 
What are your reasons for when you chose to wear the DEFO? 
Was there any time when you did not feel it acceptable to wear the DEFO? 
 What were your experiences in following the treatment protocol? 
Probe areas: 
Was there anything that went well or not so well? 
Did you think there was anything that could have been improved upon and how? 
Can you describe any negative and positive views about your experience in the 
research? 
 Was there any reason to prevent you from wearing the DEFO?  
Probe areas: 
How did you feel about wearing the DEFO? 
Was there any reason why you would prefer not to wear it? 
 Were there any additional costs?  
Probe areas: 
Did you incur any unexpected expenditure -for you or others? 
What were they? 
 Any other comments? 
Probe areas: 
What are your views about research? 
As a participant, is there anything about your research experience you wish to comment 
on? 
What could the research team have done differently to improve your experience? 
 
The above questions are asked face to face and recorded following the intervention 
phase.
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Appendix 12 
Interview Topic Guide: Qualitative data capture (Clinician)  
Clinician Ref: 
Study: Dynamic Elastomeric Fabric Orthoses (DEFO) and physiotherapy 
after Botulinum toxin type-A (BT) in adults with focal spasticity: A mixed 
methods study. 
Recently you participated in the research study above in which you were 
providing clinical input. Please tell me about your experiences: 
 What were your experiences in the study? 
Probe areas: 
Why did you decide to take part? 
What did it feel like to take part in the study? 
Did you have any concerns and what were they? 
Did you have any concerns with recruitment or retention of the participants? 
 Can you provide feedback on the study either positive or negative? 
Probe areas: 
Can you describe any benefits? 
Can you describe any difficulties? 
Did the study interfere with your usual practice? 
 What are your views on participant compliance? 
Probe areas: 
What are your views on why participants chose to wear the DEFO? 
What are your reasons why participants chose not to wear the DEFO? 
Was there any concern raised in wearing the DEFO? 
 What were your experiences in following the study protocol? 
Probe areas: 
Was there anything that went well or not so well? 
Did you think there was anything that could have been improved upon and how? 
Was the protocol feasible in your clinical practice? 
Was there any reason why the protocol was not practical to implement?  
 Was there any reason to prevent you from delivering the 
intervention?  
Probe areas: 
How did you decide what input to deliver? 
How did you decide how often to see the participant? 
What are the reasons why you would not be able to treat the participant? 
 Was there any additional impact on your service?  
Probe areas: 
Did you incur any unexpected work or expenditure-for you or others? 
What were they? 
 Any other comments? 
Probe areas: 
What are your views about research? 
Can you describe any negative and positive views about your experience in the 
research? 
As a clinician, is there anything about your research experience you wish to comment 
on? 
What could the researcher or team have done differently to improve the study or 
experience? 
The above questions are asked face to face and recorded following the intervention 
phase. 
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Appendix 13: Research Activity Log  
Please document any activities you have participated in such as social 
events, shopping, hospital /clinic appointments or significant personal 
achievements. 
Week Date Activity 
1  
 
 
 
 
 
 
2  
 
 
 
 
 
 
3  
 
 
 
 
 
 
4  
 
 
 
 
 
 
5  
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6  
 
 
 
 
 
 
7  
 
 
 
 
 
 
8  
 
 
 
 
 
 
9  
 
 
 
 
 
 
10  
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11  
 
 
 
 
 
 
12  
 
 
 
 
 
 
 
Any other comments: 
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Appendix 14 
 
DM Orthotics Ltd® agreement for copyright to publish photographs 
 
 
>>> Leanne Sawle1 <Leanne.Sawle@dmorthotics.com> 07/24/13 12:13 PM >>> 
 
 
Hi Katharine 
 
Please find photographs of the DMO sock and glove attached. 
 
Martin has given permission for you to use photographs of the DMO sock and glove, as long as DM Orthotics Ltd is 
acknowledged. 
 
Regards, 
Leanne 
 
 
 
 
 
Leanne Sawle       MSc, PGCE (FE), MCSP 
 
Sports Physiotherapist, and, Research and Development Lead 
 
 
 
   www.dmactivesport.com  
 
 
 
 
D.M.Orthotics Ltd                                                                                                 
2, Cardrew Way 
Cardrew Industrial Estate, 
Redruth, 
TR15 1SS 
United Kingdom 
Mobile: 07801 332355 
Tel:         +44 (0)1209 219205 
Fax:        +44 (0)1209 211175 
Email: l.sawle@dmorthotics.com  
www.dmorthotics.com  
 
Member BHTA 
 Company Reg No.05276121        VAT No.845173814 
Reg Office 443. Ashley Rd, Parkstone,Poole, Dorset BH14 0AX 
 
Disclaimer 
The contents of this communication and any attachments are for the confidential use of the named recipient(s) only. It 
is intended solely for the person or organisation to whom it is addressed and if you are not the intended recipient, you 
must not copy, distribute, disclose or take any action in reliance on it. If you have received this e-mail in error, please 
delete it from your computer system and notify the sender or m.matthews@dmorthotics.com as soon as possible. Any 
opinions expressed in this email are those of the individual and not necessarily of the company. While this e-mail 
message and any attachments have been scanned for the presence of computer viruses however, D.M.Orthotics Ltd 
does not guarantee that either are virus-free and accepts no liability for damage sustained as a result of a virus. It is 
the recipient's responsibility to ensure that the onward transmission, opening or use of this message and any 
attachments will not adversely affect their systems or data or otherwise incur liability in law. 
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Appendix 15 
Eligibility Criteria Explanations  
Population for recruitment: 
Inclusion: Adult (>18 years) living in the community with full capacity to 
undertake informed consent, with identified focal spasticity of one limb (in upper 
or lower limb) present for at least three months, treatment plan with Botulinum 
toxin identified and consented.  
 
Exclusion: Unable to co-operate in a rehabilitation programme (co-morbidity of 
dementia or mental health disorder), fixed joint contracture, pregnancy, arthritic 
condition, fracture and neuromuscular diseases.  
 
Inclusion criteria: 
Adult 
Person over 18 years old 
Living in the community 
Living in community accommodation (not hospital) 
Full capacity 
Able to retain information and weigh this up to make an informed decision 
(Mental Capacity Act, 2005) 
Focal Spasticity for a minimum period of 3/12  
Spasticity or over-activity of muscle is a fairly common symptom following 
damage or disease of the central nervous system (CNS). It can present in 
people with stroke, spinal cord injury, multiple sclerosis and acquired brain 
injury. It is associated with reduced movement and altered muscle control, often 
leading to pain, deformity and altered function. The population in this study have 
spasticity from different diagnostic causes and all demographic data is 
recorded.  
Focal spasticity is identified on assessment (for the purpose of this study with a 
Modified Ashworth Scale (MAS) of >2) of one muscle or group of muscles over 
one or two joints resulting in resistance to passive movement. The majority of 
the patients in clinic actually have multifocal or even global spasticity. 
Obviously, the BT treatment targets a specific focal problem, but this could be 
on a background of more widespread spasticity. It is clinically appropriate to 
inject selected muscles out of global spasticity where functional or care 
improvements can be made. Typically MAS of 2 to 3 is indicative of appropriate 
BT intervention. (MAS of 4 is not appropriate). 
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MAS for grading spasticity: 
Grade          Description 
0 No increase in muscle tone 
1 Slight increase in muscle tone, manifested by a catch and 
release, or by minimal resistance at the end of range of motion 
when the affected part(s) is moved in flexion or extension. 
11/2                     Slight increase in muscle tone, manifested by catch and release,            
followed by minimal resistance, throughout the remainder (less than half) of 
the ROM. 
2 More marked increase in muscle tone through most of ROM, 
but affected parts easily moved. 
3 Considerable increase in muscle tone, passive movement 
difficult. 
4 Affected part(s) rigid in flexion or extension.  
Upper limb  
For the study purposes: Below the shoulder to include the elbow, wrist and 
hand. The muscle(s) injected (typically Biceps, Brachialis and/ or forearm wrist 
and finger flexors) are to be identified so the orthotic can be most appropriately 
targeted. 
Lower limb 
For the study purposes: Below the hip and knee to include the foot and ankle. 
The muscle(s) injected (typically Gastro-soleus and/or Tibialis posterior) are to 
be identified so the orthotic can be most appropriately targeted. The participant 
needs to be able to walk > 10 meters x3 with/without a mobility aid. There also 
needs to be flickers of activity in the dorsi-flexor muscles (DMO Ltd). 
Treatment plan with BT 
Botulinum Toxin (BT) is derived from the bacterium ‘Clostridium Botulinum’. 
When injected into muscles, BT has local and controlled effects. It blocks 
transmission between the nerve endings and muscle fibres around the injection 
site, thereby causing weakness of the nearby muscle. Injections take effect 
within a few days and last until new nerve endings grow back, which typically 
takes three to four months.  
This safe and effective injection of toxin to targeted over-active muscles 
achieves temporary muscle weakness. BT offers a unique treatment opportunity 
to inhibit specific overactive muscles whilst leaving other muscles unaffected 
(RCP et al., 2009). 
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The potential participant has been identified by a Physiotherapist or Consultant 
independent from the researcher as potentially eligible for the study and has an 
appointment in the Spasticity Clinic with a Consultant for assessment (against 
specific criteria) and (following informed consent) intramuscular injection of 
Botulinum toxin to focal muscles with identified on-going recommended usual 
spasticity care plan (e.g. splint provision, postural management, physiotherapy 
etc.)  
(Able to co-operate in a rehabilitation programme) 
The potential participant has demonstrated previous ability to comply with a 
rehabilitation programme. The participant does not have a mental health 
condition that will impact on their compliance of implementing the intervention. 
Exclusion criteria: 
Fixed joint contracture 
No ability to move joint (either actively or passively) due to restriction of soft 
tissues with no available range of movement due to loss of elasticity in muscles 
and soft tissues.   
Note – the muscle(s) injected with BT must have the potential for improved 
available range and directly associated joints that can allow movement- these 
are pre-requisites to the BT intervention. This is sometimes difficult to clinically 
assess in the event of pain, distress or anxiety and in some cases assessment 
is only accurate under anaesthetic. 
Pregnancy 
Pregnant with child-Pregnancy is contra-indicated with BT management. 
Arthritic condition 
For the study purposes: An inflammatory arthritic condition that has a direct 
influence on the available joint range in the joint(s) which is controlled by the 
muscles injected in the affected limb. Any non-inflammatory arthritic changes 
will be recorded. 
Fracture 
A recently broken bone in the affected limb (within the last 3/12) 
Neuromuscular condition 
A genetic or acquired condition affecting the muscle strength e.g. Myaesthenia 
Gravis (Note Neuromuscular conditions are contra-indicated for treatment with 
BT). 
Eligibility is assessed by the researcher with a comprehensive assessment 
based on the above criteria. 
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Appendix 16: Example of analytic ‘Framework’ approach by coding participant data extracts (Ritchie and Spencer 
(Bryman and Burgess (eds.) 1996:176-7) 
Data extract (text)- (open code) Coded for issues- (axial code) Theme and sub-theme- (selective 
code) 
Topic guided question: Was there 
any reason to prevent you from 
wearing the DEFO?  
(I) How did you feel about wearing the 
DEFO? 
Was there any reason why you would 
prefer not to wear it? 
(P21) ‘A choice of colours might have 
been nice…..because always having to 
wash them and they always do neutral 
colours, or black…’ 
(I)  Were you offered a choice of 
colours? 
(P21) ‘No… no.  It could be made 
obvious like a medical thing rather than 
a fashion item…( like Michael Jackson 
might wear)…[giggles].  I meant as a 
physical cue for other people for if you 
have something wrong with your limb to 
be helpful for other people ‘cause if you 
have nothing on they are not aware you 
have a problem’. ‘Splints in general 
serve as a visual aid to third parties 
which prompts the public to be more 
helpful in social situations e.g. shopping 
bag packing’.  
Generating initial codes 
Issue: Choice of colour - 
Colour preference (P04) ‘Orange!’ 
(P21) ‘A choice of colours…nice’ 
(P01) ‘I dyed it purple…’ 
Issue: Appearance importance: for 
self and others Acceptable appearance 
just as important for self as others:  
(P04) ‘…people would look … flesh 
coloured…’  
(P19) ‘…you could hardly see it … just 
blended in …’ 
 
Issue: motives and perceptions of self 
and others: 
B.1 Self-perception of disability 
Acceptability appearance –individual 
attitudes explored about ‘difference’. 
Refining and naming of themes 
Analysis: Appearance and wearing 
acceptability with impact of differing 
perceptions of disability on study design, 
feasibility in clinical context, motives and 
expectations, recruitment, retention, 
adherence, acceptability, ethical issues 
etc. 
Sub-themes: 
B.1 Self-perception of disability 
B.2 Societal perceptions of disability  
B.3 Perceptions of disability in 
research 
Theme: 
Organizing Participant theme 
(OP.1): Differing perceptions of 
disability 
Impact of differing perceptions of  
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Another response: 
(P01) ‘It’s like people say what have you 
done? I’ve had a stroke and they know 
that but this is just part of the stroke and 
that’s why I’m wearing it and they all 
thought I had done something to my arm 
like broken it or something’.  
(P01) ‘so … I dyed it purple…more me..’ 
(P01) ‘It’s more what people might say. 
But I would just wear it anyway’.  
Another response: 
(P04) ‘There is always this thing… 
people would look …with short 
sleeves…I know it was flesh coloured 
even with the tones’.  
Partner ‘You did want a different 
colour…didn’t you?’ (P04)  [Laughs….] 
(I)  ‘Colour?’  
(P04) ‘Orange!’ [laughs] 
Another response: 
(P19) ‘…you could hardly see it …and 
for the colour of it …just blended in’ 
(P16) (carer) ‘Just took a dislike to it! 
That’s the reaction I got!” (P16) 
[grimaces and shakes head] I tried to 
(P19) ‘…blended in’. 
(P04) ‘flesh coloured’ 
(P01) ‘just part of the stroke …‘I would 
just wear it anyway’… ‘dyed it purple… 
more me’. 
(P16) Refused to wear DEFO-‘ dislike’ of 
its appearance. 
B.2 Societal perceptions of disability  
(P21) ‘… always do neutral colours,’ 
(P01) Medicalised not seen as a fashion 
item (P21) Cueing others in society 
useful as ‘a physical cue for other 
people… ‘prompts the 
public’(P21)‘something wrong… more 
helpful in social situations ’ 
Acceptable appearance for disability 
versus injury and disability a part of self- 
identity (P01) ‘what people might say’- 
Inferred sports injury (‘done something’) 
more acceptable in society? Relevance 
for orthotic appearance and adherence. 
Challenges in mainstream perceptions of 
disability- attitudes and ‘social model of 
disability’. 
B.3 Perceptions of disability in 
research: expectations, perspectives 
and motivation. Perspectives from 
joining research- importance of being 
disability –self and others  
Impact of differing perceptions of  
 
Main Theme: 
Global Participant theme (GP. 2): 
Perceptions of disability: impact on 
research 
 
Key: 
P= Participant code 
I= Interviewer 
B= Basic theme (sub-theme) 
O= Organizing theme (theme) 
G= Global theme (superordinate theme) 
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explain but she would not even try it on’. 
Topic guided question: What were 
your experiences in the study? 
(I) Why did you decide to take part? 
 
(P04) ‘to sort of try something …as part 
of research?’  
(P11) ‘I think in a situation like that, you 
would try anything really’.  
(P18) ‘… sometimes you can go on 
week by week,  month on month and not 
see anything has been done… that is a 
positive like a feeling of hope like 
something was being done.. it will 
improve. That was a positive. It gives 
you a feeling of confidence...’  
(P19) ‘I decided to take part because if 
you do anything like that it helps other 
people’.  
(P18) ‘…to benefit others in the future 
that was the main reason’.  
(P20) ‘Anything that can help to alleviate 
the suffering of stroke has got to be a 
good thing’.  
(P10) ‘I was glad to be helping you in 
your research and thought it would be 
good for me to help me…. in my 
progression’. 
chosen, hope, opportunity, benefit self 
and helping others. 
(P18)‘something was being done… 
feeling of hope…   feeling of confidence’ 
(P04) ‘try something’ (P11) ‘try anything 
really’ (P10) ‘…helping me…helping you 
in your research…’ 
(P18) ‘benefit others’ (P19) ‘ it helps 
other people’ (P20)  ‘…to alleviate the 
suffering…’ 
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Appendix 16: Example of analytic ‘Framework’ approach by coding clinician data extracts (Ritchie and Spencer 
(Bryman and Burgess (eds.) 1996:176-7) 
Data extract (text)- (open code) Coded for issues- (axial code) Theme and sub-theme-(selective 
code) 
Topic guided question: What were 
your experiences in following the 
study protocol? 
(I) Was there anything that went well or 
not so well? 
Was the protocol feasible in your clinical 
practice? 
Was there any reason why the protocol 
was not practical to implement?  
 
 ‘I didn’t always get the clinic letter in the 
most-timely fashion’. (C2) 
‘it was difficult to keep to the times in the 
protocol within 2 weeks post BT to have 
assessed the patient’ (C1) 
 ‘…the hardest thing about the protocol 
was just adjusting to basically this 
patient needed to be seen within a fairly 
set time frame’.(C2)  
‘…stress came from the time constraints 
of the protocol and I understand the 
protocol has to have time constraints but 
there were times when I got frustrated 
because of my other caseload was 
Generating initial codes 
Issue: Protocol issues and research 
procedural issues around feasibility. 
 Research communication clinic 
letters not  most-timely (C2) 
 Impact of co-morbidity health of 
the participant (C2) 
 Variance in timing time 
constraints (C3)… set time 
frame’.(C2) 
 Variance in fitting ‘the deadlines 
(C3) 
 Availability of DMO clinician only 
part time and not in the area’. 
(C3) 
 
Issue: Ethical considerations: ethical 
discussions around protocol and 
clinical uncertainty. 
 Uncertainty in clinical risk safety 
issues … not really sure  …sorted 
out…study follows the clinical 
needs’ (C3) 
 Uncertainty and communication in 
research regarding eligibility 
Refining and naming of themes 
Analysis: Impact on study design, 
protocol feasibility in clinical context, 
uncertainty, recruitment, retention, 
adherence, compliance acceptability, 
variance, ethical issues: consent, clinical 
risk etc. 
Sub-themes:  
BC.1 Variance in fitting 
BC.2 Variance in timing 
BC.3 Availability of DMO clinician 
BC.4 Impact of co-morbidity 
Theme: 
Organizing Clinician theme (OC.1) 
Protocol feasibility 
Also linked but broader themes 
underpinning clinical research delivery:  
 
Sub-themes: 
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being sacrificed for the protocol’. (C3) 
‘… trying to meet the deadlines 
especially due to having to liaise with 
someone… who was only part time and 
not in the area’. (C3) 
Topic guided question: What are your 
views on participant compliance? 
(I) What are your views on why 
participants chose to wear the DEFO? 
 
‘most people would suggest they are 
comfortable’ (C1) 
‘…the participant absolutely didn’t want 
to try it and that was quite difficult’ (C1) 
‘They were very compliant with it’.(C3) 
‘…in terms of compliance I think it 
affected them in terms of having 
someone around to help them put it 
on.…she really struggled getting the 
carers to help her to put it on…’ (C2) 
‘only provided the beige and there is 
possibility that some may not like that 
colour and would have preferred a 
different colour’ (C1) 
(I) Was there any concern raised in 
wearing the DEFO? 
 
‘little things that we ironed out at the 
criteria ‘little things that we ironed 
out at the beginning’  (C1) 
 Following protocol standard 
physiotherapy (C2) (fidelity). 
 
Issue: Acceptability, tolerance and 
compliance issues regarding:  
 Comfort ‘most people would 
suggest they are comfortable’(C1) 
 Colour  different colour’ (C1) 
 Safety ‘one or two safety issues’ 
(C3) 
 Compliance and wearing issues 
absolutely didn’t want to try it (C1) 
 Difficulty with donning  someone 
around to help them put it on (C2) 
 
Emergent themes: feasibility, and 
acceptability of the DEFO intervention 
in a clinical setting with analysis of 
specific ethical issues, clinical risk 
and conflicts in capacity. 
 
BC.1 Eligibility 
BC.2 Clinical risk  
BC.3 Fidelity 
BC.4 Research communication 
Theme: 
Organizing Clinician theme (OC.2): 
Ethical issues 
Main Theme: 
Global Clinician theme (GC.1): 
Research impact on clinical practice 
 
Sub-themes: 
BC.1 Comfort 
BC.2 Compliance and wearing issues 
BC.3 Difficulty with donning 
Theme: 
Organizing Clinician theme (OC.2) 
Intervention (DEFO) acceptability 
Main Theme: 
Global Clinician theme (GC.2): 
Feasibility and acceptability of DEFO 
in a clinical setting. 
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beginning’ (C1) (Eligibility) 
‘…there was one or two safety issues 
and I was not really sure initially where 
to go to with. But they did get sorted 
out’. (C3) 
‘I tried to just deliver just standard 
physiotherapy that I would normally 
do’.(C2) 
‘…so the study follows the clinical needs 
and that is fine’. (C3) 
‘the individual health of the participant 
e.g. seizures and pressure sore’ (C2) 
 
 
Key: 
C= Clinician code 
I = Interviewer 
B= Basic theme (sub-theme) 
O= Organizing theme (theme) 
G= Global theme (superordinate theme) 
 
 
 307 
 
Appendix 17 
Research Report 
 
Study Title: Dynamic Elastomeric Fabric Orthoses (DEFO) and 
physiotherapy after Botulinum toxin (BT) in adults with focal spasticity: A 
feasibility study using mixed methods. 
 
Thank you for your participation and/or involvement in the research study. The 
following is a summary report of the findings in the study. (Katharine Stone, 
Consultant Therapist in Neurology, for Doctor of Clinical Research, Exeter 
University). 
 
Ethical registration and approval: Ref: 12/SC/0518 (NRES) Committee South 
Central-Berkshire B-ethical approval registered with local NHS R&D and Exeter 
University.   
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 308 
 
The study 
Research questions 
 
This study identified three equally important questions to explore the uncertainty 
of this intervention following BT for focal spasticity in adults:  
 
 What is the likelihood of health benefits of treatment with DEFO and 
physiotherapy and usual care, compared to usual care alone? (primary 
question) 
 
 What is the feasibility of the protocol to inform the design of a larger 
study? 
 
 How acceptable is the DEFO intervention in clinical practice? 
The research questions were explored in terms of three issues; likely benefit, 
feasibility of the intervention protocol and acceptability of the intervention. 
These were considered likely to be best addressed by a mixed methods design 
(Figure 1). The research questions were subsequently linked to quantitative or 
qualitative designs to provide data sets to address the uncertainties. 
Figure 1. Procedural diagram of the mixed methods study design  
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Key findings of the study 
1. What were the identified health benefits? 
Person-centred goals achieved with significant difference in achievement in the 
DEFO group. 
Positive and tangible health benefits in real-life contexts which were valued by 
the majority of participants in the DEFO intervention group.  
 
Physical benefits  
 Pain level reduced 
 DEFO supportive and comfortable 
 More relaxed 
 Posture more normal and improved functional activity 
 
Psychosocial health benefits 
 Appearance acceptable from a health perspective with social cues 
 More ‘normal’ 
 More awareness 
 Appearance socially acceptable 
 Quality of life benefits 
 Self-image and self-awareness issues raised by participants 
 
What were the adverse effects? 
Negative findings were related to a few reported individual fitting and wearing 
issues: 
Physical: tightness, sweating and swelling in hot weather, dislike, reliance on 
others, difficulty with donning (initially) 
Impact on usual activity: A block to sunbathing and therapies (including 
acupuncture and swimming). 
 
2. Was the study feasible? 
The study was found feasible by both participants and clinicians. The DEFO 
protocol was found acceptable by evidence form the DEFO wearing Log. 
Findings:  
 High level of protocol compliance in (n=10) with Non-compliance (n=1). 
 There was minimal variance reported in protocol delivery (with delays in 
timing and fitting n=2) and level of activity between groups. 
 Feasibility of the protocol delivery was established in clinical practice with 
a high level of adherence and tolerance with compliance in the DEFO 
wearing protocol.  
 No added burden in data captures (measures). 
 Specific wearing issues contributed to feasibility of protocol including 
reliance on carers for donning DEFO.  
 Co-morbidity and rehabilitation potential were found to impact on clinical 
practice and protocol delivery.  
 The protocol was acceptable and tolerated by both clinicians and 
participants.  
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 Clinical capacity, priorities, agreement on eligibility and potential clinical 
risk were identified as factors that could impact on procedural clinical 
research feasibility. 
 Participant compliance was found to depend on level of dependency and 
reliance on carers. 
 
Protocol modifications were indicated to improve timing of the assessment and 
delivery by: 
 Earlier assessment for fitting prior to BT. 
 Longer delivery of DEFO intervention with no need for removal. 
 
3. Was the DEFO intervention acceptable? 
Participant findings: Wearing compliance and tolerance evidenced; 
preference of DEFO in combination with physiotherapy; earlier in condition 
management; also in BT cycle; and to be worn for a longer period following BT. 
Clinician findings: Clinical bias over active vs passive function and central 
over distal application; 
DEFO acceptability was tempered by co-morbidity and rehabilitation potential. 
 
Both clinicians and participants provided evidence of DEFO acceptability in 
practice/setting (with caveat of stratification of participants based on the above 
findings). 
 
Both positive and negative wearing experiences with substantive physical and 
psychosocial benefits reported. 
 Appearance was considered a significant factor in acceptability. 
 Physical benefits were established. 
 Psychosocial benefits were established. 
 Functionality of the DEFO was found beneficial in comparison to rigid 
splints.  
 A high level of DEFO wearing compliance was established. 
 Poor fitting was found to detract from acceptability. 
 Negative findings included difficulty and/or reliance with donning of the 
DEFO. 
 
Ethical considerations included:  
 
Clarification was sought on the study eligibility criteria and research guidance 
was provided for this and on management of potential clinical risks. Protocol 
amendment was submitted to improve procedural feasibility and ethical 
approval was obtained. 
Potential clinical risks were highlighted and managed clinically.  
No adverse events were reported. 
 
Future implications 
A mixed method approach is appropriate for research in a health care setting. 
From the pilot RCT: the results of the GAS indicated for a potential Phase III 
randomised clinical trial. It was estimated you would need 400 patients (200 per 
 311 
 
group). From this it is likely a multi-centre study would provide the optimal 
opportunity for recruitment to this study. A research proposal based on the 
findings of this feasibility study could be developed for research funding. 
 
The Thematic Analysis of the interviews provided rich detail to identify the 
health benefits and explain feasibility and acceptability of the RCT. Integration 
of the findings provided valuable procedural detail for a future study: 
 Choice of colour could improve cosmetic acceptability. 
 Improved fitting could also improve acceptability. 
 Availability of a carer for donning improved compliance. 
 
Also cost-analysis should be incorporated into the design of a larger study. 
Eligibility analysis suggested the need for further consideration to stratify the 
research participants to specific static or progressive neurological/stroke 
conditions so the treatment can be applicable to conditions based on: 
 Upper limb 
 Level of dependency 
 Progressive or static condition 
Patients and public should be involved to improve a future study design and 
contribute to monitoring of the research delivery. 
 
Physiotherapy modalities of delivery and contact time should be specifically 
collated to identify what treatment options are of most benefit. Physiotherapy 
clinicians could be trained as DEFO assessors to improve procedural delivery. 
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Figure 2 CONSORT Flow diagram of recruitment and attrition 
 
All of the available data was analysed for intention to treat (ITT) analysis. 
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Summary (Abstract) 
Aim: A study to investigate the feasibility, acceptability and any added health 
benefits of a dynamic elastomeric fabric orthosis (DEFO) and usual care 
compared to treatment of usual care alone in the treatment of spasticity 
following intramuscular injection of Botulinum toxin (BT). The therapy planned in 
this study was aimed at improving muscle control during this ‘window of 
opportunity’. 
Participants: Adults living in the community with focal spasticity of the arm or 
lower leg recruited from a regional Spasticity Clinic.  
Intervention:  Provision of an individually fitted DEFO (worn daily up to 8 
hours) usual care and physiotherapy as required for 6 weeks.                             
Measures:  A selection of reliable and validated measures were chosen 
together with clinical measures. Goal Attainment Scale (GAS) primary 
measure and secondary measures for function and care benefit; Arm Activity 
measure (ArmA), Leeds Arm Impact Score (LASIS), VAS for pain, European 
Quality of Life-5 Dimensions (EQ-5D), gait velocity (10MTT). Variance and 
fidelity was captured with: DEFO wearing record, Activity Log, clinical records 
and Physiotherapy modalities.                                                                                               
Method: Mixed methods embedded design feasibility study (figure 1): 
Quantitative: Feasibility pilot single-blind Randomised Controlled Trial (RCT): 
Intervention Group: Delivered as: six weeks DEFO intervention, physiotherapy 
(as required) and usual care followed by six weeks removal of the intervention 
but continued physiotherapy (as required) and usual care. 
Control Group: Delivered as: twelve weeks physiotherapy (as required) and 
usual care.  
Qualitative: Topic guided interviews of those participants in the intervention 
group and the physiotherapists who delivered the physiotherapy.   
Analysis: Statistical comparison for significance of repeated measures by 
ANCOVA adjusted means (at baseline, after six weeks and twelve weeks) 
between groups and to inform calculation for a larger study. ‘Thematic Analysis’ 
of participant and clinician transcribed interviews. Quantitative and qualitative 
findings were integrated and triangulated to inform a larger study.  
Results: Participants (n=25) recruited over twelve months, (n=22) completed 
study. Two people (n=2) withdrawal of consent before the study commenced 
and one (n=1) person withdrawal due to medical complications unrelated to the 
study (see figure 2 CONSORT flow). Statistical analysis showed improvement 
in both groups with greater health benefit in the intervention group with 
mean difference  between groups in the Goal Attainment Scaling (GAS) score 
of 12.17 (95%CI: 3.16 to 21.18; p = 0.014) but no statistical significance in the 
secondary measures. Physiotherapy modalities for spasticity were linked to 
‘passive’ and ‘active’ function. Feasibility and acceptability was established with 
Thematic Analysis providing valuable insight into patient and clinician 
perspectives on disability.     
Conclusions: Findings indicated potential added health benefits including carer 
benefit. Feasibility, acceptability and clinical application of DEFO as a potential 
new intervention were established. This has implications for future spasticity 
management with patient benefit for ‘passive’ and ‘active’ function. Further 
research is indicated with a larger phase III trial (based on the GAS sample 
results) to evaluate DEFO efficacy in people with spasticity following BT. 
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Glossary 
Analysis of covariance (ANCOVA) A statistical technique for equating groups 
on one or more variables when testing for statistical significance; it adjusts 
scores on a dependent variable for initial differences on other variables, such as 
pretest performance. 
 
Dependent variable A variable affected by the independent variable; also 
called the “outcome variable”. 
 
Generalizability (population/ecological) The degree to which results obtained 
from a sample can be generalized to a larger group, environments and 
conditions outside the research setting. 
 
Hawthorne effect A positive effect of an intervention resulting from the 
subjects’ knowledge that they are involved in a study or their feeling that they 
are special in some way receiving ‘special’ attention. 
 
Heterogenic The sample of research participants or constituents in which 
characteristics are all different with respect to one or more. 
 
Homogeneous The sample of research participants or constituents in which 
characteristics are all similar with respect to one or more. 
 
External validity The degree to which results are generalizable or applicable, 
to groups and environments outside the research setting.  
 
Independent variable A variable that affects (or is presumed to affect) the 
dependent variable under study and is included in the research design so that 
its effect can be determined. Also called the “experimental “or “treatment” 
variable. 
 
Internal validity The degree to which observed differences on the dependent 
variable are directly related to the independent variable, not to some other 
(uncontrollable) variable. 
 
Saturation The degree of availability of potential recruits which has diminished 
to none. 
 
Standard deviation (SD) The most stable measure of variability; it takes into 
account each and every score in a distribution. 
 
Triangulation mixed method design A study in which quantitative and 
qualitative data are collated simultaneously and used to validate and clarify 
findings. 
 
 References accessed: 15th December 2012 
http://highered.hill.com/sites/0072532491/student_view0/glossary.html  
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